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Table 1.1. Derivatives of the three embryonic germ layers 1
Germ layer Organs and tissues in the Adult vertebrate
Ectoderm
Epidermis of skin and its derivatives (e.g. skin glands, nails e.g.); epithelial lining 
of mouth and rectum; sense receptors in epidermis; cornea and lens of eye; 
nervous system; adrenal medulla; tooth enamel; epithelium of pineal and 
pituitary glands.
Endoderm
Epithelial lining of digestive tract (except mouth and rectum); epithelial lining 
of respiratory system; liver; pancreas; thyroid; parathyroids; thymus; lining of 
urethra; urinary bladder; and reproductive system.
Mesoderm
Notochord; skeletal system; muscular system; circulatory and lymphatic 
system; excretory system; reproductive system (except germ cells); dermis of 
skin; lining of body cavity; adrenal cortex.
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1The development of a complex organism is a fascinating process, which starts with 
the fusion of two gametes that form a single cell. In mammals, this cell will undergo many 
cell divisions during embryonic development. When reaching the gastrulation stage an 
embryo with three cell layers is formed. These layers are called ectoderm, endoderm, 
and mesoderm that will develop into different types of tissues (see Table 1.1) 1. This 
developmental process requires tightly controlled spatial and temporal regulation of gene 
expression. Deregulation of gene expression can lead to a wide range of developmental 
defects, demonstrating the importance of these processes during development.
Sequence-specific transcription factors that bind DNA by recognizing specific sequences 
can function as activators or repressors and play an important role in orchestrating the 
transcriptional changes during embryonic development 2. One such sequence-specific 
transcription factor is p63, encoded by the TP63 gene that is a key regulator in ectoderm 
development. Mutations in TP63 give rise to several ectoderm-related disorders with 
defects in skin, limb and orofacial structures 3-6. Since the discovery of p63, efforts have 
been made to identify its target genes using individual gene approaches and to understand 
p63 function in normal epithelial development and disorders in which this is disrupted. 
Various p63 target genes have been identified using mouse models and different cellular 
systems, but the complete p63-regulatory network and its function in different tissues that 
are affected in patients with TP63 mutations are yet unknown.
The research discussed in this thesis provides new insights into p63-dependent regulatory 
mechanisms that are important for basic embryonic development and for the identification 
of p63-related disease mechanisms. This is relevant to improve diagnosis and clinical 
practice of patients with phenotypes that resemble the p63-associated disorders. In the 
discussion of this thesis future perspectives are proposed to further dissect the molecular 
mechanisms of p63-mediated epithelial development and related disorders as well as for 
potential therapeutic strategies.
10
Chapter 1
1.1 Mechanisms of gene regulation
The genetic information is stored in the DNA. Every human cell contains about 2 meter of 
DNA, which is stored in the nucleus. Protein-coding genes are functional units of DNA and 
function as the basic units of inheritance. A protein-coding gene contains the instructions 
that are required to form proteins, which is facilitated by two basic processes. First, 
the DNA is copied into a pre-messenger RNA molecule (also called primary transcript) 
which occurs in the cell nucleus. This process is called transcription. Subsequently, RNA 
processing yields the mature mRNA which carries the information from the DNA out of 
the nucleus into the cytoplasm. In the cytoplasm the mRNA interacts with a ribosome 
which reads and converts the sequence into amino acids that are the building blocks of 
the protein resulting in a full protein. This process is called translation 7. The same genetic 
material is stored in each cell of the human body. Every cell expresses a different subset of 
genes to conduct specific cellular functions and perform its own role during embryonic 
development and throughout life 8. Many different molecules control temporal and spatial 
gene expression that is essential for the formation of proteins required for specific cells to 
exert their distinct function 9-11. There are several mechanisms that are essential to properly 
control gene expression, which among others include I. the recruitment of transcription 
factors that bind to regulatory elements, II. the recruitment of the RNA polymerase II pre-
initiation complex, III. chromatin state organization to form higher-order structures, and IV. 
post-transcriptional mechanisms 12-14. 
In this introduction some of the major mechanisms that control gene expression during 
tissue development are described. It should be noted that even though these mechanisms 
are described as single entities in this thesis, they are all largely intertwined to control gene 
regulation. The first part on general transcriptional mechanisms is followed by information 
on the role of p63 in gene regulation during development, with several examples of 
syndromic and non-syndromic diseases with similar phenotypic abnormalities as seen 
in patients with TP63 mutations. Next, the current treatment possibilities for patients with 
mutations in the TP63 gene are described. Finally, the outline of the work described in this 
thesis is presented. 
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1.1.1 Transcription factors and DNA elements
Transcription factors are important proteins that are involved in the control of gene 
expression by initiating, activating or repressing gene transcription. They are expressed in 
a tissue specific or ubiquitous manner, having either very specific or general functions 16. 
The start of gene transcription is determined by the core promoter sequence that lies 
directly upstream or at the 5’ end of the transcription start site (TSS) of a gene and starts 
by recruitment of the basal transcription machinery that includes general transcription 
factors. These general transcription factors (GTFs, basal factors) together with the 
mediator complex and RNA polymerase II (RNAPII) form the basal transcription machinery 
that is also called the pre-initiation transcription complex (PIC) 17 (Figure 1.1). The GTFs 
are required to recruit RNAPII to the promoter of genes to initiate transcription 17. RNAPII 
is an enzyme that catalyzes the transcription of DNA to synthesize mRNA in eukaryotic 
cells 13. There are various GTFs, including TFIID, TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH that do 
Figure 1.1. Diverse mechanisms of gene transcription regulation. Nucleosomes that contains DNA and 
histones that are wrapped around by DNA are the basic units of chromatin. Chromatin can be remodeled 
by various modifying complexes. Both DNA and histone tails can be modified (Ac, acetylation; Me, 
methylation; P, phosphorylation). The pre-initiation complex (PIC) is recruited to the transcriptional start 
site (TSS) of genes and drives gene transcription. Transcription factors and co-factors can bind to the 
promoter of the gene upstream of the TSS or to regulatory elements that lie further away from the TSS e.g. 
enhancers or silencing elements that can enhance or prevent transcription, respectively (Modified figure 
from Tedeschi 15).
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not necessarily bind to the DNA directly but are part of the PIC. The composition of the 
PIC is dynamic and regulates specific transcriptional programs 18, 19, suggesting that one 
universal basic transcription machinery does not exist. However, it has become evident 
that TFIID and RNAPII are important key players of the basal machinery. TFIID is composed 
of several subunits including several TBP associated factors (TAFs) and the TATA binding 
protein (TBP). TBP is necessary for specific binding to the conserved TATA box sequence 
that is located in the promoters of many eukaryotic genes. TFIID is thought to be the first 
main component of the PIC that binds the gene promoter and triggers PIC formation with 
other GTFs 20. 
Another part of the PIC is the mediator which is a large multi-subunit complex and appears 
to have the ability to function as a binding interface for sequence-specific transcription 
factors 13, 21-24. After the assembly of the PIC at the gene promoter, transcription is initiated, 
followed by the escape of RNAPII at the promoter, transcription elongation and termination 
25-28.
Some transcription factors that control gene expression are defined as sequence-specific 
transcription factors (STFs), because they bind to DNA via a specific DNA sequence 2. 
These transcription factor binding sequences can be found directly upstream or at the 
5’ end of the TSS of a gene and function as promoters. Or they lie further away from 
the TSS of genes and function as transcription regulatory elements called enhancers or 
silencing elements that regulate gene transcription. Enhancers and silencing elements can 
be located thousands of nucleotides away from the transcription start site of the gene that 
it regulates. In the nucleus the DNA is in a folded and coiled conformation. This 3D DNA 
conformation enables contact between distant regulatory elements and the promoter of 
a gene. Enhancers can stimulate or enhance gene transcription when bound by STFs that 
function as activators 29. In contrast, silencing elements are bound by STFs that function as 
repressors that can prevent gene transcription 13, 30. Repressors bind to silencing elements 
that are located adjacent to or overlapping an enhancer sequence causing loss of binding 
of the corresponding activator to DNA 2. The STFs that bind to these regulatory elements 
can also recruit co-factors that can function as either co-activators or co-repressors of 
gene transcription 17, 31. 
It was previously shown that enhancers can come in two copies, one ‘primary enhancer’ 
that lies close to the coding region and one ‘shadow enhancer’ that lies further away 
from the coding region that regulate individual developmental control genes by driving 
expression in specific spatio-temporal domains 32-34. These duplicated cis-regulatory 
control elements can drive similar gene expression patterns and were demonstrated to 
provide a buffer against intrinsic (genetic) and extrinsic (environmental) perturbations 33, 
35, 36.
13
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1Some transcription factors (TFs) are capable of binding DNA as monomers while, others 
require oligomerization for efficient DNA-binding 37. TFs can form dimers or tetramers, 
which cause differences in binding and/or co-factor recruitment 38. Many TFs can also 
recruit histone modifying enzymes or guide chromatin remodelers that induce structural 
changes necessary for transcription initiation 39.  
TFs that are crucial in the establishment of cell identity are defined as master transcription 
factors. Recent studies identified clusters of enhancers that are bound by master 
transcription factors and the mediator, called super-enhancers 40. It was shown that the 
inhibition of the function of one such master transcription factor results in a reduction of 
cooperative binding at super-enhancers and causes transcriptional elongation defects of 
genes near these super-enhancers 40. H3K27ac occupancy defines active enhancers 41. In 
a recent study super-enhancers identified using previously established H3K27ac binding 
profiles from different cell types were shown to regulate genes that define cell identity 42, 
43. In addition, an enrichment of disease-associated variants was found within these super-
enhancers 43. These results strengthen the importance of super-enhancers and master 
transcription factors in regulating gene transcription, defining cell identity and their role 
in diseases. 
1.1.2 Epigenetics
The DNA is tightly packaged in the nucleus in a condensed DNA-protein structure. This 
structure is called chromatin (Figure 1.1). The basic repeating structure unit of chromatin 
is the nucleosome. The nucleosome is composed of an octameric nucleosome core 
that consists of one histone H3-H4 protein tetramer opposite of two histone H2A-H2B 
dimers. Approximately 147 bp of DNA is wrapped around the nucleosome core 44. The 
DNA around this nucleosome core is kept in place by histone H1. Each histone contains a 
globular DNA-binding domain and a N-terminal tail that protrudes from the nucleosome 
45. 
Both the DNA and the histones can be modified by chemical changes that leave the 
genetic code intact (Figure 1.1). These chemical changes that modify DNA and histones 
and that shape the physical structure of the genome, are called epigenetic modifications. 
The combination of all epigenetic modifications that regulate the activity (expression) of 
all genes within the genome is called the epigenome. The establishment of a mark (or 
modification) on either DNA or the histone tail is mediated by enzymes termed ‘writers’. 
These modifications can be removed or modified by ‘editing’ enzymes, and the interaction 
of a mark with a protein complex to exert effects on transcription is mediated by the ‘reader’ 
enzymes of an epigenetic mark 46. Modifications of the epigenome facilitate or prohibit the 
access of transcription factors to DNA to control gene transcription that is essential in 
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healthy growth and development of many different tissues 47, 48. Epigenetics is the study of 
these modifications that result in alterations of gene expression. There are different forms 
of chromatin state that reflect the level of activity in the cell. Euchromatin is lightly packed 
in the cell nucleus, enriched in genes and usually in active gene transcription. While, 
heterochromatin is more tightly packaged, commonly found on the peripheral areas of 
the nucleus and is more abundant in cells with less active or no transcription 49, 50. 
DNA methylation
Tight regulation mechanisms are in place to orchestrate the DNA accessibility in its 
chromatin environment. DNA methylation is a process that adds a methyl group to a 
cytosine or adenine DNA nucleotide. Adenine methylation in DNA is widely present in 
prokaryotes and was determined to be relatively uncommon in eukaryotes 51.
In vertebrates, cytosine is known to be modified by DNA methylation, resulting in the 
conversion of the cytosine to 5-methylcytosine. This typically occurs at regions of DNA 
in which a cytosine nucleotide occurs next to a guanine nucleotide in a linear sequence 
of bases, called CpG sites. Genomic regions that have a high frequency of CpG sites are 
called CpG islands. During development, most CpGs in mammalian genomes (70 to 80%) 
are methylated (5mC), except for CpG islands that are localized in gene promoters 52. 
Approximately 70% of all annotated gene promoters of the vertebrate genome contains 
CpG’s 14, 53, suggesting that many genes can potentially be regulated by DNA methylation.
DNA methylation was shown to play essential roles during normal development, for 
example in genomic imprinting, X-chromosome inactivation, suppression of repetitive 
elements and carcinogenesis 54. DNA methylation was initially shown to act in the 
repression of gene transcription by inhibiting the transcription machinery to associate 
with the DNA and recruiting repressive histone modifiers (see Section 1.2.2) 14, 55. More 
recently it was shown that DNA methylation may play both a passive and active role in 
gene regulation, showing more complexity and variability in the mechanistic relationship 
between DNA sequence variability and gene expression 56. Recent studies revealed that 
5mC in CpG islands can also be hydroxylated into 5-hydroxymethylcytosine (5hmC) by 
TET enzymes 57. However, the biological function of 5hmC is currently unclear 58.
Development in technology has enabled the detection of very low levels of methylation 
and has recently lead to the detection of adenine methylation (N6-methyladenine, 6mA) 
and the DNA demethylase that regulates 6mA in green algae, worms, and flies 59-61. These 
studies propose a function for 6mA and its demethylase in these organisms and suggest 
that these might also play a potential role in higher eukaryotes but no evidence for the 
latter has been described so far.
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1Histone modifications
There are more than 60 different post-translational modifications known that alter the 
N-terminal tails of the core histones, including methylation, acetylation, phosphorylation, 
SUMO-ylation and ubiquitination. Many of these modifications can occur on various 
amino acids at numerous positions of the protruding histone tails (Figure 1.1). These 
histone modifications alter the chromatin structure and function to mediate cell type 
specific gene regulation. However their exact and potentially combinatorial roles have yet 
to be understood.
The most widely studied histone modifications are acetylation and methylation. 
Acetylation correlates with transcription. For example, acetylation of lysine residues was 
found to correlate with transcriptional activation, associate with histone deposition and 
was more recently found to also be associated with DNA repair. The writing of histone 
acetylation occurs by histone acetyltransferases (HATs) that are recruited by transcription 
activators, whereas transcriptional repressors and co-repressors associate with histone 
deacetyltransferases (HDACs) that erase the histone acetylation mark 62, 63.
Histone methylation occurs on lysine and arginine residues and functions as a major 
determinant for formation of transcriptionally active and inactive regions of chromatin 
64. The lysine residues can be mono-, di- or tri-methylated, with each distinct methyl 
group addition, producing specific effects on chromatin structure and on the interactions 
of regulatory proteins with chromatin and causing unique functional consequences 
65. Methylation of histone 3 lysine 4 (H3K4) and lysine 36 (H3K36) is correlated with 
transcriptional activation. In contrast, methylation of histone 3 lysine 9 (H3K9) and lysine 27 
(H3K27) is correlated with transcriptional repression 66. The enzymatic activities of histone 
methylation are controlled by histone methyltransferases (HMTs) that catalyze methylation 
(writer), while histone demethylases (HDMs) remove methyl groups (eraser) 62, 63.
Here, several specific histone modifications are described within the scope of this thesis. 
This involves methylation and acetylation at various locations of the protruding N-tail of 
histone H3. Tri-methylation of H3K4 (H3K4me3) can be found at the TSS of genes and 
correlates with active gene transcription and expression 41, 67, while tri-methylation of 
H3K27 (H3K27me3) that is established by the HMT Polycomb repression complex (PRC2) 
is related to gene repression 68-70. Mono-methylation of H3K4 (H3K4me1) can be found at 
regulatory elements, such as enhancers but does not directly associate with a functional 
role of these elements in gene regulation. Acetylation of H3K27 (H3K27ac) was found at 
promoters and active enhancer elements and correlates with active gene expression 41. In 
addition, the previously mentioned H3K27me3 was also identified at regulatory elements, 
and correlates with inactive elements, so called poised enhancers 71, 72. These histone 
modifications regulate different aspects of cellular signaling and function.
16
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1.1.3 Higher order of regulation
Besides histone modifications, the higher-order arrangement of nucleosomes is also 
relevant to control gene regulation by organizing the chromatin structure. Arrays of 
nucleosomes are linked together by binding of a linker histone H1 to the nucleosome core 
particle, which produces higher-order chromatin structures, which is shown to influence 
chromatin arrangement and compaction 73, 74. This regulation of the compaction of the 
chromatin structure determines the accessibility of the DNA to transcription factors and 
the transcription machinery, and thereby plays a role in controlling gene regulation.
Recently, large, megabase-sized local chromatin interaction domains were identified, 
called topological domains or topologically associated domains 75. The borders of these 
domains were enriched for several factors including the insulator binding protein CTCF, 
housekeeping genes, transfer RNAs and short interspersed element retrotransposons. 
This suggests that these factors are essential in establishing this structure in the genome 
75. CTCF binding is often found at transitions between distinct chromatin states. The 
CTCF binding regions define distinct chromatin domains with unique epigenetic states, 
suggesting that CTCF bound regions can act as so called boundaries 76. These borders 
of topological domains are often referred to as insulators and function as barriers to the 
effect of distal enhancers and silencing elements. 
The topological domains are suggested to be an inherent property of the mammalian 
genomes since they are found to be stable across different cells types and highly conserved 
across species 75. Controlled gene regulation within defined topological domains starts 
to become evident. It was shown that genes located in the same topological domains 
show greater expression correlation than genes located in different topological domains 
77. Other studies demonstrated that disruption of topological domains causes pathogenic 
rewiring of gene enhancer interactions leading to malformation syndromes 78, 79. For 
example, the loss of an insulator causes limb malformation due to alterations in the 
regulatory landscape that results in misregulation of gene expression 78, 79. These findings 
demonstrate the important role of properly established and defined regulatory landscapes 
in controlling spatio- and temporal gene expression.
1.1.4 Post-transcriptional mechanisms
Processes that regulate gene expression after mRNA synthesis are called post-transcriptional 
processes. There are many post-transcriptional processes known, such as mRNA splicing, 
capping, cleavage, editing and polyadenylation, export and degradation 80. Recently, 
it has become evident that non-coding RNA’s (ncRNAs) such as microRNAs (miRNAs), 
small interfering RNAs (siRNAs), small nuclear RNA (snRNAs), and long non-coding RNA’s 
(lncRNAs) are also essential in post-transcriptionally regulating gene expression. 
17
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1Small non-coding RNAs are functional RNA molecules that are transcribed from DNA 
sequences but not translated into a protein. Small non-coding RNAs can have multiple 
functions within a cell, including activation, repression, or interference with gene 
expression and have been implicated in a number of developmental disorders 81. Short 
double-stranded RNA molecules can disrupt gene expression of single-stranded RNAs. 
This biological process is called RNA interference (RNAi) 82. One of the most abundant 
classes of small RNA regulators are microRNAs (miRNAs) comprising approximately 1%-
5% of mammalian genes. MiRNAs are small non-coding hairpin-like RNA structures of 
approximately 20-24 nt’s and shown to be key regulators of gene expression 83-85. MiRNAs 
function via base-pairing with complementary sequences within mRNA molecules, usually 
the 3’ untranslated regions (3’ UTR) to repress protein synthesis. The mRNA molecule can 
subsequently be silenced as a result of one or more mechanisms, such as RNA cleavage, 
destabilization of the mRNA transcript, or translational repression 86, 87. Another class of 
non-coding RNAs are lncRNAs. These lncRNAs are defined as molecules greater than 200 
nucleotides in length. LncRNAs regulate diverse processes, such as epigenetic control 
of chromatin 88, promoter-specific gene regulation 89, 90, maintenance of nuclear body 
structure 91, and control pluripotency or lineage commitment programs in stem cells 92. 
Recent studies also showed a role for lncRNAs in epidermal differentiation 93, 94. However, 
the function of the vast majority of lncRNAs in humans remain unknown 95.
1.2 Characterization of gene regulation by genome sequencing
The first human genome draft was released in 2003. The arrival of high throughput whole-
genome sequencing has made it possible to sequence the human genome cheaper and 
faster. This technological development has enabled the study of different aspects of gene 
regulation at an unparalleled scale and resolution. 
In recent years, many research groups and consortia, such as the ENCODE consortium, 
have made break-through advances in gaining knowledge of the epigenome using high-
throughput genomic techniques in many cell lines and tissues 96, 97.
Here, some techniques are described that are relevant within the scope of this thesis 
(Figure 1.2). Genome-wide analysis technologies such as exon expression arrays and high-
throughput RNA sequencing (RNA-seq) allow the detection of expression at the individual 
exon level. Exon arrays rely on pre-designed complementary sequence detection probes 
whereas RNA-seq uses direct sequencing of transcripts. The latter has the capacity to 
generate data that cover the entire transcriptome and enable the detection of junctions 
between exons without prior knowledge of the gene structure and isoforms 98-101. ChIP-seq 
can be used to identify specific genomic regions that are bound by transcription factors or 
18
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histones. It is for example used to study DNA-binding of I) sequence-specific transcription 
factors such as p63, II) RNA polymerase II (RNAPII) that catalyzes transcription 102, and 
III) histone modifications such as H3K27ac that marks active promoters and enhancers 71 
(Figure 1.2). There are also various methods, including FAIRE-seq, DNase-seq, and ATAC-
seq that enable the identification of accessible DNA regions, such as regulatory elements 
on a genome-wide scale 103. Other techniques such as 4C, 5C, Hi-C, ChIA-PET and 
Capture-C provide information on 3-dimensional chromosomal interactions 104-108 (Figure 
1.2). These techniques are used to identify regulatory regions and to map the chromatin 
landscape to understand their role in gene regulation. As we gain more knowledge on the 
complex gene regulation programs, we will further understand not only the mechanisms 
of human development, but also the etiology of many human diseases.
Figure 1.2. Schematic representation of methods used to study gene regulation. Methods are indicated in 
grey boxes (modified figure from ENCODE consortium).
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11.3 Transcription factor p63 and its family members1
Transcription factors are important regulators that control gene expression essential for 
proper cell proliferation and differentiation during embryonic development. Disruption 
of gene regulation through dysfunction or de-regulation of transcription factors results 
in developmental disorders 109. One key (sequence-specific DNA-binding) transcription 
factor for ectoderm development and related diseases is p63, a member of the p53 family 
that includes the TP53, TP63 and TP73 genes 110-113. 
The TP53 gene was identified in 1979 as a key factor in tumor suppression 114. The other p53 
family members, the TP73 and TP63 genes were discovered in 1997 and 1998, respectively 
111, 115. Due to the structural similarity of these genes to TP53, it was speculated that p63 and 
p73 may also play a role in cancer. However, the TP73 gene was shown to play a role in 
embryonic neurodevelopment 110, and the role of p63 in the development of ectoderm 
derived epithelial tissues and structures became evident when Tp63 knockout mouse 
models and mutations associated with human diseases were reported. Tp63 knockout mice 
showed defects in the development of ectoderm derived epithelial structures and tissues 
including skin, hair, limbs and palate 6, 116. At the same time, heterozygous mutations in the 
human TP63 gene were found to be causative for an ectodermal dysplasia syndrome 5. At 
present, seven developmental disorders that are characterized by three major hallmarks 
namely, ectrodactyly (split-hand/foot malformation, SHFM), orofacial clefting (CL/P), and 
ectodermal dysplasia are known to be caused by TP63 mutations (Figure 1.4) 4, 5. Recent 
knock-in mouse models carrying TP63 human disease mutations show developmental 
defects corresponding to the human phenotype 117, 118.
1.3.1 Differences in p53 family genes
The genes of the p53 family share a high degree of sequence homology, especially in 
the DNA binding domain and all have the ability to bind as a tetramer to the DNA 119-121. 
Although all the p53 family members show high homology and conservation at the amino 
acid level in certain domains (DNA binding domain, transactivation and oligomerization 
domains), there are several structural differences that partially explain the differences in 
function between p53 and the other family members. The TP63 and TP73 genes contain 
two functional domains, the sterile-alpha-motif (SAM) and transactivation inhibitory (TI) 
domains that are absent in TP53 122 (Figure 1.3). The SAM domain is known to be important 
for protein-protein interactions and TI domain can enforce structural conformation 
changes. Moreover, the 3’-end of exon 10 corresponding in TP63, TP53, as well as TP73 
encodes the tetramerization domain which is part of the oligomerization domain 38 (Figure 
1. Some of the next paragraphs are published in: Evelyn N. Kouwenhoven, Hans van Bokhoven, Huiqing Zhou. Gene 
regulatory mechanisms orchestrated by p63 in epithelial development and related disorders. BBA. 2015
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1.3). However, only p63 and p73 can form tetramers with other family members in different 
combinations, while p53 cannot 37, 38, 123. The structural complexity of these genes results in 
a complicated interplay between the family members and their isoforms and affects their 
function 124-126. 
Furthermore, even though common binding sites were previously identified near target 
genes that can be bound by all p53 family-members in human osteosarcoma and cervical 
carcinoma cell lines 127, 128, specific binding sites have been identified that are only bound 
by one of the family-members. These identified specific binding sites were mainly subsets 
of specific binding sites of p63 and p73 in the human osteosarcoma cell line 127 and of p63 
in primary human foreskin keratinocytes 129. While the p53 binding sites mostly overlapped 
both p63 and p73 binding sites 127, 129. This specificity of the binding sites could be partially 
explained by a slight difference of nucleotide preference in the DNA binding sequences 
(also called consensus motif) of these individual family members 121, 130-132. Or it may depend 
on different expression levels of the p53 family proteins in a specific cellular context 133.
1.3.2 Gene and protein structures of p63
The TP63 gene was shown to be the ancestral member of the p53 family 112, 113, and is 
located on the long arm of chromosome 3 (3q27-q28) (Figure 1.3). It is transcribed by two 
different promoters yielding a TA (TAp63) isoform with exons 1-3 and a deltaN (ΔNp63) 
isoform with exon 3’ at its N-terminal end. Another N-terminal isoform ΔΔNp63 resulting 
from an alternative translational start site methionine 26 was also reported 134. Alternative 
splicing routes give rise to various isoforms with different C-terminal ends, α, β, g and δ 
isoforms 111, 135, 136. At the C-terminal end, there is another isoform, the e isoform that results 
from premature transcriptional termination in exon 10 135, 136. The p63 protein contains 
several functional domains including the transactivation domain (TA) which bears high 
homology to the TA domain of TP53. For a long time the ΔNp63 isoform that does not 
contain the TA domain was thought to be a dominant repressor. It has been shown however 
that ΔNp63 also exhibits transactivation activity and contains a TAΔN activation domain at its 
N-terminus 134, 137-141. Another activation domain (TA2) is found positioned between amino 
acids 410 and 512, and encoded by exon 11 and 12 138. The DNA binding domain (DBD) 
and oligomerization domain are present in all isoforms and crucial for the binding to DNA 
and for the dimerization of p63 molecules, respectively. Two additional domains are found 
at the C-terminal end, the sterile-alpha-motif domain (SAM) and transactivation inhibitory 
domain (TI). The SAM domain is known to be important for protein-protein interactions 
and only present in the longest α-isoform. The inhibitory TI domain is encoded by exons 13 
and 14, and found in α, β, and δ isoforms 138. The TI domain is able to block transactivation 
by masking a few residues of the N-terminal TA domain intra-molecularly. It may also 
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1be responsible for oligomerization with other isoforms 122, 142-145. There are also reports of 
more p63 isoforms in the mouse skin 146 and in prostate cancer cells 147. Throughout this 
thesis, I have used the TP63 gene nomenclature and the numbering of mutations based 
on the original TP63 published sequence (Genbank AF075430), which does not encode 
the 39 amino acids at the N-terminal end contained in the presently accepted TP63 Refseq 
sequence (NM_003722.4) formerly known as TA*p63 111.
1.3.3 Expression of p63 isoforms
Studies on expression of TAp63 and ΔNp63 isoforms during epithelial development 
showed contradicting findings that resulted in different hypotheses of p63 function. 
Koster and colleagues reported that TAp63 isoforms can be detected before the 
initiation of epidermal stratification and that expression of ΔNp63 isoforms starts later 149. 
Therefore they suggested that TAp63 initiates the stratification and inhibits the terminal 
differentiation of the epidermis. However, other studies showed that TAp63 isoforms were 
not detected during early development and only in low amounts during the development 
of ectodermal appendages 150-158. In contrast, these studies showed that ΔNp63 is the main 
isoform expressed in the developing embryonic epidermis, tooth, hair, palate, thymus and 
Figure 1.3. Gene and protein structures of TP63. Two separate promoters (P1 and P2) give rise to two 
isoforms at the N-terminus, the transactivating (TA) and N-terminally truncated (ΔN) isoforms. Alternative 
splicing and premature termination at the C-terminus of p63 yields α, β, g, δ and e isoforms. Exons 
encoding the various functional domains in p63 are color coded as indicated. aa, amino acid; TAΔN, 
transactivation domain of the ΔNp63 isoforms 148.
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the apical ectodermal ridge of the limb bud 150-157. Moreover, ΔNp63α was found to be 
the main isoform in proliferating keratinocytes residing in the basal layer of the human 
epidermis and its level decreases during keratinocyte differentiation 154, 159. Interestingly, 
the same studies showed that TAp63 seems to contribute to the formation of the outer 
stratified layers of the epidermis, and was found to be expressed in the outer layers of the 
epidermis 150.
Furthermore, expression of TAp63 was clearly shown to be functionally relevant in germ 
cells including oocyte nuclei 160-162 and spermatogenic precursors 147, endodermal cells 
lining the heart 163, 164, and in cochlea 165. Due to the high expression level of the ΔNp63 
isoforms and low expression of TAp63 in epithelial cells, gene regulation in epithelial 
development may mainly result from ΔNp63 function.
1.3.4 The role of p63 in epithelial development and related diseases
It has been well established that p63 plays an important role in epithelial commitment 
and development. The Tp63 knockout mice show craniofacial abnormalities, truncated or 
absent limbs, and absence of hair follicles, tooth placodes, nails and also loss of sebaceous, 
mammary, and salivary glands 5, 6, 116. These mice lack all stratified epithelia including the 
epidermis, which causes dehydration and death shortly after birth. In zebrafish, p63 is 
highly expressed throughout late gastrulation and early segmentation, and the expression 
is confined to the ventral ectoderm that gives rise to cells and tissues with epithelial and 
non-neural fates during zebrafish development 166. Loss of p63 in the zebrafish embryo 
showed clear defects during formation of the Apical Ectodermal Ridge (AER) that will give 
rise to the zebrafish fin and skin-forming ectodermal derivatives 166. In cellular models, 
p63 is essential for epithelial commitment. Tp63-deleted mouse embryonic stem cells 
(mESCs) or human induced pluripotent stem cells (hiPSCs) with mutations in TP63 can be 
differentiated as far as the ectodermal stage that is marked by KRT8/KRT18 expression, but 
failed to develop to mature epithelial cells (keratinocytes) as determined by KRT5/KRT14 
expression 167, 168. These observations demonstrate the important role of p63 in epithelial 
commitment.
In epithelial cells from the skin, prostate and breast, high expression of p63 correlates 
with a high proliferation capacity, while low or no expression of p63 was observed in 
cells that lose their proliferative capacity, indicating the function of p63 in proliferation 169. 
Furthermore, p63 deficient mouse models 5, 6, 116 and keratinocytes with TP63 knock down 
170, 171 show defects in epidermal differentiation. These data support the hypothesis that p63 
maintains proliferation and regulates the differentiation initiation of epidermal stem cells 
159, 169. The role of p63 in both the epidermal stem cell maintenance and differentiation is 
not surprising because stem cell proliferation and differentiation are tightly linked events 
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1and the proliferation capacity of stem cells may directly affect differentiation. 
Human disorders associated with mutations in TP63
In humans, autosomal dominantly inherited heterozygous mutations in TP63 give rise 
to five syndromes and two non-syndromic clinical conditions (Figure 1.4). Syndromes 
associated with TP63 mutations include Ectrodactyly, ectodermal dysplasia, and cleft 
lip/palate syndrome (EEC, MIM 604292), Limb mammary syndrome (LMS, MIM 603543), 
Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC, MIM 106260), Rapp-
Hodgkin syndrome (RHS, MIM, 129400), Acro-dermato-ungual-lacrimal-tooth syndrome 
(ADULT, MIM 103285). These disorders exhibit a combination of defects in different tissues 
with three major hallmarks: ectrodactyly (split hand/foot malformations, SHFM), orofacial 
clefting (CL/P) and ectodermal dysplasia (ED) including defects in skin, teeth, nails, hair, 
and diverse exocrine glands 4, 5, 172. Non-syndromic SHFM (SHFM4, MIM 605289) and CL/P 
(NSCL/P, MIM 129400) are also occasionally caused by TP63 mutations 172. 
Figure 1.4. Phenotypic hallmarks of disorders caused by mutations in TP63. Mutations in TP63 give 
rise to five syndromic disorders, EEC, LMS, AEC/RHS and ADULT and two non-syndromic conditions, 
non-syndromic cleft lip/palate (NSCL/P) and split hand/foot malformation (SHFM). Three phenotypic 
hallmarks are present in these disorders, namely ectodermal dysplasia (defects in the epidermis and 
related appendages), orofacial clefting (CL/P) and limb malformations (SHFM). Patients with EEC and 
LMS show all these three hallmarks, whereas ADULT patients show ectodermal dysplasia and limb 
malformation and AEC and RHS patients have a combination of ectodermal dysplasia and CL/P.
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No ED phenotypes are observed in patients with a chromosome 3q deletion in which 
TP63 is located 173, 174 and in heterozygous p63 knockout mice 5, 6. These observations 
suggest that dose-dependent disease mechanisms such as haploinsufficiency are unlikely 
to cause the p63-associated phenotypes, and that the p63 mutant proteins have dominant 
negative or gain-of-function properties. 
EEC syndrome is the most common disorder among patients with TP63 mutations. EEC 
patients display split-hand/foot malformations, cleft lip/palate, and ectodermal dysplasias 
affecting skin, sweat glands, hair, nails, and/or teeth. The main cause of EEC syndrome is 
point mutations in the DNA binding domain (DBD) of TP63 5. These mutations in the DBD 
cause disruption of DNA binding or structural conformation changes 5. Interestingly, from 
all patients with EEC syndrome, 87% are caused by five hotspot mutations found in the DNA 
binding domain. These hotspot mutations display specific phenotypic signatures 4, which 
suggests that these individual mutations will affect differential subsets of target genes. 
Common characteristics observed in patients with ADULT syndrome are limb, teeth, skin 
and nail defects, and adermatoglyphia (loss of fingerprints) 175. No orofacial clefting was 
observed in ADULT patients. One missense mutation (R298Q) that lies in the DBD of TP63 
gives rise to ADULT syndrome. This mutation is probably a gain-of-function mutation, as 
it does not affect DNA-binding 176. The phenotype of LMS patients overlap with the EEC 
syndrome. Patients with LMS display severe hand/foot anomalies and hypoplasia/aplasia 
of the mammary gland and nipples. Defects such as lacrimal-duct atresia, nail dysplasia, 
hypohydrosis, hypodontia, and cleft palate with or without bifid uvula are less frequently 
observed. Mutations that cause LMS were found in both the N- and C-terminus of the TP63 
gene. In a large LMS family a point mutation in exon 4 (G76W) was found just downstream 
of the TA and TAΔN domain 3, 177, and other mutations were found also just downstream of 
the TA, TAΔN, and in the SAM and TI domain of TP63 3, 4, 177-179. The AEC and RHS syndromes 
are associated with missense, frameshift or deletion mutations in the TAΔN or TI and SAM 
domain, which are suggested to affect protein-protein interactions, result in the inability 
to form homo-or hetero-oligomeric complexes or cause a truncated ΔNp63α isoform 
(ΔΔNp63α)  that possibly functions as a dominant-negative regulator of ΔNp63α 134, 180-
185. AEC patients are characterized by clefting and ectodermal dysplasias with severe skin 
fragility defects manifested as erosive skin lesions 185-187. Patients with RHS display strong 
clinical overlap with AEC patients, and currently these two conditions are often considered 
variable manifestations of the same clinical entity. Due to phenotypic variability in severity 
of specific phenotypic defects, it is often difficult to make an accurate diagnosis based on 
clinical diagnosis 134, 188, 189. 
25
General introduction
1Non syndromic cleft lip and palate (NSCL/P) was associated to one missense mutation 
(R313G) in the TP63 DBD causing a gain-of-function 172. 
Widely distributed missense mutations in the TP63 gene, in the TA, DBD, or TI domains, 
were found to cause limb defects resulting in the Split-hand/foot malformation (SHFM4) 
syndrome diagnose. Several of these mutations are shown to disrupt sumoylation sites 
and are reported to cause changes in the p63 protein activation and stability 190-193. 
There is a good genotype-phenotype correlation for p63-associated disorders. For 
example, EEC that contains all three hallmarks of p63-associated diseases is almost 
exclusively caused by mutations in the DNA binding domain of TP63. In contrast, AEC 
and RHS that have severe epidermal erosion and CL/P are caused by mutations in the 
N-terminal TA domain of the ΔNp63 isoform (TAΔN) or the C-terminal SAM and TI domains. 
These observations might be explained by a subset of p63 target genes affected by different 
types of mutations. Furthermore, phenotypic differences are not only observed between 
the different syndromes, but also within one syndrome. Different mutations associated 
with each individual syndrome display incomplete penetrance and variable expressivity 
4, 181, 182, 184, 185, 194. This suggests that different mutations associated with one syndrome 
may affect different subsets of target genes that contribute to the type and severity of 
manifesting developmental defects. These findings demonstrate the high complexity of 
p63 pathogenesis.
Only a small proportion of patients with the same features as those observed in p63-
associated disorders can be explained by mutations in the TP63 gene. Hence, a large 
group of patients with phenotypes that resemble the p63-associated syndromes remain 
of which the underlying cause is still unknown, such as cases of patients with syndromic 
or nonsyndromic SHFM, CL/P, and certain ectodermal dysplasias (ED).
Split-hand/split foot malformation
SHFM is a clinically variable and genetically heterogeneous group of limb malformation. 
It is characterized by a deficiency of the central rays of the hand and feet, resulting in 
missing or malformed digits and is one of the main hallmarks in patients with mutations in 
TP63. This phenotype can be identified in isolated (non-syndromic) cases or be associated 
with other developmental abnormalities (syndromic). Although limb malformations are 
the second most common form of human congenital abnormalities (prevalence of 1 
in every 500 births), very few gene mutations leading to non-syndromic/isolated limb 
malformations have been identified. There are six chromosomal loci reported that have 
been associated with non-syndromic SHFM, of which only three have been explained by 
mutations within a gene in that region 195.
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The SHFM1 (MIM 183600) locus consists of various translocations, inversions, deletions 
and duplications on chromosome 7q21. The smallest region of overlapping deletions in 
SHFM1 patients spreads several genes including the candidate genes: DSS1, DLX5, and 
DLX6. Expression of DSS1 was identified in the mesenchyme of the developing mouse limb 
196, and DLX5 and DLX6 show expression in the apical ectodermal ridge (AER) during limb 
development 197, 198. Interestingly, p63 was previously shown to directly regulate DLX5 and 
DLX6 199. Recently, a research group showed the first strong evidence of the involvement 
of DLX5 in the pathogenesis of human SHFM. They identified homozygous missense 
mutations in the homeodomain of DLX5 to be causative for the observed limb phenotype 
in a consanguineous family with putative autosomal recessive SHFM 200. Another research 
group identified a heterozygous DLX5 missense mutation that results in incompletely 
penetrant autosomal dominant isolated SHFM1 201, providing further evidence for the 
contribution of DLX5 point mutations to the development of ectrodactyly.  
Another locus that is associated with SHFM has been mapped to a 5.1 Mb region on 
chromosome Xq26.3 (SHFM2, MIM 313350), which is only reported in a single SHFM 
family with X-chromosomal inheritance of isolated ectrodactyly 202.
Submicroscopic gene rearrangements were identified at chromosome 10q24 in patients 
with SHFM3 (OMIM 600095). The tandem duplications were approximately 440-570 kb 
and encompass either all or a portion of FBXW4 (also known as Dactylin), and several 
other genes, including BTRC, POLL and LBX1 203. Another research group could narrow the 
minimal region of duplication down to a 325 kb DNA sequence encompassing the BTRC 
and POLL genes. They suggest that the extra copies of BTRC (present in three copies, 
within the duplication) and SUFU (present in two copies, ~700 kb distal to the duplication), 
which were identified in lymphoblastoid cells are disease causative. Both BTRC and SUFU 
are essential in regulating β-Catenin signaling 204, 205. Since these pathways are essential 
for proper limb development, it is likely that an increase of BTRC and/or SUFU dosage 
can lead to altered regulation of these critical signaling events during digit formation, and 
cause SHFM. However, since this is demonstrated in lymphoblastoids cells the precise 
underlying mechanisms that are affected in the early embryonic limb during development 
are still unclear 206. 
As described earlier, non-syndromic SHFM can also be caused by mutations in the 
transcription factor TP63 gene (SHFM4, MIM 605289). 
SHFM5 (MIM 606708) in patients with SHFM including monodactyly is associated with 
deletions at chromosome 2q31 that encompass the entire HOXD gene cluster (HOXD1-
HOXD13) 207-209. The causative region within this locus causing SHFM5 is currently under 
discussion and the exact mechanisms are still unknown 210-213. 
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1Lastly, homozygous mutations in WNT10B that lies on chromosome 12q13 are associated 
with an autosomal recessive form of SHFM, SHFM6 (MIM 225300). WNT10B is a member 
of the Wnt ligand gene family and specifically activates the canonical Wnt/β-Catenin 
signaling pathway and functions in limb morphogenesis and development 214, 215. 
The role of long-range regulation in limb development has become evident by various 
cases of limb malformations that were caused by disruption of a cis-regulatory element 
or disruption of the topological domain structures. For example, the SHH ZRS enhancer is 
an important regulatory element that is active in limb development. Mutations in this cis-
regulatory element modify its activity and cause disruption of SHH expression which lies 
1 Mb away, resulting in limb malformations 216. This shows that this cis-regulatory element 
drives gene expression in a tissue specific manner and demonstrates the importance 
of long-range gene regulation in limb development. Another group that studies limb 
development found two flanking topological domains in the HOXD gene region and 
showed the importance of each domain in regulating gene expression for specific 
patterning of different parts of the limb during development. One domain regulated the 
expression of genes essential for forelimb and the other domain for regulating genes 
relevant in hand development 72. The crucial role of topological domains is supported by 
many other studies that showed that distinct human limb malformations are caused by 
deletions, inversions, or duplications that alter the structure of a topological domain 79. 
This is consistent with regulatory elements and topological domains being required for 
orchestrating spatio-temporal regulation of developmental gene expression.
More research is required including detailed analysis of the regulatory landscape to unravel 
the underlying disease mechanisms in the SHFM1- SHFM6 and other loci associated with 
SHFM.
Orofacial clefting
The development of the head and face requires complex gene regulation during 
embryogenesis. This process is orchestrated by a network of transcription factors 
and signaling molecules together with proteins that control cell polarity and cell-cell 
interactions. Disturbance of this tightly controlled cascade can result in an orofacial cleft. 
Cleft lip and/or cleft palate (CL/P) is one of the most frequent birth defect in humans, with 
a prevalence of approximately 1 in 700 births worldwide 217. Orofacial clefts are present 
as isolated cases or as part of a syndrome, with clinical manifestations that encompass a 
broad spectrum. The majority of CL/P cases are non-syndromic where CL/P occurence is 
not associated with other disease phenotypes. The risk of orofacial clefting is significantly 
higher in siblings than in the normal population 218, indicating that genetics plays a role in 
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the complex etiology of non-syndromic orofacial clefting. Besides a genetic cause for 
orofacial clefting, numerous environmental factors are known to cause an increased risk 
for clefting, such as maternal smoking, nutrition and alcohol use 219-223. 
The recent advantages in genetics and molecular biology have started to reveal the 
basis of orofacial development 224. Using linkage and candidate gene approaches several 
genes and genetic pathways were identified that are involved in orofacial clefts, mainly by 
studying syndromic cases of CL/P, demonstrating that genetic factors contribute to cleft 
lip and cleft palate formation. Genes that were shown to associate with syndromic forms 
of orofacial clefting include TP63, TBX22 225, PVRL1 226, FGFR2b 227-229, MSX1 230, and IRF6 
231-233.
Many of the identified causative genes of orofacial cleft are transcription factors, such 
as TP63 and T-box transcription factor TBX22. TBX22 was found to be causative of 
X-linked cleft palate (CPX, MIM 303400) that is characterized by isolated cleft palate and 
ankyloglossia (tongue-tie) 225. The PVRL1 gene is a member of the immunoglobulin super 
family that plays a role in the initiation and maintenance of epithelial adherens junctions. 
Mutations in PVRL1 give rise to cleft lip and palate/ectodermal dysplasia 1 syndrome 
(CLPED1, MIM 225000) 226. Mutations in FGFR2b are associated with various EDs, of 
which craniofacial abnormalities are the most prominent feature. Mutations in FGFR2b 
are causative for several craniosynostasis syndromes, including Apert syndrome (MIM 
101200), Pfeiffer syndrome (MIM 101600), and Crouzon syndrome (MIM 12350) 227-229. 
These findings show the important role of FGFR2b in orofacial development. Mutations 
were also observed in MSX1 that is causative of tooth agenesis with and without CL/P 230, 
234, 235. MSX1 plays a crucial role in the program of craniofacial morphogenesis during the 
development of teeth and craniofacial skeleton by functioning as a transcriptional repressor 
in cellular differentiation 236, 237. MSX1 can interact with other protein factors to modulate 
differentiation and proliferation 238 and has been proposed to direct terminal differentiation 
239. Another gene that is essential for palate development during embryogenesis is IRF6 
that was shown to regulate the proliferation-differentiation switch in epidermal cells 240, 241. 
Mutations in IRF6, give rise to Van der Woude syndrome (VWS, MIM 119300) or popliteal 
pterygium syndrome (PPS, MIM 119500). VWS is a dominantly inherited developmental 
disorder that is characterized by cleft lip and/or cleft palate (CL, CP, CL/P), and lower lip 
pits with variable penetrance 231-233. Similar phenotypes are observed in patients with PPS, 
but PPS patients also present facial and genital malformations, syngnathia (adhesion of the 
maxilla and mandible), and popliteal pterygia (skin webbing of lower limbs) 242-244. 
Although the identification of genetic mutations underlying syndromic forms of cleft lip and 
palate has been successful in several cases, there are many isolated orofacial clefting cases 
in which the causative variants are yet unknown. The majority of isolated orofacial clefting 
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1is considered to represent complex multi-factorial diseases with implication of gene-
gene interactions, gene-environmental interactions, and environmental and mechanical 
factors. This makes it a challenging task to study the etiology of NSCL/P. In recent years, 
great efforts have been made to identify the genes involved in the susceptibility to isolated 
CL/P and to characterize their relationship with specific environmental risk factors for 
the understanding of the pathogenic mechanism leading to the malformation. Due to 
the the multifactorial nature of NSCL/P, genome-wide association studies (GWAS) studies 
have been mainly performed to identify common genetic variants (SNPs) that have a high 
association with the phenotypic trait to identify the cause of isolated CL/P. These SNPs 
segregate with the specific phenotypic trait and can be used as a reference to identify the 
causative variant that causes CL/P 245. 
In several NSCL/P cases, mutations were identified in some of the known genes that are 
associated to orofacial clefting 246-249. This is true for variations observed in PVRL1 248, 250, 
TBX22 251, and MSX1 249, 252, 253.
Several studies also showed a role for genetic variants within the IRF6 locus in isolated 
CL/P 254-259. Recently, a common SNP that lies approximately 10 kb away from the IRF6 
gene was shown to be associated with an increased risk of isolated CL/P. This SNP was 
found to disrupt the binding of TFAP-2α in an enhancer near IRF6 256, 260. This demonstrates 
that it is worthwhile to study the IRF6 locus and its surrounding region in more detail and 
also the loci of other genes associated with CL/P to unravel new pathologic mechanisms 
that cause the CL/P phenotype.
Furthermore, there are several loci identified by GWAS studies that have been reported 
to associate with NSCL/P of which the pathogenic mechanism is still unknown. These 
loci include a gene desert region on chromosome 8q24, and loci near the ABCA4, and 
MAFB genes 254. Another study expanded their datasets and found association of SNPs in 
or near the VAX1 gene (chromosome 10q25), for which a role in palate development was 
shown by Vax1 mouse knockouts that display cleft palate, and at chromosome 17q22 that 
encompass the noggin gene (NOG) 261. Further delineation of these NSCL/P associated 
regions by identification of regulatory elements and non-coding genes will provide new 
information and potentially helps to identify variant(s) that cause or contribute to the 
observed orofacial malformations.
Ectodermal dysplasias
The most common definition of ectodermal dysplasias (EDs) is by primary defects in the 
development of two or more tissues that are derived from embryonic ectoderm. EDs 
represents a large and complex group of inherited disorders comprising more than 180 
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different clinical conditions 262. Common affected structures in ED are hair, teeth, nails, and 
sweat glands. Other structures of the ectodermal origin that may be involved in EDs are 
for example epidermis, mammary glands, and cornea 262. Although more than 60 genes, 
including TP63 have been found to associate with ED 262, the etiology of many ED cases 
is still unknown.
In some cases one gene can cause the manifestation of a specific ED phenotype, but in 
other cases mutations in one gene could result in clinically different ED phenotypes, while 
mutations in different genes could also cause similar ED phenotypic defects. Mutations in 
some disease genes, such as CTSC are responsible for various clinical ED phenotypes and 
give rise to Papillon-Lefevre syndrome (MIM 245000) that displays keratosis palmoplantaris 
with periodontopathia or Haim-munk syndrome (MIM 245010) that is characterized by 
palmoplantar keratoderma, severe periodonitis, arachnodactyly, acro-osteolysis, atrophic 
changes of the nails, and a radiographic deformity of the fingers 263. Another disease gene 
that causes various phenotypes is GJB2, mutations in this gene disturb the gap junction 
system of one or several ectodermal epithelia, thereby giving rise to: A. non-syndromic 
sensorineural hearing loss (SNHL), B. syndromic SNHL with palmoplantar keratoderma, 
and C. keratitis-ichthyosis-deafness syndrome that is characterized by sensorineural 
hearing loss (SNHL), vascularizing keratitis, and erythrokeratoderma 264. Some examples of 
transcriptional regulators that upon mutation cause phenotypes in various epithelial tissues 
include I. TP63 (associated disorders and phenotypes are described at the beginning of 
section 1.3.4.), II. TRPS1 which causes Trichorhinophalangeal syndrome type I and type 
III (MIM 190350 and 190351) that display craniofacial and skeletal abnormalities 265, and III. 
MSX1 that gives rise to a tooth-and-nail syndrome (Witkop, MIM 189500), orofacial clefting 
(MIM 608874), and tooth agenesis with or without orofacial clefting (MIM 106600) 230, 249, 
266. 
The syndromes caused by mutations in EDAR, CDH3, and PVRL1 226, 267, 268 share striking 
clinical overlap with EEC syndrome and related diseases. This suggests that these genes 
may be involved in common pathways or up- or down-stream targets of p63. The CDH3 
gene for example is a known target of p63 155, indicating that it might be worthwhile to 
investigate whether also other p63 target genes are mutated in phenotypically related 
diseases of p63-associated disorders.
1.3.5 Gene regulation controlled by p63 in epithelial-related tissues
The key role of p63 in epithelial development and related diseases underscores the 
necessity for elucidating gene regulation orchestrated by p63. Better understanding of 
the regulatory mechanisms will not only shed light on the molecular mechanism of 
normal epithelial development, but also provide insights into disease mechanisms of 
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1p63-associated diseases and other similar type of disorders, as genetic studies show that 
phenotypically related disorders are often caused by genetically linked genes 269. Initially, 
many p63-regulated genes were identified using candidate gene approaches, often by 
testing genes that have similar expression patterns and cellular functions as p63 or that are 
involved in diseases with phenotypes resembling p63-associated diseases 270, 271. In these 
studies, p63 binding to promoter regions of individual genes and affected gene expression 
caused by p63 deficiency are often demonstrated. Recent development of genomics 
techniques has made it possible to identify genes and regulatory mechanisms controlled 
by p63 in a genome-wide scale by determining the p63-dependent transcriptome and 
global p63-bound genomic regions.
Identification of p63-regulated genes by candidate gene approaches
The human skin has various important functions including temperature regulation, 
sensation, and protects the body against pathogens and excessive water loss. The 
epidermis, the outmost layer of the skin, affected in five of the seven p63-associated 
ED syndromes, is one of the major affected structures in p63-associated disorders. The 
epidermis is a multilayered epithelial structure that functions as a barrier and protects 
the body against outside insults. The structural integrity of the epidermis is dependent 
on proper proliferation and differentiation of epidermal keratinocytes. The epidermal 
basal layer consists of highly proliferative self-renewing keratinocytes that give rise to two 
daughter cells of which one remains in the basal layer and the other daughter cell undergoes 
multiple stages of cell differentiation. Upon differentiation, keratinocytes migrate upwards 
and give rise to the suprabasal spinous layer, the granular layer, and eventually the stratum 
corneum that consists mainly of enucleated corneocytes 272 (Figure 1.5). The skin has to 
withstand great mechanical stress; thus to maintain epidermal homeostasis it relies on 
replenishment provided by epidermal stem cells, tight intercellular adhesion and adhesion 
to the underlying basement membrane and proper repair after injury. This process of 
epidermal stratification is tightly controlled by gene regulation, including regulation of 
genes by p63. 
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As the importance of p63 in the epidermis is well established, many p63 target genes have 
been studied in the context of epidermal development (see Table 1.2). The keratinocyte 
marker gene KRT14 that is highly expressed in the basal layer of the epidermis similar to 
p63 expression, was shown to be a direct target of p63 270. KRT5, the partner of KRT14, is 
also expressed in a similar manner and was identified as a p63 target gene 271, although 
expression of KRT5 is also partially controlled through p63-independent pathways. 149, 157, 
167. Many other genes that are highly expressed in the basal layer of the epidermis and 
involved in adhesion and cell-cell junction are also directly regulated by p63. One of 
these is dystonin (BPAG-1) that is essential in anchoring the keratin-containing filaments to 
hemidesmosomes 273. Other p63-regulated genes involved in epithelial adhesion include 
Integrin-α3 (ITGA3), Integrin α5, α6, β4, Laminin g2, P-cadherin and PERP 274, 275. Although 
genes involved in epidermal barrier function are generally expressed at later stages of 
epidermal differentiation and stratification 276, p63 also regulates some of these genes. 
Examples include Claudin1 (CLDN1), a protein that functions in tight junction formation 
required for epidermal barrier formation 277, 278 and ZNF750 which is required for terminal 
epidermal differentiation 279. A mutation in ZNF750 is associated with a disease of barrier 
function defects, autosomal dominant seborrhea-like dermatitis with psoriasiform 
elements 280. ZNF750 also regulates KLF4, a known effector of terminal differentiation 279.
In addition to the epidermis, p63 target genes have been identified in other epithelial tissues 
such as hair, nails, mammary-, sebaceous-, and sweat glands, and also limbs and palatal 
shelves (see Table 1.2). Some of the p63 target genes are involved in the development of 
multiple structures. For example, the transcription factor GATA-3 that is involved in the 
Figure 1.5. Schematic model of human epidermis. The epidermis is the outer part of the human skin that 
can be subdivided into different layers (also referred to as strata). It is composed of a stratum basale that 
contains proliferating stem cells of which one cell remains in this layer and the other daughter cell moves 
up undergoing multiple stages of cell differentiation giving rise to the stratum spinosum and stratum 
granulosum to eventually become anucleated corneocytes that form the most outer barrier of the skin, 
called the stratum corneum.
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1cell fate decision of skin and hair follicle is regulated by p63 through direct binding of 
p63 at its promoter 281. GATA-3 subsequently regulates IκB kinase-α (IKKα) that plays a 
role in epidermis formation and limb development 281, 282. IKKα is also directly regulated 
by p63 281. The GJB6 gene encoding connexin-30 (Cx30) is associated with hidrotic 
ectodermal dysplasia (Clouston syndrome, MIM 129500), a rare autosomal dominant skin 
disorder. Direct regulation of GJB6 by p63 was shown in hair follicles, in the epidermis 
and in the nail unit 283. P-cadherin (CDH3), a member of the classical cadherin family that 
forms the transmembrane core of adherens junctions, is essential for hair, retina and 
limb development. The expression of CDH3 is regulated by p63 by direct binding to its 
promoter 155.
DLX3, another p63 target gene 284 plays a role in proper hair and tooth development 
287-289, as mutations in DLX3 are associated with tricho-dento-osseous syndrome (MIM 
190320) with phenotypes of hair, tooth, and bone malformations. Direct p63 target genes 
in limb skeletal development include DLX5 and DLX6 which are co-expressed with p63 
in the Apical Ectodermal Ridge (AER), a structure important for limb bud outgrowth and 
patterning 278. Mutations in the DLX5 and DLX6 genes have also been associated with inner 
ear defects 290. These defects were also observed in the p63 null mice, thus indicating a 
role for p63 in regulating inner ear development 165. 
Despite the key role of p63 in regulating many different epithelial-related tissues, little is 
known about the regulation of p63 expression during development. Some studies showed 
that initiation of TP63 expression is induced by bone morphogenetic protein (BMP4) 166, 
291, 292. Subsequent studies on mechanisms regulating p63 expression identified strong 
binding of p63 at two cis-regulatory elements that lie in intron 5 of TP63, downstream of 
the ΔNp63 promoter (P2) 293, 294. These enhancers were found to act synergistically and 
are bound concomitantly by other transcription factors that can control tissue-specific 
expression of TP63 both in vitro and in vivo 294. These data indicate that p63 can regulate 
its own expression in a tissue-specific manner through an auto-regulatory loop.
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Table 1.2. p63 target genes identified by individual candidate gene approaches
Gene name Cells/tissues References
BPAG-1 HaCaT, SAOS2 273
IKKA
p63-/- mice epidermis, HaCaT, NHEK, and Tet-on SAOS2 
cell lines
281
GATA3
p63-/- mice epidermis, HaCaT, NHEK, and Tet-on SAOS2 
cell lines
281
DLX3
Primary mouse keratinocytes, NHEK, SAOS2, HaCaT, and 
H1299
284
KRT14
Mouse keratinocytes, Ptk2, ME180, HEK293, MCF-7, 
HaCaT, and HeLa
270, 271
DLX5/DLX6
AER in developing limbs of p63-/-, p63EEC (R279H) 
mutant, and Dlx5 and Dlx6-/- mice, HaCat, and H1299
199
Integrin-α3 (ITGA3) U/p51A, U/p53, U937, NHK, HEK293 274
PERP
Perp-/- and p63-/- mice keratinocytes, p63-/- MEFs, and 
H1299
285, 286
CDH3 (P-cadherin) AER in developing limbs of mice, HeLa, HEK293 155
KRT5 Mouse keratinocytes, Ptk2, HaCaT, and HeLa 271
Claudin1 (CLDN1)
p63-/- mice, primary mouse keratinocytes, mouse 
ectoderm from fore limbs and hind limbs, H1299, U2OS, 
skin biopsy AEC patient
278
Note: SAOS2: Human osteosarcoma cell line; HaCaT: Immortalized human keratinocyte cell line; H1299: Non-
small-lung carcinoma cell line; NHEK: Human primary keratinocytes from newborn foreskin; HFK: Primary 
neonatal Human Foreskin Keratinocyte; NHK: Neonatal human foreskin keratinocytes; HeLa: Human cervical 
adenocarcinoma cell line; ME180: Human cervical squamous cell carcinoma cell line; HEK293: Human 
embryonic kidney epithelia; NIH3T3: Mouse fibroblasts; MEF: Mouse embryo fibroblasts; Ptk2: Rat kangaroo 
kidney epithelia.
Dissecting of regulatory mechanisms controlled by p63 with genome-wide approaches
A number of studies have provided valuable information for understanding the role of p63 
in the regulation of specific genes during the development of the epidermis and other 
epithelial tissues. However, as differentiation and developmental processes are often 
regulated by the interplay of diverse gene networks rather than individual genes 295-297, 
individual candidate gene approaches might not be sufficient to dissect the regulatory 
mechanisms controlled by p63. Fast developing technology has made it possible to study 
the role of p63 in epithelial development on a genome-wide scale.
Oligonucleotide microarray technology provided the first technology that allowed a 
comprehensive analysis of the entire transcriptome of tissues and cell lines in a single 
experiment 298. Many p63-regulated gene expression studies have been reported using 
microarray techniques (see Table 1.3) 131, 140, 170, 275, 299-302. Many of these studies used the RNA 
interference (RNAi) approach to knock-down TP63 in different types of p63-expressing 
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1cells, and each study identified several hundreds of p63-dependent genes 131, 140, 170, 171, 275. 
However, possibly due to the difference in cellular models and expression array platforms 
used in these studies, the overlap of p63-dependent genes is limited. Some other studies 
used approaches of overexpression of p63 isoforms or of TP63 mutants involved in 
diseases, and these studies revealed different sets of p63-regulated genes 170, 299.
In addition to expression analyses of p63-regulated genes, genome-wide p63 binding 
profiles were also generated (see Table 1.4). Initial experiments were performed with 
chromatin immunoprecipitation (ChIP) followed by cloning of the genomic fragments 
307 or by DNA microarray hybridization (ChIP-on-chip) 131, 140. The ChIP-cloning approach 
is tedious and only 62 p63-bound genomic regions were identified 307. ChIP followed 
by hybridization to the promoter or CpG island array also resulted in a small number 
of p63-bound regions 140. One comprehensive ChIP-on-chip study was performed 
using the ME180 cervical carcinoma cell line and ChIP followed by a tiling array 131. This 
analysis identified 3000-5000 p63-bound regions in the genome. Furthermore, this 
study combined expression analysis using the p63 knock-down approach and p63 DNA-
binding by ChIP-on-chip. Interestingly, although there is a correlation of p63 binding 
and p63-dependent gene expression with a statistical significance, only 10-20% of p63-
dependent genes have p63-bound regions in the vicinity, and conversely, only 15-20% 
of p63-bound genes exhibit concomitant gene expression change in a p63-dependent 
manner. These data raised an interesting question on the relation between p63 binding 
and p63-dependent gene expression. The initial genome-wide array analyses including 
gene expression and p63 binding gave rise to a considerable number of potential p63 
target genes that are associated with a broad range of functions such as cell proliferation, 
differentiation, adhesion, cell cycle regulation and apoptosis. With the fast developing 
sequencing technology, some of the array-based genome-wide analyses have gradually 
been replaced by sequencing analyses (see Table 7.1 and 7.2 in Chapter 7).
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1Table 1.4. Methods to determine p63 DNA-binding
Approach Cells/ Tissues Type of array Antibody References
p63 ChIP-on-
chip
Human ME180 cells
Affymetrix 14 array 
set of high-density, 
tiled whole human 
genome
4A4 131
p63 ChIP-on-
chip
Primary Human 
Keratinocytes from 
thigh skin
12K CpG islands and 
12K promoters
anti-p63 140
p63 ChIP-
cloning
HaCaT cells
H129 (Santa 
Cruz) and 
RR-14
307
p63 ChIP-on-
chip
Primary Mouse 
Keratinocytes
Agilent 244K-array 
60-mer Oligo
H137 (Santa 
Cruz)
170
p63 ChIP-on-
chip
HaCaT cells
12K CpG islands and 
the 12K promoters
4A4 (Santa 
Cruz) and 
anti-p63
308
1.3.6 Post-transcriptional and post-translational regulation of p63
Post-transcriptional changes
MiRNA-203 has been shown to target the 3’ UTR of the p63 mRNA, thereby blocking 
its translation process 309, 310. In situ hybridization showed that miRNA-203 was largely 
confined to suprabasal cells of epithelial tissues, and especially prominent in skin 311. The 
expression of miRNA-203 is completely opposite to the expression of p63 during skin 
differentiation. While p63 is highly expressed in the basement membrane and reduced 
upon differentiation, its negative regulator miRNA-203 is highly expressed in the late 
differentiation stages of the skin cells but expressed very low in the early differentiation 
stages 310. The role of miRNA-203 was studied in mice by ectopic expression under the 
KRT14 promoter and resulted in a thinner skin with aberrant expression of differentiation 
markers throughout the epidermal layers, and most transgenic mice died shortly after birth. 
In contrast, the inhibition of miRNA-203 resulted in an increase of epidermal proliferation 
309.
Post-translational changes
Many post-translational changes can regulate transcription factors activity, such as 
phosphorylation, acetylation, lipid modification, glycosylation, ubiquitination, for which 
various proteins are involved 25. It has been suggested that the different p63 isoforms are 
subjected to specific post-translational modifications, which correlates to their functions. 
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Here, a couple of the known proteins that have a function in post-translational control of 
p63 are described.
The phosphorylation of proteins can be controlled by protein kinases and protein 
phosphatases, and the phosphorylation of a protein can affect its stability. Most of the 
intracellular phosphorylation takes place at the serine and threonine basis. Data indicated 
that ΔNp63 is phosphorylated in primary human keratinocytes and in tumor-derived cells 
in response to different cellular stresses 312. Stratifin (14-3-3σ)-mediated nuclear export of 
ΔNp63α followed by binding of p63 by RACK1 (receptor for protein kinase C) targeted 
proteasomal degradation has been proposed to be involved in degrading ΔNp63 isoforms 
in response to genotoxic stress 313. A known target gene of p63, Dlx3, was found to induce 
phosphorylation of Raf1 resulting in induced Raf1 kinase activity and subsequently mediates 
p63 phosphorylation targeting p63 for proteasomal degradation 314, 315. This demonstrated 
a regulatory feedback loop between p63 and Dlx3 mediated by Raf1 314, 315. Another p63 
target gene that was found to reduce p63 protein levels by a feed-back mechanism is 
Irf6. However, the precise mechanism of Irf6-mediated degradation of the p63 protein is 
yet unknown 316. Phosphorylations on Ser/Thr residues was shown to stabilize exogenous 
TAp63α and g isoforms upon genotoxic treatment 317. 
E3 ligase-mediated ubiquitylation is the essential step for proteasomal degradation of 
proteins that have become substrates for particular E3 ubiquitin ligases only when they are 
phosphorylated 318. Many different proteins were shown to be involved in the ubiquitin-
dependent proteasomal degradation of p63 proteins that is triggered by phosphorylation. 
Various E3 ligases for p63 proteins have been identified, such as Itch, Nedd4, WWP1, 
SUMO-conjugated enzyme Ubc9, and Dlx3 190, 319, 320. Itch is involved in the control of p63 
protein levels in keratinocytes. Itch, a Nedd4-like ubiquitin E3 ligase, and its analogues 
Nedd4 and WWP1 can target p63 for ubiquitin-mediated proteosomal degradation by 
directly binding to the PPPY motif existing in the SAM domain of p63α 190, 319, 320. Peptidyl-
prolyl isomerase Pin1 was shown to inhibit binding of WWP1 E3 ligase to p63α and thereby 
preventing proteosomal degradation of p63α 321.
Sumoylation was proposed to regulate the biologic activity of p63. It was shown to have 
diverse functional effects involved in the regulation of subcellular transport, transcriptional 
activity, chromosome segregation, and cell cycle control 322, 323. Modification by Ubc9 of 
the SUMO-1 modification site in p63 destabilizes the p63α protein levels, modulates the 
transcriptional activity of p63, and affects its ability to induce cell cycle arrest and apoptosis 
190, 324.
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11.4 Potential treatment for p63-related disorders
So far, plastic and reconstructive surgery is the only method that is used to help p63 
patients with teeth, orofacial, and limb defects. However, after reconstruction, life-long 
care is often needed due to complications. In a recent publication a profoundly negative 
influence on post-operatively wound healing was demonstrated in patients with mutations 
in TP63 325. Furthermore, treatment of skin related defects in patients with p63-associated 
disorders is limited to general wound care and antibiotic treatment to prevent or cure 
infections. However, these skin defects, especially in patients with AEC or RHS syndrome 
can be severe and life-threathening in early life. This demonstrates the importance to 
discover therapeutic targets for the development of new strategies towards treatment of 
patients with p63-associated disorders.
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1.5 Thesis aims and outline
Transcription factor p63 was shown to function as a master regulator of ectodermal 
development. Although many p63 target genes have been identified, the complete p63-
controlled gene regulatory network remains to be elucidated. Little is known about the 
role of p63 in regulating gene transcription and the underlying p63-dependent disease 
mechanisms in the various ectoderm-derived epithelial structures and tissues that are 
affected in p63-associated disorders. Furthermore, besides surgery to treat the orofacial 
clefts and limb abnormalities, no major improvements in the development of therapeutics 
are available to specifically treat patients with mutations in TP63 for example to treat skin 
abnormalities and improve wound healing.
The first aim of my thesis was to elucidate the gene regulatory network of p63 by genome-
wide approaches by identification of p63-bound regulatory elements and p63 target 
genes using different ectoderm-derived epithelial tissues, such as primary human adult 
keratinocytes and mouse palatal tissues.
The second aim was to determine whether this p63 gene regulatory network including 
novel p63 target genes and regulatory elements can be used to elucidate the etiology 
of disorders with similar phenotypic characteristics to p63-associated disorders, such as 
SHFM, ED and CL/P.
The third aim of my thesis was to examine the role of p63 in epidermal differentiation, 
using an in vitro 2D differentiating model generated from human keratinocytes that 
mimics epidermal stratification.
The final aim was to investigate whether a small compound, APR-246/PRIMA-1MET, has the 
ability to restore the function of mutant p63, and to rescue the epidermal differentiation 
defects that were observed in skin equivalent models generated from EEC- and AEC- 
patient derived keratinocytes.
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1Outline of this thesis
Chapter 2 describes the first experiments to dissect the gene regulatory network of p63. 
Here, the genomic locations that are occupied by p63 were identified using p63 ChIP-seq 
experiments with different p63 antibodies in proliferating keratinocytes. My results show 
that the disruption of a p63-dependent cis-regulatory element is causative, as a novel 
disease mechanism of split hand/foot malformation (SHFM1).
Chapter 3 shows the importance of p63 in regulating gene expression during palatal 
development. A p63-dependent regulatory element was identified using the established 
p63-binding profile (Chapter 2) and it can drive the gene expression of IRF6 that has been 
associated with CL/P and thereby identify IRF6 as a novel p63 target gene during palatal 
development. Genetic studies using mouse models also demonstrated a cooperative role 
of p63 and Irf6 during palate development.
Chapter 4 reports p63 binding and expression profiles from specific stages of mouse 
palatal development that demonstrate a role for p63 in gene regulation involved in an 
adhesion program to maintain adhesion homeostasis in the developing palate and shows 
the requirement of p63 for periderm formation. Some of the identified p63 target genes 
in palatal tissue were also shown to be regulated by p63 in keratinocytes confirming the 
important function of p63 in transcriptionally regulating adhesion molecules in both the 
epidermis and developing palate.
Chapter 5 provides a comprehensive catalogue of differentially expressed epidermal 
genes, p63-regulated genes and DNA elements that control gene expression, identified 
using transcriptome and epigenome profiling of various stages of epidermal differentiation. 
My data suggest that p63 acts as a placeholder by bookmarking enhancers during the 
commitment of the epithelial lineage and regulates genes through temporal- and spatial-
specific active enhancers. This work provides a rich resource to study the development 
and disease mechanisms of epithelial tissues, skin diseases in particular.
Chapter 6 presents the results from treatment of skin organotypic reconstructions of 
mutant TP63 patient-derived keratinocytes using the mutant p53-targeting molecule, 
APR-246/PRIMA-1MET that is being tested in phase II/III clinical trials for cancer patients 
with p53 mutations. I show that APR-246/PRIMA-1MET can partially but consistently rescue 
the expression of specific p63 target genes and several terminal differentiation genes, 
providing novel directions for therapeutic development.
Finally, the results presented in this thesis are discussed in Chapter 7.
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Author Summary
Mammalian embryonic development requires precise control of gene expression 
in the right place at the right time. One level of control of gene expression is through 
cis-regulatory elements which are regulated by transcription factors. Deregulation of 
gene expression by mutations in such cis-regulatory elements has been described in 
developmental disorders. Heterozygous mutations in the transcription factor p63 are 
found in patients with limb malformations, cleft lip/palate and defects in skin and other 
epidermal appendages, through disruption of normal ectodermal development during 
embryogenesis. We reasoned that the identification of target genes and cis-regulatory 
elements controlled by p63 would provide candidate genes for defects arising from 
abnormally regulated ectodermal development. To test our hypothesis, we carried out 
a genome-wide binding site analysis and identified a large number of target genes and 
regulatory elements regulated by p63.  We further showed that one of these regulatory 
elements controls expression of DLX6 and possibly DLX5 in the apical ectodermal ridge in 
the developing limbs. Loss of this element through a microdeletion was associated with 
split hand foot malformation (SHFM1). The list of p63 binding sites provides a resource for 
studies of the regulation of normal ectodermal development, and should further be useful 
for the identification of mutations that cause ectodermal dysplasias and malformations in 
humans.
Abstract
Heterozygous mutations in p63 are associated with split hand/foot malformations (SHFM), 
orofacial clefting and ectodermal abnormalities. Elucidation of the p63 gene network 
that includes target genes and regulatory elements may reveal new genes for other 
malformation disorders. We performed genome-wide DNA-binding profiling by chromatin 
immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) in primary human 
keratinocytes, and identified potential target genes and regulatory elements controlled by 
p63. We show that p63 binds to an enhancer element in the SHFM1 locus on chromosome 
7q and that this element controls expression of DLX6 and possibly DLX5, both of which are 
important for limb development. A unique microdeletion including this enhancer element 
but not the DLX5/DLX6 genes was identified in a patient with SHFM. Our study strongly 
indicates disruption of a non-coding cis-regulatory element located more than 250 kb 
from the DLX5/DLX6 genes as a novel disease mechanism in SHFM1. These data provide 
a proof-of-concept that the catalogue of p63 binding sites identified in this study may be 
of relevance to the studies of SHFM and other congenital malformations that resemble the 
p63-associated phenotypes. 
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2
Introduction
The p63 protein encoded by the TP63 gene is a transcription factor of the p53 family 
and functions as a master regulator of ectodermal development. The key function of p63 
during ectodermal development is underscored by phenotypic features in p63 knockout 
mice 6, 116 and in p63 knock-down zebrafish 166, 326. The developmental abnormalities in 
animal models are reminiscent of those in p63-associated human disorders. Heterozygous 
mutations in p63 give rise to at least seven dominantly inherited clinical conditions with 
three major characteristics, ectrodactyly (also known as split hand/foot malformation, 
SHFM), orofacial clefting and ectodermal dysplasia with defects in skin, hair, teeth, nails and 
exocrine glands 5, 194. There is a clear genotype-phenotype correlation in p63-associated 
disorders 4. The most prominent of these disorders is the Ectrodactyly Ectodermal 
dysplasia and Cleft lip/palate syndrome (EEC, OMIM 604292) which combines all of 
the three phenotypic hallmarks and is almost invariably caused by missense mutations 
in the DNA binding domain of p63. Ankyloblepharon Ectodermal defects Cleft lip/palate 
syndrome (AEC, OMIM 106260) is caused by mutations in the SAM domain of the p63 
that is involved in protein interaction. Nonetheless, mutations of p63 can explain only a 
minority of patients with only one of the three cardinal features, such as in patients with 
isolated SHFM (~10%) and in patients with isolated cleft lip/palate (~0.1%) 4. There remains 
a large group of ectodermal dysplasia syndromes with phenotypes that resemble p63-
associated syndromes 327. The genetic basis of many of these clinically related conditions, 
referred to as the p63 phenotype network, is presently unknown. 
There is ample evidence that diseases clustering within such phenotype networks are 
caused by mutations in functionally related genes that constitute a gene network 269, 328, 
329. Elucidation of functional interactions among genes within the p63 gene network, their 
encoded proteins and regulatory elements which control expression of these genes will 
therefore provide new candidate genes for genetic disorders from the p63 phenotype 
network. Identifying target genes and cis-regulatory elements controlled by p63 is 
an important step in dissecting the p63 gene network. Previous studies have focused 
on transcriptional target genes of p63 identified through individual candidate gene 
approaches 199, 270, 273 or through genome-wide approaches 131, 140, 170, 275, 330. However, the 
role of regulatory elements controlled by p63 in transcription has not yet been addressed 
so far.
Split hand/split foot malformation (SHFM, OMIM 183600) is characterized by a deficiency 
of the central rays of the hands and feet, resulting in missing or malformed digits. SHFM 
may be isolated (non-syndromic) or be associated with other developmental anomalies 
(syndromic). Six distinct chromosomal loci for non-syndromic SHFM have been reported. 
Specific gene mutations have been identified in SHFM6 and SHFM4. SHFM6 (OMIM 
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225300, chromosome 12q13) is caused by a homozygous WNT10B mutation and it is the 
only autosomal recessive form of SHFM 331. SHFM4 (OMIM 605289, chromosome 3q27) 
is caused by p63 mutations 192. Chromosomal aberrations underlie three other types of 
isolated SHFM: 7q21 deletions and re-arrangements in SHFM1 (OMIM 183600) 332, 10q24 
duplications encompassing the Dactylin gene (FBXW4) in SHFM3 (OMIM 600095) 333, and 
2q31 deletions encompassing the HOXD gene cluster in SHFM5 (OMIM 606708) 208, 210. In 
addition, linkage analysis has mapped SHFM2 (OMIM 313350) to chromosome Xq26 202. 
The SHFM1 locus on chromosome 7q21 has been delineated by various translocations, 
inversions, deletions and duplications 334. The smallest region of overlapping deletions 
in SHFM1 patients 335 encompasses several genes: DYNC1I1, SLC25A13, DSS1, DLX5 and 
DLX6, of which only DLX5 and DLX6 have been shown to clearly play a role in early limb 
development. Dlx5 and Dlx6 are highly expressed in the apical ectodermal ridge (AER) of 
the developing limbs of mice 197, 336, 337 and in the fins of zebrafish 166, 326. The AER is critical 
for limb outgrowth and patterning 198 and there is strong evidence that a failure to maintain 
the AER signaling is the main pathogenic mechanism in ectrodactyly 338. The importance 
of the DLX5/DLX6 genes in limb development has been highlighted in mouse models. 
Dlx5 deficient mice do not show any limb defects 336. However, an SHFM-like phenotype 
has been observed when both Dlx5 and Dlx6 were simultaneously deleted (Dlx5/Dlx6 
-/-). The limb developmental phenotype in Dlx5/Dlx6 -/- mice could be fully rescued by 
overexpression of Dlx5 in the AER 197, 339. These observations suggest that the DLX5 and 
DLX6 genes cooperate in limb development by controlling a common developmental 
program. DLX5 and DLX6 are further expressed in the craniofacial prominence, the otic 
vesicle and in the brain 197, 336, 337, which correlates well with the hearing loss and mental 
retardation that are present in 30% of the SHFM1 patients 334. While DLX5 and DLX6 are 
obvious candidate genes for SHFM1, mutations have not been found in either of the two 
genes. 
Here, we used a genome-wide DNA-binding profiling approach using Chromatin 
Immunoprecipitation (ChIP) followed by deep sequencing (ChIP-seq) in human primary 
keratinocytes to generate a catalogue of highly informative target genes and regulatory 
elements controlled by p63. One cis-regulatory element identified by DNA-binding 
profiling is located in the SHFM1 critical region and acts as an enhancer element for gene 
expression mediated by p63 during embryonic limb development. Our data indicate that 
loss of this element leads to SHFM1. This example illustrates that our catalogue of p63 
binding sites can identify candidate genes and loci for the elucidation of disorders from 
the p63 phenotype network. 
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Results 
Genome-wide p63 binding profile in human primary keratinocytes
The most common isoform of p63, ΔNp63α, is highly expressed in the basal layer of the 
epidermis that consists mainly of keratinocytes. We therefore established human primary 
keratinocyte cultures (HKCs) from adult skin as our model system to elucidate p63 gene 
networks under physiological conditions. To identify target genes and regulatory elements 
controlled by p63, high-resolution global binding profiles of p63 were obtained from HKC 
cell lines established from two unrelated control individuals (wt1 and wt2) by ChIP-seq 
analysis using two antibodies recognizing different epitopes in p63 (4A4 and H129). Analysis 
of the sequenced reads using the peak recognition algorithm of Model-based Analysis of 
ChIP-Seq (MACS) 340 gave a highly significant overlap of 11,369 peaks from three profiles (P 
value < 1E-300) (Figure 2.1A). Overlapping peaks were therefore considered as a collection 
of high-fidelity p63 binding sites in HKCs. Indeed, a set of 17 representative binding sites of 
various peak heights, conservation scores and consensus motif scores (see below) were 
tested with independent ChIP followed by qPCR analysis (ChIP-qPCR) with two antibodies 
(4A4 and H129) and all of them could be validated (Table S2.1, Figure S2.1). This confirmed 
that the obtained p63 binding profile is highly reliable.
To determine the specific p63-binding sequences in the detected binding sites, a de novo 
consensus motif prediction pipeline was applied to generate a Position Weight Matrix 
(PWM) (see Methods for details). A highly significant consensus sequence was identified 
that is similar to the previously reported p63 and p53 consensus motifs (P value < 1E-250) 127, 
131, 170, 306 (Figure 2.1B, Table S2.2). An additional significant AP1-like motif that can be bound 
by c-Fos and c-Jun proteins 341 was also identified in the detected binding sites (P value < 
1E-50, Table S2.2). We combined our previously developed p53scan algorithm 127 with the 
newly identified p63 PWM, hereafter referred to as p63scan. Comparison of p63scan with 
the previously described motif algorithms p63MH 306 and p53scan 127 showed that p63scan 
had clearly higher sensitivity for motif recognition without compromising the specificity 
(Figure 2.1C). A slight increase of motif scores correlated with an increase of peak heights 
of the binding sites (Figure S2.2), suggesting a stronger binding of p63 to binding sites with 
higher motif scores. Using p63scan, 10,702 out of a total 11,369 p63 binding sites (94%) 
were found to contain at least one p63 motif (motif score 4.74, False Discovery Rate, FDR 
10%). The high percentage of motif-containing binding sites indicates that most binding 
sites identified in this study participate in direct binding of p63. 
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Figure 2.1. Characterization of identified p63 binding sites. A| A screenshot of chromosome 3 using 
UCSC genome browser shows similar DNA-binding profiles from our ChIP-seq analysis of two normal 
human primary keratinocyte cell lines (wt1 and wt2) with two different antibodies (4A4, pan-p63 and 
H129, a-specific). The p63 binding sites analyzed with MACS 340 using P value 1x10-9 are shown in 
red, and previously reported p63 binding sites in ChIP-on-chip analysis 131  are shown in black. B| The 
p63 motif was identified by a de novo motif analysis (see Material and Methods). Based on a previously 
developed p53scan algorithm 127 with this newly identified p63 Positional Weight Matrix (PWM), p63scan 
was developed. C| The performance of p63scan using the de novo identified motif shows superior 
sensitivity compared to previously reported p63MH without compromising specificity. D| Distribution 
of the p63-binding site location relative to RefSeq genes. Locations of binding sites are divided into: 
TSS flanking region (5 kb upstream of TSS, first exon and first intron), intragenic region (all introns and 
exons except first), < 25 kb (5–25 kb upstream or 25 kb downstream of last exon), or intergenic regions 
(everything else). The asterisk represents significant enrichment.
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The de novo consensus motif prediction pipeline was applied to the subgroup of binding 
sites without p63 binding motifs to search for consensus motifs of other transcription 
factors or novel binding motifs of p63. A degenerate p63 binding motif was identified, and 
interestingly, the AP1 motif was also found more strongly enriched as compared to the 
motif analysis of all binding sites (Table S2.2). 
An alternative approach also was taken to examine all known motifs of transcription 
factors in TRANSFAC Professional database (version 2009.3) 342 for their significant over-
representation (P value < 1E-10, after Bonferroni correction) in the p63 motif-less binding 
sites relative to the p63 motif-containing sites. Consistent with the de novo consensus 
motif search, the AP1 motif as well as the BACH1 and BACH2 motifs that are similar to AP1 
was found (Table S2.3). These data suggest that p63 can bind to DNA by collaborating with 
other transcription factors such as c-Jun or c-Fos. Interestingly, a previous report showed 
that p63 binds to an AP1 responsive element to regulate Keratin 1 in keratinocytes in a 
c-Jun dependent manner 343. No other novel consensus binding motifs were detected.
Out of 11,369 binding sites, 1460 lie between 5 kb upstream of the transcription start 
site (TSS) and the end of the first intron of genes, referred to as TSS flanking regions, and 
1908 binding sites are located within 25 kb distance to a gene (< 25kb region) (Figure 
2.1D). Statistical analysis showed that binding sites at these two chromosomal regions are 
enriched compared to genomic distributions of all binding sites (P value < 0.001). Genomic 
distribution of binding sites with or without a p63 binding motif was similar to that of all 
binding sites (Figure S2.3). In total, 10,895 genes had one or more p63 binding sites within 
25 kb up- and down-stream of the gene, and they were considered as potential target 
genes (PTGs) of p63. GO annotation of these 10,895 PTGs using DAVID Bioinformatic 
Resources 6.7 (NIAID, NIH) 344 showed a non-random distribution with enrichment 
in functional categories of biological processes, such as development, adhesion, cell 
communication and intracellular signaling cascade (Table S2.4). Binding sites with or 
without a p63 motif were also mapped to genes as separate subgroups, and 10,438 and 
944 genes, respectively, have p63 binding sites within 25 kb of the gene. GO annotation of 
genes mapped by binding sites with motifs resulted in very similar GO terms as annotation 
of all PTGs (Table S2.2).  However, 944 genes mapped by binding sites without motifs were 
seemingly involved in slightly different biological processes (Table S2.4). 
The p63 gene arose from two sequential gene duplications at the root of the vertebrates 
and has unambiguous orthologues only in that taxon 345. We therefore assessed the 
evolutionary conservation of the identified binding sites and the p63 consensus motifs 
therein in aligned vertebrate genomes (PhastCons). The identified binding sites had higher 
average PhastCons Conservation Scores (PCCS) and were significantly more conserved 
than random sequences of the same size (Figure 2.2A). Moreover, PCCS of motifs identified 
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in the p63 binding sites were also compared to that in the random genomic regions. By 
p63scan, 10,702 motifs were identified in 11,369 p63 binding sites and they were more 
conserved than 4,003 motifs identified in 100,000 random genomic regions (Figure 2.2B). 
These data support the functionality of the identified p63 binding sites. We did not observe 
a correlation between PCCS and peak height (Figure S2.4A) or a clear difference in PCCS 
of binding sites with and without p63 binding motifs (Figure S2.4B).
Association of potential p63 target genes with the disease phenotypes
To validate whether the identified binding sites represented target genes and regulatory 
elements relevant to the p63-associated and other diseases with clinical similarities, the 
OMIM database was searched for diseases associated with the 10,895 potential target 
genes in this study. We found 904 OMIM disease entries associated with these genes 
(Table 2.1, Table S2.5), referred to as p63 potential target gene-associated diseases (PTG-
associated diseases). To assess the relationship amongst PTG-associated diseases, their 
clinical features were analysed by text mining  (Table S2.6) and evaluated with a similarity 
algorithm 346 (Table 2.1). The potential target genes of p63 do not have strong tendency 
to associate with diseases (P value = 1). However, the feature terms in PTG-associated 
diseases are similar, as the similarity score of these diseases (0.284) is significantly 
higher than for a random distribution (0.200) (P value < 1E-6). This shows that PTGs are 
associated with diseases that have similar clinical phenotypes. Features associated with 
p63 syndromes are enriched in the top 10% of overrepresented feature terms for the 
Figure 2.2. Conservation of p63 binding sites and motifs in vertebrates. The percentage of p63 binding 
sites (y-axis) is plotted against decreasing cut-off values of the PhastCons Conservation Score (PCCS) 
(x-axis). A point on the line indicates the percentage of binding sites with that particular PCCS or higher. 
A| Average PCS of 100-nucleotide regions centered at the summit of 11,425 p63 binding peaks (peaks 
100) and that of 100,000 100nt regions randomly chosen from the whole genome (random 100). B| 
Average PCCS of 10,659 10-nt p63 motifs detected by p63scan in the 11,425 p63 binding peaks (peaks 
motifs) and of the 7,600 motifs detected in 100,000 random genomic regions (random motifs).
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PTG-associated syndromes (P value < 1E-28). Many of these terms such as stem cell and 
epithelium reflect p63 functioning (Table S2.6). This suggests that identified PTGs tend 
to cause similar disease phenotypes to p63-associated diseases. We did not observe a 
significant difference between terms derived from motif-containing binding sites or those 
from motif-less binding sites (Table S2.6). The significant similarity of disease features of 
PTGs suggests that these binding sites are relevant to p63-related developmental disorders. 
Table 2.1. Diseases associated with genes containing p63 binding sites
Diseases associated with 
genes with p63 binding sites
Total diseases in OMIM 
associated with genes
P valueC
No. of diseases 904 2033 1
Similarity score of
feature termsA
0.284 0.200B <10-6
A Text mined feature terms that are associated with diseases are calculated for their similarity scores (0, no overlap 
and 1, identical overlap). 
B Randomized sampling of 904 diseases from OMIM database are used for the similarity score.
C Chi-square test.
Table 2.2. p63-binding sites in the chromosomal regions near SHFM-associated genes (hg 18)
Gene Chr
No. of 
peaks*
Location of peaks
p63 chr3 4 191025109-191025933; 191034090-191035150; 191100798-
191101709; 191150499-191151202
SNX3 chr6 3 108392374-108393394; 108590949-108591991; 108862963-
108863753
GJA1 chr6 1 121848018-121848681
FOXP2 chr7 6
113725067-113725994; 113840901-113841821; 114182940-
114183839; 114211827-114212755; 114250288-114251274; 
114344204-114345050
DSS1 chr7 8
96029986-96030688; 96079266-96079792; 96110917-
96111692; 96132694-96133405; 96177547-96178220; 96194972-
96195903; 96337204-96338894; 96388802-96389666
DLX6 chr7 3 96194972-96195903; 96337204-96338894; 96388802-
96389666
DLX5 chr7 3 96194972-96195903; 96337204-96338894; 96388802-
96389666
FBXW4 chr10 1 103514476-103515097
SMC3 chr10 4 112103092-112103960; 112147937-112149561; 112223542-
112224445; 112243209-112244187
BRCA2 chr13 1 31904891-31905392
CDH3 chr16 2 67249490-67250527; 67259342-67260368
PORCN chrX 1 48204855-48205660
*Binding sites of p63 were searched within 300kb distance to the SHFM-associated genes and without CTCF 
binding sites in between.
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To assess whether p63 binding sites can function as regulatory elements in the p63-
related disease network, we focused on SHFM. From the human malformation disease 
database POSSUM 347 and the Jackson Laboratory’s Mouse Genome Database 348, 20 
genes were selected based on their localization in the human SHFM loci (Table S2.7). In 
addition, these genes are known either to associate with SHFM in human or to have similar 
phenotypes in mice. These genes are further referred to as SHFM-associated genes (Table 
S2.7). As regulatory elements can function over a large distance but might be blocked 
by insulator elements that are defined by CTCF binding sites 349, p63 binding sites were 
searched in broad chromosomal regions containing the SHFM-associated genes (up to 
300kb from the genes) provided that no known CTCF binding sites are located between 
the binding site and the gene. With these criteria, p63 binding sites were identified near 12 
SHFM-associated genes (Table 2.2). We propose that these p63 binding sites are potential 
regulatory elements that might contribute to SHFM. 
Identification of p63 binding sites in a 7q21.3 microdeletion in an SHFM1 patient 
In the SHFM1 locus on chromosome 7, several deletions have been identified which 
invariably contain the DLX5 and DLX6 genes as well as DYNC1I1, SLC25A13 and DSS1 
(Figure S2.5) 196, 335, 350-353. We identified a new patient with non-syndromic SHFM (for 
clinical phenotype, see Material and Methods) and a novel microdeletion of chromosome 
7q21 by a targeted 385K chromosome 7-specific microarray. Surprisingly, the 880kb 
chromosomal deletion at 7q21.3 encompassed DSS1, SLC25A13 and part of DYNC1I1 
but left the SHFM1 candidate genes DLX5 and DLX6 intact (Figure 2.3). The deletion 
was confirmed by genomic qPCR analysis (Figure S2.6). Compared with the previously 
reported minimal chromosomal deletion (Figure S2.5) 196, 335, 350-353, the protein-coding 
genes in the overlapping region are DYNC1I1, SLC25A13 and DSS1 but these are not likely 
to contribute to the phenotype 196, 354, 355. We therefore hypothesized that disruption of one 
or more regulatory elements caused the SHFM1 phenotype. To test this hypothesis, p63 
binding sites were searched in the chromosomal region spanning the DLX5/DLX6 genes, 
taking into account the published CTCF binding sites to define the borders of enhancer 
activity 349. Consistent with our hypothesis that DLX5/DLX6 are controlled by long distance 
regulatory elements, DLX5/DLX6 are located in a broad chromosomal region between two 
CTCF binding sites (chr7: 95882240-95882467 and chr7: 96495007-96495206) spanning 
approximately 600kb (green arrows in Figure 2.3). This region contains nine putative p63 
binding sites that were identified by our ChIP-seq analysis. These include three high peaks 
(SHFM1-BS1, -BS2 and -BS3) and six lower ones (a-f) (Figure 2.3, Table 2.3). 
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A p63 binding site within the SHFM1 deletion acts as an enhancer element in limb 
development
To identify the binding sites potentially important for limb development, the average 
PhastCons conservation score (PCCS) 356 of each of the nine binding sites was examined. 
Figure 2.3. A microdeletion at SHFM1 locus on chromosome 7. A screenshot of UCSC genome browser 
shows the p63 binding profile from two HKC cell lines (wt1 and wt2) with two p63 antibodies (4A4 and 
H129) near DLX5 and DLX6 on chromosome 7. SHFM1-BS1, -BS2 and -BS3 are three high peaks and 
a-f are low ones. SHFM1-BS2 and -BS3 are in close proximity and therefore seen as a single peak in 
this large genomic view. Ultra-high Comparative Genomic Hybridization array analysis performed with 
DNA of a SHFM1 patient showed a chromosomal deletion of 880 kb on chromosome 7 (95,390,000-
96,270,000, hg18, the orange arrow) which includes DSS1, SLC25A13 and part of DYNC1I1 but not 
DLX5 and DLX6. Breakpoints and 20kb averaged log2 ratios were visualized in the genome browser. A 
previously reported minimal deletion determined by markers D7S527 and D7S1796 335 is marked with a 
black arrow. Binding sites identified in this ChIP-seq study and in previous ChIP-on-chip 131 are labeled in 
red and black, respectively. CTCF binding sites revealed by previous ChIP-seq analysis 349 are labeled in 
green and two binding sites (chr7: 95,882,240-95,882,467 and 96,495,007-96,495,206) that define 
the enhancer activity of SHFM1-BS1 are marked by green arrows. A p63 consensus binding motif was 
identified in SHFM1-BS1 with the essential cytosine and guanine bases labeled in red.
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Table 2.3. PhastCons Conservation Scores (PCCS) of the identified p63 binding sites that potentially 
function as enhancer elements
Binding sites start end PCCS*
a 96030294 96030493 0.434
b 96079364 96079563 0.234
c 96111217 96111416 0.041
d 96133015 96133214 0.010
e 96177897 96178096 0.043
BS1 96195551 96195750 0.456
BS2/BS3 96337526 96337725 0.002
f 96389201 96389400 0.088
*Average PhastCons Conservation Score of the binding sites (hg18).
We found that SHFM1-BS1 had the highest PCCS (0.456) (Table 2.3) that belongs to the top-
ranking 11.6% of all 11,369 binding sites (Figure 2.2 and Figure S2.3). To test the functionality 
of p63 binding sites, the three high p63 binding peaks, SHFM1-BS1, -BS2 and -BS3, were 
cloned directly in front of a luciferase reporter that is followed by the SV40 enhancer to test 
whether they are responsive to p63 transactivation. Transient transfection assays showed 
that only SHFM1-BS1 was highly responsive to p63 (Figure 2.4A). Transactivation activity 
was completely abolished by mutations in the p63 binding motif present in SHFM1-BS1 
(Figure 2.4B; motif shown in Figure 2.3), indicating that the observed transactivation is 
p63-specific. Mutations in the DNA-binding domain of p63, R204W, R279H and R304W, 
that are found in EEC syndrome disrupted transactivation, whereas mutations found in 
non-syndromic SHFM4, K194E, and in AEC syndrome, L517F, reduced the transactivation 
activity not more than 2-fold (Figure 2.4C). Based on the structure of the DNA-binding 
domain in p53 that is highly homologous to that in p63, lysine 194 (Q165 in p53) is located 
in the DNA-binding domain but does not have direct contact with DNA 5, 357. The AEC 
syndrome mutation L517F is located in the SAM domain of p63. Therefore these mutations 
are unlikely to have major effect on p63 DNA-binding. To examine the enhancer activity 
of SHFM1-BS1, -BS2 and -BS3, these elements were cloned in front of the SV40 promoter 
or endogenous mouse Dlx5 and Dlx6 promoters that drive the luciferase gene, but no 
clear additional activation upon co-transfection of p63 was observed (Figure 2.4D, 2.4E 
and data not shown). Furthermore, in the absence of the enhancer, we did not detect p63 
activation on the Dlx5 promoter (Figure 2.4E, no BS) that was previously reported 199. This 
discrepancy is probably due to different cells used in transient transfection assays. These 
results indicate that enhancer activity controlling expression of DLX5 and DLX6 genes may 
not be correctly recapitulated in a cellular system irrelevant to limb development. 
To understand gene expression controlled by enhancer elements in embryonic limb 
development, we tested SHFM1-BS1, -BS2 and -BS3 in a transgenic reporter assay in 
zebrafish.  A specific expression pattern of the GFP reporter controlled by SHFM1-BS1 but 
not by SHFM1-BS2 and -BS3 (data not shown) was observed in the AER and weakly in the 
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ear and in the forebrain (Figure 2.5A). Expression of p63 detected by in situ hybridization 
was only clearly localized to the AER (Figure 2.5B). The reporter expression promoted by 
the SHFM1-BS1 in the AER that directs growth and patterning of limbs and fins correlated 
perfectly with the expression of p63, Dlx5 and Dlx6 during embryonic fin or limb 
development (Figure 2.5C) 199. To further determine whether gene expression regulated by 
SHFM1-BS1 depends on p63 in zebrafish, we examined the enhancer activity of SHFM1-
BS1 in p63-knockdown embryos injected with a specific p63 morpholino 326. 
In p63-morphant embryos at 48 hours post fertilization (hpf), the fin buds were severely 
reduced (mild) or absent (severe) (Figure 2.5C), as reported previously 166, 326. In the mild 
phenotypes, the expression of GFP induced by the enhancer was strongly reduced, as was 
the expression of the zdlx5a and zdlx6a genes. No fin defects were observed in embryos 
injected with a control morpholino (data not shown). Enhancer activity of SHFM1-BS1 was 
also tested in transgenic reporter assays in mice. Consistent with the zebrafish data, specific 
expression was observed in the AER in mouse embryos (E9.5 and E15), and the expression 
was lost when the p63-binding motif was mutated in SHFM1-BS1 (Figure 2.5D). These data 
showed that the specific expression in AER is dependent on p63. Taken together, our data 
obtained from animal models clearly demonstrated that SHFM1-BS1 can function as an 
enhancer element to control gene expression during embryogenesis and its activity is 
dependent on p63.
Having shown that gene expression regulated by SHFM1-BS1 correlates with that of Dlx5 
and Dlx6 in zebrafish and mice, we tested whether SHFM1-BS1 physically interacts with 
the Dlx5 and Dlx6 promoters. To do that, we used the Chromosome Conformation 
Capture technique (3C) 358 that allows detecting the three-dimensional proximity of two 
chromosomal locations (Figure 2.5E and 2.5F; Figure S2.7). In mouse embryonic limb 
tissues (E10), the interaction frequencies of SHFM1-BS1 with the promoter of Dlx6 and 
with the intergenic region between Dlx5 and Dlx6 were clearly higher than with the 
surrounding regions. This indicates that SHFM1-BS1 indeed strongly interacts with Dlx6. A 
weaker interaction of SHFM1-BS1 with Dlx6 was also detectable in E15 limbs. In addition, 
SHFM1-BS1 appeared to interact with the intergenic region between Dlx5 and Dlx6 that 
contains highly conserved enhancer elements 359, 360. We did not observe clear interaction 
of SHFM1-BS1 with the promoter of Dlx5. Taken together, our data show that p63 binding 
sites identified in HKCs can function as regulatory elements to control gene expression in 
embryonic limb development. We further conclude that disruption of regulation of DLX5 
and DLX6 controlled by p63 likely causes SHFM1. 
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Figure 2.4. Transient transfection analysis of p63 binding sites at SHFM1 locus on chromosome 7. A| The 
p63 binding sites SHFM1-BS1, -BS2 and -BS3 were tested in transient transfection assays in Saos2 cells. 
Transcription of the luciferase reporter was strongly activated by ΔNp63α through SHFM1-BS1 binding 
site but only weakly activated through -BS2 and -BS3. B| Activation was abolished when point mutations 
were introduced into the p63 binding motif in the SHFM1-BS1 binding site where the essential cytosine 
and guanine bases were mutated to adenosines. C| Activation was impaired by p63 EEC mutations 
R204W, R279H and R304W and slightly reduced by SHFM1 mutation K194E and AEC mutation L517F. 
D| No additional activation was observed when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the 
SV40 promoter driving luciferase. E| No activation was observed on the mouse Dlx5 promoter (no BS) 
and when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the Dlx5 promoter.
57
Genome-wide profiling of p63 DNA-binding sites identifies an element with a role in limb development
2
Figure 2.5. Functional analysis of SHFM1-BS1 to control gene expression in zebrafish and mice. A| 
SHFM1-BS1 was cloned in a reporter construct carrying GFP. Expression of the GFP gene in zebrafish 
showed that SHFM1-BS1 can control gene expression at the apical ectodermal ridge (AER), the ear and 
the forebrain. The red fluorescence expressed in the muscles in the first zebrafish panel corresponds to the 
positive control of transgenesis. B| Expression of zp63 in the AER was detected by in situ hybridization. C| 
Expression patterns of transgene GFP controlled by SHFM1-BS1, zdlx5a and zdlx6a were analyzed by in 
situ hybridization in 48hpf zebrafish embryos. The same specific expression of these genes was observed 
in the AER. Treatment of p63 morpholino in zebrafish embryos resulted in mild (reduced fins) and severe 
(no fins) phenotypes. Accordingly, the expression of GFP, zdlx5a and zdlx6a is either reduced or absent 
in p63 morphant embryos. D| SHFM1-BS1 was cloned in a reporter construct carrying the LacZ gene to 
generate transgenic mice. Specific expression of lacZ in the AER was shown at E9.5 and E15. Mutations 
in the p63 binding motif in SHFM1-BS1 disrupted the specific expression pattern in mice (E15). E| A 
diagram shows chromosomal locations of SHFM1-BS1 and Dlx5/Dlx6. PCR primers used in the 3C 
experiment are indicated. F| Three-dimensional physical interaction of SHFM1-BS1 to Dlx5/Dlx6 was 
analysed by Chromosome Conformation Capture (3C) technique in mouse embryonic limb tissues (E10 
and E15). SHFM1-BS1 interacts strongly to the Dlx6 gene, as interaction frequency was clearly higher at 
the Dlx6 gene than at surrounding regions. Interaction frequency is expected to attenuate over distance 
to SHFM1-BS1 if there is no active interaction. Error bars represent standard errors (N = 8 or 11 for E10 
or E15 limbs, respectively). 
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Discussion
In this study, we established the DNA-binding profiles of p63 in a physiologically relevant 
human cellular system to identify target genes and regulatory elements controlled by p63. 
We show that one of the identified p63 binding sites acts as a cis-regulatory element to 
control gene expression in the AER that correlates perfectly with the expression pattern of 
DLX6 and DLX5 during embryonic development. A novel microdeletion that includes this 
binding site but leaves DLX5 and DLX6 intact leads to SHFM. 
With a prevalence of 2-6% in humans, congenital malformations represent a major 
medical problem 361. Elucidation of the genetic basis of this heterogeneous group of 
disorders is important for genetic counseling and for basic research. Although current 
main stream genetic studies still focus on mutations in the coding regions of genes, 
disease mechanisms associated with genetic variants in short- or long-range regulatory 
elements are increasingly recognized. Consistent with regulatory elements being required 
for correct spatio-temporal expression of developmental genes 362, mutations in non-
coding cis-regulatory elements have been reported to cause congenital defects and 
have emerged as a disease mechanism 216, 363-365. Evolutionary conservation can be a 
powerful tool in the identification of regulatory elements 366-368. A recent study identified 
a number of highly-conserved elements surrounding the IRF6 gene which is known to 
be involved in several types of syndromic and non-syndromic cleft lip/palate 260. In one 
of these elements a SNP that affects an AP-2alpha binding site was identified to associate 
with increased risk of cleft lip. This conserved element was able to drive the expression 
of a reporter gene during mouse orofacial development. Interestingly, in our ChIP-seq 
study we identified the very same cis-regulatory element as a strong p63 binding site 
that functions as an enhancer element to control expression of IRF6 156. However, as only 
ultra-conserved elements are the focus of the evolutionary conservation approach, not 
all important regulatory elements can be identified. For example, conservation analysis in 
vertebrates of the enhancer element SHFM1-BS1 in our study was not found as an ultra-
conserved element (Figure S2.8 and data not shown), even though it is well conserved. In 
addition, the identity of the transcription factors controlling regulatory elements may not 
always be derived from the genomic sequences. Our functional strategy of genome-wide 
p63 binding profiling does not depend on motif prediction or evolutionary conservation 
and reveals a large number of potential cis-regulatory elements controlled by p63. 
We used human keratinocytes for our studies as recent work on transcription factor p53 
revealed that responsive elements are not always conserved across species 369. Moreover, 
primary HKC cell lines represent a cell type that is highly significant for p63-associated 
disorders. As many as 43% of the binding sites (2510 out of 5807) from a p63 binding 
dataset using the ChIP-on-chip technique in a cervical carcinoma cell line 131 were also 
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present in our ChIP-seq dataset. Given that different cell types and techniques were used 
in these studies, the overlap of these two datasets is remarkable. Nevertheless, our data 
from HKCs are highly reliable (Figure S2.1; Table S2.1) and appear to represent functional 
p63 binding sites more accurately 131. 
Similar to recent reports on DNA-binding profiles of other gene-specific transcription 
factors 102, 108, 370, 371, the number of identified p63 binding sites is large, which was not 
predicted by the classical paradigm of gene transactivation. Our extensive bioinformatic 
analyses suggest that the majority of the identified p63 binding sites are biologically 
functional, as 94% of the binding sites contain a p63 consensus motif, and evolutionary 
conservation (Figure 2.2) and phenotypic similarity of PTG-associated diseases (Table 2.2) 
are significantly higher than random expectation. The binding sites are frequently located 
in intronic regions or at a distance from promoters. Thus gene-specific transcription 
factors may not only activate transcription at proximal promoters but also regulate 
gene expression at a distance perhaps by looping mechanisms. A recent report on the 
chromatin interaction map of the Oestrogen-Receptor-α (ERα) 108 also found long-range 
interaction of ERα binding sites and their target genes. This proposed looping mechanism 
is consistent with the notion that SHFM1-BS1 physically interacts with the DLX5/DLX6 
genes that are located more than 250kb downstream from SHFM1-BS1 (Figure 2.5E and 
2.5F). Furthermore, binding sites identified in a certain cell type may also represent target 
genes and regulatory elements that can be regulated at different developmental stages 
in other cells and tissues. For example, SHFM1-BS1 was identified in human adult skin 
keratinocytes where DLX5/DLX6 are moderately expressed and their expression is not 
altered in EEC patient keratinocytes (our unpublished data). Nevertheless, SHFM1-BS1 can 
drive gene expression in the AER during early embryonic limb development.
It has been well established that p63 plays an important role in limb development, as 
mutations in p63 give rise to limb defects in complex syndromes as well as to isolated 
SHFM (SHFM4) 192. In this report, our data strongly indicate that p63 plays a role in SHFM1 by 
regulating DLX5/DLX6 through SHFM1-BS1 that physically interacts with the Dlx6 promoter 
in the AER (Figure 2.5F). DLX5 and DLX6 were previously reported as target genes of p63 
as p63 binds to Dlx5/Dlx6 promoters and activate these genes 199. However, we did not 
detect p63 binding sites at the promoter regions of these two genes in our HKCs (Figure 
2.3). It is plausible that looping of SHFM1-BS1 to the promoters may result in a binding 
signal in a ChIP experiment. We also did not observe p63 activation on the Dlx5/Dlx6 
promoters in transient transfection assays (Figure 2.4E and data not shown). In addition, 
the SHFM4 mutations only affected transactivation mediated by SHFM1-BS1 moderately 
in our transfection assay using Saos2 cells which do not express any endogenous p53 
and p63 (Figure 2.4C). The disruption of activation on Dlx5/Dlx6 promoter was previously 
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reported in transfection assays using U2OS cells where endogenous wild type p53 is 
expressed 199. The use of different cells in transfection assays may be responsible for the 
variable results of transactivation assays. Moreover, our observations suggest that SHFM4 
mutations that do not directly affect DNA-binding might disrupt protein-protein interaction 
or DNA looping to the Dlx5/Dlx6 promoters to abolish transactivation. Importantly, we 
showed that the enhancer element SHFM1-BS1 activates gene expression in the AER 
during embryogenesis and that this activation is p63 dependent.
In addition to the functional data in model systems, we provide genetic data that 
support an important role for the enhancer element SHFM1-BS1 in limb development 
by the identification of a novel microdeletion 7q21 in an SHFM patient. This is a unique 
microdeletion, as the reported deletions in the SHFM1 patients so far all contain SHFM1-
BS1 and DLX5/DLX6 (Figure S2.5) 196, 332, 335, 350-353, 372-377. Within the novel deletion, DYNC1I1 
and SLC25A13 are unlikely to play a role in limb development 354, 355. The other gene within 
the minimal deletion is DSS1. DSS1 is expressed in the mesenchyme of the developing 
mouse limb 196, and the causative role of DSS1 in SHFM1 has not been demonstrated. 
Moreover, the expression of DSS1 in limb bud mesenchyme remains normal in DLX5/
DLX6-/- mice displaying typical SHFM phenotypes 339. Our functional analyses support the 
notion that the enhancer element SHFM1-BS1 regulates expression of DLX6 and possibly 
DLX5, and that loss of this gene regulation gives rise to SHFM1. This model is in agreement 
with recent reports on genomic aberrations in 7q21 that were associated with SHFM1. 
In one report, a human breakpoint located at 38 kb telomeric to DSS1 and at 258 kb 
centromeric to DLX6 is associated with SHFM and hearing loss phenotype (Figure S2.5) 378. 
This breakpoint leaves the SHFM1-BS1 association with DSS1 intact, but disconnects it from 
DLX5 and DLX6. Interestingly in this translocation, the chromosomal context between the 
p63 binding sites SHFM1-BS2 and -BS3 with DLX5/DLX6 is not affected, which suggests 
that SHFM1-BS2 and -BS3 do not play a role in SHFM1. Another report identified a familial 
paracentric inversion-deletion 7q21 that affected a potential enhancer element (Figure 
S2.5) 379. However, the spatio-temporal expression mediated by the identified element in 
this report did not support a role in limb development. Therefore, it is more likely that 
the SHFM phenotype in this family is due to the dissociation of the DLX5/DLX6 genes 
from SHFM1-BS1 by the inversion. It should be noted that in the same report, a 5,115 bp 
deletion (chr7:96,402,577–96,407,691, hg18) was identified at the breakpoint. We did not 
observe a p63 binding site in this deletion (Figure S2.5). Our results and those from others 
thus support the hypothesis that SHFM1-BS1 plays an essential role in the regulation of 
DLX5/DLX6. A genetic approach to delete SHFM1-BS1 in mice can give an unambiguous 
demonstration of its role to control expression of Dlx5 and Dlx6. Intriguingly, whereas 
Dlx5/Dlx6 are expressed in the craniofacial region at later stages of development (E14-17 
in mice) 197, 339, absence of specific expression controlled by SHFM1-BS1 in craniofacial 
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regions indicates that SHFM1-BS1 is not a regulatory element for orofacial development 
(data not shown). Different enhancer elements may regulate DLX5 and DLX6 in these 
tissues. It will be of interest to test other less conserved p63 binding sites within the CTCF 
boundaries for a role in craniofacial development. 
In summary, we have identified binding sites of p63 and taken the first step to build a gene 
network regulated by p63 with ChIP-seq analysis in human primary keratinocytes. Our study 
provides potential target genes as well as high-resolution regulatory elements relevant to 
p63-related diseases. Reporter assays in a large scale to test p63 binding sites in the animal 
models will provide valuable information on functions of p63 target genes in ectodermal 
development. Our findings strongly indicate that loss of the regulatory element SHFM1-
BS1 identified by a p63 binding site constitutes a novel disease mechanism responsible for 
SHFM1. Identified target genes and regulatory elements of p63 can therefore be analysed 
for mutations and microdeletions to understand the disease mechanisms of unresolved 
diseases that resemble p63-associated syndromes.
Materials and methods
Ethics statement. All procedures regarding establishing human primary keratinocytes were approved 
by the ethical committee of the Radboud University Nijmegen Medical Centre (“Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen”). Informed consent was obtained. All animal work 
has been conducted according to relevant national and international guidelines.
Clinical summary of the SHFM1 patient. The patient was born with bilateral foot anomalies and had no 
other dysmorphic features, in particular no hand anomalies, evidence of ectodermal dysplasia, scalp 
defects, oral cleft, bifid uvula, tear duct anomalies, eyelid adhesions or abnormal nails. On review at 
age 2 years and 7 months of age, she was healthy and was well grown and development was within 
normal limits. 
Human primary keratinocyte culture. Skin biopsies were taken from the trunk of healthy volunteers 
to set up the primary keratinocyte culture 380. Keratinocyte cultures in Keratinocyte Growth Medium 
(KGM) under undifferentiated condition were previously described 134. 
ChIP and ChIP-seq. Human primary keratinocytes under proliferating condition where p63 is 
expressed at the highest level were used for ChIP and ChIP-seq analysis. Cells were crosslinked 
with 1% formaldehyde for 10 minutes and chromatin was collected as described 381. Chromatin was 
sonicated using a Bioruptor sonicator (Diagenode) for 2 times of 8 minutes at high power, 30s ON, 
30s OFF. p63 antibodies 4A4 (Abcam) and H129 (Santa Cruz) were used in ChIP-qPCR and ChIP-
seq analyses. ChIP experiments were performed as previously described 127. ChIP-seq analysis was 
performed on a Solexa Genome Analyzer (Illumina) as described previously 102. 
ChIP-seq data analysis. All 32-bp sequence reads were uniquely mapped to the human genome NCBI 
build 36.1 (hg18) with zero or one mismatch using ELAND (Illumina), resulting in 3.2, 6 and 20 million 
unique reads for the three analyzed samples, wt1 with 4A4 ChIP, wt2 with 4A4 ChIP and wt2 with 
H129 ChIP, respectively. Peak recognition was performed using MACS 340 with default settings and 
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a P value threshold of 1E-9, giving 18,133, 14,963 and 29,166 peaks in ChIP-seq tracks of wt1 with 
4A4 ChIP, wt2 with 4A4 ChIP and wt2 with H129 ChIP, respectively. Peaks were mapped to RefSeq 
genes, downloaded from the UCSC Genome Browser (hg18), to determine genomic location. The 
ChIP-seq data and associated peaks have been deposited in NCBI’s Gene Expression Omnibus 382 and 
are accessible through GEO Series accession number GSE17611 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE17611). 
de novo motif search. To determine the p63 motif, a de novo motif prediction pipeline combining 
three motif prediction tools, MotifSampler 383, Weeder 384 and MDmodule 385, was run on 2273 (20%) 
randomly selected 200-bp peak sequences (centered at the peak summit as reported by MACS) and 
PWMs were generated. We used the ‘large’ analysis setting for Weeder. MDmodule and MotifSampler 
were each used to predict 10 motifs for each of the widths between 6 and 20. The significance of 
the predicted motifs was determined by scanning the remaining 80% of the peak sequences and 
two different backgrounds: a set of random genomic sequences with a similar genomic distribution 
as the peak sequences and a set of random sequences generated according to a 1st order Markov 
model, matching the dinucleotide frequency of the peak sequences. P values were calculated 
using the hypergeometric distribution with the Benjamin-Hochberg multiple testing correction. All 
motifs with a P value < 0.001 and an absolute enrichment of at least > 1.5-fold compared to both 
backgrounds were determined as significant. We calculated the ROC AUC for all significant motifs 
and chose the best performing motif based on the ROC AUC (See Table S2.2 for the results). The 
PWM of this motif was used with the p53scan algorithm and an optimal threshold, determined by the 
maximum f-measure as described previously 127, and to generate p63scan. The p63scan algorithm 
can be downloaded from http://www.ncmls.nl/bioinfo/p63scan/. To examine the correlation of motif 
score and peak height, all peaks were divided in quartiles according to peak height (the number of 
reads per peak). For each quartile the distribution of the motifs score as determined by p63scan is 
depicted as a boxplot.
Motif over-representation analysis using TRANSFAC. To detect putative transcription factor motifs 
reported in the TRANSFAC Professional database version 2009.3 342, the MotifScanner program 386 
was used. The search was performed on both strands using a 3rd-order Markov model calculated 
from the human promoter set of the Eukaryotic Promoter Database (EPD) as a background model. 
The parameter p (a prior probability of finding one instance of the motif in a sequence) was set to 
a value of 0.5. To identify motifs that are overrepresented in the p63 motif-less binding sites, the 
binomial test was used. The obtained P values were corrected for multiple testing (631 motifs for 
which sites were found in the p63-binding regions) using a Bonferroni correction. 
Quantitative PCR. Quantitative PCR primers were designed using Primer3 (http://frodo.wi.mit.edu) 
387, and qPCR reactions were performed in the 7500 Fast Real Time PCR System apparatus (Applied 
Biosystems) by using iQ SYBR Green Supermix (Biorad) according to the manufacturer’s protocol. For 
qPCR of ChIP analysis, one primer set was used for each tested binding region (Table S2.6) and ChIP 
efficiency of certain binding sites was calculated using percentage of ChIPped DNA against input 
chromatin. 
Analysis of potential target genes associated with phenotypic defects using human and mouse 
disease bases. Text mining-based 346 feature overrepresentation and gene to disease mapping were 
determined using the Online Mendelian Inheritance in Man (OMIM) disease database 388, 389. Detailed 
information can be found in supplementary information. Human diseases associated with SHFM 
were taken from the Pictures Of Standard Syndromes and Undiagnosed Malformations (POSSUM) 
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database 347, current as of August 2007, and mapped to genes through their OMIM IDs. Mouse SHFM-
associated phenotypes and associated genes were taken from the Jackson Laboratory’s Mouse 
Genome Database (http://www.informatics.jax.org/) 348.
Evolutionary conservation of binding sites. To assess the evolutionary conservation of the 11,369 sites 
bound by p63, the PhastCons 356 conservation track from the UCSC Genome Browser was used to 
calculate PhastCons Conservation Score (PCCS). Conservation based on 44 vertebrate genomes was 
chosen because the p63 gene has 1-1 orthologs throughout the vertebrates 345. The conservation 
for a region was calculated as the average conservation of each nucleotide therein. To analyse the 
correlation of PCCS and peak height, all peaks were divided in quartiles according to peak height (the 
number of reads per peak). For each quartile the distribution of the PhastCons Conservation Scores 
(PCCS) is depicted as a boxplot.
Mapping deletion in a SHFM patient using ultra-high comparative genomic hybridization. For detailed 
detection of chromosome 7 aberration, high resolution NimbleGen HG18 chromosome 7 specific 
385K arrays were used (B3738001-00-01; Roche NimbleGen Systems, Madison, Wisconsin, USA). 
The 385K average probe distance was 365bp. DNA labeling, array hybridization, post-hybridization 
washes and scanning were performed according to the manufacturer’s instructions (Roche 
NimbleGen). The acquired images were analyzed using NimbleScan V2.4 extraction software (Roche 
NimbleGen). For each spot on the array, the log2 Cy3/Cy5 ratio (relative intensity of the Cy3 labeled 
patient DNA vs. the Cy5 labeled male DNA reference pool of 5 healthy male individuals) was calculated 
using the segMNT algorithm, which also applied an automatic segment detection. A 50x averaging 
window was generated, resulting in 20kb segments for this array. Breakpoints were determined with 
SignalMap V1.9 software (Roche NimbleGen) and 20kb averaged log2 ratios were visualized in the 
UCSC genome browser. 
Constructs and transactivation assays. The genomic regions of p63 binding site peaks were amplified 
by PCR with gateway cloning primers and cloned into a modified ccdB-containing pGL3-Enhancer 
Vector, or a ccdB-containing pGL3-Promoter Vector, or a ccdB-containing pGL3-Dlx5 Vector. The 
ccdB-containing pGL3-Dlx5 Vector was generated by amplification of mouse genomic DNA using 
primers described in Table S2.8 to obtain the mouse Dlx5 promoter to replace the SV40 promoter 
with BglII and HindIII sites in the ccdB-containing pGL3-Promoter Vector. Point mutations were 
introduced into p63-binding motifs of SHFM1-BS1 to generate mutant p63 binding sites, where the 
essential cytosine and guanine bases were mutated to adenosine. The ΔNp63α wild-type (pcDNA-
mM_ΔNp63α) expression plasmid has been described previously 134. Point mutations were introduced 
into this plasmid to generate R204W, R279H, R304W, K194E and L517F mutations. Transfection and 
luciferase assays were described previously 134. All cloning and mutagenesis primers are described in 
Table S2.8.
Transgenic reporter analyses in zebrafish and mice. Human genomic fragments containing the 
SHFM1-BS1, -BS2 and -BS3 were amplified with primers described in Table S2.8. The PCR fragments 
were subcloned in PCR8/GW/TOPO vector and then transferred, through recombination using 
Gateway technology, to the ZED destination vector for zebrafish transgenesis 390. This vector 
contains the Xenopus Cardiac actin promoter driving DsRed as a positive control for transgenesis. To 
generate the zebrafish transgenic embryos, we used Tol2 transposon/transposase method 391 with 
minor modifications. Volume of 2-5nl of mixture containing 25ng/ul of transposase mRNA, 20ng/
ul of phenol/chloroform purified ZED constructs and 0.05% phenol red was injected in the cell of 
1 cell stage embryos. Three or more independent stable transgenic lines were generated for each 
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construct. For the generation of transgenic mice, the genomic fragments with and without point 
mutations in p63 consensus motif were transferred into a vector containing the human minimal 
beta-globin promoter, lacZ and a SV40 polyadenylation signal. Constructs were linearized and the 
vector backbone removed prior to microinjection into the pronucleus of one-cell mouse embryos. 
F0 embryos of 9.5-13 dpc stages were harvested and stained for lacZ activity.
Morpholino injections and in situ hybridizations in zebrafish embryos. Once cell stage embryos were 
injected with 3ng of ΔNp63 MO II (TCCACAGGCTCCAGGATTCTTACCC) as described previously 326. 
Injected embryos were raised at 28 °C in standard E3 medium and fixed at 48 hours post fertilization 
in 4% paraformaldehyde overnight at 4 °C. In situ hybridizations were carried out as described 392. As a 
control, we injected a similar amount of a MO directed against the Xenopus tropicalis olig2 gene that 
shows no match in the zebrafish genome 393.
Chromosome Conformation Capture (3C) assay. Chromosome Conformation Capture (3C) assay was 
performed as referred in Hagege et al., 2007 358. Limbs of E10- and E15-stage mouse embryos were 
dissected and processed to get single cells preparations. Ten million isolated cells were first fixated 
with 2% formaldehyde, and then cells were lysed and nuclei were digested with HindIII endonuclease 
(Roche). After that, DNA was ligated with T4 DNA ligase (Promega) in low concentration conditions 
to favour intramolecular ligations. A set of locus specific primers close to a HindIII site (Table S2.8) 
was designed with Primer3 v. 0.4.0 387. These primers were used to make semi-quantitative PCRs 
to measure the relative enrichment in each ligation product. The primer near to the BS1 enhancer 
was taken as the fixed primer, and the different interactions were tested using primers close to 
the promoters of DLX5 and DLX6 genes. For each interaction two negative control primers were 
designed about 30 kb upstream and downstream the promoter specific primer. PCR products were 
run in agarose gels and measured using a Typhoon scanner. Product values were related to a control 
composed of two BACs that encompass our region of interest. 
Acknowledgements
We thank E Janssen-Megens and KJ Françoijs for operating the Illumina Genome Analyzer 
and initial data output, WJ Welboren for providing modified pGL3-luc constructs and S 
Heffener for assistance in data analysis. We thank C Rose in Murdoch Children’s Research 
Institute, Parkville, Australia to allow access to the POSSUM © database and the tools for 
analysis of gene-phenotype networks. We also thank GB Peters and AP Darmanian at 
the Cytogenetics Department, Western Sydney Genetics Program, Children’s Hospital at 
Westmead, Australia for their assistance in mutation analysis. We thank K Wiman and G. 
Schaftenaar for discussion on the structure of p53/p63 DNA-binding domain. We specially 
thank D Kimelman and V Borday-Birraux for reagents. Thanks to Dr. M Buckley for critical 
reading of the manuscript. We confirm that there is no conflict of interest associated with 
this work. 
65
Genome-wide profiling of p63 DNA-binding sites identifies an element with a role in limb development
2
Figure S2.1. ChIP-qPCR analysis of p63 binding in 
human primary keratinocytes using two different p63 
antibodies 4A4 (pan-p63) and H129 (α-specific). 
Specific binding of p63 to the tested binding sites 
was observed, including to binding sites at p21WAF/
CIP19 and DST which served as positive controls, but 
not to the negative controls myoglobin exon2 (myo) 
and a no-gene region (chr11).
Figure S2.2. Correlation of motif scores to peak 
heights. All peaks were divided in quartiles 
according to peak height (the number of reads 
per peak). For each quartile the distribution of 
the motifs score as determined by p63scan is 
depicted as a boxplot.
Figure S2.3. Genomic distribution of p63 binding sites with and without p63 consensus binding motifs.
Figure S2.4. Correlation of PhastCons Conservation Scores (PCCS) to peak heights and p63 binding 
motifs of the p63 binding sites. A| The percentage of p63 binding sites (y-axis) is plotted against 
decreasing cut-off values of the PhastCons Conservation Score (PCCS) (x-axis) for two groups of peaks; 
those with a p63 motif and those without a p63 motif, as determined by p63scan. B| All peaks were 
divided in quartiles according to peak height (the number of reads per peak). For each quartile the 
distribution of the PhastCons Conservation Scores (PCCS) is depicted as a boxplot.
B
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A
with p63 motifs without p63 motifs
66
Chapter 2
Figure S2.5. Previously reported chr.7 deletions involved in SHFM1 (hg18). A| The grey track CGH array 
CNV data with deletion in the SHFM1 patient is compared to the minimum critical regions for SHFM1 
based on the literature. Pale green tracks represent deleted intervals in patients with SHFM1 who have 
cytogenetic deletions 332, 372-377. Dark green tracks represent deleted intervals in patients with SHFM1 
where mapping has been done with STS markers 196, 335, 351, 352. Purple tracks represent summed mapping 
of deletions combined from many patients with SHFM1 350, 353. The brown track represents a microdeletion 
at the breakpoint of a chromosome inversion in a patient with SHFM1 379. The red bar represents three 
p63 binding sites. B| A zoomed- in view of the region including SHFM1-BS1, -BS2 and -BS3 and DLX5/6. 
A translocation in SHFM1 that disconnects SHFM1-BS1 with DLX5/6 is depicted with a black arrow.
Figure S2.6. Genomic qPCR analysis of deletion of the p63 binding site SHFM1-BS1 in the SHFM1 
patient. Genomic qPCR was performed to confirm the deletion in the SHFM1 patient revealed by CGH 
analysis. Copy number was calculated against an internal control primer set in the CFTR gene.
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Limb E10 Limb E15
Figure S2.7. Raw data of 3C experiments in mouse limbs at E10 and E15.
Figure S2.8. Evolutionary conservation 
of the p63 binding site SHFM1-BS1 in 
vertebrates. SHFM1-BS1 was examined 
for its conservation in vertebrates using 
USCS genome browser. The consensus 
motif of p63 is highlighted in the red 
box.
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Table S2.1. Validation by ChIP-qPCR of detected binding sites in ChIP-seq analysis (Excel file, not 
included).
Table S2.2. Motif analysis with a de novo motif prediction pipeline (Excel file, not included).
Table S2.3. The motifs significantly overrepresented in the p63 motif-less binding sites.
Transcription 
factor
Motif no. in 
the TRANSFAC 
database
p63 motif-
containing sites
p63 motif-less 
binding sites
Corrected two-
sided p-value
AP1* 199 33.99 % 53.97 % 4∙10-23
BACH1 495 9.28 % 22.04 % 7∙10-20
BACH2 490 31.16 % 48.88 % 2∙10-18
* For AP1, only the most significantly over-represented motif is reported. Nine other AP1 motifs were also 
significantly over-represented, with p-values (two-sided and corrected for multiple testing) ranging from 3∙10-10 to 
6∙10-16.
Table S2.4. The most significant GO annotation terms of potential target genes of p63.
GO No. Term
No. of 
genes
P value*
All genes
(10895)
GO:0009987 cellular process 4143 7.60E-24
GO:0048856 anatomical structure development 1092 9.21E-13
GO:0032502 developmental process 1329 4.74E-12
GO:0048519 negative regulation of biological process 803 5.39E-12
GO:0007155 cell adhesion 346 6.21E-12
GO:0022610 biological adhesion 346 7.81E-12
GO:0048731 system development 1000 8.47E-11
GO:0016043 cellular component organization 1064 1.49E-10
GO:0007275 multicellular organismal development 1206 1.95E-10
GO:0010646 regulation of cell communication 480 2.05E-10
GO:0007242 intracellular signaling cascade 569 2.10E-10
GO:0048869 cellular developmental process 747 5.97E-10
Genes 
with 
motifs
(10438)
GO:0009987 cellular process 3990 5.71E-25
GO:0048856 anatomical structure development 1056 3.64E-13
GO:0032502 developmental process 1287 8.03E-13
GO:0007155 cell adhesion 336 3.73E-12
GO:0022610 biological adhesion 336 4.68E-12
GO:0048519 negative regulation of biological process 774 8.13E-12
GO:0007242 intracellular signaling cascade 554 3.73E-11
GO:0048731 system development 965 6.81E-11
GO:0007275 multicellular organismal development 1166 6.86E-11
GO:0048869 cellular developmental process 723 2.81E-10
GO:0010646 regulation of cell communication 463 2.95E-10
Genes 
without 
motifs 
(944)
GO:0048872 homeostasis of number of cells 11 0.001205
GO:0051173
positive regulation of nitrogen compound 
metabolic process
35 0.002269
GO:0050793 regulation of developmental process 36 0.002614
GO:0051094 positive regulation of developmental process 19 0.003227
GO:0009891 positive regulation of biosynthetic process 36 0.004333
GO:0007155 cell adhesion 36 0.004702
* P value was obtained using default setting in DAVID Bioinformatic Resources 6.7 (NIAID, NIH) without multiple 
testing. 
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Table S2.5. OMIM IDs associated with genes containing p63 binding sites (Excel file, not included).
Table S2.6. Affected features in p63 potential target gene-associated diseases (PTG-associated 
diseases) (Excel file, not included).
Table S2.7. Genes potentially involved in SHFM mouse models or human SHFM phenotypes
Gene Mouse model Human SHFM (POSSUM)
BRCA2 0 1
CDH3 0 1
DLX5 1 0
DLX6 1 0
FBXW4 1 1
FOXP2 0 1
GJA1 0 1
HOXA13 1 0
HOXD 1 0
HOXD13 1 1
NIPBL 0 1
PITX2 0 1
PORCN 0 1
RECQL4 0 1
SHFM1 0 1
SHFM2 0 1
SMC1A 0 1
SMC3 0 1
SNX3 0 1
TP63 1 1
Table S2.8. Primers for expression, ChIP analyses, and for cloning (Excel file, not included).
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Abstract
Cleft palate is a common congenital disorder that affects up to 1 in 2500 live births and 
results in considerable morbidity to affected individuals and their families. The aetiology of 
cleft palate is complex with both genetic and environmental factors implicated. Mutations 
in the transcription factors p63 and IRF6 are major individual causes of cleft palate; 
however, a relationship between these two key molecules has not been determined. 
Here, we demonstrate that Irf6 and p63 interact epistatically during development of the 
secondary palate. Mice simultaneously carrying a heterozygous deletion of p63 and the 
Irf6 knock-in mutation Arg84Cys display ectodermal abnormalities that lead to cleft palate. 
Furthermore, we show that p63 strongly transactivates IRF6 by binding to an upstream 
enhancer element, genetic variation within which increases susceptibility to cleft lip. 
Our findings establish p63 as a key regulatory molecule during palate development and 
provide a mechanism for the co-operative role of p63 and IRF6 in orofacial development 
in mice and humans.
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Introduction
Development of the secondary palate involves a complex series of integrated events 
that are frequently disturbed resulting in the congenital malformation, cleft palate. Cleft 
palate, which has an estimated incidence of 1 in 2500 live births depending on geographic 
origin, racial and ethnic variation, and socio-economic status 394, 395, results in considerable 
morbidity to affected families as individuals who exhibit this condition may experience 
problems with eating, speaking and hearing which can be corrected to varying degrees 
by surgery, dental treatment, speech therapy and psychosocial intervention 396, 397. The 
frequent occurrence and significant healthcare burden imposed by cleft palate emphasise 
the need to identify the molecular and cellular interactions that lead to facial clefting, with 
the ultimate aim of improving diagnosis, treatment, counselling and care for affected 
individuals and their relatives.
In approximately 50% of cases cleft palate occurs as an isolated entity while the remainder 
arise as part of syndrome where structures other than the palate are affected 398. The 
genetic basis of non-syndromic clefting is complex as variations in numerous genes 
together with environmental factors are known to play a role in its aetiology 396-398. Recent 
advances in delineating the molecular mechanisms underlying cleft palate have therefore 
resulted largely from analysis of syndromic forms of cleft palate; for example mutations in 
the p53 family member, p63, and interferon regulatory factor 6 (IRF6) underlie congenital 
malformation syndromes that display cleft palate as part of the phenotype 3, 5, 399, 400. The 
combination of genetic studies in humans and analysis of targeted mutations in mice has 
identified several factors that play key roles during palate development 401, 402.
The IRF6 gene encodes a transcription factor characterized by a highly conserved penta-
tryptophan, DNA-binding domain and a less well-conserved protein interaction domain 
403. Mutations in IRF6 underlie Van der Woude syndrome (VWS) and popliteal pterygium 
syndrome (PPS) which are autosomal dominant disorders characterized by varying 
combinations of cleft lip, cleft palate, lower lip pits, dental anomalies, ectodermal and 
genital anomalies 399. Importantly, genetic variants in and around IRF6 confer a significant 
attributable risk for non-syndromic cleft lip 260. Gene targeting of the Irf6 locus has resulted 
in two mouse models; a knock-in of the most common mutation found in PPS patients, 
Arg84Cys (R84C), which expresses a mutant Irf6 protein 240, and a complete loss-of-
function allele 241. Although the function of the R84C mutation is still largely unknown, 
a recent study has demonstrated that this mutation results in a loss of DNA binding 404. 
In both cases, homozygous mice exhibit a hyper-proliferative epidermis which fails to 
undergo terminal differentiation and severe intra-oral epithelial adhesions 240, 241.
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The p63 gene encodes at least six protein variants as the result of usage of two different 
transcription start sites and alternative splicing. Different promoters give rise to two 
alternative N-termini: TA-isoforms which contain a transactivation sequence (TA) similar to 
that in p53, and ΔN-isoforms which contain a shorter activation domain (TA2) 134. Alternative 
splicing towards the carboxy terminus generates three subtypes, α, β and g 111. All isoforms 
contain DNA-binding and isomerization domains but vary in their ability to activate or 
repress their target genes 131, 138. ΔNp63α is the major isoform expressed in basal epithelial 
cells and is essential for epidermal and palatal development 134, 152, 405. Heterozygous 
mutations in p63 underlie seven autosomal dominant developmental disorders that are 
characterized by varying combinations of cleft lip, cleft palate, ectodermal dysplasia and 
limb abnormalities 3. Two mouse models of p63 have been reported to date; one a loss-of-
function allele 116 and another which has recently been found to express p63g isoforms 6, 
406. Both mouse models exhibit a similar phenotype comprising severe limb abnormalities, 
a thin and undifferentiated epidermis and lack of epidermal derivatives 6, 116.
Despite the established roles of IRF6 and p63 in orofacial development, the molecular 
pathways in which they function during development of the lip and palate are poorly 
characterized. In the current study, we demonstrate that Irf6 and p63 interact epistatically, 
mice heterozygous for the p63 loss-of-function allele and for the Irf6 knock-in mutation 
R84C exhibit cleft palate as a result of ectodermal abnormalities that occur during palate 
development. To dissect the mechanism underlying this genetic interaction, we have used 
a combination of chromatin immunoprecipitation and expression analyses to show that 
IRF6 is a direct target gene of p63 and that p63 activates IRF6 transcription through an 
enhancer element, variation within which increases susceptibility to cleft lip. 
Results
Epistatic interaction between Irf6 and p63 in palatal development
In light of the striking phenotypic overlap exhibited by syndromes resulting from mutations 
in IRF6 and p63, we investigated the potential interaction between p63 and Irf6 using an 
epistatic approach in which we inter-crossed p63 +/- and Irf6 +/R84C mice. We examined 
seventeen litters of p63 +/-/Irf6 +/R84C mice aged between embryonic day (E) 14.5 and post-
natal day (P) 0 (total number of embryos = 145). While mice heterozygous for the mutant 
p63 allele (n = 27) or a mutant Irf6 allele alone (n = 38) appeared grossly normal and 
comparable to their wild-type littermates (n = 45), ~89% of compound heterozygous p63 
+/-;Irf6 +/R84C embryos (n = 35) exhibited a cleft of the secondary palate (Figure 3.1). 
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Scanning electron microscopy and histological analysis of a developmental series 
of embryos indicated that the initial stages of palatal development appeared normal: 
the palatal shelves of p63 +/-;Irf6 +/R84C embryos grew vertically down the sides of the 
tongue and elevated at the expected developmental stage (Figure 3.1A- 3.1E, and 3.1G); 
however, in 31/35 p63 +/-;Irf6 +/R84C embryos the palatal shelves failed to fuse (Figure 3.1F 
and 3.1H). Examination of five litters at E14.5 (number of p63 +/-;Irf6 +/R84C embryos = 15) 
revealed that the palatal shelves achieved intimate contact (Figure 3.1H); nevertheless, 
with continued growth of the craniofacial complex, the p63 +/-;Irf6 +/R84C palatal shelves 
separated such that by E18.5 a large oronasal space was apparent (Figure 3.1J). Despite 
this observation, histological analysis indicated that the oral and nasal palatal epithelia of 
p63 +/-;Irf6 +/R84C embryos differentiated normally (Figure 3.1K and 3.1L). Newborn p63 +/-
;Irf6 +/R84C mice exhibited gasping behaviour and died shortly after birth. Histological and 
Figure 3.1. Phenotype analysis of wild-type and p63+/-;Irf6+/R84C mice. A, B, E, and F| Scanning electron 
microscope and C, D, G, and H| histological analyses of E13.5 and E14.5 wild-type and p63 +/-;Irf6 
+/R84C mice.  A to D| indicate that palatal development initiates normally. E, G| At E14.5, the palatal 
shelves of wild-type mice have adhered and commenced fusion; F, H| in contrast the secondary palate of 
p63 +/-;Irf6 +/R84C embryos remains cleft. I to L| A low magnification view at E18.5 indicates that while the 
palatal shelves of wild-type mice have fused, those of p63 +/-;Irf6 +/R84C mice have pulled apart leaving a 
large oronasal cavity. K, L| Higher magnification views of the regions boxed in I, J| respectively, indicate 
that the palatal epithelia of p63 +/-;Irf6 +/R84C embryos exhibit signs of differentiation with distinct nasal and 
oral characteristics. ps, palatal shelf; n, nasal epithelium; o, oral epithelium; t, tongue; ns, nasal septum. 
Scale bars: A, B, E and F, 500 µm; C, D, G and H, 200 µm; I and J, 400 µm; K and L, 50 µm.
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immunofluorescence analyses indicated that the epidermis of E18.5 p63 +/-;Irf6 +/R84C 
embryos differentiated normally (Figure S3.1).
To gain greater insight into the pathogenesis of the cleft palate observed in p63 +/-;Irf6 +/
R84C mice, we examined the morphology of the medial edge epithelium (MEE) from E13.5 
to E15.5. As immunostaining for desmoplakin, alpha- and beta-catenin, and E-cadherin 
indicated no gross differences in the distribution of these adhesion molecules between 
wild-type and p63 +/-;Irf6 +/R84C embryos (Figure S3.2 and data not shown), we examined 
the palatal epithelia in greater detail using transmission electron microscopy. At E14.5 the 
MEE of wild-type mice consisted of a 2-3 cell thick layer of basal and intermediate cells 
containing well-rounded nuclei, covered by a surface layer of flattened periderm cells 
(Figure 3.2A). In contrast, the equivalent region in p63 +/-;Irf6 +/R84C embryos contained 
basal and intermediate cells with irregular nuclei covered by morphologically abnormal 
periderm cells (Figure 3.2B). We therefore examined the periderm in greater detail using 
immunostaining for keratin 17 (K17). Deconvolution images from E13.5 p63 +/-;Irf6 +/
R84C embryos indicated that K17 immunostaining appeared filamentous and incorrectly 
localized  (Figure 3.2C and 3.2D) and at E14.5, we observed that it was not confined to 
the most superficial cells; rather K17 appeared to be expressed throughout the epithelium 
(Figure 3.2E and 3.2F). This observation was confirmed by deconvolution analysis of K17/
K14 dual stained sections. In wild-type mice, the basal cells were positive for keratin 14 
only, with a superficial layer of periderm cells positive for K14 and K17; in contrast, in p63 
+/-;Irf6 +/R84C embryos, the entire MEE stained positively for both keratins (Figure 3.2G- 
3.2J). Analysis of E15.5 p63 +/-;Irf6 +/R84C embryos using K17 immunostaining revealed that 
abnormal periderm cells persisted over the medial edge after the palates had fused in the 
wild-type embryos (Figure 3.2K- 3.2M). 
To assay whether the palatal shelves of p63 +/-;Irf6 +/R84C embryos were competent to fuse, 
we used in vitro organ culture. Palatal shelves dissected from E13.5 wild-type and p63 
+/-;Irf6 +/R84C mice were placed in contact and cultured for 24, 48 or 72 hours. Histological 
analysis confirmed that after 72 hours palatal fusion was essentially complete in embryos 
of both genotypes (Figure 3.2N and 3.2O). Immunofluorescence analysis confirmed that 
K14 was present only in patches of the oral and nasal epithelia (Figure 3.2P and 3.2Q). K17 
expression was undetectable, except in the tooth germs (data not shown). 
As increased K17 immunoreactivity has previously been observed in hyperproliferative skin 
conditions 407, we performed cell proliferation assays in p63 +/-;Irf6 +/R84C embryos. These 
assays demonstrated that, as reported previously 408, the MEE of E14.5 wild-type mice had 
ceased proliferating (Figure S3.2). In p63 +/-;Irf6 +/R84C embryos the abnormal medial edge 
epithelial cells, comprising both the basal layer and the abnormal periderm cells, were 
neither hyper-proliferative nor undergoing abnormal cell death (Figure S3.2). 
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IRF6 expression is dependent upon functional p63
Having established a genetic interaction between Irf6 and p63, we next examined the 
expression of these molecules during development of the secondary palate in wild-type 
mice in which the palatal shelves fuse, and in p63 -/- and Irf6 R84C/R84C embryos, both of 
which display cleft palate 116, 240, 241, 405 (Figure 3.3). In E13.5 wild-type mice, p63 and Irf6 
were expressed in similar domains in the oral epithelia and the developing tooth germs 
(Figure 3.3A and 3.3B). Interestingly, at E14.5, while Irf6 expression could still be detected 
in the midline epithelial seam, p63 expression was down-regulated in this region (Figure 
Figure 3.2. Analysis of the cleft palate observed in p63 +/-;Irf6 +/R84C mice. A and B| TEM analysis of the 
medial edge epithelia (MEE) at E14.5 revealed highly disordered basal and periderm cells in p63 +/-;Irf6 
+/R84C mice (B) compared with their wild-type litter mates (A). C-J| Deconvolution analysis of the palatal 
shelves. At E13.5, keratin 17 (K17) appeared filamentous and incorrectly localized in the MEE (arrows 
in D). E, F| At E14.5, while K17 expression was confined to the periderm of wild-type mice, K17 was 
expressed throughout the MEE in p63 +/-;Irf6 +/R84C embryos. G-J| K14 and K17 dual staining. G, I| In 
wild-type mice, K14-positive basal cells are covered by K17/K14-positive periderm cells. H, J| In p63 
+/-;Irf6 +/R84C embryos, the entire MEE stained positively for both K14 and K17. K-M| At E15.5, while the 
MEE of wild-type mice have degenerated, K17-positive cells persist over the MEE of p63 +/-;Irf6 +/R84C 
embryos. M| A higher magnification view of the region boxed in L. N-Q| In vitro culture indicates that 
after 72 hours of forced contact the palatal shelves of p63 +/-;Irf6 +/R84C mice have fused. K14 expression 
in both wild-type and p63 +/-;Irf6 +/R84C palates was evident in remnants of the nasal and oral epithelia 
only (asterisks; P and Q). bm, basement membrane; p, periderm cell; b, basal cell; ne, nasal epithelium. 
Scale bars: A and B, 5 µm; C to F, I, J and M, 10 µm; G and H, 50 µm; K, L, N to Q, 100 µm.
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3.3D). To further characterise the interaction between these two transcription factors, we 
examined their expression patterns in the corresponding mutant mice, however, as p63 
-/- epithelia are hypomorphic and slough off due to aberrant differentiation 6, 116, we first 
confirmed that p63 -/- palatal epithelia were competent to express keratin 14 (Figure 3.3E 
and 3.3F). In p63 +/- and Irf6 +/R84C mice, expression of Irf6 and p63, respectively, appeared 
unchanged from that observed in wild-type littermates (Figure 3.3G and 3.3H); however, 
in p63-/- mice, Irf6 was down-regulated in the epithelia at the tips of E13.5 (data not shown) 
and E14.5 palatal shelves (Figure 3.3I). Strikingly, in contrast to its expression in wild-type and 
in Irf6 +/R84C mice, we observed that p63 was not down-regulated in the presumptive MEE 
in Irf6 R84C/R84C mice (Figure 3.3J). Quantitative real-time PCR (RT-qPCR) assays performed 
on RNA extracted from palatal shelves dissected from E13.5 mice confirmed that Irf6 
expression in p63 -/- embryos was down-regulated significantly in comparison to either 
heterozygous or wild-type littermates (Mann-Whitney U test; P value = 0.01 for wild-type 
or p63 heterozygote compared to p63-null; Figure 3.4A). As isolated palatal epithelial cells 
have not been cultured successfully, we investigated the relationship between p63 and 
Irf6 using mouse primary keratinocytes. Using siRNA we knocked-down p63 (Figure 3.4B) 
and demonstrated a statistically significant decrease in the level of Irf6 transcript (Mann-
Whitney U test; P value = 0.05, Figure 3.4C). Western analysis also indicated decreased 
protein levels (Figure 3.4D). These data suggested that p63 may regulate Irf6 expression. 
To extend the observations obtained in mice, we assessed whether IRF6 expression is 
affected in a human disease model. We established human primary keratinocyte cell lines 
from three patients with ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome, 
who exhibit mis-sense mutations in the DNA-binding domain of p63 3. These patients 
have phenotypes typical of EEC syndrome including cleft lip and palate. RT-qPCR analysis 
of the R204W, R279H and R304W mutant cell lines after 48 hours of differentiation 
indicated that p63 transcript levels were similar to those detected in cell lines established 
from control individuals and the presence of the early differentiation markers keratin 1 
and keratin 10 suggested that differentiation had occurred normally at this stage (data not 
shown). Interestingly, all three cell lines exhibited reduced levels of IRF6 transcript (Figure 
3.4E). A Kruskal-Wallis one-way analysis of variance followed by a post hoc Dunn’s test 
demonstrated that the decrease in Irf6 transcript levels was statistically significant in two 
cell lines; R279H (P value = 0.001) and R304W (P value = 0.05). These data indicate that the 
function, as well the level, of p63 is important for appropriate expression of IRF6.
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wild-type mice. C, D| At E14.5, Irf6 transcripts are strongly expressed in the midline seam and epithelial 
triangles (C; arrowed); in contrast, p63 protein levels are down-regulated in the MEE (D; arrowed). E, 
F| Immunofluorescence assays using keratin 14 indicate that the palatal shelves of p63 -/- mice, which 
exhibit a thin and fragile epithelium, are competent to express this protein. G, H| Analysis of p63 and Irf6 
in Irf6 +/R84C and p63 +/- embryos respectively, indicates that expression is unchanged in the heterozygous 
animals. I| In E14.5 p63 -/- palatal shelves, Irf6 transcripts are down-regulated in the MEE (arrowed). J| 
p63 expression is maintained throughout the MEE of E14.5 Irf6 R84C/R84C palatal shelves (arrowed). ps, 
palatal shelf; tg, tooth germs. Scale bars: 100 µm.
Figure 3.4. Analysis of Irf6 in p63 deficient cells. A| qPCR analysis of palatal shelves dissected from E13.5 
wild-type, p63 +/- and p63 -/- embryos indicates that Irf6 transcripts are reduced to approximately 90% 
and 63% of normal levels, respectively. The level of Irf6 detected in p63 -/- mice is significantly different 
from both heterozygous and wild-type littermates (Mann-Whitney U test; P value = 0.01 in both cases). 
B| siRNA knockdown of p63 in mouse primary keratinocytes reduces p63 levels 5-fold (Mann-Whitney 
U test; P value = 0.05). C| Irf6 transcript levels after p63 siRNA knockdown are reduced by over 60% 
(Mann-Whitney U test; P value = 0.05). D| Western analysis reveals reduced Irf6 protein levels in mouse 
primary keratinocytes after p63 siRNA knockdown. Upper panel represents quantitation of the western 
blot indicating the levels of Irf6 relative to tubulin. Samples were run on the same gel but were non-
contiguous. E| qPCR analysis of IRF6 in human primary keratinocytes derived from normal individuals 
(WT) and EEC patients (R204W, R279H and R304W) indicates that IRF6 levels are reduced when the 
DNA-binding function of p63 is impaired. A Kruskal-Wallis one-way analysis of variance, followed by a 
post hoc Dunn’s test, show that the decrease in Irf6 transcript levels is statistically significant in two EEC 
cell lines; R279H (P value = 0.001) and R304W (P value = 0.05). Data represent mean ± SEM.
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IRF6 is activated by p63 through an enhancer element
To understand how IRF6 is regulated, we tested whether IRF6 is a direct transcriptional 
target of p63. ChIP-seq analysis using chromatin isolated from a normal human primary 
keratinocyte cell line and a pan-p63 antibody identified a single p63 binding site within a 
100 kb genomic region encompassing the IRF6 locus. This site is located approximately 
10 kb upstream of the transcription start site of IRF6 and is a double peak with strong 
p63 binding affinity as indicated by the number of sequenced tags (peak heights 229 and 
58) (Figure 3.5A). Peak detection using the MACS model 340 revealed that the binding site 
from the double peak covers approximately 900 bp. Interestingly, peak 229 of this p63 
binding site overlaps an enhancer element of IRF6 recently identified by searching for 
multispecies conserved sequences (Figure S3.3), and a single nucleotide polymorphism 
(SNP) in this enhancer has been associated with higher risk of cleft lip 260. This binding site 
is located within a broader site identified previously in a genome-wide study of p63 using 
ChIP-on-chip analysis of a carcinoma cell line 131. In that study, a second binding site was 
detected in intron 1 of IRF6 which was not detected in our ChIP-seq analysis. The binding 
profile of p63 in close proximity to IRF6 was confirmed by independent ChIP-seq analysis 
using a second primary keratinocyte cell line established from a different normal individual 
(data not shown). The algorithm p53scan, which is suitable for binding motif searches for 
p53 family members 127, identified two consensus binding motifs in peak 229 and one 
additional motif in peak 58 (Figures 3.5B; Figure S3.3).
To confirm the p63 binding site identified in ChIP-seq analysis, we performed independent 
ChIP-qPCR experiments using two p63 antibodies which recognize different epitopes in 
the p63 protein. Compared to two known targets of p63, the p21 and BPAG genes 273, 
409, ChIP efficiencies expressed as percentage of input chromatin at peak 229 and peak 
58 regions were higher or at least similar to those known binding sites (Figure 3.5C). The 
use of two different p63 antibodies confirmed that the observed binding is specific for 
p63 (Figure 3.5C). Of note, the independent ChIP-qPCR analysis confirmed the lack of 
p63 binding to the previously reported site in the first intron of IRF6 131 (Figure S3.4A). As 
enhancer elements have been shown to exhibit tissue- and species-specific activities 
11, we performed ChIP-qPCR in palatal shelves dissected from wild-type E13.5 mice. 
Consistently, we observed p63 binding to the upstream enhancer region of Irf6 but not to 
the intron 1 region in Irf6 (Figure S3.4B and S3.4C). We next assayed whether p63 binding is 
affected in patient keratinocyte cell lines with heterozygous p63 mutations. For both peak 
229 and peak 58 regions, we observed a marked reduction of p63 binding in keratinocytes 
with the EEC mutations R204W and R304W (Figure 3.5D); however, as both wild-type 
and mutant p63 proteins are present in the patient keratinocytes, it is probable that the 
detected residual DNA binding is mediated by the wild-type protein. 
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Figure 3.5. A p63 binding site upstream of IRF6 functions as an enhancer element. A| ChIP-seq analysis 
of p63 binding in human primary keratinocytes is shown using a screenshot from the UCSC genome 
browser. The p63 binding site obtained from ChIP-seq is shown as a black bar below the double peak 
(peak 229 and peak 58), and p63 binding sites reported previously by ChIP-on-chip 131 are shown as 
grey bars. B| The two p63 binding motifs identified within peak 229 are highlighted in yellow with the 
most conserved cytosine and guanine bases shown in red. C| ChIP-qPCR analysis of p63 binding using 
two p63 antibodies (4A4 and H129). Specific binding of p63 to the positive controls p21 and BPAG 
as well as to peak 229 (p229) and peak 58 (p58) regions was observed, but not to negative controls 
myoglobin exon 2 (myo) and a no-gene region (chr11). D| ChIP-qPCR analysis of keratinocytes from 
EEC patients (R204W and R304W) indicates reduction of p63 binding. E| Transient transfection assays 
show that wild-type p63 strongly activates transcription through peak 229. In contrast, activation by 
the p63 mutants R204W, R279H and R304W was greatly reduced, with the highest level observed for 
R304W (~2-fold activation). F| Site-directed mutagenesis of the conserved cytosine and guanine bases 
shows that both motifs in peak 229 are responsive to p63 and that mutation abolishes transactivation. 
wt, reporter of wild-type peak 229, M1 = mutation of motif 1, M2 = mutation of motif 2, M1+M2 = 
mutation of both motifs.  
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To test this hypothesis further we generated stable SAOS2-derived cell lines that express 
wild-type or ΔNp63α containing the mutation R304W in the absence of endogenous p63. 
ChIP experiments performed with these cell lines showed strong binding of wild-type 
p63 at the identified peak58 binding site, whereas binding was abolished in the ΔNp63α 
R304W cell line (Figure S3.4D).
p63 can act as either an activator or a repressor depending on the target gene. To investigate 
how the binding site regulates IRF6 transcription, we cloned the region surrounding peak 
229 (Figure 5B) in a firefly luciferase reporter construct. In a transient transfection assay, wild-
type ΔNp63α activated the luciferase reporter greater than six-fold. In contrast, activation 
by the p63 mutants R204W, R279H and R304W was greatly reduced, with the highest 
level observed for R304W (~2-fold activation) (Figure 3.5E). These data are consistent with 
our results from the mouse model and keratinocytes derived from EEC patients in which 
IRF6 expression is dependent on functional p63 (Figure 3.3I, 3.4A, and 3.4E). Furthermore, 
mutation analysis showed that both motifs identified in the peak 229 are responsive to 
p63 and p63 transactivation is abolished when both motifs are mutated (Figure 3.5F). 
These data demonstrate that p63 binds directly to peak 229 to activate transcription. Taken 
together our data establish that this binding site is an enhancer element through which 
p63 regulates expression of IRF6. 
Discussion
Recent research has been highly successful in identifying the genetic mutations underlying 
syndromic forms of cleft lip and palate; for example X-linked cleft palate with ankyloglossia 
results from mutations in TBX22 410, Bamforth-Lazarus syndrome in FOXE1 411, 412, cleft lip 
and palate-ectodermal dysplasia syndrome in PVRL1 226; cleft lip and palate with tooth 
agenesis in MSX1 230, otopalatodigital syndromes types 1 and 2 in FLNA 413, autosomal 
dominant Kallmann syndrome in FGFR1 414, and branchio-oculo-facial syndrome in 
TFAP2A 415. Moreover, variation within IRF6, TBX22, PVRL1 and MSX1 is a contributory factor 
to non-syndromic forms of cleft lip and cleft palate 246-249, 252, 416. Despite these successes, 
the molecular pathways in which the proteins encoded by these genes function during 
development of the lip and palate remain poorly characterized as such studies are not 
feasible in human embryos. The identification and use of mouse models for orofacial 
clefting allows such networks to be characterized and the morphogenetic, cellular, and 
molecular changes involved in clefting to be dissected 401, 402, 417.
In the current study, we have utilized two different mutant mouse models to identify and 
characterise a novel interaction; mice heterozygous for both p63 and the Irf6 knock-in 
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mutation R84C exhibit cleft palate. Although Irf6+/R84C mice occasionally exhibit mild intra-
oral adhesions between the mandible and the maxilla which result in restricted opening 
of the mouth, failure to suckle and neonatal lethality 240, neither of these mouse models 
display cleft palate in the heterozygous state, presumably because a critical threshold level 
for each of these genes during palate development in mice is reached. Importantly, we 
further demonstrate that IRF6 expression is dependent on functional ΔNp63α protein 
which activates IRF6 transcription through an enhancer element located approximately 
10 kb upstream of the transcription start site of IRF6. These results provide a molecular 
basis for the epistatic interaction between IRF6 and p63 that is required for appropriate 
palatal development and thereby preventing cleft palate. Previous research has shown that 
p63 plays a central role in maintaining cellular proliferation during development 166, 326, 418. 
For example, ΔNp63α, the major p63 isoform expressed in primary keratinocytes and the 
palatal epithelia 152, 271, 405, has been found to repress the transcription of numerous cell cycle 
mediators which act in an anti-proliferative manner including p21WAF1/CIP19, stratifin (14-3-
3σ), IGFBP-3 and p53 111, 326, 409, 419. In addition to its role in maintaining proliferation, it has 
been proposed that p63 has an anti-apoptotic role by negative regulation of transcription 
of pro-apoptotic molecules such as IGF-IR and IGF-BP3 419, 420; consequently, cell death 
is rarely observed in cells which over-express ΔN-p63α 111, 421. In contrast, IRF6 promotes 
differentiation of mammary epithelial cells by promoting cell cycle arrest 422 and mice 
homozygous for either the R84C mutation or the loss-of-function mutation in Irf6 exhibit 
a hyper-proliferative epidermis 240, 241. In wild-type mice, we observed high levels of Irf6 in 
the MEE of the palatal shelves, whereas p63 was down-regulated in the same cells as the 
palatal shelves approached each other. In contrast, in Irf6R84C/R84C mice, p63 expression 
was maintained throughout the MEE which fail to degenerate and remain intact along 
the antero-posterior axis of the secondary palate 423. Taken together, these data suggest 
that down-regulation of ΔNp63α in the MEE is a pre-requisite for appropriate periderm 
development and palatal fusion and that persistent expression of p63 in Irf6R84C/R84C mice 
prevents this process. Interestingly, consistent with our data, Moretti and co-workers have 
demonstrated that induction of IRF6 by p63 results in proteasome-mediated degradation 
of p63 and that the DNA-binding domain mutation R84C abolishes degradation of p63 316. 
Previous research has shown that cytochalasin D inhibits periderm cell migration resulting 
in failure of formation of the periderm-derived epithelial triangles, absence of periderm 
and basal MEE cell death, and incomplete adhesion of the palatal shelves 424. We therefore 
hypothesise that although the palatal shelves contact in p63+/-;Irf6+/R84C embryos, the 
abnormal periderm cells which persist over the MEE at E15 act as a barrier to the formation 
of strong adhesion complexes between adjacent palatal shelves. As a consequence, the 
initial contact between the palatal shelves in p63+/-;Irf6+/R84C mice is weak and the shelves 
separate owing to continued craniofacial growth. In vitro culture experiments indicate that 
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if contact is forced for a sufficient period of time, adhesion and subsequent fusion of the 
palatal shelves occurs. Together, observations from our p63 +/-;Irf6 +/R84C mouse model and 
possible feedback regulation of p63 by IRF6 indicate that reciprocal regulation of p63 and 
IRF6 is essential for the appropriate specification of MEE fate during palatogenesis. 
In previous biochemical studies, ΔNp63α has been shown to bind to many p53-
responsive promoters and behave as a dominant negative repressor towards p53 111, 285, 409. 
Recently, p63-specific target genes related to epithelial development have been reported 
and ΔNp63α has also been shown to activate a subset of these genes 271; in contrast, no 
direct p63 target genes have been reported in the developing secondary palate. Here, we 
provide firm evidence that IRF6 is a novel direct target of p63 during palate development 
which can be activated by ΔNp63α through a p63-binding site upstream of the IRF6 gene. 
Interestingly, the binding site identified in this study overlaps with a recently reported 
regulatory element that was identified by searching for evolutionarily conserved sequences 
260. The importance of this regulatory element during facial development is highlighted 
by its ability to drive reporter gene expression in the ectoderm covering the fusion sites 
between the developing facial prominences, consistent with known sites of endogenous 
Irf6 expression 260. As a single nucleotide polymorphism within this regulatory element 
has been shown to disrupt weak AP-2α binding owing to a nucleotide change in the 
degenerate AP-2 motif, AP-2α is thought to control IRF6 expression through this element 
260. In the current study we clearly show that p63 also strongly transactivates this element, 
raising the question of whether p63 and AP-2α co-operate to regulate IRF6. 
 
As cleft lip and cleft palate are not fully penetrant in patients with p63 mutations, genetic 
modifiers have been suggested to play a role in the disease pathway 3. Based on previous 
findings that genetic variants in IRF6 are associated with different cleft phenotypes 260, 
together with data obtained in the current study, we speculate that IRF6 may act as a 
modifier in p63 disease phenotypes. Similarly, disease-causing IRF6 mutations have 
only been detected in approximately 70% of VWS families 400. Given that IRF6 can be 
regulated by the upstream p63 binding site, genetic variants in this site may disrupt normal 
transcriptional regulation of IRF6. Therefore, the p63 binding site identified in this study 
offers a new opportunity to search for the genetic causes of unresolved cases of non-
syndromic cleft lip and cleft palate as well as VWS and PPS that map genetically to the IRF6 
locus but in which the causative mutation has not been identified.
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Our discovery of an interaction between two key transcription factors which contribute 
to cleft lip and cleft palate provides opportunities for further dissection of the pathways 
involved in the complex process of mammalian palate development. Further elucidation 
of how these genes are regulated and the identification of both shared and individual 
targets for p63 and IRF6 in future studies may unearth new candidates as contributing 
factors for the aetiology of facial clefting. 
Materials and methods
Mouse breeding, genotyping and phenotype analysis. Generation and genotyping of p63-/- and Irf6R84C/
R84C mice have been described previously 240, 405. Mice were housed in accredited animal facilities at the 
University of Manchester. All procedures were approved by local Ethical Review Committees and are 
licensed under the Animal (Scientific Procedures) Act 1986, issued by the Home Office, Her Majesty’s 
Government, London, United Kingdom. Compound heterozygous embryos were obtained by inter-
crossing p63+/- and Irf6+/R84C mice, the morning of the vaginal plug being considered E0.5. Tissues 
dissected from E14.5 to P0 embryos were fixed in either 4% paraformaldehyde or Bouins reagent and 
processed for histological examination, scanning electron microscopy or immunohistochemistry 
using standard protocols 405. Antibodies were obtained from P. Coulombe (keratin 17); F. McKeon 
(p63, 4A4); D. Garrod, (desmoplakin, 115F); Covance Research Products, New Jersey (loricrin and 
keratin 10); BD Biosciences, San Jose, California (E-cadherin); Abcam, Cambridge, UK (alpha and beta 
catenin) and R & D systems, Minneapolis, USA (activated caspase 3). The section in situ hybridization, 
cell proliferation assays and transmission electron microscopy have been described previously 240, 405. 
For palate culture, E13.5 palatal shelves were dissected from p63+/-;Irf6+/R84C embryos and wild-type 
littermates and cultured as described previously 425.
Cell culture. Skin biopsy procedures, culture of human primary keratinocytes and the maintenance 
of cell lines were carried out as described previously 134. The Tet-on inducible expression system 
established in SAOS2 cells described previously 127 was used to generate myc-tagged mouse ΔNp63α 
wild-type and R304W stable cell lines. Doxycyclin (Sigma) was used to induce expression of myc-
ΔNp63α wild-type and myc-ΔNp63α R304W proteins at a similar level.
Constructs and transactivation assays. The genomic regions of p63 binding site peak 229 was 
amplified by PCR using gateway cloning primers (Table S3.1) and cloned into a modified SmaI site in 
pGL3-Enhancer Vector which contains a firefly luciferase reporter gene followed by a SV40 enhancer. 
To mutate the p63 binding motifs, the most conserved cytosine and guanine bases (labelled in red in 
Figure 3.5) were mutated to adenosine. The ΔNp63α wild-type expression plasmid has been described 
previously 134. Point mutations were introduced into this plasmid to generate R204W, R279H and 
R304W mutations. Transfection and luciferase assays were described previously 134.
RNA extraction and cDNA synthesis. RNA isolation was performed from 48-hour differentiated 
keratinocyte cultures as described previously 134 and from mouse palatal tissue using the Qiagen 
RNeasy kit. Total RNA was transcribed into cDNA according to the manufacturer’s protocol using 
reverse transcriptase PCR iScriptTM cDNA Synthesis kit (BioRad) and using random primers in 
combination with MMLV reverse transcriptase (Invitrogen). The cDNA produced was purified by 
NucleoSpin Extract II kit (Macherey-Nagel, Bioke) according to the manufacturer’s protocol. 
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ChIP and ChIP-seq. Primary keratinocytes and SAOS-2 cultures were crosslinked with 1% 
formaldehyde for 10 minutes and chromatin was collected as described 381. Chromatin was sonicated 
using a Bioruptor sonicator (Diagenode) for 2 times of 8 minutes at high power, 30s ON, 30s OFF. 
Antibodies 4A4 (Abcam) and H129 (Santa Cruz) were used in ChIP-qPCR experiments as they are 
raised against the N-terminus (aa 1-205) and the α-tail of p63 (aa 513-641), respectively. As such, the 
binding of these antibodies was predicted to be unaffected by DNA-binding domain mutations. 4A4 
was used for ChIP-seq analysis. ChIP experiments were performed as previously described 127. ChIP-
seq analysis was performed on a Solexa sequencing machine (Illumina) as described previously 102. 
All 32-bp sequence reads were uniquely mapped to the human genome NCBI build 36.1 (hg18) with 
zero or one mismatch using ELAND (Illumina), which gave 3.2 million unique reads. Peak recognition 
was performed using MACS 340 with default settings and a P value threshold of 1e-9.
siRNA transfection. Primary mouse keratinocytes were cultured in medium at low calcium 
concentrations and transfected with 200 nM of validated siRNAs for mouse ΔNp63α mRNA (Invitrogen 
SiDNp63a-732 siRNA: sense: UCA CAA CAG UCC UGU ACA AUU UCA U; anti-sense: AUG AAA UUG 
UAC AGG ACU GUU GUG A) and corresponding control scrambled siRNAs as previously described 
426. Cells were analyzed 48 hours after transfection by real-time RT-PCR.
Quantitative PCR. Quantitative PCR primers were designed using Primer 3 (http://frodo.wi.mit.edu) 
and qPCR reactions were performed in the 7500 Fast Real Time PCR System apparatus (Applied 
Biosystems) by using iQ SYBR® Green Supermix (Biorad) according to the manufacturer’s protocol. 
For qPCR of cDNA analysis, three exon-spanning primer sets for IRF6 were used (Table S3.2). Human 
acidic ribosomal protein (hARP) was used as a housekeeping gene to normalize the amount of cDNA. 
Differences in expression of IRF6 between wild-type and mutant samples (relative expression) were 
calculated by 2ΔΔCt method 427, 428. The relative expression was averaged using three primer sets. For 
qPCR of ChIP analysis, one primer set was used for each tested binding region (Table S3.3) and ChIP 
efficiency of certain binding sites was calculated using percentage of ChIPped DNA against input 
chromatin. Occupancy used in ChIP experiment with SAOS2 cells was calculated using ChIP efficiency 
of IRF6 P58 region standardized by that of myoglobin exon 2 region. For qPCR of palatal cDNA mouse 
Gapdh (4352932E) and mouse Irf6 (Mm00516797_m1) TaqMan probes (Applied Biosystems) were 
used. Twenty microlitre reactions were established in 1X PCR buffer (Invitrogen) containing 5 U of Taq 
polymerase (Invitrogen), 100 mM MgCl
2
, 4 mM dNTP and 4 μl of cDNA. Reactions were performed in 
triplicate on an OpticonII thermal cycler (MJ Research). Relative levels of expression were calculated 
from a standard curve and normalized to Gapdh. 
Bioimaging. Immunofluorescence and histology images were acquired on a Leica DMRB and DMLB 
respectively, using 2.5x to 63x Plan Fluotar lenses and a SPOT RT camera (Diagnostic Instruments). For 
deconvolution, images were acquired on a Delta Vision RT (Applied Precision) restoration microscope 
using 40x/1.3 Uplan FLN and 60x/1.42 Plan Apo objectives and the Sedat filter set (Chroma 89000). 
The images were collected using a Coolsnap HQ (Photometrics) camera with a Z optical spacing of 
0.2μm. Raw images were deconvolved using the Softworx software and single optical sections of a 
deconvolved stack are shown.
Statistical Analysis. Mann-Whitney U statistical tests were performed for Figure 3.4, A-C, using SPSS 
software. A Kruskal-Wallis one-way analysis of variance, followed by a post hoc Dunn’s test was 
performed for Figure 3.4E, using Prism software. A P value of less than 0.05 was considered significant. 
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Supplementary Information
Figure S3.1. Analysis of E18 wild-type and p63 +/-;Irf6 +/R84C epidermis. A, B| Histological analyses 
indicate that the epidermis of p63 +/-;Irf6 +/R84C mice is indistinguishable from that of their wild-type 
littermates. C to H| Immunofluorescence assays confirm that the epidermis of wild-type and p63 +/-;Irf6 
+/R84C mice undergoes an identical differentiation program as judged by expression of keratin 14, keratin 
1 and loricrin. Scale bars: 50 µm.
Figure S3.2. Analysis of the MEE of the palatal shelves of wild-type and p63 +/-;Irf6 +/R84C embryos. A to 
D| Immunofluorescence analyses of E14.5 mice indicate that the expression patterns of desmoplakin (A 
and B) and E-cadherin (C and D) are the same in wild-type and p63 +/-;Irf6 +/R84C embryos. E, F| TUNEL 
assays indicate that cell death was present in the seam and epithelial triangles of wild-type embryos; in 
contrast, as the palates have not fused in the p63 +/-;Irf6 +/R84C embryos, cell death was only detected in 
small islands on the oral surface of the palate (arrowed in F). G to L| BrdU analyses, in conjunction with 
keratin 17 (G to J) and keratin 14 (K and L) immunostaining, indicate that neither the abnormal periderm 
cells nor the basal cells are hyper-proliferative in p63 +/-;Irf6 +/R84C embryos. Scale bars: A to F, 100 µm; 
G to L, 50 µm.
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Figure S3.3. Analysis of binding motifs of p63 and AP-2α in the enhancer element for IRF6. A zoomed 
in screenshot of the double peak of p63 binding site upstream of IRF6 is shown in the upper panel and 
the corresponding sequences are shown in the lower panel. The MSC-9.7 region is a recently reported 
enhancer element for IRF6 identified by multispecies conservation alignment analysis 260. Binding motifs 
for p63 identified using p53scan are shown in yellow. Motifs for AP-2α identified with Transcription 
Element Search System (TESS; http://www.cbil.upenn.edu) shown in blue appear to be degenerate and 
are located throughout the peak region. The boxed nucleotides are known SNPs and the SNP rs642962 
associated with higher risk for cleft lip 260 is indicated with a red box.
Figure S3.4. ChIP-qPCR analysis of p63 binding sites near the IRF6 gene in human primary keratinocytes, 
mouse palatal shelves and in SAOS-2 stable cell lines expressing p63. A| ChIP-qPCR analysis of p63 
binding was performed in human primary keratinocytes using two different p63 antibodies [4A4 (pan-p63) 
and H129 (α-specific)]. Specific binding of p63 to the reported binding sites upstream of the IRF6 gene 
(IRF6-p58), but not to the putative site in the first intron region (IRF6_intron1) was observed. Promoter 
regions of p21 and BPAG were used as positive controls and that of myoglobin exon 2 (myo) as the 
negative controls. B, C| Mouse palatal shelves were dissected from E13.5 embryos and used for ChIP-
qPCR analysis using antibody 4A4. IgG was used for control ChIP (ctr in B). In mouse palatal shelves, 
p63 binds specifically to the upstream enhancer region of Irf6 (homologous to p229 region in human) 
but not to intron 1 and negative control genes (myo and no gene). D| ChIP-qPCR analyses performed 
with antibody 4A4 in SAOS-2-inducible cell lines expressing ΔNp63α wild-type (wt) and mutant R304W 
proteins show abolition of p63 binding as a result of the R304W mutation.
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Table S3.1. Cloning primers for peak 229 region in the p63 binding site
Primers Sequences
IRF6_cloning_p229_FW ggggacaagtttgtacaaaaaagcaggcttcTGTGTGACCATCTGCCTGTC
IRF6_cloning_p229_RV ggggaccactttgtacaagaaagctgggtgGCTTAAGGGGGAAACCTTTG
IRF6_SDM_p229_M1_FW CTGTGCTGTGGAAAATGCCAGATTATCCTCTCTTCCCC
IRF6_SDM_p229_M1_RV GGGGAAGAGAGGATAATCTGGCATTTTCCACAGCACAG
IRF6_SDM_p229_M2_FW GCATTTCTAGTTAAGACCCAGAACCATCCTGGCAGCC
IRF6_SDM_p229_M2_RV GGCTGCCAGGATGGTTCTGGGTCTTAACTAGAAATGC
Table S3.2. Primers for RT-qPCR analysis
Primers Sequences
IRF6_exp1_FW TAGAGAAGCAGCCACCGTTT
IRF6_exp1_RV GCCACTACTGGAATGACCTGA
IRF6_exp2_FW ttctggtggacagattgagc
IRF6_exp2_RV Agggccatgatatggaagag
IRF6_exp3_FW caagtgtgtgacatccctcag
IRF6_exp3_RV ccacatcattatccttctcatcc
hARP_exp_FW CACCATTGAAATCCTGAGTGATGT
hARP_exp_RV TGACAAGCCCAAAGGAGAAG
mIrf6 F AGGGCTCTGTCATTAATCGAG
mIrf6 R TGATTCGGGGCTGCAGTTTC
Table S3.3. Primers for ChIP analysis
Primers Sequences
IRF6_ChIP_p229_FW ACCGGCAGCATTTCTAGTTC
IRF6_ChIP_p229_RV ACTGGGCTGAGATGAGCTTC
IRF6_  ChIP_p58_FW TTTCTCACATTCCCACATGC
IRF6_  ChIP_p58_RV CCAACCTGACAGACTCCTACC
p21_ChIP_FW GTGGCTCTGATTGGCTTTCTG
p21_ChIP_RV CTGAAAACAGGCAGCCCAAG
BPAG_ChIP_FW tcctggacatctgtgaggca
BPAG_ChIP_RV ccaattgcaaccacctaaaaaac
myo ex2_FW aagtttgacaagttcaagcacctg
myo ex2_RV tggcaccatgcttctttaagtc
chr11_nogene_FW TTGCATATAAAGGAAACTGAAATGCT
chr11_nogene_FW TTACTGCCATGGGTCCGTATC
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Abstract
Clefts of the lip and/or palate (CL/P) are common congenital disorders that result from 
failure of fusion of a series of facial processes during embryonic development. Although 
the Mendelian loci identified to date explain a proportion of the genetic causes of CL/P, 
the developmental pathogenesis remains poorly characterised in most cases. Mutations 
in the transcription factor p63 underlie of a series of human malformation syndromes 
which are defined by a combination of epidermal, limb and craniofacial abnormalities 
including CL/P. To determine the role of p63 during palatogenesis in vivo, we performed 
ChIP-Seq in combination with microarray expression analysis on mouse palatal shelves. 
We demonstrate that p63 directly regulates an adhesion program in the developing palate 
to maintain adhesion homeostasis. We identify that p63 is required for periderm formation 
through regulation of Grhl3 and Sfn and demonstrate that p63-null mice display adhesion 
defects between the periderm and basal cells. Importantly, we also define a critical role 
for p63 in preventing the human skin disorders epidermolysis bullosa and pterygium 
syndromes through transcriptional regulation of adhesion molecules in the epidermis.
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Introduction
Cleft lip and/or cleft palate (CL/P) are common, distressing congenital anomalies. While 
CL/P affects on average 1 in 700 live births, prevalence rates vary across geographic, racial 
and ethnic groups 397. Although not a major cause of increased mortality in developed 
countries, CL/P causes considerable morbidity to affected children who may experience 
problems with feeding, speaking, hearing and social integration. Consequently, CL/P 
requires multidisciplinary care involving surgery, dental treatment, speech therapy and 
psychosocial intervention with lifelong implications for affected individuals 429.
CL/P is aetiologically heterogeneous which has implications for understanding the 
biology of facial development and how environmental and genetic risk factors interact 429. 
Although genome-wide association studies have identified novel loci that are significantly 
associated with CL/P 254, 261, 430-433, our understanding of the molecular pathogenesis of CL/P 
stems largely from analysis of syndromic forms, including those arising from mutations in 
genes such as P63, IRF6, PVRL1, TFAP2A and RIPK4 3, 226, 399, 415, 434, 435.
The transcription factor p63 is essential for formation of the epidermis and other 
stratifying epithelia in addition to ectodermal appendages 6, 116. Mutations in p63 underlie 
seven autosomal dominant disorders including: ankyloblepharon-ectodermal dysplasia-
cleft lip/palate (AEC) syndrome and ectrodactyly-ectodermal dysplasia-clefting (EEC) 
syndrome, which are characterised by combinations of epidermal, limb and craniofacial 
abnormalities, including CL/P 3. Previous studies have indicated that p63 is a key 
regulator of epithelial development with fundamental roles in cell proliferation, adhesion, 
differentiation and survival 272, 275, 305. The function of p63 is mediated by several isoforms 
derived from distinct transcripts generating biological complexity and functional diversity. 
The p63 gene encodes at least six protein variants generated by alternative transcription 
start sites that give rise to two different N-termini; a transactivation (TA) domain or a shorter 
ΔN domain. In addition, both TA and ΔN isoforms undergo alternative splicing towards 
the C-terminus giving rise to α-, β-, g-, δ and e-isoforms 135. Although all isoforms contain 
DNA-binding and isomerisation domains, their ability to activate or repress their target 
genes is variable 131, 138. In contrast to other isoforms, the α-isoforms contain a sterile alpha 
motif domain that mediates protein–protein interactions. Although the functional role of 
the different isoforms remains unclear, studies have suggested that ΔNp63α is the major 
isoform expressed in basal epithelial cells during embryogenesis 152, 156, 405.
In mice, development of the secondary palate mirrors that of humans; consequently, the 
mouse is the pre-eminent model organism for the study of mammalian palatogenesis 
436. Development of the murine secondary palate commences on embryonic day (E) 11 
with outgrowth of the palatal shelves from the maxillary processes. During E12 and E13, 
the palatal shelves grow vertically down the sides of the developing tongue. At this stage, 
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each palatal shelf consists of a core of neural crest cell-derived mesenchyme surrounded 
by an epithelium composed of a basal layer of cuboidal ectodermal cells and a surface 
layer of flattened periderm cells, similar to the remainder of the oral epithelia 436. During 
E14, the palatal shelves re-orientate to a horizontal position above the tongue and contact. 
The medial edge epithelia (MEE) of the apposed palatal shelves adhere to form a midline 
epithelial seam which subsequently degenerates to allow mesenchymal continuity across 
the palate by E15 436. Mice lacking p63 display a complete cleft of the secondary palate 6, 
116, 405. Previously we have shown that p63 is expressed in the basal cells of the oral/palatal 
epithelia during development; that correct p63 signalling is essential in the initial stages 
of palatal shelf outgrowth; and that down-regulation of p63 in the MEE precedes palatal 
fusion 156, 405.
Given the critical role that p63 plays during palatal development, we sought to determine 
the transcriptional targets of p63 in the palatal epithelia. Although existing p63 ChIP-Seq 
datasets have extended our knowledge of p63 targets during epidermal development, 
they have been generated from cell lines such as human adult keratinocytes 437, 
human neonatal keratinocytes 438, and human immortalised, epithelial prostate cells 439. 
These studies are therefore of limited use for analysing the developmental control of 
palatogenesis as numerous gene regulatory elements show species- and tissue-specificity 
11. We have therefore catalogued p63 interactions on a genome-wide basis in vivo using 
palatal shelves dissected from mouse embryos. We have used a hypothesis-generating 
approach, in which p63 ChIP-Seq and microarray datasets were intersected, to elucidate 
a subset of the initial layers of the in vivo molecular networks controlled by p63. Using this 
approach, we demonstrate that in the secondary palate p63 orchestrates a cell adhesion 
network to maintain adhesion homeostasis in stratified epithelia and identify several novel 
transcriptional targets. Furthermore, we elucidate a critical role for p63 in development 
and maintenance of the oral periderm. Finally, we have identified a large number of p63 
target genes associated with the skin disorders epidermolysis bullosa and pterygium 
syndromes, indicating that appropriate p63 signalling is essential in preventing these 
devastating human conditions.
Results
Expression of p63 isoforms in the secondary palate
To determine which p63 isoforms are expressed in the palatal epithelia, we performed 
high-throughput sequence analysis of RNA (RNA-Seq) extracted from E13.5 and E14.5 
mouse palatal shelves. A total of 35 million and 64 million mapped reads were obtained 
from E13.5 and E14.5 palates, respectively. Of these, 1265 and 1566 reads were mapped 
to the p63 gene at E13.5 and E14.5 respectively. At both time-points, we were unable to 
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detect any reads mapping to the TA-isoforms (Figure 4.1A and Figure S4.1), confirming 
previous reports that ΔNp63 is the predominant isoform expressed during embryogenesis 
152, 156, 405. Analysis of ΔNp63-isoform-specific reads indicated that the two isoforms which 
encode ΔNp63α (transcript 4 and 5) were the most highly expressed isoforms, accounting 
for 46% of total reads at E13.5 and almost 85% of total reads at E14.5. ΔNp63β and ΔNp63g 
were expressed at lower levels at both ages (Figure S4.1).
Genome-wide distribution of ΔNp63α binding sites in the secondary palate
To determine the genome-wide profile of ΔNp63α binding regions in the developing 
secondary palate, we performed ChIP-Seq analysis of chromatin isolated from E13.5-E14.5 
mouse palatal shelves using a p63α-specific antibody. Analysis of sequenced reads using 
the MACS algorithm 340 identified 6295 genomic regions bound by p63 in vivo (P value = 
≤1e-5) (Table S4.1). To confirm the validity of p63 binding sites, we tested 15 regions with a 
range of peak heights and chromosomal locations using ChIP-qPCR. Fourteen of these 15 
regions were validated as bona fide p63 binding sites (P value = ≤0.05) (Figure 4.1B). Next, 
we assessed the genomic distribution of the p63 binding sites using RnaChipIntegrator. In 
total 36% of the binding sites identified flanked the transcription start site (TSS) of the closest 
gene. A further 14% of binding sites were located intragenically and 16% were located <25 
kb from the last exon. The remaining 34% were intergenic (Figure 4.1C). Analysis of the 
binding sites using p63scan software 437 indicated that 72% contained at least one p63 
motif.
Consistent with the functional significance of p63 binding events identified in other 
studies 437, 438, bioinformatics analysis of the ChIP-Seq dataset using the Genomic Regions 
Enrichment of Annotation Tool (GREAT) 440, indicated that the top biological process GO 
term was ‘skin development’, the highest ranking mouse phenotype term was ‘abnormal 
epidermis stratum corneum’ and the top Mouse Genome Informatics (MGI) expression term 
detected was ‘oral epithelium’ (Figure 4.1D). Interrogation of the dataset also revealed that 
numerous terms related to cell adhesion, including cell junction organisation/assembly, 
adherens junctions, and hemi-desmosome assembly, were significantly enriched in the 
data, suggesting that p63 plays an important role in controlling adhesion during palatal 
development (Figure 4.1D). Moreover, we identified significant enrichment of p63 binding 
sites surrounding genes associated with the disease epidermolysis bullosa, a genetic skin 
disorder of altered cell adhesion that results in epithelial blistering.
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Figure 4.1. Genome-wide distribution of ΔNp63α binding sites in the secondary palate. A| RNA-
Seq analysis indicates that ΔNp63 isoform transcripts are the predominant isoforms expressed in the 
developing secondary palate. Transcript reads are indicated by black bars. B| ChIP-qPCR validation of 
p63-bound sites. Fold-enrichment for each binding region was calculated relative to a control region 
in exon 2 of myoglobin (set at 1; pale bar), to which p63 does not bind. Asterisks represent level of 
significance: * P value <0.05, ** P value <0.01, *** P value <0.001, Student’s t-test. C| p63 binding 
site distribution relative to RefSeq genes. Binding site regions are divided into TSS flanking region (5 kb 
upstream of TSS, first exon & first intron), intragenic region (all introns and exons excluding first), <25 
kb (5–25 kb upstream or 25 kb downstream of last exon), or intergenic regions. D| GREAT functional 
annotation of the genes associated to the p63-bound regions.
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p63 regulates a cell adhesion network in the secondary palate
To dissect the potential functional relevance of the binding events identified by ChIP-Seq, 
we performed microarray analysis of palatal shelves dissected from E14.0 wild-type versus 
p63-null embryos (Figure 4.2A and Table S4.2). Analysis of the 889 differentially-expressed 
genes (P value = ≤0.05) indicated that 441 were down-regulated in p63-null palatal shelves 
compared to their wild-type littermates whilst 448 genes were up-regulated. Consistent 
with GREAT analysis of the ChIP-Seq dataset, Gene Ontology 344 indicated that genes 
involved in ectodermal development, cell junction, and tight junction formation, and cell 
adhesion were over-represented among these genes (Figure 4.2B). 
Analysis of the cell adhesion gene cluster indicated that more than 50% (32/57) were down-
regulated in the palatal shelves of p63-null embryos (Table S4.3). Further investigation 
indicated that many of these genes were associated with specific types of cell adhesion 
complex including desmosome formation (Dsc3, Dsg2, Dsg3, Perp, Jup, Pkp1 and Pkp3), 
adherens junction formation (Jub, Cdh3, Dsp, Plekha7 and Pvrl1), and cell-matrix adhesion 
(Col7a1, Col17a1, Col18a1, Itga3, Itgb4 and Lamb3). Conversely, genes associated with 
tight junction formation, including Claudin-3, -4, -6, -7, -9, -10, -23, ZO-3 and occludin, 
were up-regulated in p63-null palatal shelves (Figure 4.2 and Table S4.3). The positive 
regulation of desmosome formation, adherens junction and cell matrix adhesion by p63, 
in addition to negative regulation of tight junction formation, suggests that p63 plays a 
critical role in modulating the profile of cell adhesion complexes in the secondary palate.
To identify direct transcriptional targets of p63 in the secondary palate, we intersected 
the ChIP-Seq and microarray datasets to identify p63 binding sites in close proximity (<25 
kb) to the TSS of candidate genes. A total of 466 binding sites were identified close to 307 
candidate genes (Table S4.4). As bioinformatics analysis identified a large number of genes 
associated with cell adhesion/cell junction formation, we focused on genes implicated 
in these processes. qPCR analysis of 12 of these genes was performed on E14.0 p63-
null versus wild-type palatal shelves. All 12 genes were significantly down-regulated, 
confirming the results of the microarray analysis (Figure 4.2C). Next, we performed ChIP-
qPCR with chromatin extracted from E14.5 wild-type palatal shelves to validate the binding 
sites associated with each candidate gene. All 12 p63 binding regions were confirmed as 
p63 binding sites in vivo (Figure 4.2D) indicating that p63 transcriptionally orchestrates a 
large cell adhesion network in the secondary palate.
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Figure 4.2. p63 regulates an adhesion programme in the secondary palate. A| Heatmap of cell adhesion 
genes that are differentially expressed in the palatal shelves of wild-type versus p63-null embryos 
(green, down-regulation; black, no significant change; red, up-regulation). B| Functional annotation of 
differentially expressed genes in the palatal shelves of wild-type versus p63-null embryos as assessed by 
DAVID analysis. C| qPCR analysis of genes indicated as differentially regulated in microarray analyses 
using RNA extracted from palatal shelves dissected from E14.0 wild-type and p63-null mice. D| ChIP-
qPCR analysis of p63-bound sites within <25 kb of cell adhesion genes. Fold-enrichment for each 
binding region was calculated relative to a control region in exon 2 of myoglobin (set at 1; pale bar), to 
which p63 does not bind. Asterisks represent level of significance: * P value <0.05, ** P value <0.01, 
Student’s t-test (C), Mann Whitney U test (D).
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p63 is a key regulator of cleft palate-associated genes 
Heterozygous mutations in p63 underlie seven autosomal dominant developmental 
disorders characterised by varying combinations of ectodermal dysplasia, limb 
abnormalities, and CL/P, indicating that p63 plays a critical role in the development of 
these tissues 3. Furthermore, it has been shown that p63 transcriptionally regulates a large 
number of genes associated with cleft palate 438. However, as the McDade study was 
performed in human foreskin keratinocytes, the validity of p63 binding in the developing 
palate remains unclear 438. Interrogation of our palatal ChIP-Seq dataset revealed that p63 
binding sites were associated with Fgfr2, Irf6, Pvrl1, Pdgfa, Sfn and Jag2, mutations in 
which result in cleft palate in either humans and/or mice 226, 399, 436, 441. Interestingly, we also 
identified a novel p63 binding site within the region flanking the TSS of the transcription 
factor Grhl3, mutations in which cause a subset of cases of Van der Woude syndrome 
(VWS) 442. Mutations in TCFAP2A, which encodes the transcription factor AP2α, result in 
branchio-oculo-facial syndrome, in which CL/P is a defining feature 415. Previous in vitro 
studies have shown that TFAP2α transcriptionally regulates p63 isoforms by binding to a 
regulatory region downstream of p63, functioning co-operatively with p63 to induce its 
activity 293. We identified three p63 novel binding sites around Tcfap2α (Figure 4.3A). In 
addition, interrogation of our palatal ChIP-Seq dataset identified three p63 binding sites 
close to Pvrl1, including a previously reported intragenic binding site 443 as well as novel 
binding regions upstream (-25 kb) and downstream (+45 kb) of Pvrl1. In total, 12 potential 
p63 binding sites in cleft palate-associated genes, including novel sites in Pvrl1 and 
Tcfap2α, were validated in palatal tissue by ChIP-qPCR, suggesting tissue-specific control 
of gene regulation (Figure 4.3A).
As ChIP-Seq and microarray data indicated that Tcfap2α is a transcriptional target of 
p63, we analysed Ap2α expression in vivo (Figure 4.3B and 4.3C). Ap2α expression was 
detected in the palatal epithelia and mesenchyme of E14.0 wild-type mice (Figure 4.3B). In 
contrast, in the palatal shelves of E14.0 p63-null mice, while Ap2α expression in the palatal 
mesenchyme and epithelium of the tongue was comparable to that observed in wild-
type mice, it was markedly reduced in the palatal epithelia (Figure 4.3C). Recent in vitro 
experiments have shown that p63 and AP2α transcriptionally co-regulate several target 
genes including PVRL1 438. To confirm that Ap2α, nectin-1 and p63 are co-expressed in the 
palatal shelves, we performed immunofluorescence analysis and demonstrated that all 
three proteins are expressed in E14.0 wild-type palatal epithelia (Figure 4.3D and 4.3E). The 
finding that Tcfap2α is a direct transcriptional target of p63, together with the observation 
that AP2α transcriptionally regulates p63 293, indicates that there is a negative feedback 
signalling mechanism in palatal epithelia that enables p63 and AP2α to co-regulate the 
expression of downstream targets such as Pvrl1 (Figure 4.3F) 260, 316, 444.
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Figure 4.3. p63 is a master regulator of cleft palate-associated genes. A| ChIP-qPCR validation of p63-
bound sites within regulatory regions surrounding cleft palate-associated genes. Fold-enrichment for each 
binding region was calculated relative to a control region in exon 2 of myoglobin (set at 1; pale bar), 
to which p63 does not bind. (P) genes associated with periderm formation; Intra, intragenic; asterisks 
represent level of significance: * P value <0.05, ** P value <0.01, *** P value <0.001, Student’s t-test. 
B| At E14.0, AP2α protein expression is detected in the palatal epithelia (arrowhead) and mesenchyme 
(arrow) of wild-type mice. C| AP2α expression in the palatal epithelia of p63-null embryos is down-
regulated (arrowhead), whereas expression in the palatal mesenchyme (arrow) and tongue epithelium is 
unchanged. D, E| Expression analysis confirms AP2α, p63 and nectin-1 are co-expressed in E14.0 wild-
type palatal epithelia. P, palate; T; tongue. Scale bars: B and C, 100µm; D and E, 25 µm. F| Proposed 
signalling pathway between p63, AP2α, Grhl3 and Pvrl1 in the secondary palate. Black lines, published 
research (135, 156, 260, 293, 316, 439, 444); red lines, novel.
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p63 is required for periderm formation 
Periderm is a layer of flattened epithelial cells which forms the outermost cell layer of the 
embryo before subsequently sloughing off during late gestation 441. Periderm is critical for 
the prevention of inappropriate adhesion between intimately apposed epithelial surfaces 
441. Intriguingly, Irf6, Sfn, Grhl3 and Jag2, which we identified as potential p63 transcriptional 
targets in the secondary palate (Figure 4.3A), play an essential role in periderm formation 
441, 442. To determine if p63 is required for periderm formation, we examined the palatal 
shelves at E12.5. Histological analysis of wild-type palatal shelves revealed basal epithelial 
cells covered by a continuous layer of flattened cells, a morphological characteristic of 
periderm (Figure 4.4A). In contrast, the palatal shelves of p63-null mice lacked this layer, 
with only ‘bead-like’ cells observed above the basal layer (Figure 4.4B). To exclude the 
possibility that periderm formation was delayed in p63-null mice, we analysed E13.5 
palatal shelves. Similar to observations at E12.5, wild-type palatal shelves displayed a basal 
layer with an overlying periderm (Figure 4.4C) while p63-null embryos exhibited a highly 
disorganised basal layer and with a large number of rounded cells that appeared to be 
detaching from the basal layer (Figure 4.4D).
To confirm that periderm was absent from the palatal shelves of p63-null embryos, we 
analysed the expression of keratin 17 (K17), a marker of oral periderm 445. At E12.5 and E13.5, 
peridermal expression of K17 expression was observed (Figure 4.4E and 4.4G). In contrast, 
we failed to detect K17 expression in the palatal shelves of E12.5 p63-null mice (Figure 4.4F). 
However, by E13.5 patchy K17 expression was detected in the basal epithelia of p63-null 
palatal shelves (Figure 4.4H). Next, we examined the expression of the adherens junction 
protein, E-cadherin. Expression of E-cadherin in wild-type palatal shelves was detected 
throughout the plasma membrane of basal epithelial cells at E12.5 and E13.5 (Figure 4.4I 
and 4.4K). Consistent with previous studies, higher magnification of wild-type palates at 
E12.5 revealed that E-cadherin was absent from the apical surface of the periderm cells 446 
(Figure S4.2).  A similar pattern of E-cadherin expression was observed in the ‘bead-like’ 
cells above the basal layer in E12.5 p63-null palatal shelves (Figure S4.2).
Mice lacking either the cell cycle regulator Sfn (14-3-3σ) or the transcription factor Grhl3 
exhibit abnormal periderm, indicating that both proteins play a critical role in periderm 
formation 441, 442.  As we had identified p63 binding sites close to the TSS of Sfn and Grhl3 at 
E14.0 (Figure 4.3A), we confirmed that p63 binds to these regions at E12.5 (Figure 4.5A). To 
determine if Sfn and Grhl3 are regulated by p63, we performed qPCR analysis (Figure 4.5B). 
Sfn transcripts were down-regulated in the palatal shelves of p63-null mice compared 
with their wild-type littermates whilst we failed to detect a statistically significant change 
in Grhl3 expression (Figure 4.5B). Using immunofluorescence, we observed high levels of 
Sfn and Grhl3 expression in the periderm with lower levels in the basal epithelia of wild-
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type palatal shelves at E12.5 (Figure 4.5C and 4.5E). In contrast, Sfn and Grhl3 expression 
was markedly reduced in the palatal epithelia of E12.5 p63-null mice (Figure 4.5D and 
4.5F). To provide additional support for these results, we performed p63 knockdown using 
siRNA in mouse keratinocytes and found that Sfn and Grhl3 were significantly down-
regulated (Figure 4.5G). To determine if the p63 binding sites associated with Sfn and 
Grhl3 are conserved, we interrogated a ChIP-Seq dataset generated from human primary 
keratinocytes 437. The binding site <1 kb downstream of Sfn was conserved in the human 
keratinocyte ChIP-Seq data. Although the p63 binding site associated with Grhl3 in mouse 
palatal shelves was not conserved in human keratinocytes, we identified a p63 binding 
region within 6 kb of the Grhl3 TSS (-6 kb). Both regions were validated by ChIP-qPCR 
analyses of HaCaT cells (Figure 4.5H). 
Figure 4.4. Abnormal periderm formation in the palatal shelves of p63-null embryos. A-D| Histological 
analysis of palatal epithelia at E12.5 and E13.5. A, C| Coronal sections of wild-type palatal shelves 
at E12.5 and E13.5 reveal a layer of flattened periderm cells overlying the basal epithelia. B, D| In 
p63-null palates, the flattened cells are absent and individual ‘bead-like’ cells are observed above the 
basal epithelia at E12.5 (B) and E13.5 (D). Boxed insets represent higher magnification of the respective 
regions. E-H| K17 expression at E12.5 and E13.5. E| K17 is expressed in a number of flattened cells 
overlying the basal epithelia in wild-type palatal shelves at E12.5. F| In contrast, K17 is not detected in 
p63-null palatal epithelia at E12.5. G| From E13.5, K17 expression is observed throughout the periderm 
layer in wild-type palatal epithelia. H| However, K17 expression marking the periderm is absent in p63-
null palates although ectopic expression of K17 is detected in basal epithelial cells at E13.5 (arrow). I, K| 
In wild-type palatal shelves E-cadherin expression is observed throughout the basal membrane of basal 
epithelial cells but absent from the apical side of the periderm cells at E12.5 (I) and E13.5 (K). J, L| A 
similar E-cadherin expression pattern is observed in p63-null basal epithelial cells. In addition, apical 
expression is absent from individual ‘bead-like’ cells (arrowhead) detected above the basal layer in p63-
null palates at E12.5 (J) and E13.5 (L). Scale bars: 50 µm.
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p63 regulates adhesion between basal epithelia and periderm
Components of adherens and desmosomal junctional complexes are localised at 
the boundary between the basal epithelial cells and periderm 441, 446. As analysis of the 
p63 ChIP-Seq and microarray datasets indicated that p63 orchestrates a cell adhesion 
programme in the secondary palate, including direct regulation of a number of adherens 
junction and desmosomal proteins, we investigated whether p63 regulates adhesion 
between periderm and basal cells in the palatal epithelia.
We assessed the expression patterns of several cell adhesion molecules that we identified 
as p63 transcriptional targets in the E14.5 secondary palate. Expression of the desmosomal 
protein plakoglobin was detected along the entire apical side of the basal layer of wild-type 
Figure 4.5. p63 regulates Sfn and 
Grhl3. A| ChIP-qPCR confirms p63 
binds to the genomic regions flanking 
the TSS of Sfn and Grhl3 in E12.5 
palatal shelves. B| Real-time PCR 
reveals that Sfn transcripts are down-
regulated in the palatal shelves of 
p63-null embryos compared to their 
wild-type littermates. In contrast, 
Grhl3 transcript levels in p63-null 
palatal shelves are unchanged. C-F| 
Immunofluorescence analysis of Sfn 
and Grhl3 in E12.5 palatal epithelia. 
C, E| High levels of Sfn and Grhl3 
expression are detected in the 
periderm with lower levels observed 
in the basal cells of the palatal 
epithelia of E12.5 wild-type mice 
(arrowed). D| In contrast, only small 
amounts of punctate Sfn expression 
are observed in the basal cells of 
p63-null palatal shelves whereas F| 
Grhl3 expression is absent from the 
periderm of p63-null palatal shelves. 
Scale bars: 50 µm. G| siRNA knock-
down of p63 in mouse keratinocytes 
reduces Sfn and Grhl3 transcript 
levels. H| ChIP-qPCR demonstrates 
that p63 binds to the genomic 
regions flanking the TSS of Sfn and 
Grhl3 in human cells. Asterisks 
represent level of significance: * P 
value <0.05, ** P value <0.01, *** 
P value <0.001. Student’s t-test (A, 
G and H), Mann Whitney U test (B).
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palatal shelves. Deconvolution images of the palatal epithelia revealed that plakoglobin 
was present at the basal/periderm border in wild-type palatal shelves (Figure 4.6A and 
4.6B). In contrast, plakoglobin expression was markedly reduced in p63-null palatal shelves 
and expression at the apical border of the basal cells was absent (Figure 4.6C and 4.6D). 
The keratin cytoskeleton plays an important role in desmosome maintenance and 
intercellular adhesion 447. As we had identified Krt5 as a transcriptional target of p63 
(Figure 4.1B; Figure S4.3), we analysed keratin 5 expression in the palatal shelves. Similar to 
plakoglobin, cytoplasmic keratin 5 expression was observed in basal epithelial cells in wild-
type palatal shelves (Figure 4.6E and 4.6F). In contrast, keratin 5 expression was severely 
diminished in p63-null palatal shelves (Figure 4.6G and 4.6H).
To determine if adherens junction complexes between the basal cells and periderm are 
regulated by p63, we assessed the expression of nectin-1, encoded by Pvrl1, which has also 
been identified as a p63 transcriptional target (Figure 4.3). Similar to plakoglobin, nectin-1 
expression was observed along the basal epithelial layer in wild-type palatal shelves (Figure 
4.6I). Furthermore, nectin-1 localised specifically to the basal/periderm junction (Figure 
4.6J). In contrast, nectin-1 expression was markedly down-regulated in p63-null palatal 
shelves. Deconvolution images revealed that the localised expression of nectin-1 at the 
basal/periderm junction was absent (Figure 4.6K and 4.6L). 
To determine if loss of expression of adherens junction proteins was specific to 
transcriptional targets of p63, we analysed Pvrl4 which encodes nectin-4. qPCR analysis 
of Pvrl4 confirmed the microarray analysis which indicated that Pvrl4 transcript levels are 
similar in the palatal shelves of wild-type and p63-null embryos (Figure S4.4). Subsequently, 
we performed immunofluorescence analysis of nectin-4 in the palatal shelves. Nectin-4 
expression was similar to that of nectin-1 with expression at the basal/periderm junction 
throughout the palatal epithelia of wild-type mice (Figure 4.6M and 4.6N). In contrast, 
nectin-4 was mis-localised in the palatal epithelia of p63-/- mice with expression detected 
between adjacent basal cells (Figure 4.6O and 4.6P).
p63 is a key regulator of epidermolysis bullosa-associated genes 
GREAT analysis of the ChIP-Seq dataset identified significant enrichment of p63 binding 
sites surrounding genes associated with the human epithelial disease epidermolysis 
bullosa. Ten genes identified as transcriptional targets of p63 in the secondary palate are 
mutated in EB, including the novel p63 transcriptional targets Col7a1, Fermt1, Jup and 
Lamb3 (Figure 4.2C and 4.2D). In addition, we verified several known p63 transcriptional 
targets including Krt5, Krt14, Dsp, Col17a, Pkp1 and Itgb4 (Figure 4.1B and 4.2D) 118, 270, 271, 
275, 448.
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As EB is a collection of human genetic disorders which primarily affect the epidermis, we 
analysed a human primary keratinocyte p63 ChIP-Seq dataset 437 and, consistent with our 
palatal ChIP-Seq data, identified p63 binding sites associated with the TSS of Col7a1 and 
Fermt1 as well as intragenic p63 binding sites within Lama3 and Plec1, indicating that they 
may also be direct targets of p63 in the epidermis. These binding regions were validated by 
ChIP-qPCR in HaCaT cells (Figure 4.7A). To complement these findings, we also knocked-
down p63 in mouse primary keratinocytes using a pan-p63-specific siRNA and found a 
statistically significant decrease in the levels of Col7a, Plec1 and Lama3 transcripts levels, 
but not Fermt1 (Figure 4.7B).
Figure 4.6. Loss of p63 results in adhesion defects in palatal epithelia. A, B, E, F, I and J| Immunofluorescence 
analysis of the  desmosome component plakoglobin (Pg), the cytoskeleton protein keratin 5 (K5) and 
the cleft palate-associated gene Pvrl1, encoding nectin-1, reveals strong expression of these markers 
throughout the periderm and at the junction between the periderm/basal cells in the  palatal epithelia 
of wild-type mice. C, D, G, H, K and L| In contrast, all three proteins are markedly down-regulated in 
p63-null palatal shelves. M-P| Nectin-4 expression levels in p63-null palates are comparable to those of 
the wild-type; however deconvolution images reveal that expression pattern of nectin-4, which is normally 
restricted to the peridermal/basal junction (M and N), is mis-localised in the p63-null palatal shelves and 
is expressed between adjacent basal cells (O and P). Scale bars: A, C, E, G, I, K, M, O = 50 µm; B, D, 
F, H, J, L, N, P = 20 µm.
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The extracellular matrix protein Col7a1 is a major component of the anchoring fibrils 
required for adhesion between the epidermis and dermis 447. Mutations in Col7a1 result 
in dystrophic epidermolysis bullosa, a major type of EB caused by disrupted dermal/
epidermal adhesion 447. Identification of a p63 binding region in the TSS of Col7a1, in 
addition to decreased Col7a1 transcript levels following p63 knock-down, indicates that 
p63 transcriptionally regulates Col7a1 in the epithelium. To provide an in vivo context to 
Figure 4.7. p63 regulates genes mutated in epidermolysis bullosa. A| Validation of p63 binding sites 
surrounding EB genes by ChIP-qPCR analysis of chromatin extracted from HaCaT cells. B| siRNA 
knockdown of p63 in mouse keratinocytes reduces expression of epidermolysis bullosa-associated genes. 
Asterisks represent level of significance: * = P value <0.05, ** = P value <0.01, *** = P value <0.001, 
Student’s t-test. C, D| Expression of Col7a1 (red) and E-cadherin (green) in E17.5 wild-type and p63-null 
snout skin. C| Expression of Col7a1 is observed along the basement membrane (arrowed) in wild-type 
skin. D| In contrast, expression of Col7a1 is markedly down-regulated in p63-null skin. E| A summary 
of EB genes, both previously reported direct targets and novel direct targets identified in this study, “ 
indicates validated as a transcriptional target of p63 by ChIP-qPCR analysis of HaCaT cells and/or E14 
palatal shelves.
Novel
Novel
Novel
Novel
Novel
Ref. 448
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Ref. 275
Ref. 275
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these findings, we performed Col7a1 immunofluorescence analysis on wild-type versus 
p63-null snout skin at E17.5 (Figure 4.7). In wild-type skin, Col7a1 expression was observed 
along the epidermal basement membrane (Figure 4.7C). In contrast, expression of Col7a1 
was markedly down-regulated in p63-null skin (Figure 4.7D).  Collectively, our data 
indicate that a number of EB-associated genes are p63 transcriptional targets, suggesting 
that correct p63 signalling is critical in preventing this disease (Figure 4.7E) 118, 157, 270, 271, 275, 448. 
Discussion
Although previous research has identified a large number of genes that are transcriptionally 
regulated by p63 to control epithelial development and differentiation, all of these studies 
have been performed in vitro 275, 305, 437, 438. A lack of genome-wide studies of p63 binding 
performed in vivo has therefore limited our ability to dissect the molecular events controlled 
by p63 in specific developmental systems. In the current study, we present the first in vivo 
characterisation of p63 binding in a developing tissue. In this regard, the distribution of 
binding sites may shed light on the nature of p63 binding; in the dataset generated by 
Kouwenhoven et al. 437, 13% of binding sites were located at the TSS of genes and 37% 
were intragenic, in our dataset 36% were located at the TSS and 14% were intragenic with 
the other two categories of intergenic (33% and 34%) and within 25 kb of a gene (17% 
and 16%) remaining relatively similar. Indeed, Kouwenhoven and colleagues suggested 
that, as a large percentage of their binding sites were located in intronic regions or at a 
distance from promoters, p63 may activate transcription at proximal promoters but also 
regulate gene expression at distance perhaps by a looping mechanism in keratinocytes 437. 
In contrast, our dataset suggest that in the developing palate, the p63 binding events may 
more likely represent direct control of gene regulation.
Analysis of the RNA-Seq data demonstrated that ΔNp63 is the predominant isoform 
expressed in developing epithelia. This finding is in agreement with previous reports that 
indicate that ΔNp63, rather than TAp63, is indispensable for epithelial development 449, 450. 
Concordant with previous reports using p63 isoform-specific antibodies, we show that 
ΔNp63α is the predominant isoform expressed in the palatal epithelia 156. In addition, we 
report for the first time that the ΔN-p63 isoforms ΔNp63β and ΔNp63g are expressed in the 
palate suggesting that they may also play a key role in palatal development. 
Using a hypothesis-generating approach, we demonstrate that p63 orchestrates a cell 
adhesion network in the palatal epithelia. By performing functional annotation analysis of 
microarray data generated from the palatal shelves of p63-null embryos, we report that 
p63 positively regulates the formation of adherens junction and desmosome complexes 
whilst suppressing tight junction formation in palatal epithelia. These findings highlight 
the importance of p63 in regulating the balance of normal adhesion junction formation 
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in palatal epithelia; maintaining high expression of adherens junction complexes and low 
levels of tight junction formation in p63-positive proliferating basal cells, whilst allowing 
tight junction formation to occur in the p63-negative, suprabasal layers.
By intersecting ChIP-Seq and microarray datasets we demonstrate that p63 directly 
regulates a network of cell adhesion molecules in palatal epithelia. These findings are 
in agreement with previous studies which have shown that p63 plays a critical role in 
transcriptionally regulating adhesion molecules in keratinocytes and mammary epithelial 
cells 275. We identified 12 cell adhesion genes that are transcriptionally regulated by p63 
in palatal epithelia, including the novel targets Col7a1, Fermt1, Ajuba and Lamb3. While 
initial studies suggested that ΔNp63 isoforms predominantly behave in a dominant 
negative manner 137, recent studies indicate that ΔNp63 also plays a fundamental role 
in transcriptionally activating target genes 275, 451. In this study, we report that the 12 cell 
adhesion genes, all of which contain a verified p63 binding site within close proximity (<25 
kb) to the TSS, are down-regulated in the palatal shelves of p63-null embryos, supporting 
the notion that p63 transcriptionally activates cell adhesion genes in vivo.
Previous studies have reported the genome-wide distribution of p63 binding sites in 
human keratinocytes 437, 438. Furthermore, McDade noted that several p63 transcriptional 
targets identified in keratinocytes are associated with cleft palate 438. Consistent with this 
work, we identified a large number of p63 binding sites that are known to regulate genes 
associated with cleft palate including Fgfr2, Pdgfa and Pvrl1, demonstrating for the first 
time that p63 transcriptionally regulates these genes in palatal tissue. 
Interestingly, we identified novel p63 binding sites around the Tcfap2α locus suggesting 
that the transcription factor AP2α is transcriptionally regulated by p63. Furthermore, we 
show that AP2α is down-regulated in the palatal epithelia of p63-null mice suggesting 
that p63 positively regulates Tcfap2α. It has previously been demonstrated that AP-2a 
positively regulates p63 expression 293. Furthermore, recent in vitro experiments have 
shown that p63 and AP2α transcriptionally activate and co-regulate a number of target 
genes including Pvrl1 438. In this report we show that AP2α is itself a transcriptional target of 
p63 in the palate, suggesting that a negative feedback signalling pathway between p63 and 
AP2α exists in palatal epithelia to ensure co-regulation of the expression of downstream 
target genes such as Pvrl1. 
The finding that genes required for periderm formation are direct targets of p63 led us to 
hypothesis that p63 signalling may be required for correct periderm formation in the palate. 
p63-null mice lack flattened periderm cells indicating that p63 signalling is critical for the 
formation of this transient epithelial layer. We demonstrate that two proteins required for 
proper formation and differentiation of the periderm, Sfn and Grhl3, are regulated by p63 
during the initial stages of palate development. We report that p63 acts as a transcriptional 
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activator as shown by the down-regulation of Sfn expression at both transcriptional and 
protein levels in the palatal shelves of p63-null embryos. This result was also supported 
by p63 siRNA analysis in mouse keratinocytes which showed down-regulation of Sfn and 
Grhl3 levels following knockdown of p63 170.
We have previously shown that p63 transcriptionally activates Ripk4 and Irf6, mutations 
in which lead to the pterygium syndromes Bartsocas Papas syndrome and VWS 156, 434. 
Furthermore, we confirm that the Notch ligand Jag2, which is also required for periderm 
differentiation, is a direct target of p63 in the palate. For the first time we demonstrate that 
Grhl3, a transcription factor that has been shown to be mutated in a subset of cases of 
VWS, is a direct p63 target in mouse palatal shelves and keratinocytes 442. 
We report that p63-null mice display ectopic expression of the periderm marker K17 in 
basal oral epithelia; a phenotype we have previously reported in p63+/-;Irf6+/R84C mice 156. 
Intriguingly, IRF6 binding sites are located within 1 kb of the p63 binding sites located 
upstream of Grhl3 and Sfn 452. It has been shown that Irf6 promotes periderm differentiation 
through activation of Grhl3 444. Furthermore, Sfn and Irf6 interact genetically to ensure 
proper epidermal development 240. Based on these findings, we postulate that p63 and 
IRF6 may cooperatively regulate periderm formation and differentiation by controlling the 
expression of Sfn and Grhl3 in the periderm. 
Analysis of the palatal epithelia of p63-null embryos revealed that adherens junction 
and desmosome complexes are lost at the basal/periderm border indicating that p63 is 
required to maintain adherence of the periderm cells to the basal epithelia. Previously, it 
has been shown that the polarised expression of the adherens junction protein nectin-1 
between the basal cells and periderm is lost prior to fusion 446. Furthermore, studies in the 
mouse have shown that periderm cells migrate from the MEE once the palatal shelves 
have elevated 446. This observation is of particular interest as periderm migration coincides 
with down-regulation of p63 expression in the MEE 156. Based on the data presented in this 
report we hypothesize that p63 signalling activates adherens junction and desomosome 
formation to maintain periderm/basal cell adhesion during initial stages of palate 
development. Subsequent down-regulation of p63 after palatal shelf elevation leads to 
loss of adhesion between the periderm and basal cells, enabling periderm cells to migrate 
from the MEE into the nasal and oral epithelial triangles, thus ensuring proper fusion of the 
palatal shelves. 
Previous reports have demonstrated that failure of periderm formation and/or maintenance 
leads to pathological adhesions between apposed epithelial surfaces, a phenotype we 
do not observe in p63-null mice 405, 441. Given the critical role that p63 plays in palatal 
adhesion, we postulate that down-regulation of a large number of adherens junction- 
and desmosome-associated genes in the basal epithelia compromises epithelial adhesion 
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in p63-null mice thereby preventing intraoral fusions from occurring. Collectively, our 
results demonstrate that p63 functions in two phases: it is initially required for periderm 
formation and subsequently functions to maintain adhesion between the periderm and 
basal epithelia. 
Using GREAT analysis, we identified a role of p63 in preventing the congenital skin disorder 
epidermolysis bullosa. We have identified several novel transcriptional targets of p63 
including Lama3, Lamb3 and Plec, mutations in which lead to EB 447. Furthermore we 
show that p63 is a transcriptional activator of Col7a1. In summary we have demonstrated 
that p63 is a master regulator of cell adhesion in the palatal epithelia. We reveal an essential 
role of p63 in both the formation and maintenance of periderm. Importantly our results 
reveal a critical role of p63 signalling in the prevention of the devastating human skin 
disorders pterygium and epidermolysis bullosa syndromes.
Materials and Methods
Maintenance of mutant mice. Genotyping of p63 mutant mice has been described previously 405. 
p63 −/−  embryos were obtained by heterozygous matings, the morning of the vaginal plug being 
considered embryonic day (E) 0.5. All animal experiments were approved by 4the University of 
Manchester Ethical Review Committee and performed in accordance with the Animals (Scientific 
Procedures) Act, 1986, United Kingdom.
ChIP-Sequencing. Palatal shelves dissected from E13.5 and E14.5 mouse were cross-linked with 1% 
formaldehyde for 20 minutes. Chromatin was prepared by homogenising the tissue in PBS using an 
Ultra-Turrax Homogeniser and incubating the resultant cells in PIPES buffer according to the Upstate 
ChIP assay protocol (Merck Millipore). Chromatin was sonicated using a Sonics Vibracell with seven 
10 second pulses set to an amplitude of 40. Chromatin was prewashed with Protein A-Agarose beads 
(SC-2001; Santa Cruz,) and incubated with 2 μg of α isoform-specific p63 antibody (H129; Santa Cruz) 
overnight at 4 oC. Antibody-bound chromatin was recovered using protein A-agarose beads (Santa 
Cruz). ChIP-Seq sample preparation for sequencing was performed according to the manufacturer’s 
instructions (Illumina) and sequenced using the Illumina GAII. 32 base-pair single end reads were 
mapped to the mouse genome (mm9, NCBI Build 37) using bowtie 0.12.7 453 reporting unique, full-
length alignments with a maximum of 1 nucleotide mismatch to the reference sequence. Mapped 
reads were peak-called using MACS 1.3.7 340 with default parameters and a P value threshold of 1 x 
10-5. Binding sites were associated to genes using RnaChipIntegrator (http://fls-bioinformatics-core.
github.com/RnaChipIntegrator/). ChIP-Seq data are available from ArrayExpress: E-MTAB-3179.
RNA Sequencing. RNA was isolated from E13.5 and E14.5 mouse palatal shelves using the Qiagen 
RNeasy kit. RNA-Seq libraries were generated using the SOLiDTM Total RNA-Seq Kit. Samples were 
run on SOLiDTM v4 for single-end 50 bp reads. Poor reads were filtered from the data with SOLiD 
Preprocess Filter 454. TopHat software 455 was used to align reads against the mm9 reference genome. 
The RNA-Seq data are available from ArrayExpress: E-MTAB-3157.
Microarray analysis. Amplified sense-strand cDNA was generated from 100 ng of total RNA (Ambion 
WT Expression Kit). Fragmentation, labelling (Affymetrix Genechip WT Terminal labelling kit), and 
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subsequent hybridisation utilising Affymetrix Genechip Mouse Exon 1.0 ST Array was performed 
(Genomic Technologies Core Facility, University of Manchester). Microarray data were analysed using 
Partek Genomics Solution (version 6.6, Copyright 2009, Partek Inc. St. Charles, MO, USA). Probe 
sets of a core subset were quantile normalised and Robust Multi-array Average (RMA) background 
correction applied. Exons were summarised to genes by calculating the mean of the exons (log 2). To 
establish relationships and compare variability between replicate arrays and experimental conditions, 
principal components analysis (PCA) was used 456. Correction for false discovery rates was completed 
using the method of QVALUE 457. Microarray expression data are available from ArrayExpress 
E-MTAB-3145 and ChIP-Seq data, E-MTAB-3179. Heatmaps were generated for 62 genes. These 
genes were clustered based on expression profiles. For each sample, expression levels (log2) were 
normalised prior to clustering by z-transformation (mean = 0, Standard deviation = 1 for each gene). 
Genes were segregated into two clusters using a K-means algorithm (Manhattan distance) followed 
by hierarchical clustering of each resulting K-means cluster using the maxdView software ”Super 
Grouper” plugin (available from http://bioinf.man.ac.uk/microarray/maxd/).
qPCR analysis. RNA was extracted as above and total RNA transcribed into cDNA according to the 
manufacturer’s protocol (Invitrogen). Primers were designed using Primer 3 (http://frodo.wi.mit.
edu), and qPCR reactions were performed using Power SYBR Green PCR Master Mix according to 
the manufacturer’s protocol (Life Technologies). For qPCR analysis of cDNA, exon-spanning primer 
sets for p63 candidate target genes were used (Table S4.5). Mouse β-actin was used to normalize the 
amount of cDNA. Differences in relative  transcript expression between wild-type and p63 mutant 
samples were calculated by the 2ΔΔCt method 427. Statistical significance was assessed using the Mann 
Whitney U test with at least four biological replicates for each genotype.
For qPCR of ChIP results, one primer set was used for each tested binding region (Table S4.5). Each 
binding region was tested using chromatin extracted from E14.5 palatal shelves using three independent 
litters. ChIP efficiency of binding sites was calculated using percentage of immunoprecipitated DNA 
against input chromatin. Occupancy used in ChIP experiments was calculated using ChIP efficiency 
of candidate binding regions standardised against that of a region within exon 2 of the myoglobin 
gene. Statistical significance was assessed using the Students T-test. 
Immunofluorescence and histological analysis. Heads dissected from E13.5 and E14.5 mice were 
fixed in 4% paraformaldehyde and processed for histological examination using standard protocols. 
For immunofluorescence analyses, sections were treated with 10 mm citrate buffer at 96 °C for 10 min 
for antigen retrieval. Sections were incubated overnight at 4 °C with antibodies against AP-2a (1/100), 
Col7a1 (1/200; Clone LH7.2, Sigma), (E-cadherin (1:200; Clone-36, BD Bioscience), Grhl3 (1/100) 458, 
keratin 5 (1/1000; PRB-160P, Covance), keratin 17 (1/1000) 445, nectin-1,  (1:200; Santa Cruz SC-28639), 
nectin-4 (1:100; HPA010775 Sigma), Plakoglobin (1/200; Clone 15F11 Sigma), stratifin (1/1000; Santa 
Cruz SC-7683), p63 (1:1000; Santa Cruz 4A4). Sections were counterstained with DAPI and visualised 
using a Leica DMRB microscope.
siRNA. RNA interference was performed by transfection of primary mouse keratinocytes with 200 nM 
pan-p63 siRNA and control siRNAs (Table S4.5). Total RNA was extracted 48 h after transfection using 
TRIzol reagent (Invitrogen) and treated with RNase-free DNase I (Promega), and cDNA was synthesised 
using Superscript II (Invitrogen). Real time RT–PCR analysis was performed using Power SYBR Green 
PCR Master Mix (Applied Biosystems) in a Real Time PCR System 7000 (Applied Biosystems).
Statistical analysis. Statistical significance was determined using an unpaired, two-tailed Student’s 
t-test or a Mann Whitney U test (see above). A P value less than 0.05 was considered significant.
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Supplementary information
Figure S4.1: RNA-sequencing analysis of p63 isoforms in E13.5 and E14.5 palates. RNA-sequencing 
reads were mapped to specific p63 transcripts at E13.5 and E14.5. In total, over 97% of reads were 
mapped to ΔN isoforms during E13.5 and E14.5. The highest number of reads was mapped to p63 
isoforms 4 and 5 that encode ΔNp63α and approximately a quarter of total p63 reads mapped to 
the ΔNp63β isoform. Fewer reads (~17%) were detected for ΔNp63g in E13.5 palatal shelves which 
decreased considerably by E14.5 (4%). Less than 3% of total reads were mapped to TAp63α and TAp63β 
whilst no reads were mapped to TAp63g.
Figure S4.2: Abnormal periderm cells in 
the palatal shelves of p63-null embryos 
at E12.5. A-B| Deconvolution analysis of 
E-cadherin in palatal epithelia at E12.5. 
A| Coronal sections of E12.5 wild-type 
palatal shelves reveals that E-cadherin 
is expressed throughout the plasma 
membrane in basal cells but is absent 
from the apical side of periderm cells 
(arrowhead). B| In the p63-null palatal 
shelves, although the periderm cells have 
an abnormal morphology, the expression 
of E-cadherin is similar to that of the wild-
type littermates. Scale bars; A – B = 20µm.
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Table S4.1. p63 binding sites identified from palatal shelves tissue (Excel file, not included).
Table S4.2. Differentially regulated genes of palatal shelves E14.0 WT versus p63-null embryos (Excel 
file, not included).
Table S4.3. List of differentially regulated genes that were enriched for cell adhesion GO term (Excel 
file, not included).
Table S4.4. List of differentially regulated genes with p63 binding site in clode proximity to the TSS (< 
25 kb)  (Excel file, not included).
Table S4.5. Primers used in quantitative RT-PCR analysis (Excel file, not included).
Figure S4.3: Krt5 expression in wild-type versus 
p63-null palates. Real-time PCR analysis of 
palatal shelves dissected from E14.5 wild-type 
and p63–null palates demonstrates that Krt5 
transcripts are significantly reduced in p63-null 
palates (P value <0.05).
Figure S4.4: Pvrl1 and Pvrl4 expression in wild-
type versus p63-null palates. Real-time PCR 
analysis of palatal shelves dissected from E14 
wild-type and p63–null palates indicates that 
Pvrl1 transcripts are significantly reduced in p63-
null palates whilst Pvrl4 levels are comparable to 
wild-types (P value <0.05).
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Abstract
The transcription factor p63 plays a pivotal role in keratinocyte proliferation and 
differentiation in the epidermis. However, how p63 regulates epidermal genes during 
differentiation is not yet clear. Using epigenome profiling of differentiating human primary 
epidermal keratinocytes, we characterized a catalogue of dynamically regulated genes and 
p63-bound regulatory elements that are relevant for epithelial development and related 
diseases. p63-bound regulatory elements occur as single or clustered enhancers, and 
remarkably, only a subset is active as defined by the co-presence of the active enhancer 
mark histone modification H3K27ac in epidermal keratinocytes. We show that the 
dynamics of gene expression correlates with the activity of p63-bound enhancers rather 
than with p63 binding itself. The activity of p63-bound enhancers is likely determined by 
other transcription factors that cooperate with p63. Our data show that inactive p63-bound 
enhancers in epidermal keratinocytes may be active during the development of other 
epithelial-related structures such as limbs, and suggest that p63 bookmarks genomic loci 
during the commitment of the epithelial lineage and regulates genes through temporal- 
and spatial-specific active enhancers. 
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Introduction
Orchestrated spatial and temporal gene regulation during embryonic development 
is essential for proper organogenesis. The transcription factor p63 is a key regulator in 
epithelial development including the development of epidermis, limbs and craniofacial 
tissues. The role of p63 in epithelial lineage commitment has been demonstrated by many 
studies in human diseases and mouse models. In humans, heterozygous mutations in 
the TP63 gene are associated with at least seven clinical conditions where epithelial-
related structures are affected, characterized by combinations of ectrodactyly (split hand/
foot malformations), orofacial clefting and ectodermal dysplasia 4. Several p63 mouse 
models including knock-outs and knock-ins with TP63 disease mutations show similar 
developmental and structural defects as those in human p63-associated diseases 6, 116-118, 
199. In mouse embryonic stem cells, knock-down of p63 or overexpression of p63 mutants 
associated with diseases prevented the epithelial commitment marked by KRT5/KRT14 
expression 167, 299. 
The epidermis is one of the affected epithelial structures in p63-associated disorders and 
in p63 mouse models. The human epidermis is a multi-layered epithelial tissue, and the 
structural integrity of the epidermis is dependent on proper proliferation and differentiation 
of epidermal keratinocytes. The epidermal basal layer consists of highly proliferative self-
renewing keratinocytes. Upon initiation of differentiation, keratinocytes migrate upwards 
and differentiate into cells that comprise the suprabasal spinous layer, the granular 
layer, and the stratum corneum that consists mainly of enucleated corneocytes 272. The 
differentiation process of keratinocytes is tightly controlled by gene regulation, and de-
regulated gene expression leads to disturbed epidermal differentiation and skin diseases 
459. Many epidermal disease genes are expressed in specific layers of the epidermis and 
associated with distinct disease phenotypes. In general, mutations in genes that are highly 
expressed in the basal layers such as keratin 5 (KRT5 ) and keratin 14 (KRT14 ) are associated 
with blistering phenotypes 460, whereas mutations in genes that are expressed in the most 
outer layers of the epidermis, such as loricrin (LOR ) are associated with hyperkeratosis and 
dry or scaly skin 459, 461. Although significant progress has been made in genetic studies with 
the fast-developing Next Generation Sequencing technology, the causes of many skin 
diseases are not yet explained. Furthermore, many of these conditions are heterogeneous, 
suggesting that the expressivity of gene mutations is modulated by genetic modifiers that 
play roles in epidermal differentiation. This scenario is supported by the observation that 
epidermal differentiation is regulated by the interplay of diverse gene networks rather 
than individual genes 295. Therefore, comprehensive catalogues of gene networks that 
are controlled by key regulators such as the transcription factor p63 during epidermal 
differentiation will be instructive for understanding the molecular processes underlying 
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skin disease. 
It has been shown that p63 is essential for the initiation of epidermal differentiation. In 
human epidermal keratinocytes, knock-down of p63 prevents epidermal differentiation 171, 
whereas in single-layered lung epithelial cells, overexpression of p63 results in stratification 
that is normally typical for epidermal keratinocytes 149. Human epidermal keratinocytes 
established from patients with TP63 mutations show stratification defects 300. A number of 
studies have aimed at the identification of p63 target genes to understand the role of p63 
in epidermal differentiation. Some studies took the RNAi approach to knock-down p63 
in proliferating keratinocytes and identified several hundreds of potentially p63-regulated 
genes 170, 171. However, as p63-depleted keratinocytes have differentiation defects 170, 171, 
potential direct p63 target genes at later stages of epidermal differentiation might not 
be identified using this approach. Furthermore, ChIP-seq analysis in human epidermal 
keratinocytes identified tens of thousands p63 binding sites in the human genome 437, 438. 
The large difference between the number of p63 binding sites 437, 438 and p63-regulated 
genes found using RNAi approaches 170, 171 raises the question whether all identified p63 
binding sites are functional in gene regulation in epidermal keratinocytes. Here, we 
present the first comprehensive catalogue of p63-regulated genes and enhancers during 
epidermal differentiation through epigenomics and transcriptomics profiling. Only a subset 
of these enhancers is dynamically regulated and the activity of these enhancers marked by 
the active enhancer histone modification H3K27ac correlates with gene expression during 
epidermal differentiation. 
Results
Gene expression dynamics during epidermal differentiation
Using an in vitro differentiation model of human epidermal keratinocytes 300, 462, we 
generated a complete map of dynamically regulated genes during epidermal differentiation 
at a genome-wide scale using RNA Polymerase II (RNAPII) ChIP-seq that measures the 
occupancy of RNAPII in mainly gene-associated genomic regions, as well as RNA-seq 
that measures the steady-state mRNA level. With both methods, the detected expression 
pattern of epidermal marker genes such as KRT5, KRT1, and involucrin (IVL) (Figure 5.1A), 
and KRT14, KRT10 and LOR (Figure S5.1A) was consistent with our RT-qPCR and western 
blotting analyses (Figure S5.1B and S5.1C). Expression of these marker genes was also in 
agreement with their expression dynamics in vivo 462, 463. At the global level, our RNA-
seq analysis showed a good correlation (Spearman, rho > 0.8 for all comparisons) with 
a previous RNA-seq study that used a slightly different in vitro keratinocyte differentiation 
method (Figure S5.2A) 93. Thus, our results show that this in vitro differentiation model of 
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epidermal keratinocytes recapitulates the epidermal stratification process. Of note, RNAPII 
ChIP-seq and RNA-seq profiles at the TP63 locus showed that ΔNp63 is the main isoform 
expressed in keratinocytes throughout the epidermal differentiation process, and the 
expression of the TAp63 isoform was not detected with both RNAPII ChIP-seq and RNA-
seq methods (Figure S5.1D). Western blot analysis confirmed the decreased protein level of 
ΔNp63 during differentiation, and that the expression of TAp63 was undetectable (Figure 
S5.1B). The decreased ΔNp63 expression at the mRNA and protein levels is in agreement 
with previous reports 300, 464.
To capture the gene expression dynamics during differentiation, we clustered the genes 
according to their expression levels quantified as reads per kilobase per million mapped 
reads (RPKM) in both the RNAPII ChIP-seq and RNA-seq profiles. For RNAPII ChIP-seq 
analyses, 7223 genes with an RPKM value (expression level) of at least 1.0 were clustered 
using K-means clustering into nine groups with distinct expression patterns (Figure 5.1B; 
Table S5.1A). To assess the function of these gene clusters and their association to human 
diseases, we performed functional annotation analyses using the web tools DAVID Gene 
Ontology (GO) 344 (Figure 5.1B; Table S5.1B) and the Human Phenotype Ontology (HPO) 
database 465 (Table S5.1C), respectively. For examples, genes that are expressed highly in 
proliferating keratinocytes (cluster 4) are associated with skin blistering and hyperkeratosis 
(e.g. KRT5). Genes that are highly expressed at late differentiation stages (cluster 3, e.g. LCE 
genes and cluster 6, e.g. TGM1) are specifically enriched for late differentiation genes and 
those involved in the regulation of apoptosis and cell death. These genes are associated 
with dry and scaly skin and non-blistering phenotypes. Cluster 1 contain genes with high 
expression at early differentiation stages (day 2 and day 4) and reduced expression at the 
late stage (day 7), e.g. KRT1 and KRT10, and are enriched with genes involved in epidermis 
development, blistering and hyperkeratosis. For the RNA-seq analyses, we identified 3813 
genes that were significantly differentially expressed between keratinocyte differentiation 
stages (P value < 0.05, cuffdiff2 software) and with an RPKM >10 in at least one stage.  Six 
distinct gene clusters were defined based on the expression dynamics of these genes 
using K-means clustering (Figure S5.2B; Table S5.2A). Similar to the RNAPII ChIP-seq 
data, the RNA-seq data also showed that genes with distinct expression patterns during 
epidermal differentiation are associated with distinct roles during epidermal differentiation 
and with different skin disease phenotypes (Figure S5.2B; Table S5.2B and S5.2C).
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We further investigated and compared gene expression detected by RNAPII ChIP-seq and 
by RNA-seq. The global analysis showed that the range of expression levels (RPKM values) 
is narrower in the RNAPII ChIP-seq profile than in the RNA-seq profiles (Figure S5.2C). 
Nevertheless, the relative expression levels of genes (gene ranks based on their RPKM) are 
generally similar in both RNAPII ChIP-seq and RNA-seq profiles (Figure S5.2D; Table S5.3A), 
as the relationship between RNAPII occupancy and steady state mRNA level remains largely 
unchanged during epithelial differentiation for most genes. However, a small proportion 
of genes showed substantially higher RNAPII occupancy than mRNA levels (Figure S5.2D, 
the bottom cluster), and these genes are strongly enriched for non-coding RNAs (mean-
rank gene set enrichment, P value < 10-95 at all stages) (Table S5.3C and S5.3D). Despite the 
global similarity, closer inspection reveals different dynamics of gene expression patterns 
between these two methods for many genes (Figure 5.1A and 5.1C).  For example, the 
highest expression level of KRT10 was detected at differentiation day 2 in RNAPII ChIP-
seq, while its expression in the RNA-seq profile only reached its highest level at day 4 
(Figure S5.1A). The expression pattern detected in the RNA-seq analysis correlates with 
Figure 5.1. Transcriptional and expression dynamics of epidermal differentiation. A| Screenshot of 
the UCSC genome browser from normalized RNA-seq ChIP-seq and RNAPII data during keratinocyte 
differentiation (day 0, 2, 4 and 7 after differentiation initiation) at gene loci of differentiation markers 
(KRT5, KRT1, and IVL). RNAPII dataset was generated from human primary keratinocytes of one donor 
(HKC1). RNA-seq data sets were generated from human primary keratinocytes of two donors (HKC1 
and HKC2). Expression dynamics of RNA-seq (in blue) and RNAPII ChIP-seq (in green) represented 
by the average z-scores (calculated from log2 (RPKM)) were plotted for KRT5, KRT1, and IVL for all 
keratinocyte differentiation stage (day 0, 2, 4, and 7) of HKC1. B| Heatmap of RNAPII expression patterns 
of differentially transcribed genes at days 0, 2, 4, and 7 during differentiation by K-means clustering 
analysis. Genes with an RPKM > 1 at any differentiation stage are included (n= number of genes per 
cluster). Enriched GO terms of genes per gene cluster are summarized in the table on the right (Complete 
data summarized in Table S5.1A). C| Expression dynamics of RNA-seq (in blue) and RNAPII ChIP-seq 
(in green) represented by the average z-scores (calculated from log2 (RPKM)) were plotted from genes in 
each RNAPII gene cluster for all differentiation stages (day 0, 2, 4, and 7). Standard deviations for genes 
per stage in each cluster are summarized in Table S5.20.
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the protein levels (Figure S5.1B). Consistent with expression of individual marker genes, 
expression patterns of genes in the RNAPII ChIP-seq clusters were often more dynamic 
than their corresponding RNA-seq expression patterns, with the expression changes in 
the RNAPII ChIP-seq profiles preceding those in the RNA-seq profiles (Figure 5.1C). These 
observations are consistent with RNAPII-mediated transcription preceding mRNA build-
up, and highlight differences between transcription rate control and steady state mRNA 
level maintenance. Interestingly, Spearman correlation analysis showed a slightly better 
correlation of H3K27ac levels with the RNAPII occupancy at gene bodies than with the 
steady-state mRNA abundance (Figure S5.2E). This may reflect the influence of post-
transcriptional processes such as RNA stability and processing of mRNA by miRNAs on 
mRNA steady state levels. These data suggest that RNAPII ChIP-seq is a preferred method 
to study the direct effect of transcription factors on gene regulation as compared to 
RNA-seq. Based on this rationale, we used the RNAPII occupancy at the gene body as 
the measure of gene expression to study the p63-regulated transcription in subsequent 
analyses. 
MicroRNAs (miRNAs) have been shown to play an important role in epidermal 
differentiation 466-468, and therefore we analyzed our RNA-seq and RNAPII ChIP-seq for 
expression of miRNAs. Examining the RNAPII occupancy at annotated miRNA genes using 
K-means clustering analysis showed dynamically regulated expression of 103 primary 
miRNA (pri-miRNA) transcripts during differentiation (Figure S5.3A; Table S5.4A) 469. Some 
of these miRNAs have been reported to play a role in epidermal differentiation such as 
miR-205 and miRNA-203 (Figure S5.3B) 309, 310, 467. For most of these miRNAs, RNA-seq 
signals at miRNA regions are low and the correlation between RNAPII ChIP-seq and RNA-
seq signals are poor (Table S5.4C). Thus RNAPII occupancy appears to give a better read-
out of pri-miRNA transcription
p63-bound enhancers during epidermal differentiation
Next, we assessed the role of p63 in regulating dynamic gene expression during epidermal 
differentiation. We performed ChIP-seq of p63 from keratinocytes at different stages of 
differentiation. Among a total number of 38,980 p63 binding sites detected from all stages 
(Table S5.5E), more than 90% were found to contain at least one p63 binding consensus 
motif using our previously established p63scan algorithm 437, and there is a significant 
enrichment of p63 binding in promoter regions and within 25 kb distance of genes 
compared to genomic distributions of all binding sites (Hypergeometric test, P value < 
1E-323 and P value = 6.97E-174, respectively) (Figure S5.4A). Surprisingly, in contrast to the 
dynamic gene expression pattern observed in RNAPII ChIP-seq and RNA-seq analyses 
(Figure 5.1C), the number of p63 binding sites and the p63 binding signals only showed a 
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minor overall decrease during differentiation (Figure 5.2A; Fig S5.4B). This is probably due 
to the decreasing p63 protein levels during epidermal differentiation (Figure 5.1B) 300, 464.
To resolve the seeming inconsistency between the rather static p63 binding and the 
dynamic gene expression during differentiation, we examined the epigenetic state of 
p63 binding sites using ENCODE data of primary human keratinocytes (NHEK) 96. Of all 
p63 binding sites, 50.5% are co-localized with the H3K27ac histone mark associated with 
active enhancers (Table S5.6A). This suggests that approximately half of the identified 
p63-bound regions are active enhancer elements in human keratinocytes. H3K27me3 
and H3K9me3, repressive histone modification marks associated with poised enhancers 
in embryonic stem cells and heterochromatin 96, 470, respectively, were not detected at 
any of the identified p63 binding sites (Figure 5.2A), even though these marks are present 
at promoters of inactive genes (examples in Figure S5.5A). As ENCODE data of NHEKs 
were collected at only one condition and provide limited information for the transcription 
program during epidermal differentiation, we further investigated the H3K27ac occupancy 
at all four stages during epidermal differentiation to gain insight into the activity dynamics 
of the p63-bound regions. Our data showed that 56.9% of all identified p63 binding sites 
were co-occupied by H3K27ac at any of the four stages (Table S5.6B-S5.6F), consistent 
with the ENCODE data analysis (Figure 5.2A; Table S5.6A). The p63 binding sites with a 
Figure 5.2. Epigenetic signature of p63 binding sites and correlation of p63 binding with gene regulation 
in epidermal keratinocytes. A| Heatmap of DNase1 hypersensitivity sites (DHS) and histone modifications 
(H3K4me1, H3K27ac, H3K27me3, H3K9me1, and H3K9me3) occupancy in NHEK cells (ENCODE), 
and p63 and H3K27ac occupancy from differentiating keratinocytes at p63 binding sites (genomic regions 
of a 4kb window with summits of p63 binding sites in the middle in each panel). The p63 binding sites are 
categorized in two groups: active p63 binding sites with high H3K27ac signal (indicated with black bar) 
and inactive p63 binding sites with low H3K27ac signal (indicated with grey bar). B| Correlation of p63 
binding or H3K27ac at enhancers with transcription of nearby genes during differentiation. Distribution of 
the Pearson correlation coefficients for ChIP-seq signals at enhancers compared to the RNAPII occupancy 
of associated transcribed genes during keratinocyte differentiation. Blue line: enhancers marked by 
H3K27ac that overlap with p63 binding sites; green line: enhancers marked by H3K27ac that do not 
overlap with p63 binding sites; red line: p63 signal of p63 binding sites.
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detectable level of H3K27ac were considered as active p63 binding sites. When active 
p63 binding sites were mapped to adjacent genes (Table S5.6G), a strong correlation 
was observed between the RNAPII occupancy at most genes and H3K27ac levels at the 
nearby p63 binding sites across the four stages of differentiation (median Pearson’s R = 
0.77) (Figure 5.2B). In contrast, the p63 levels at these binding sites showed no tendency to 
correlate with nearby gene body RNAPII levels during differentiation (median Pearson’s R = 
0.09). These results indicate that H3K27ac occupancy at p63 binding sites, rather than p63 
occupancy itself, reflects the regulatory activity of p63 binding sites in the transcription of 
nearby genes. Additionally, H3K27ac occupancy also correlates well with gene expression 
in general apart from at p63 binding sites (median Pearson’s R = 0.72) (Figure 5.2B), which 
is consistent with previous reports of the correlation of H3K27ac with gene transcription 471. 
These findings suggest that p63-regulated gene expression can be predicted by dynamic 
H3K27ac occupancy at p63 binding sites.
To further investigate the dynamics of H3K27ac occupancy at p63 binding sites, we 
clustered p63 binding sites into seven groups based on the co-localized H3K27ac signals 
using K-means clustering (Figure 5.3A; Table S5.9A). Subsequently, we compared genes 
associated with these H3K27ac clusters (H3K27ac occupancy clusters in Figure 5.3B) with 
those in the nine clusters based on gene body RNAPII occupancy (Figure 5.1B, RNAPII 
occupancy clusters in Figure 5.3B), to assess the correlation between the H3K27ac 
occupancy at the p63 binding sites and transcription of the nearest genes. We observed 
that RNAPII and H3K27ac clusters with similar dynamics shared more genes than expected, 
while those with divergent dynamics shared fewer genes than expected (Figure 5.3B). For 
example, genes associated with H3K27ac cluster 2 with increased H3K27ac signal are 
enriched for genes present in RNAPII cluster 3 that show increased expression during late 
differentiation (e.g. KRT23 ) (Figure 5.3B and 5.3C; Table S5.1A, 5.S9A, S5.9B). In contrast, 
genes associated with H3K27ac cluster 2 are depleted for genes present in RNAPII clusters 
1, 4, 5 and 7, all of which show decreased expression during differentiation (e.g. DSG3 ) 
(Figure 5.3B and 5.3C; Table S5.1A, S5.9A, S5.9B). Genes associated with H3K27ac cluster 
3 with first increased and then decreased H3K27ac signal are enriched for genes from 
RNAPII cluster 1 that show similar dynamics (e.g. SFN) (Figure 5.3B and 5.3C; Table S5.1A, 
S5.9A, S5.9B). 
Taken together, both general and per-cluster correlation analyses of RNAPII and H3K27ac 
occupancy indicate that H3K27ac signal at p63 binding sites rather than p63 binding signal 
alone is informative for prediction of the transcriptional program regulated by p63, and 
that assessing H3K27ac occupancy at p63 binding sites could facilitate the identification 
of p63 target genes in keratinocytes. 
129
Transcription factor p63 bookmarks and regulates dynamic enhancers during epidermal differentiation 
5
Potential co-activators of p63
As p63 binding alone does not explain epidermal gene expression, we searched for 
potential p63 co-regulators by transcription factor motif enrichment analysis using position 
weight matrices (PWM) of known transcription factor family motifs (Threshold, P value  = 
0.01, 1.5 fold enrichment versus background) 472. An enrichment of motifs from the ZFX, 
RUNX and EBF1 families was detected in active p63 binding sites with the H3K27ac mark 
(Figure 5.4A; Table S5.7, S5.8A). Among transcription factors that can bind to these motifs, 
RUNX1 is expressed in proliferating and differentiating keratinocytes (Supplementary Fig 
S5B; Supplementary Table S5.7). ChIP-qPCR analysis showed that RUNX1 was indeed 
bound to a number of tested p63 binding sites with the RUNX motif (Figure 5.4B; Table 
S5.8B), indicating that RUNX1 can cooperate with p63 in epidermal cells. For ‘inactive’ p63 
binding sites that were not co-localized with the H3K27ac mark, an enrichment of the NR2 
nuclear receptor family motif was found (Figure 5.4A; Table S5.7), and among transcription 
factors that can bind to this motif, RXRA is expressed in keratinocytes. Some motifs were 
enriched in both active and inactive p63 binding sites. For example, a strong enrichment 
of the motif sequence bound by the p53 family proteins including p63 was detected (Table 
S5.7). This is consistent with the high percentage of p63 motif-containing p63 binding sites 
detected by p63scan (90%). Other motifs that were enriched in both active and inactive 
binding sites include the motif of TFAP2α that has been reported to be a co-regulator of 
p63 (Table S5.7). TFAP2α binding to p63-bound regions in keratinocytes was confirmed by 
ChIP-qPCR (Figure 5.4B; Table S5.8C).
To search for potential p63 co-regulators during specific stages of epidermal stratification, 
we determined motif enrichment in the seven clusters of p63 binding sites that show 
differential H3K27ac occupancy patterns during differentiation. Several transcription factor 
family motifs were enriched in specific clusters. For example, FOXQ1 in H3K27ac cluster 1, 
MAFB and SP100 in cluster 2, E2F in cluster 5, and VDR in cluster 6 (Figure 5.4C; Table S5.9C). 
Although the precise function of these transcription factors in epidermal stratification is 
not yet clear, it is likely that they cooperate with p63 in keratinocyte differentiation as they 
have been shown to regulate cell proliferation and differentiation 473-477. 
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Figure 5.3. Dynamically regulated active p63 binding sites during epidermal differentiation. A| H3K27ac 
dynamics at p63 binding sites during epidermal differentiation. p63 binding sites were clustered to 
seven groups by K-means clustering based on the co-localized H3K27ac signals at the binding sites 
(genomic regions of a 4 kb window with summits of p63 binding sites in the middle in each panel) 
during differentiation. The average H3K27ac signal at p63 binding sites in each panel is depicted in 
black. H3K27ac signal range of 50% and 90% of p63 binding sites is depicted in purple and light 
purple, respectively. Clusters are arranged along the horizontal axis, stages of differentiation along 
the vertical axis. B| Over- and under-representation of shared genes associated with p63 binding sites 
clustered based on H3K27ac occupancy dynamics (seven clusters) (Figure 5.3A) compared with clusters 
defined by RNAPII occupancy dynamics (nine clusters, Figure 5.1B) during differentiation. Significant fold 
enrichments per gene cluster with active p63BS nearby (Hypergeometric analysis, P value < 0.001) are 
depicted in log2-transformed values (< 0.5-fold (depletion, green box), and > 1.5-fold (enrichment,
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purple box)), the insignificant associations are depicted in grey text. The graphs on the top illustrate 
the average H3K27ac occupancy (average z-score of log2 (RPKM)) at p63BS at all four selected time 
points of keratinocyte differentiation (day 0, 2, 4, and 7) per H3K27ac cluster. The graphs depicted 
on the left shows the average signal (average z-score of log2 (RPKM)) of RNAPII at the four days of 
keratinocyte differentiation (day 0, 2, 4, and 7) per gene cluster. C| Screenshot from UCSC genome 
browser of normalized RNAPII ChIP-seq (green), H3K27ac ChIP-seq (purple), and p63 ChIP-seq (red) 
signals at KRT23, DSG3 and SFN loci. Examples of genes from specific RNAPII gene clusters that show 
positive correlation of dynamic H3K27ac signals at nearby p63 binding sites with the gene transcription 
patterns during keratinocyte differentiation; KRT23 (gene cluster 3) with p63 peaks (H3K27ac cluster 2), 
DSG3 (gene cluster 4) with p63 peaks (H3K27ac cluster 4 and 7), SFN (gene cluster 1) with p63 peaks 
(H3K27ac cluster 1 and 3).
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Figure 5.4. Co-factors of p63 in epidermal keratinocytes. A| Differential enrichment (in blue boxes, 
Threshold, P value  = 0.01, 1.5 fold enrichment versus background) of transcription factor binding 
motifs in active or inactive p63 binding sites as compared to random sites . Only the enriched motifs in 
either active or inactive p63 binding sites with a fold change ratio (log2) of >1.5 and <0.7 are shown. 
The transcription factors (TF) that can bind to these motifs and are expressed in keratinocytes, RUNX1 
and RXRA, and the corresponding binding motif sequences are indicated on the right (Table S5.7). Both 
RUNX1 and RXRA have at least one p63 binding site nearby indicated by the asterisks, *** with active 
cl-p63BS. B| ChIP-qPCR analysis of RUNX1 and TFAP2α binding to p63 binding sites. Specific binding 
of RUNX1 was observed at p63 binding sites near active genes SMAD3, miRNA-205 and TFAP2α. Low 
RUNX1 binding was also detected at the p63 binding site near LCE6A, but not at the negative control 
region myoglobin exon 2 (myo). Specific binding of TFAP2 was observed at p63 binding sites near p21, 
IRF6 and ID1, but not at the negative control region myo. Occupancy represents the fold enrichment 
of the percentage of input DNA at the target region over that at the negative control region myo. This 
ChIP-qPCR analysis (n=1) was confirmed by other independent experiments (data not shown). C| Fold 
enrichment of transcription factor binding motifs in each of the seven dynamically regulated active p63 
binding site clusters (Figure 5.3A). The corresponding transcription factors that can bind to these motifs 
and are expressed in keratinocyte are indicated on the right (Table S5.9C). All these transcription factors 
have at least one p63 binding site nearby indicated by the asterisks, * with inactive p63 binding sites, ** 
with active single p63 binding sites, or *** with active cl-p63BS.
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Clustered p63 binding sites (cl-p63BS) and clustered epidermal enhancers 
Clustered enhancers, also referred as super-enhancers, are defined as stretches of active 
enhancers that are bound by high levels of lineage-specific master transcription factors and 
co-activators that drive gene expression to define cell lineage identity 42, 43. The essential 
role of p63 for the commitment to the epithelial lineage has been well established, and 
it is likely that p63 binds to clustered enhancers. Therefore we investigated whether p63 
can bind to clustered enhancers for its function in epithelial lineage determination. We 
observed an enrichment of clusters of five or more p63 binding sites (Hypergeometric test, 
P value = 9.06E-13) within 100 kb of the transcription start site of transcribed genes (RNAPII 
occupancy, RPKM > 1) relative to all genes (Supplementary Table S5.10). We subsequently 
performed analyses using an established algorithm for detecting clustered enhancers 
43 on two of our datasets: on p63 ChIP-seq data to identify regions with clustered p63 
binding sites with high p63 binding signals, referred as clustered p63 binding site regions 
(cl-p63BS) (Table S5.14A); and on H3K27ac ChIP-seq data to identify regions with clustered 
H3K27ac marked enhancers. Regions with clustered H3K27ac marked enhancers have 
been reported to drive cell-type specific gene expression 43, 478, and are therefore referred 
as clustered epidermal-specific enhancers (cl-epidermal enhancers) hereafter (Table 
S5.11A). Our analyses identified 1293 cl-epidermal enhancers (Figure 5.5D and 5.5E) and 
1991 regions as cl-p63BS (Figure 5.5E). Of all 1293 identified cl-epidermal enhancers, 
1182 (91.4%) sites overlapped with at least one p63 binding site (Figure 5.5A and 5.5D). In 
addition, p63 preferentially binds to cl-epidermal enhancers (clustered H3K27ac marked 
enhancers) rather than to single active enhancers (single H3K27ac peaks) and random 
controls (Hypergeometric test and normal distribution probability test, respectively, P value 
< 1E-323 in all cases) (Figure 5.5A). Three p63 binding sites on average were identified 
within each cl-epidermal enhancer, whereas randomized control sets contained zero p63 
binding sites on average (Figure 5.5B). These observations show that p63 binding sites 
are enriched in cl-epidermal enhancers in epidermal keratinocytes, and underscore the 
importance of p63 as a key transcription factor in epithelial lineage commitment. Out 
of a total number of 1991 cl-p63BS, 617 share genomic regions with 589 cl-epidermal 
enhancers out of a total number of 1293 (Figure 5.5E), are hereafter considered as active 
epidermal cl-p63BS (Table S5.15A and S5.15B). Interestingly, approximately two thirds of 
the cl-p63BS do not overlap with active cl-epidermal enhancers. Next, we used K-means 
clustering to identify six gene clusters associated with cl-epidermal enhancers showing 
different patterns of H3K27ac occupancy during differentiation (Figure 5.5C; Table S5.11A). 
These clusters were enriched for genes with concordant RNAPII occupancy patterns 
during differentiation, and depleted for genes with discordant RNAPII differentiation 
dynamics (Figure 5.5C). Compared to the association of single p63-bound enhancers with 
gene expression (Figure 5.3B), these p63 binding site-containing cl-epidermal enhancers 
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showed higher fold enrichment of gene clusters with similar expression patterns (Figure 
5.5C). In summary, our data showed that p63 binds to clustered enhancers, consistent 
with the role of p63 in epithelial commitment, and that these clustered enhancers play 
roles not only in epithelial commitment but also during epidermal differentiation.
p63-regulated genes and their relevance to disease
Knock-down or knockout of p63 in epithelial cells to identify de-regulated genes 170, 171 
has been the major approach in previous p63 target gene studies. The main drawback 
of this approach is that loss of p63 results in epithelial differentiation defects, and genes 
that are expressed at a later stage of differentiation and regulated by p63 may not be 
identified. In this study, we took a different approach and used differentiating normal 
keratinocytes. To identify p63 target genes, we first associated all identified p63 binding 
sites (38,980) with their nearest gene (11,890) (Table S5.12A) and analyzed gene function 
using DAVID Gene Ontology annotation 344. This showed an enrichment of genes involved 
in intracellular signaling cascade, phosphorylation, vascular development, cell migration, 
and cell death (Table S5.12B). Altogether, 10,020 p63 binding sites were identified in the 
proximity of differentially regulated genes (RNAPII ChIP-seq clusters, RPKM > 1) during 
epidermal differentiation and 74,2% of these binding sites are co-localized with H3K27ac 
(Table S5.1D). These differentially regulated genes with active p63 binding sites nearby 
were considered potential p63 target genes (1961 based on RNAseq and 2760 based on 
RNAPII) (Table S5.1D and S5.2D). For example, p63-binding sites with increasing levels of 
the H3K27ac mark during differentiation were observed near the IVL, LCE1B, and LCE1C 
genes that are highly expressed in late differentiating keratinocytes (Figure S5.5C). Several 
of these potential p63 target genes are known to be causative genes involved in epidermal 
diseases, such as CDH3, DSG1, KRT5, KRT10, and FLG (Figure S5.5C; Table S5.13A and 
S5.13B) 155, 451, 459, 460, 479. Of note, many of these potential p63 target genes such as KRT1 
and PRDM1 were not previously considered as direct p63 target genes (Figure S5.5D; Table 
S5.13A-S5.13D). Furthermore, we compared the potential p63 targets identified in this 
study with previous p63 RNAi knock-down experiments (Table S5.13C) 170, 171. Among the 
120 p63-regulated genes previously reported in two p63 RNAi knockdown experiments 
170, 171, we found that 70 of them (57.5%) are among potential direct p63 target in this study 
(Table S5.13D). Interestingly, many co-regulators of p63 including RUNX1 480, VDR 481, RXRA 
482 and FOXQ1 in epidermal keratinocytes are either known p63 target genes or identified 
as potential p63 targets in this study (Figure 5.4A and 5.4C). Taken together, our data show 
that p63 targets are expressed in different layers of the epidermis and associated with 
distinct disease phenotypes (Figure S5.2B). 
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Intriguingly, p63 binding sites were also identified in the vicinity of 80 pri-miRNAs of the 
130 pri-miRNAs that are differentially regulated during keratinocyte differentiation (Figure 
S5.3A; Table S5.4B). Among these pri-miRNAs, 74 of them contain at least one p63 binding 
site with H3K27ac occupancy, including pri-miR-203 and pri-miR-205 (Figure S5.3B; Table 
S5.4B), which suggests that these miRNAs are targets of p63. Among these p63-regulated 
miRNA genes, miR-205 is a known p63 target 483, 484. Another potential p63-regulated 
miRNA is miR-203 that is known to regulate p63 at the mRNA level during keratinocyte 
differentiation 310, and thus our data suggest a regulatory feedback loop of p63 and 
miRNA-203 during differentiation.
In comparison to genes mapped to single p63 binding sites, genes mapped to the 1991 
cl-p63BS (clustered p63 binding sites) (Figure 5.5E) showed a stronger enrichment of 
genes involved in ectoderm and epithelium development (Table S5.14A-S5.14D). This 
may be due to genes in the vicinity of cl-p63BS being more likely to be true p63 target 
genes compared with those near single p63 binding sites. Genes associated with nearby 
cl-epidermal enhancers (clustered epidermal enhancers marked by H3K27ac) (Figure 
5.5D and 5.5E) are enriched for genes with epidermal-related functions (Table S5.11C). 
Genes mapped to these active epidermal cl-p63BS (overlap of cl-p63BS and cl-epidermal 
enhancers) likely play a role in epidermal development (Table S5.15C), similar to genes 
mapped to cl-epidermal enhancers (Table S5.11C). Human Phenotype Ontology (HPO) 
analysis showed that this group of genes including CLDN1, p63, and KRT17 are associated 
with skin-related abnormalities such as epidermal thickening, aplasia/hypoplasia of the 
nails, and hyperkeratosis (Figure 5.5E; Table S5.15D). Genes in the vicinity of cl-epidermal 
enhancers that do not overlap cl-p63BS were enriched with genes that play a role in 
epidermal development (Table S5.16C), similar to the genes that were mapped by all cl-
epidermal enhancers (Table S5.11C). In contrast, the 69% of cl-p63BS that do not overlap 
cl-epidermal enhancers mapped to genes with broader functions including regulation of 
cell proliferation, tube development, vascular development, and regulation of apoptosis 
(Table S5.17D). HPO analysis revealed that these genes are associated with epithelial 
related non-skin phenotypes such as limb and tooth defects (Figure 5.5E; Table S5.17D), 
suggesting that inactive enhancers regulate gene expression during the development of 
other epithelial related structures. 
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Discussion
Tightly regulated gene expression during epidermal differentiation is crucial for the 
establishment and maintenance of the epidermis, and therefore it is essential to obtain 
a complete gene regulatory map to understand the biology of the epidermis and related 
diseases. Here, we report an atlas of differentially expressed genes during epidermal 
differentiation and regulatory regions that are bound by p63, a key regulator in epidermal 
differentiation. We show that the activity of p63 binding sites as defined by co-localized 
H3K27ac signals, rather than p63 binding itself, correlates with expression of nearby genes. 
Many of these epidermal genes are associated with distinct skin disease phenotypes 
and likely regulated by p63. Furthermore, our data show that not all p63 binding sites 
are active and suggest that the p63 binding sites that are ‘inactive’ during keratinocyte 
differentiation are active and regulate genes in other epithelial tissues during different 
stages of development, and are relevant to epithelial-related diseases. 
Figure 5.5. p63 binding sites (p63BS), clustered p63 binding sites (cl-p63BS) and clustered epidermal 
enhancers (cl-epidermal enhancers) in gene regulation. A| Percentage of individual H3K27ac peaks 
that contain at least one p63-binding site in cl-epidermal enhancers (genomic regions with clustered 
H3K27ac signals, dotted), single enhancers (single H3K27ac peak, diagonal stripes), and a control set of 
randomly shuffled single enhancers (white) (Hypergeometric analysis, * P value < 1E-323, ** P value < 
1E-323, *** P value < 1E-323). The rightmost two bars show the percentage of cl-epidermal enhancers 
that contain at least one p63 binding site (black) compared to the mean percentage of 1000 randomly 
shuffled control sets (grey) (S.E. = 0.001%) (****P value < 1E-323; calculated from normal distribution 
fitted to the random control percentages, which are normally distributed (Shapiro-Wilk normality test 
P value = 0.52)). B| Distribution of the number of p63 peaks per cl-epidermal enhancer (black) and 
1000 randomized controls (grey). C| Over- and under-representation of shared genes associated with 
cl-epidermal enhancers clustered based on H3K27ac occupancy dynamics (six clusters) compared with 
clusters of genes defined by RNAPII occupancy dynamics (nine clusters, Figure 5.1B) during keratinocyte 
differentiation. Significant fold enrichments (Hypergeometric analysis, P value < 0.001) are depicted 
in log2-transformed values (< 0.5-fold (depletion, green box), and > 1.5-fold (enrichment, purple 
box)); not significant associations are depicted in grey text. The graphs on the top illustrate the average 
H3K27ac occupancy at p63BS at all four selected time points of keratinocyte differentiation (day 0, 2, 
4, and 7) per H3K27ac cluster. The graphs depicted on the left show the average signal of RNAPII at 
the four days of keratinocyte differentiation per gene cluster. D| Overlap of individual p63 binding sites 
and cl-epidermal enhancers. Of a total number of 38980 p63 binding sites (red), 35278 lie outside 
the cl-epidermal enhancers. Majority of the cl-epidermal enhancers (1182 (*) of 1293, blue) contains 
at least one p63 binding site (red). Only 111 cl-epidermal enhancers do not contain any p63 binding 
site (blue). E| Overlap of cl-epidermal enhancers (blue) and cl-p63BS (brown). 617 cl-p63BS out of a 
total number of 1991 and 589 (*) cl-epidermal enhancers out of a total number of 1293 share genomic 
regions, and these regions are referred as active cl-p63BS. A proportion of cl-p63BS (1474) do not 
overlap cl-epidermal enhancers, while 704 cl-epidermal enhancers do not overlap cl-p63BS. Human 
phenotype ontology (HPO) analysis of genes near active cl-p63BS and cl-epidermal enhancers shows 
enrichment for genes associated with skin phenotypes, whereas HPO analysis of those near inactive 
cl-p63BS shows enrichment for genes associated with defect in other epithelial-related developmental 
processes. Complete data summarized in Table S5.11, S5.14-S5.17.
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In this study, we used an established keratinocyte differentiation model 300. Expression 
of epidermal marker genes shown by the individual gene approaches such as RT-qPCR 
analysis (Figure S5.1B and S5.1C) and by the RNAPII ChIP-seq and by RNA-seq profiling 
approaches (Figure 5.1A; Figure S5.1A) is consistent with expression of these genes in vivo 
462, 463. These data confirm previous reports that this differentiation model under submerged 
condition allows the expression of genes that are normally found in the differentiating 
epidermis 300, 462, 485. 
The genome-wide unbiased RNAPII ChIP-seq and RNA-seq profiling approaches not 
only revealed the global expression dynamics but also provided information that is not 
easily obtained by specific gene approaches, such as expression of gene isoforms and 
transcription of miRNAs. Our RNAPII ChIP-seq and RNA-seq data at the TP63 gene locus 
showed that ΔNp63 is the main isoform during keratinocyte differentiation, whereas 
expression of the TAp63 isoform was not detected (Figure S5.1D). These data are consistent 
with results from a recent RNA-seq analysis of the developing mouse epidermis 146 and 
from p63 isoform specific knockout experiments that demonstrated the major functional 
role of ΔNp63 in the epidermis 450, 486. These observations do not however rule out the 
possibility that the TAp63 isoform is expressed at an extremely low level, and the expression 
might be detected with deeper sequencing. So far, studies on the biogenesis of miRNAs 
have mainly been focused on processing of pri-miRNAs to miRNAs 83, 487, while data on 
transcriptional regulation of miRNA genes are limited. We show that RNAPII ChIP-seq 
analysis enables the detection of pri-miRNA transcription (Figure S5.3A; Table S5.4A) 469. 
Many of these miRNAs are known to have a role in epidermal differentiation such as miR-
205 and miRNA-203 (Figure S5.3B) 309, 310, 467. In combination with our p63 and H3K27ac 
ChIP-seq analyses, some of these miRNAs are identified as potential direct p63 targets, as 
they have an active p63 binding site with the co-localization of H3K27ac nearby (Figure 
S5.3B; Table S5.4B).
Our data showed that approximately half of all identified p63 binding sites were co-
occupied by H3K27ac, and are considered as active binding sites (Figure 5.2A). Consistently, 
about one third of cl-p63BS (stretches of p63 binding sites) share genomic regions with 
cl-epidermal enhancers (stretches of H3K27ac sites) (Figure 5.5E), and are considered as 
active epidermal cl-p63BS. These data suggest that p63 binding alone is not sufficient 
for the regulation of gene transcription, and indeed gene expression dynamics correlates 
better with the H3K27ac signal at p63 binding sites than with p63 binding itself (Figure 
5.2B). This suggests the involvement of other co-regulators in p63 gene regulation during 
differentiation. Indeed, our analyses of transcription factor motif enrichment and ChIP-
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qPCR experiments showed that RUNX1 potentially cooperates with p63 at active p63 
binding sites in keratinocytes (Figure 5.4A and 5.4B). In contrast, p63 binding sites that 
are not co-localized with the H3K27ac mark were enriched for the NR2 Nuclear receptor 
family motif that can be bound by RXR family proteins (Figure 5.4A), suggesting that 
these proteins may function as repressors at p63 binding sites in keratinocytes. Other co-
regulators seem to play a role in cooperating with p63 to regulate dynamic gene expression 
during keratinocyte differentiation (Figure 5.4C). Interestingly, Some of these identified p63 
co-regulators are known or potential p63 targets (Figure 5.4A and 5.4C), suggesting that 
p63 regulates expression of these co-regulators and that these co-regulators cooperate 
with p63 to regulate its target genes, which is consistent with the role of p63 as a master 
regulator in epithelial cells.
The absence of dynamic p63 binding during epidermal differentiation in keratinocytes 
is distinct from the induced binding of lineage-specific transcription factors during early 
embryogenesis 488 and differentiation of embryonic stem cells into specific lineages 489. 
A plausible explanation is that epidermal keratinocytes are a type of established epithelial 
cells, and differentiation of this type of multipotent stem cells might require different gene 
regulation mechanism compared to that in pluripotent embryonic stem cells or in early 
embryogenesis. It should be noted that our analyses do not discriminate whether p63 
acts as an activator or a repressor factor. Especially for genes with ‘inactive’ p63 binding 
sites (without H3K27ac signal) nearby, p63 may function as a repressor. However, it is 
unlikely that p63 recruits repression complexes such as polycomb proteins or induces 
heterochromatin formation, as p63 binding sites are co-localized with open chromatin 
regions marked by DHS and with enhancer marks such as H3K4me1 but are not co-
localized with H3K27me3 and H3K9me3 marks (Figure 5.2A). One scenario is that the 
binding of p63 may mark epithelial lineage-related regulatory elements as a placeholder 
during epithelial commitment, and the recruitment of different sets of co-regulators is 
required for gene regulation in an epithelial related tissue- and stage-specific manner. This 
hypothesis is supported by previous reports that p63 binding sites identified in epidermal 
keratinocytes have been found associated with limb and palate development and with 
relevant diseases, Split Hand/Foot Malformation 437 and van der Woude Syndrome where 
cleft lip/palate is one of the major features 156, 490. The placeholder paradigm of transcription 
factor-mediated regulation has been reported for a group of transcription factors such as 
FoxA and GATA proteins in lineage progenitor cells 491. These transcription factors are the 
first factors to engage in enhancers during development and their expression is required 
for lineage establishment.
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In summary, we provide an expression atlas of epidermal genes including non-coding 
RNAs during epidermal differentiation, as well as a catalogue of p63-regulated genes and 
regulatory regions that are bound by p63, a key regulator in epidermal differentiation. 
We show that the activity of p63 binding sites as defined by co-localization of histone 
modification mark H3K27ac signals correlates with the expression of nearby genes. Many 
of these epidermal genes are associated with distinct skin disease phenotypes. Among 
these p63-regulated genes, those that are not yet associated with skin diseases can be 
used as candidate causative genes for genetic studies such as the prioritization of exome 
sequencing data. The catalogue of p63-regulated enhancers and clustered epidermal 
enhancers may provide potential genomic regions to study causative variants or genetic 
modifiers in non-coding regions and to elucidate the heterogeneity of sub-phenotypes 
of skin diseases. Importantly we show that not all p63 binding sites are active in gene 
regulation in epidermal cells. This suggests that the p63 binding sites that are ‘inactive’ 
during keratinocyte differentiation are active and regulate genes in other epithelial tissues 
during different stages of development. These ‘inactive’ p63 binding sites may be relevant 
to other p63-related diseases. We propose that the transcription factor p63 serves as a 
placeholder and bookmarks enhancers that can regulate gene expression at different 
stages and in different tissues during development. It will be of interest to investigate 
whether p63 occupies genomic loci in a passive manner or actively shapes chromatin 
accessibility during epithelial lineage commitment.
Materials and methods
Ethics statement. All procedures regarding establishing human primary keratinocytes were approved 
by the ethical committee of the Radboud University Nijmegen Medical Centre (“Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen”). Informed consent was obtained. 
Human primary keratinocyte culture. Skin biopsies were taken from the abdomen of two healthy 
volunteers to set up the primary keratinocyte culture, referred to as HKC1 and HKC2 380. Keratinocyte 
cultures in Keratinocyte Growth Medium (KGM) under undifferentiated condition were previously 
described 134, differentiation of keratinocyte cultures was induced by cell contact inhibition and 
excluding several growth factor supplements: bovine pituitary extract (Bio Whittaker), EGF (Sigma), 
insulin (Sigma), and hydrocortisone (Calbiochem) from the medium. The medium was changed every 
second day, and before harvesting of the RNA and chromatin. Cells were collected on day 0, and on 
days 2, 4 and 7 after induction of differentiation.
ChIP and ChIP-seq. Human primary keratinocytes under proliferating, early-, mid- and late- 
differentiation condition generated from HKC1 were used for ChIP and ChIP-seq analysis. ChIP-
sequencing datasets were generated with an antibody recognizing the alpha isoforms of p63 (H129, 
Santa Cruz), an antibody that detects all forms of the large subunit of RNA polymerase II (8WG16, 
Santa Cruz), and a H3K27ac antibody recognizing the acetylation of the lysine 27 residue of Histone 
H3 (H3K27ac, C15410174, pAb-174-050, Diagenode). ChIP-qPCR experiments were performed using 
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2 μg RUNX1 antibody (ab23980, Abcam) and 1 μg TFAP2 antibody (C18X, Santa cruz). RNAPII, p63, 
H3K27ac, RUNX1, and TFAP2 ChIP experiments were performed as previously described 127, with a 
minor change of using magnetic beads (Novex by Life Technologies, 10008D and 10009D).
RNA extraction and RNA-seq. Human primary keratinocytes under proliferating, early-, mid- and late- 
differentiation condition were used for RNA-seq analysis. RNA extraction was carried out using the 
NucleoSpin RNA II kit (740955.50; MACHEREY-NAGEL, Düren, Germany). cDNA synthesis from 1 μg 
total RNA as control for RNA-seq was carried out using the iScript cDNA synthesis kit (Bio-Rad; 170-
8891, CA, Hercules, USA). Starting amount of RNA-seq sample was 1 μg, and rRNA was depleted 
using the Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat; MRZH11124, Epicentre, Madison, WI, USA) 
according to the manufacturer’s instructions. RNA fragmentation reactions were performed using 
fragmentation buffer (5×; 200 mM Tris-Ac, 500 mM Potassium-Ac, 150 mM Magnesium-Ac) in a final 
concentration of 1× per reaction. Each 50 μl fragmentation reaction was incubated at 95°C for 1.5 
minutes on a thermal cycler, and placed on ice for 10 minutes. Ethanol precipitation was used to purify 
the reactions. The fragmented rRNA depleted RNA was combined with 5 μg of random hexamers 
(Roche) in a final volume of 11 μl, incubated at 65°C for 5 minutes, and afterwards immediately placed 
on ice. The remaining reagents were added to the reaction: 4 μl 5× First strand buffer (Invitrogen), 2 
μl DTT (0.1 M Invitrogen), 1 μl dNTP mix (10 mM Invitrogen), 2 μl Actinomycin D (0.1 μg/ μl Sigma), 1 
μl of RNase H (40U/ml Ambion), and 1 μl SuperScript III (200 U Invitrogen). The first strand reaction 
was incubated at 25°C for 10 minutes, 50°C for 90 minutes, followed by deactivation at 70°C for 
15 minutes, followed by MinElute Reaction Cleanup Kit (Qiagen), according to the manufacturer’s 
protocol. The second strand was synthesized by adding 20 μl 5x Second strand buffer (Invitrogen), 
4 μl 5x First strand buffer (Invitrogen), 2 μl DTT (0.1 M Invitrogen), 1 μl random hexamers (5 mg/ml 
Roche), dUTP mix (12.5 mM Invitrogen), 1 μl RNase H (8U/ml Ambion), 1 μl E. coli DNA polymerase 
I (10U/ μl Invitrogen), and 1 μl E. coli DNA ligase (10 U/μl NEB) to the purified sample (100 μl total 
volume). After 2 hours at 16°C, 1 μl of T4 DNA polymerase (10U/μl Promega) was added and the 
reaction was incubated at 16°C for 10 minutes. The ds-cDNA was purified using the MinElute Reaction 
Cleanup Kit (Qiagen), according to the manufacturer’s protocol.
Illumina Library preparation. DNA samples were prepared for sequencing by end repair of 6 ng total 
DNA (H129 ChIP-seq, and RNAPII ChIP-seq samples), 10 ng total DNA (H3K27ac ChIP-seq samples), 
and 5 ng total cDNA (RNA-seq samples) as measured by Qubit (Invitrogen). Adaptors were ligated to 
the DNA fragments, followed by a pre-PCR of 4 cycles, size selection (∼300 bp) and subsequently 11 
cycles of PCR amplification. Cluster generation and sequencing (50 bp) was performed with the hiSeq 
Solexa Genome analyzer according to standard Illumina protocols. 
Quantitative Real-time (qRT-PCR). Quantitative PCR primers were designed using Primer3 (http://
frodo.wi.mit.edu), and qPCR reactions were performed in the CFX96 Real-Time system (C1000 
Touch-Thermal Cycler, Biorad) by using GoTaq qPCR mix (Promega) according to the manufacturer’s 
protocol. For qPCR of cDNA analysis, human acidic ribosomal protein (hARP) was used as a 
housekeeping gene to normalize the amount of cDNA. Differences in expression of each gene during 
differentiation (relative expression) was calculated by 2ΔΔCt method 427. For qPCR of ChIP analysis, one 
primer set was used for each tested binding region (Table S5.18) and ChIP efficiency of each binding 
sites was calculated by comparison of the percentage of ChIPped DNA against input chromatin to this 
percentage at a negative control region. Validation experiments were performed by RT-qPCR with 
primers (Biolegio BV, Nijmegen, The Netherlands) as shown in Table S5.18.
ChIP-seq data analysis. All 50-bp sequence reads were uniquely mapped to the human genome 
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NCBI build 37 (hg19) using bwa 0.6.1 with standard parameters 492 (Table S5.19). All p63, H3K27ac and 
RNAPII ChIP-seq datasets were normalized to the same sequencing depth by randomly removing 
aligned reads. Duplicated reads were removed before normalization. Peak recognition for p63 ChIP-
seq and RNAPII ChIP-seq datasets was performed using MACS2, an updated version of MACS 493 
that is specifically designed to process mixed signal types (URL https://github.com/taoliu/MACS) 
with default settings and a P value threshold of 1E-9 using a genomic DNA as background control, 
results are summarized in Table S5.19. Peaks were mapped to RefSeq genes, downloaded from 
UCSC Genome Browser (hg19), to determine genomic location of the p63 binding sites at promoter 
regions (defined as 5 kb upstream of the transcription start site and the end of the first intron of genes), 
intragenic, intergenic, or 25 kb away from the transcription start site of the gene. Peak recognition for 
the H3K27ac ChIP-seq dataset was performed using MACS2 using default settings for broad peak 
calling and a P value threshold of 1E-9 using a genomic DNA as background control, results are 
summarized in Table S5.19. The identified p63 peaks (38,980) that overlap with the identified H3K27ac 
peaks by MACS2 are considered active p63 binding sites (22,190), while those that do not overlap the 
MACS2 detected H3K27ac peaks are considered inactive p63 binding sites (16,790).
RNA-seq data processing. All 50-bp single end RNA-seq reads from two keratinocyte cell lines 
(biological replicates) were mapped to the human genome NCBI build 37 (hg19) using gsnap 
version 2013-03-31 494. The generated data per condition are summarized in Supplementary Table 
S5.19. Spliced reads were mapped using the Ensembl 68 reference transcriptome 495. Transcript 
quantification and differential expression analysis were done with cufflinks and cuffdiff v2.1.1 496, using 
the RefSeq transcriptome 497, downloaded from the UCSC genome browser website 498 in June 2013. 
RNA-seq clustering. RNA-seq RefSeq genes were filtered for those determined to be differentially 
expressed in at least one comparison by cufflinks cuffdiff (P value <0.05, beta negative binomial 
model). These were filtered for genes with RPKM expression level of at least 10 in at least one 
condition, resulting in a set of 3639 distinct genes, and 3813 when considering different isoforms. 
RPKM of gene body from RNA-seq was clustered into 6 clusters using the PAM clustering algorithm 
in R (R core team (2013) R: A language and environment for statistical computing. R foundation for 
Statistical Computing. Vienna, Austria. URL http://www.R-project.org/, Bioconductor 499) using the 
z-scores calculated from the log10 (RPKM) values. GO analysis was performed with DAVID (http://
david.abcc.ncifcrf.gov/).
RNAPII and H3K27ac gene body occupancy quantification. The occupancy of RNAPII and H3K27ac 
of the ChIP-seq datasets from HKC1 at Refseq gene transcripts (hg19) was quantified by detection of 
the sequenced reads and the Reads per kilobase per million mapped reads (RPKM) was calculated for 
each gene.
RNAPII ChIP-seq clustering. RNAPII ChIP-seq RefSeq genes were filtered for genes with RPKM 
expression level of at least 1 in at least one condition, resulting in a set of 7223 distinct genes, and 
8741 when considering different isoforms. These genes were clustered into 9 clusters using the PAM 
clustering algorithm in R 499 using the z-scores calculated from the log2 (RPKM) values.
RNAPII occupancy versus RNA steady state comparison. Rank-based comparisons of expression 
levels were used to compare RNAPII occupancy and RNA steady state due to the different distributions 
of RNAPII occupancy and RNA-seq expression levels. Genes were ranked separately according to 
RNAPII ChIP-seq occupancy and RNA-seq RPKM. For each gene the difference between the RNA-seq 
and ChIP-seq ranks was taken, and the genes were ranked according to this difference. Subsequently, 
the enrichment of non-coding RNAs with high RNAPII occupancy relative to RNA-seq levels was 
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determined using mean-rank gene set enrichment analysis 500 as implemented in the “limma” R 
package. Overall correlations between the RNA-seq and RNAPII levels of different samples were 
calculated using the Spearman rank correlation coefficient, due to the fact that the genome-wide 
gene expression profiles per sample do not follow a normal distribution.
Correlation between enhancer H3K27ac, p63 signal and gene body RNAPII ChIP-seq signal. For all 
expressed genes mapped to nearby enhancers, the Pearson correlation coefficient was calculated 
between the H3K27ac or p63 ChIP-seq read counts at the associated enhancers (normalized for per-
sample total read count) and the gene body RNAPII RPKM score across the four differentiation stages. 
H3K27ac enhancer signal was defined as a 4kb window around the identified p63 ChIP-seq peak 
center to accommodate its broader binding pattern. When multiple enhancers mapped to a single 
gene their read counts were summed. 
Clustered enhancers calling. Clustered epidermal enhancers were called using the ROSE tool, version 
0.1 43. The identified H3K27ac peaks were used to call the cl-epidermal enhancers using the same 
settings as described in Hnisz et al., 2013, with an enhancer stitching distance of 12kb and a 4kb 
exclusion window around promoters. H3K27ac (cl-epidermal) enhancer differentiation profiles were 
clustered into 6 clusters using PAM clustering, applied to the z-scores of the normalized read counts.
P63-bound enriched regions were determined using the same approach and settings as the detection 
of cl-epidermal enhancers, except that the identified p63 peaks from p63 ChIP-seq files were used. 
Additionally the 4kb exclusion window around promoters was not used. Enriched regions consisting 
of only one single p63 peak were removed from the set.
Association between H3K27ac signal dynamics at single enhancers and gene body RNAPII dynamics. 
The H3K27ac signal at co-localized single p63 binding sites was defined by calculation of RPKM using 
a 4kb window around the identified p63 ChIP-seq peak center from the H3K27ac ChIP-seq datasets 
of all four differentiation stages of HKC1. To analyze H3K27ac dynamics z-scores of log2(RPKM) was 
determined and clustered in 7 clusters by K-means. These enhancers were mapped to the closest 
gene (human genome NCBI build 37, hg19). The detected RNAPII gene body occupancy (RPKM > 
1) and clustering was defined as previously described from the RNAPII ChIP-seq datasets of all four 
differentiation stages of HKC1. Over- and under-representation of shared genes associated with p63 
binding sites with H3K27ac occupancy dynamics (for all 7 clusters) was compared with the gene 
clusters defined by RNAPII occupancy dynamics (for all 9 clusters). Significant fold enrichment or 
depletion were defined using hypergeometric distribution analysis (P value < 0.001) combined with a 
fold change higher than 1.5 or smaller than 0.5, respectively.
Association between H3K27ac signal dynamics at cl-epidermal enhancers and gene body RNAPII 
dynamics. The H3K27ac signal at cl-epidermal enhancers was defined by summing the reads falling 
within each cl-epidermal enhancer region from the count-normalized H3K27ac ChIP-seq datasets 
of all four differentiation stages of HKC1. The BAM files containing the H3K27ac ChIP-seq reads were 
normalized to the same number of reads per dataset by randomly removing excess reads from the 
larger BAM files. To analyze H3K27ac dynamics the z-scores of the normalized counts across the four 
differentiation stages were calculated and clustered into 6 clusters using K-means clustering. These 
cl-epidermal enhancers were mapped to the closest gene or any overlapping genes (human genome 
NCBI build 37, hg19). The detected RNAPII gene body occupancy (RPKM > 1) and clustering was 
defined as previously described from the RNAPII ChIP-seq datasets of all four differentiation stages 
of HKC1. Over- and under-representation of shared genes associated with cl-epidermal enhancer 
H3K27ac occupancy dynamics (for all 6 clusters) was compared with the gene clusters defined by 
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RNAPII occupancy dynamics (for all 9 clusters). Significant fold enrichment or depletion were defined 
using hypergeometric distribution analysis (P value < 0.001) combined with a fold change higher than 
1.5 or smaller than 0.5 respectively.
Enrichment of p63 binding sites in clustered epidermal enhancers. Enrichment of p63 binding sites 
in clustered epidermal enhancers was determined by randomly shuffling the clustered enhancers 
across the genome using the “bedtools shuffle” command from the BEDTools suite 501, excluding 
unsequenced genomic gaps larger than 10kb. Overlap with p63 binding sites was determined using 
the “bedtools intersect” command. The P value of p63 binding site enrichment in clustered enhancers 
was determined by fitting a normal distribution to the overlap percentages for the shuffled regions 
(which were normally distributed, Shapiro Wilks P value = 0.52), and determining the area under the 
cumulative probability curve to the right of the actual overlap percentage.
Detected transcribed miRNAs by RNAPII occupancy. The occupancy of RNAPII ChIP-seq datasets 
at the transcribed miRNAs was quantified by RPKM calculation of the detected sequenced reads for 
each identified RNAPII peak. A cutoff of RPKM > 1 was set, and only miRNAs, smaller than 200 bp, 
intersecting these RNAPII peak regions were considered.
Motif enrichment analysis. Motif enrichment was determined using Gimme scan of the GimmeMotifs 
package 502, which was used to scan the p63BS datasets for motif enrichment with a motif score 
of at least 99% of known family motifs 300, including the RUNX family motifs. The p63BS datasets 
were centered on the peak summit of the identified p63 peaks (Table S5.5) and extended 300 bp to 
both directions. A background file of 10,000 genomically matched random peaks was generated 
using Gimme background, of which a validation set (sequences not used for motif prediction) was 
generated using Gimme threshold of all known family motifs with a false discovery rate P value of 
0.01 (considering a motif score of at least 99%). Motif enrichment in active versus inactive p63 binding 
site and motif enrichment for the different p63 binding site clusters with H3K27ac occupancy was 
determined. For each set of p63BS sequences a background set was generated, and the validation 
set was used as a cutoff file to determine enrichment in the family motifs of all p63BS datasets. We 
used 1.5 fold as a cutoff to determine enrichment of motifs present in the datasets versus matched 
genomic background data sets, and between the different datasets.
ENCODE data. H3K27ac ChIP-seq (GSM733674), H3K4me1 ChIP-seq (GSM733698), H3K27me3 
ChIP-seq (GSM733701), H3K9me1 ChIP-seq (GSM733655), H3K9me3 ChIP-seq (GSM1003528), and 
Open chromatin by DNaseI HS (GSM816635) data from NHEK was downloaded from the ENCODE 
UCSC browser (URL http://genome.ucsc.edu/ENCODE/).
Accession codes. All RNA-seq and ChIP-seq data have been deposited in the Gene Expression 
Omnibus 382 (GEO GSE59827).
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Supplementary information
Figure S5.1. Gene expression analysis of epidermal marker genes and TP63. A| Screenshot of the UCSC 
genome browser from normalized RNAPII and RNA-seq ChIP-seq data during keratinocyte differentiation 
(day 0, 2, 4 and 7 after differentiation initiation) at gene loci of differentiation markers (KRT14, KRT10, 
and LOR). RNAPII dataset was generated from human primary keratinocytes of one donor (HKC1) and 
RNA-seq data sets were generated from human primary keratinocytes of two donors (HKC1 and HKC2). 
B| Protein immunoblot analysis of epidermal marker genes, p63, KRT14, KRT10, IVL, and LOR expression 
during differentiation (day 0, 2, 4 and 7 after differentiation initiation) in HKC1 cells. C| RT-qPCR analysis 
of expression of KRT5, KRT1, and IVL in differentiating keratinocytes from HKC1 and HKC2 at day 0, 2, 
4 and 7, using the hARP gene as internal control. KRT5 showed high expression in proliferating and early 
differentiating cells, KRT1 shows induced expression in early differentiating cells and is reduced in late 
differentiated cells, and IVL is only detectable at late differentiation stage. (n=1, confirmed by RT-qPCR 
with biological and technical replicas). D| Screenshot of the UCSC genome browser from normalized 
RNAPII and RNA-seq ChIP-seq data at the TP63 locus during keratinocyte differentiation in HKC1 and 
HKC2. Expression of exons that are specific for the TA isoform were not detected.
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Figure S5.2. Comparison of genome-wide data of RNA-seq, RNAPII ChIP-seq and H3K27ac ChIP-seq. 
A| Comparison of RNA-seq gene expression patterns between keratinocyte samples (HKC1 and HKC2) 
from this study and those of Kretz et al., 2013. The heatmap shows the Spearman rank correlation 
coefficients between each pair of samples, indicated by both color and number. Columns are in the 
same order as rows, with the diagonal indicating the correlation of each sample with itself. B| Heatmap 
of K-means clustering of RNA-seq expression patterns of differentially expression genes (P value < 0.05) 
from HKC1 (1) and HKC2 (2) at days 0, 2, 4, and 7 of differentiation. Only genes with high expression 
(RPKM > 10) at least at one stage are included. n= number of genes per cluster. Enriched GO terms, 
HPO terms, and associated disease genes and potential p63 target disease genes per gene cluster are 
summarized in the table on the right. Complete data are summarized in Table S5.2. C| Distribution of
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gene expression levels (log10-transformed RPKM) for RNAPII ChIP-seq and RNA-seq data of HKC1. 
Data for all days are combined. D| Heatmap of PAM clustering (clusters 1-6, top to bottom) of per-gene 
rank differences between RNAPII ChIP-seq and RNA-seq expression levels of HKC1. Genes were ranked 
according to their RNA expression or RNAPII occupancy, and the difference in their RNA vs RNAPII rank 
is shown for each day. Y-axis: genes, X-axis: days. Colors indicate RNA-seq minus RNAPII rank difference, 
ranging from orange (RNA expression rank > RNAPII occupancy rank) to purple (RNAPII occupancy 
rank > RNA expression rank). Clusters are indicated in the color bar on the left, colored according 
to the degree of non-coding RNA enrichment (red) or depletion (blue). The cluster at the bottom (red) 
showed higher expression detected by RNAPII ChIP-seq, and this cluster is enriched for non-coding 
RNAs. Complete data are summarized in Table S5.3. E| Spearman correlation analysis of genome-wide 
RNA-seq, RNAPII-, and H3K27ac ChIP-seq signals (RPKM per gene) at the gene body during epidermal 
differentiation of HKC1.
Figure S5.3. Transcribed miRNAs in keratinocytes. A| Heatmap of all identified transcribed miRNAs 
outside gene body regions determined by RNAPII occupancy at the pri-miRNA region at four stages of 
HKC1 keratinocyte differentiation. B| Screenshot from genome browser (UCSC) of normalized RNA-seq 
(shades of blue), RNAPII ChIP-seq (shades of green), H3K27ac ChIP-seq (shades of purple), and p63 
ChIP-seq (shades of red) signals at miRNA-203 and miRNA-205 during HKC1 keratinocyte differentiation.
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Figure S5.4. Genomic distribution of p63 binding sites relative 
to RefSeq genes. A| Peak detection analysis of p63 ChIP-seq 
data with a stringent statistical threshold (P value of 10-9) of 
HKC1 resulted in the identification of 32,888, 31,995, 29,539, 
and 28,169 p63 binding sites at differentiating day 0, 2, 4, 
and 7, respectively. The total of p63 binding sites identified in 
all datasets was 38,890. Genomic distribution of p63-binding 
site (p63BS) location of these 38,980 peaks relative to RefSeq 
genes was determined at promoters (5kb upstream of TSS, first 
exon and first intron), in intragenic regions (all introns and exons 
except first), <25 kb (5-25 kb upstream or 25 kb downstream 
of last exon), and intergenic regions (everything else). The 
asterisk represents significant enrichment. B| Bandplot of p63 
occupancy at all p63 binding sites (genomic regions of a 4kb 
window with summits of p63 binding sites in the middle in each 
panel) during HKC1 keratinocyte differentiation. The average 
p63 signal is depicted in black. p63 binding signal range of 
50% and 90% of p63 binding sites is depicted in purple and 
light purple, respectively.
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Table S5.1: Nine clusters of genes with distinct expression patterns based on K-means clustering of 
genes identified in RNAPII ChIP-seq (RPKM > 1.0) (Excel file not included).
Figure S5.5. Screenshots of genome browser of RNA-seq, H3K27me3 ChIP-seq, RNAPII ChIP-seq, 
H3K27ac ChIP-seq and p63 ChIP-seq data at GRASP, PRRX1, RUNX1, CDH3, LCE1B/LCE1C, Involucrin, 
KRT1, and PRDM1 loci from four stages of keratinocyte differentiation of HKC1. A| Screenshot of the 
UCSC genome browser at the genomic locus surrounding GRASP and PRRX. H3K27me3 track generated 
from NHEK cells are depicted in pink. B| Screenshot of the UCSC genome browser at the genomic locus 
surrounding RUNX1. C| Screenshot of the UCSC genome browser at the genomic loci surrounding CDH3, 
LCE1B/LCE1C, and Involucrin (IVL). D| Screenshot of the UCSC genome browser at the genomic loci 
surrounding KRT1 and PRDM1 with clustered epidermal enhancer marked with a black box. Normalized 
RNA-seq, in d crea ing shades of blue during differentiati ; RNAPII ChIP-seq, in decreasing shades of 
green; H3K27ac ChIP-seq, in decreasing shades of purple; and p63 ChIP-seq, in decreasing shades of 
red. Detected individual p63 binding sites and cl-p63BS are marked with a black box.
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Table S5.1: Nine clusters of genes with distinct expression patterns based on K-means clustering of 
genes identified in RNAPII ChIP-seq (RPKM > 1.0) (Excel file not included).
S5.1A: Gene clustering and RPKM of RNAPII ChIP-seq results
S5.1B: Gene Ontology of gene clusters from RNAPII ChIP-seq
S5.1C: HPO analysis of gene clusters from RNAPII ChIP-seq
S5.1D: p63BS association to nearest genes identified in RNAPII ChIP-seq
Table S5.2: Six clusters of genes with distinct expression patterns based on K-means clustering of 
genes identified in RNA-seq (P value < 0.05, cuffdiff2 software, and with an RPKM >10) (Excel file not 
included).
S5.2A: Gene clustering and RPKM of RNA-sequencing results
S5.2B: Gene Ontology of gene clusters from RNA-seq
S5.2C: HPO analysis of gene clusters from RNA-seq
S5.2D: p63BS association to nearest genes identified in RNA-seq
Table S5.3: Comparison of RNAPII ChIP-seq and RNA-seq analysis (Excel file not included).
S5.3A: Rank difference of RNA-seq gene rank - RNAPII ChIP-seq gene rank
S5.3B: GO annotation of genes from different clusters with ranking differences between RNA ChIP-
seq and RNA-seq
S5.3C: Non-coding RNA enrichment/depletion log2 fold changes per-cluster with rank differences 
RNAPII ChIP-seq versus RNA-seq
S5.3D: P-values for tendency of non-coding RNAs to have higher RNAPII occupancy rank than RNA-
seq expression rank (HKC1)
Table S5.4: microRNAs identified by RNAPII ChIP-seq (Excel file not included).
S5.4A: Identified pri-miRNAs using RNAPII ChIP-seq data
S5.4B: Identified pri-miRNAs with p63BS and information on their H3K27ac status
S5.4C: Spearman correlation of pri-miRNAs from RNAPII ChIP-seq signal versus RNA-seq signal
Table S5.5: p63 binding sites identified during epidermal differentiation (Excel file not included).
S5.5A: p63 binding sites identified in HKC1 at day0 using MACS2
S5.5B: p63 binding sites identified in HKC1 at day2 using MACS2
S5.5C: p63 binding sites identified in HKC1 at day4 using MACS2
S5.5D: p63 binding sites identified in HKC1 at day7 using MACS2
S5.5E: All 38,980 identified p63 binding sites (p63BS)
Table S5.6: Co-localization of p63 binding sites and H3K27ac mark during epidermal differentiation 
(Excel file not included).
S5.6A: p63BS that overlap H3K27ac marker from ENCODE NHEK cells
S5.6B: H3K27ac peaks identified in HKC1 at day0 using MACS2
S5.6C: H3K27ac peaks identified in HKC1 at day2 using MACS2
S5.6D: H3K27ac peaks identified in HKC1 at day4 using MACS2
S5.6E: H3K27ac peaks identified in HKC1 at day7 using MACS2
S5.6F: p63BS that overlap H3K27ac occupancy identified at four stages of keratinocyte differentiation
S5.6G: p63BS that overlap H3K27ac and nearby genes
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Table S5.7: Motif enrichment at identified active and inactive p63BS (Excel file not included).
Table S5.8: Co-activator RUNX1 and TFAP2A binding to p63 binding sites (Excel file not included).
S5.8A: RUNX1 motif location in active p63BS
S5.8B: RUNX1 ChIP-qPCR results
S5.8C: TFAP2 ChIP-qPCR results
Table S5.9: p63 binding sites clusters based on H3K27ac dynamics and associated motifs (Excel file 
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Abstract
p53 and p63 share extensive sequence and structure homology. p53 is frequently mutated 
in cancer, whereas mutations in p63 cause developmental disorders manifested in 
ectodermal dysplasia, limb defects and orofacial clefting. We have established primary 
adult skin keratinocytes from ectrodactyly, ectodermal dysplasia and cleft lip/palate (EEC) 
syndrome patients with p63 mutations as an in vitro human model to study the disease 
mechanism in the skin of EEC patients. We show that these patient keratinocytes cultured 
either in submerged 2D cultures or in 3D skin equivalents have impaired epidermal 
differentiation and stratification. Treatment of these patient keratinocytes with the mutant 
p53-targeting compound APR-246/PRIMA-1MET that has been successfully tested in a 
phase I/II clinical trial in cancer patients partially but consistently rescued morphological 
features and gene expression during epidermal stratification in both 2D and 3D models. 
This rescue coincides with restoration of p63 target gene expression. Our data show 
that EEC patient keratinocytes with p63 mutations can be used for characterization of 
the abnormal molecular circuitry in patient skin and may open possibilities for the design 
of novel pharmacological treatment strategies for patients with mutant p63-associated 
developmental abnormalities.
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Introduction
The p53 family of transcription factors p53, p63 and p73 share high sequence and 
structure homology, especially in their DNA-binding domains. p53 plays a key role in 
tumor suppression and is mutated in around 50% of human tumors 503, whereas p63 is 
a master regulator during ectodermal and epidermal development 6, 116. p63 is expressed 
as several isoforms with different N-terminal ends, the TA and ΔN isoforms, and different 
C-terminal ends, designated α, β, g, δ and e 136. ΔNp63α is the major isoform expressed in 
the epidermis 504.
The key role of p63 in ectodermal and epidermal development has been demonstrated 
in animal models as well as in human developmental disorders. Disruption of p63 in mice 
and zebrafish causes severe epidermal and limb defects 6, 116, 326. In humans, heterozygous 
mutations in p63 give rise to several clinical conditions with autosomal dominant 
inheritance 194. The three major characteristics of these developmental disorders are 
limb defects, orofacial clefting and ectodermal dysplasia (ED) which is comprised of 
defects in skin, hair, teeth, nails and several exocrine glands. Among these disorders, the 
ectrodactyly, ectodermal dysplasia and cleft lip/palate (EEC) syndrome displays all three 
major hallmarks. p63 mutations associated with the EEC syndrome are point mutations in 
the DNA-binding domain affecting all isoforms. Some of the amino acid residues mutated 
in the EEC syndrome correspond to the tumor-associated hotspot mutations in p53; p63 
R204 corresponds to p53 R175H, p63 R304 to p53 R273, and p63 R279 to p53 R248 5. 
Another p63-associated disorder is the ankyloblepharon-ectodermal defects-cleft lip/
palate (AEC) syndrome which differs from the EEC syndrome mainly by the severity of the 
skin phenotype, the occurrence of an eyelid fusion at birth and the absence of limb malfor-
mations. Mutations associated with the AEC syndrome are localized in the C-terminal SAM 
domain which is absent in the p53 protein 184, 194.
The cellular mechanisms of epidermal differentiation and stratification controlled by p63 
have mainly been studied in mouse models including p63-deficient mice with or without 
rescue by p63 isoforms, and in mouse ES cells 149, 299, 505. However, these studies are not able 
to illustrate the disease mechanism underlying the phenotypes caused by heterozygous 
p63 point mutations in humans 136. Two knock-in models of p63 mutations have been 
reported so far, L514F for the AEC syndrome 118 and R279H for the EEC syndrome 199. The 
L514F mice fully recapitulate the human AEC syndrome with abnormalities in skin and 
craniofacial structures. In the R279H knock-in model, limb phenotypes resembling that 
of p63 knock-out mice have been observed, whereas skin phenotypes have not been 
reported. Furthermore, there is a clear clinical variability among EEC syndrome patients 
with p63 mutations 4, which suggests that individual genetic background is one of the 
important determinants for the phenotypes. Therefore, mouse models established so far 
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are not appropriate platforms to uncover the molecular circuitry in the skin that is affected 
in the EEC syndrome and to perform drug screening. 
The current therapy for disorders caused by p63 mutations is limited to cosmetic surgery. 
Opportunities for improved treatment may come from studies of the family member 
p53. Due to the important tumor suppressor function of p53 506, 507, novel strategies for 
targeting p53 for cancer therapy have been intensively pursued. Several compounds have 
been reported to restore wild type function to mutant p53 and induce p53-dependent 
cell death 508. Previously, we found that the low molecular weight compounds PRIMA-1 
and APR-246/PRIMA-1MET (henceforth referred to as APR-246) restore conformation and 
tumor suppressor activity to mutant p53 509, 510. APR-246 has recently been tested in a 
phase I/II clinical trial in patients with hematological malignancies or hormone-refractory 
prostate cancer 511. Interestingly, we found that APR-246 can restore the pro-apoptotic 
function to mutant TAp63g in tumor cells 512. This suggests that APR-246-mediated rescue 
of mutants of the p53 family members involves a conserved molecular mechanism due 
to the extensive structural homology in the DNA-binding domains among these proteins. 
Therefore, APR-246 might be suitable as a lead compound to initiate development of 
new drugs targeting developmental and differentiation defects caused by p63 mutations, 
especially those located in the DNA-binding domain such as mutations involved in the 
EEC syndrome. 
In this work, we established an in vitro model to study the disease mechanism of the skin 
phenotype of the EEC syndrome, namely keratinocytes obtained from EEC syndrome 
patients with p63 mutations. These keratinocytes showed differentiation defects based 
on morphology and gene expression. We found that these defects were consistently 
rescued upon APR-246 treatment and this rescue coincided with enhanced p63 target 
gene expression.
Results
De-regulated transcription program in keratinocytes from EEC syndrome patients with 
p63 mutations during early epidermal differentiation
To study the epidermal defects in EEC syndrome patients with p63 mutations, we 
established keratinocyte cultures from the epidermis of patients carrying p63 mutations 
that are located in the DNA-binding domain of p63, R204W, R279H and R304W 
(henceforth referred to as R204W, R279H and R304W keratinocytes). Expression array 
analysis of these EEC patient keratinocytes grown in submerged 2D cultures was 
performed at early differentiation stage (day 2 after initiation of differentiation) to detect 
de-regulated gene expression caused by p63 mutations, as compared to keratinocytes 
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from five normal controls with wild type p63. As shown by exon array analysis, exons 3’ 
to 14 but not exons 1-3 and 15 were expressed at a comparable level above the detection 
threshold, demonstrating that the ΔNp63α is the only isoform expressed at a high level in 
primary keratinocytes (Figure S6.1C). The low expression, if any, of other isoforms was also 
confirmed by RNA-seq data from the ENCODE consortium (Figure S6.1A, S6.1B) 513 as well 
as by our RNA polymerase II (RNAPII) ChIP-seq followed by qPCR analysis (ChIP-qPCR) 
at the p63 TA- and ΔN promoters (Figure S6.1D). Hierarchical clustering analysis showed 
that gene expression patterns in the five normal controls were relatively similar to each 
other, as compared to those of keratinocytes with p63 mutant R204W, R304W or R279H 
(Figure S6.1E). This indicates that the effect of p63 mutations on the transcription program 
is more substantial than influence of different genetic backgrounds. To identify aberrantly 
regulated genes common to the EEC syndrome and to minimize the effect of the genetic 
background of each individual patient, we analyzed expression profiles in keratinocytes 
from three EEC patients (Figure 6.1A). A total number of 328 genes (66 and 89 genes of 
which were up- and down-regulated more than 1.5-fold, respectively) showed significant 
and consistent changes in expression in all three mutant cells, henceforth referred to as 
differentially expressed genes (Figure 6.1A and 6.1B, Dataset S6.1). The expression pattern 
in R279H cells was significantly different from those in R204W and R304W cells (Figure 
6.1A, Figure S6.1E).
Figure 6.1. Expression analysis 
of EEC patient keratinocytes 
carrying p63 mutations 
identified ADH7 as one of the 
potential p63 target genes. 
A| Overlap of differentially 
expressed genes in three EEC 
patient keratinocyte cultures 
compared to the controls 
(ANOVA P value < 0.05). 
B| The expression pattern of 
328 differentially regulated 
genes shown by heatmap. 
p63 binding sites represented 
in black bars are shown to the 
right of the heatmap. C| Two 
binding sites near ADH7 (BS1, 
BS2) 514 were validated using 
ChIP-qPCR. A p63 binding 
site near IRF6 was used 
as the positive control and 
myoglobin exon 2 and a no 
gene region on Chromosome 
11 as negative controls. D| 
Transactivation by ΔNp63α 
through the wild type ADH7 
BS1 and BS1 with mutated p63 
binding motif. 
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We searched for p63 binding sites in the vicinity of the 328 differentially expressed genes 
using our previously reported p63 binding profiles 514, and identified 208 potential p63 target 
genes (60%) that have p63 binding sites (BS) within the gene itself or in a region within 25 
kb of the gene body (Figure 6.1B, Table S6.1). Analysis using the DAVID bioinformatics tool 
515 revealed that specific Gene Ontology (GO) terms such as epithelium, tissue and organ 
development as well as neurogenesis were the most significant for the potential direct 
target genes (Dataset S6.2). With independent RT-qPCR analysis in all three patients, 16 out 
of 20 genes were validated (Dataset S6.3). One of such genes, Alcohol dehydrogenase 7 
(ADH7 ), encodes subclass IV alcohol hydrogenase 7 subunits and possibly plays a role in 
retinol oxidation in the retinoic acid biosynthesis pathway. The expression of ADH7 was 
almost completely lost in keratinocytes with mutations in the p63 DNA-binding domain 
associated with the EEC syndrome (Dataset S6.3). Two p63 binding sites (BS1 and BS2) 
were found near the transcription start site of ADH7 (Figure S6.4A) 514, and p63 binding at 
these regions was confirmed by ChIP-qPCR analyses (Figure 6.1C). Transient transfection 
assays showed that the ADH7 BS1 was able to drive gene expression in a p63-dependent 
manner, and this activation was completely abolished by mutations in the p63 binding 
motif present in ADH7 BS1 (Figure 6.1D and S6.4A). Taken together, these data suggest that 
ADH7 is a p63 target gene.
Morphological defects in keratinocytes carrying mutations in the p63 DNA-binding 
domain are rescued by APR-246
Having detected de-regulated gene expression in p63 mutant keratinocytes during early 
epidermal differentiation, we investigated whether these cells exhibit differentiation 
defects during epidermal stratification. Due to the different gene expression pattern in 
R279H keratinocytes compared to those in R204W and R304W keratinocytes (Figure 6.1A 
and S6.1E), we decided to only use R304W and R204W keratinocytes. Under proliferative 
conditions, the morphology of R204W and R304W keratinocytes in submerged 2D 
cultures was less homogenous and cells were larger and flatter (Figure S6.2Ba and 
S6.2Bd) compared to the wild type p63 cells (Figure S6.2Bg). On day 4 and day 7 after 
differentiation, wild type p63 cells started to form multi-layer structures (Figure S6.2Bh 
and S6.2Bi), whereas many R204W and R304W keratinocytes were detached from the 
surface of the culture dish, and the remaining cells retained as a single-layer with largely 
unchanged morphology (Figure S6.2Bb and S6.2Be). This difference in morphology 
suggested differentiation defects in the R204W and R304W cells.
Next, we investigated the possibility of pharmacological rescue of the observed 
differentiation defects. We hypothesized that the compound APR-246 that has been 
shown to target mutant p53 with amino acid substitutions in the DNA-binding domain 
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and restore p53 tumor suppressor activity 509, 510 would be a candidate compound for 
restoration of differentiation defects caused by corresponding mutations in the p63 DNA-
binding domain. Thus, we treated keratinocytes carrying R204W and R304W mutations 
with 10 to 30 μM of APR-246 before initiating differentiation (Figure S6.2A). On day 7 after 
initiation of differentiation, most of the APR-246-treated R204W and R304W keratinocytes 
remained attached to the surface of culture dish. Some cells changed to a flattened 
elongated morphology, started to establish cell-cell contacts, and formed multi-layer 
structures (Figure S6.2Bc and S6.2Bf), resembling those seen in normally differentiating 
wild type p63 keratinocytes (Figure S6.2Bi). Thus, these morphological changes in APR-
246-treated keratinocytes suggest that APR-246 can at least partially restore differentiation 
in p63 mutant keratinocytes. 
Restoration of expression of stratification markers in p63 mutant keratinocytes by APR-246
To investigate whether APR-246 can restore differentiation in p63 mutant keratinocytes 
at the molecular level, we performed immunofluorescence staining of differentiation 
markers in 2D cultures. Terminal differentiation markers such as involucrin and 
transglutaminase (TGM) were lowly expressed in mutant p63 R204W keratinocytes, and 
their expression was substantially enhanced upon APR-246 treatment, as assessed by 
immunofluorescence staining (Figure 6.2A) and Western blotting (Figure 6.2C). Suprabasal 
epidermal markers such as Keratin 1 (K1) and Keratin 10 (K10) were expressed at low levels 
in untreated R304W keratinocytes and also induced on differentiation day 7 after APR-246 
treatment (Figure 6.2B). Of note, p63 expression in wild type keratinocytes was reduced 
during differentiation, which is consistent with previous findings 116, 159. Treatment with 
APR-246 did not seem to influence p63 expression levels or to induce the TAp63 isoform 
in the mutant p63 keratinocytes (Figure 6.2C and S6.1D). Quantitative analysis of protein 
expression in R304W cells by flow cytometry showed that expression of K1 was induced 
by APR-246 to an almost complete recovery as compared to wild type p63 cells, and that 
expression of K10 and TGM was also substantially rescued upon treatment with APR-246 
(Figure S6.3G, left panel). 
Restoration of differentiation marker gene expression was also confirmed at the mRNA 
level. In wild type cells, expression of all tested differentiation markers including K10 and 
Cystatin M/E (CysME, an inhibitor of asparaginyl endopeptidase required for envelope 
maturation) 516 were not significantly induced upon APR-246 treatment (Figure S6.3A). 
In contrast, induction of K10 and CysME expression in R304W cells was consistent and 
statistically significant (Fig. S6.3A and S6.3C). Expression of some differentiation markers 
including K10 and CysME was also increased in APR-246-treated R204W keratinocytes as 
compared to untreated cells, but the effect was less pronounced than in R304W 
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cells (Figure S6.3D). When the total level of detected mRNA during differentiation was 
compared, the expression of K1 and K10 in APR-treated R304W cells almost reached 
the levels observed in the differentiating wild type p63 keratinocytes (Figure S6.3G, right 
panel), whereas the rescue in R204 was less substantial (Figure S6.3G, middle panel). 
Interestingly, the expression of differentiation markers was also slightly enhanced in an 
AEC keratinocyte cell line carrying the T533P mutation upon APR-246 treatment, to similar 
levels as in R204W cells (Figure S6.3E). 
APR-246 treatment enhances transcription of p63 target genes
To understand the mechanism behind the rescue of mutant p63 by APR-246, we 
examined the effect of APR-246 on Alcohol dehydrogenase 7 (ADH7 ), one of the 
novel p63 target gene identified in our expression array analysis. ADH7 expression was 
Figure 6.2. Differentiation marker expression in APR-246-treated EEC patient keratinocytes. A| Control, 
R204W A and B| R304W B keratinocytes treated with APR-246 were stained for differentiation markers. 
R304W keratinocytes were collected on differentiation day 7. Nuclei were stained with DAPI in blue. 
C| Protein lysates of control and R204W keratinocytes treated with APR-246 were analyzed by Western 
blotting for Involucrin, p63 and β-actin (loading control). 
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undetectable at the proliferation stage and strongly induced when differentiation was 
initiated and this was almost completely lost in R204W and R304W keratinocytes (Figure 
6.3A). Restoration of ADH7 expression was readily detected in APR-246-treated R304W 
keratinocytes, approximately 5-fold, and reached statistical significance at day 4, whereas 
the slight induction of ADH7 expression in APR-246-treated R204W keratinocytes was 
not statistically significant (Figure 6.3A). Rescue of expression was also observed for some 
other potential target genes identified in our expression array study, such as glutathione 
peroxidase 2 (GPX2) (Figure S6.3B). To obtain an overview of APR-246 effects on gene 
expression, we assessed the total mRNA synthesis (or accumulation) of all the tested 
genes over time. Expression of many tested genes, including the novel target gene 
ADH7, GPX2 and differentiation markers, was partially rescued by APR-246 in a dose-
dependent manner but to variable degrees (Figure S6.3F upper and middle panel). We 
also examined Claudin-1 protein expression in R204W keratinocytes with or without APR-
246 treatment. Claudin-1 was previously reported as a direct target gene of p63 and is 
involved in epidermal differentiation 278. Expression of the Claudin-1 protein was enhanced 
in the APR-246-treated R204W cells after differentiation (Figure 6.3B and Figure S6.3H). 
The overall rescue of all tested genes at the mRNA (Figure 6.3C, left panel) and the protein 
level (quantitated by flow cytometry analysis, Figure 6.3C, right panel) were calculated 
and summarized in the box-whisker plot. The gene expression in APR246-treated R304W 
keratinocytes was clearly induced, and more pronounced than in R204W cells (Figure 
6.3C). Consistent with the slightly enhanced expression of differentiation markers in AEC 
T533P keratinocytes (Figure S6.3E), we also observed an induction of ADH7 expression in 
these cells (Figure S6.3F, lower panel). 
To further investigate the effect of APR-246 on p63 target genes, we tested transcription 
driven by either wild type or mutant p63 through ADH7 BS1 in transient transfection assays. 
Wild type p63 but not p63 mutants R204W, R279H, R304W and T533P activated transcription 
via ADH7 BS1 (Figure S6.4B, left panel). We observed a slight increase of transcription upon 
APR-246 treatment in mock or wild type p63 transfected cells. Interestingly, however, 
APR-246 induced more pronounced enhancement of transcription at ADH7 BS1 in cells 
transfected with p63 mutants R204W, R279H, R304W and T533P and the enhancement 
of treatment with 30 μM APR-246 was statistically significant (P value = 0.03) (Figure S6.4B, 
right panel). This is consistent with ability of APR-246 to induce expression of the EGFP 
reporter driven by a p53 consensus motif in the presence of mutant p63 (Figure S6.4E). 
These findings indicate that treatment of APR-246 has a stronger effect on p63 mutants 
than on wild type p63. To assess whether APR-246 enhances DNA binding of mutant 
p63 to its target sequences, we performed ChIP-qPCR analysis in SAOS2 cells stably 
transfected with R304W mutant p63. In two independent SAOS2 R304W cell lines, we 
observed a moderate increase of DNA binding at both ADH7 binding sites at high 
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concentrations of APR-246 (Figure S6.4C). This enhanced DNA binding induced by APR-
246 was corroborated by the data from an in vitro DNA binding assay (TransAM) based on 
a synthetic p53/p63 consensus sequence (Figure S6.4D).
Figure 6.3. Expression of p63 target genes upon APR-246 treatment. A| RT-qPCR analysis of ADH7 
expression at different stages of differentiation in R304W and R204W keratinocytes treated with APR-246. 
B| APR-246-treated R204W keratinocytes were stained for Claudin-1 (green). Nuclei were stained with 
DAPI (blue). C| A summary of induction of the mRNA (RT-qPCR, left panel) and proteins (flow cytometry, 
right panel) of all tested genes (GPX2, ADH7, K10, CysMe, involucrin, and K1 for mRNA and K10, TGM, 
K1, Claudin-1, and involucrin for protein) over 7-day differentiation is shown in the box-whisker plot. 
Expression levels of mRNA or protein in wild type p63 cells were set as 100%. Left panel, the paired t-test 
between untreated cells and APR-246-treated cells shows that the rescue reached statistical significance 
in R304W keratinocytes (P value = 0.025) but not in R204W keratinocytes (P value = 0.22). Right panel, 
the paired t-test showed significant rescue in R304W cells treated with 15µM APR-246 compared to 
untreated cells (P value = 0.0796, according to the Wilcoxon matched pairs test). 
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APR-246 improves stratification in 3D human skin equivalents from p63 mutant 
keratinocytes
The partial but consistent APR-246-mediated rescue of keratinocyte differentiation 
in submerged 2D culture prompted us to test the effect of APR-246 on differentiation/
stratification in a 3D human skin model. Compared to human skin equivalents established 
from wild type p63 cells (Figure 6.4Aa and 6.4Ad), those established from R204W 
keratinocytes showed a thin and poorly stratified epidermis that lacked a granular layer and 
showed parakeratosis in the cornified layer (Figure 6.4Ab and 6.4Ae). Treatment of R204W 
human skin equivalents with 10μM APR-246 at the air-liquid interface markedly improved 
epidermal morphology to a multilayered structure with a visible stratum spinosum. The 
stratum granulosum was still absent but the stratum corneum appeared more continuous 
(Figure 6.4Ac and 6.4Af). 
To investigate whether differentiation was rescued in these skin equivalents, a panel of 
differentiation markers were tested by immunostaining. Expression of the epithelial marker 
Keratin 14 (K14) and proliferation marker Ki67 was not substantially affected in the basal 
layer of the R204W and R304W skin equivalents (Figure S6.5c and S6.5e for K14 and 
S6.5yi for Ki67) compared to that of the wild type cells (Figure S6.5a for K14 and S6.5wi 
for Ki67) and also not affected by APR-246 (Figure S6.5b, S6.5d, and S6.5f for K14 and 
S6.5xi and S6.5zi for Ki67). Expression of both early (K10) and late (Involucrin, CysME, Late 
Cornified Envelope protein (LCE2) and Filaggrin) differentiation markers in R204W (Figure 
6.4Bb, 6.4Bg, 6.4Bl, S6.5i, S6.5o, S6.5u and S6.5si) and R304W (Figure 6.4Bd, 6.4Bi, 6.4Bn, 
S6.5k, S6.5q, S6.5w and S6.5ui) skin equivalents appeared irregular and discontinious as 
compared to wild type human skin equivalents (Figure 6.4Ba, 6.4Bf, 6.4Bk, S6.5g, S6.5m, 
S6.5s and S6.5y). APR-246 treatment in R204W (Figure 6.4Bc, 6.4Bh, 6.4Bm, S6.5j, S6.5p, 
S6.5v and S6.5ti) and R304W (Figure 6.4Be, 6.4Bj, 6.4Bo, S6.5l, S6.5r, S6.5x and S6.5vi) cells 
enhanced expression of these early and late differentiation markers. For K10, Involucrin 
and CysME, APR-246 treatment resulted in a continuous expression pattern resembling 
that of wild type epidermis, and for LCE2 and Filaggrin, the rescue was less pronounced. 
APR-246 treatment did not seem to affect expression of tested markers in skin equivalents 
from the wild type keratinocytes (Figure S6.5). Furthermore, protein expression of the 
novel p63 target gene ADH7 was visible in wild type skin equivalents (Figure 6.4Ag) but 
almost undetectable in R204W skin equivalents (Figure 6.4Ah). Treatment with APR-246, 
however, resulted in enhanced ADH7 expression in R204W skin equivalents (Figure 6.4Ai). 
Taken together, our results show that expression of both differentiation markers and p63 
target genes was partially but consistently restored by APR-246 treatment.
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Figure 6.4. Differentiation marker expression in APR-246-treated 3D human skin equivalents. A| Human 
skin equivalents generated from p63 wild type and R204W keratinocytes treated with APR-246 at the 
air-liquid interface culture were stained with heamatoxylin/eosin (H&E) and an ADH7 antibody. B| 
Proteins expression of K10, Involucrin and CysM/E was examined by immunofluorescence staining of skin 
equivalents generated from wild type keratinocytes and R204W and R304W keratinocytes which were 
treated with APR-246. Nuclei were stained with DAPI (blue). Bar = 50 µM. 
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Discussion
Here we have established an in vitro model, primary skin keratinocytes from EEC patients 
with p63 mutations in 2D submerged cultures and in 3D human skin equivalents. Using 
this unique model, we identified distinct clusters of potential direct target genes of p63, 
and tested our hypothesis that the differentiation defects caused by p63 mutations may be 
rescued by the mutant p53-targeting compound APR-246.
The DNA binding-domains of p53 and p63 share extensive structural homology 116, and 
amino acid residues in p63 that correspond to tumor-associated hotspot mutations in p53 
are often mutated in human developmental disorders such as EEC 3. Various strategies 
have been developed to target mutant p53 for cancer treatment. Small molecules that 
bind to mutant p53 and restore wild type function have been identified 517. In the current 
study, we asked whether one such compound, APR-246, could reactivate endogenous 
mutant p63 with amino acid substitutions in the DNA-binding domain in keratinocytes 
derived from patients with the EEC syndrome. Indeed, treatment with APR-246 resulted in 
significant rescue of morphology and gene expression in R304W and R204W keratinocytes 
during epidermal differentiation. We recently showed that APR-246 can restore DNA-
binding, target gene expression and pro-apoptotic activity to mutant isoforms of TAp63g 
in human tumor cells 512. As different isoforms of p63 may regulate distinct target genes, 
it can be envisaged that APR-246-mediated restoration of wild type function to different 
isoforms of mutant p63 expressed in various cell types may result in distinct biological 
consequences. Our finding that a potential novel anticancer drug against mutant p53 can 
be used to target mutations in another p53 family member in a developmental disease 
raises the interesting possibility of developing targeted therapy for phenotypically distinct 
diseases that are caused by a similar underlying molecular mechanism.
We examined expression of differentiation markers in different layers during stratification, 
including K1 and K10 as suprabasal epithelial markers, involucrin as a late-stage marker in 
the spinous layer, and TGM, CysME, LCE2 and Filaggrin as markers in the granular layer 
and in the terminally differentiated cells of the skin. The APR-246-mediated induction of 
expression of these markers in specific stratified epidermal layers in patient keratinocytes 
suggests that restoration of normal function to mutant p63 can rescue not only 
differentiation initiation but also differentiation at terminal stages.
We found that the p63 R304W mutant is more amenable to reactivation by APR-246 than 
the R204W mutant. This observation is in agreement with our previous study of APR-246-
mediated rescue of pro-apoptotic activity in human tumor cell lines 512. The difference in 
the response to APR-246 might be due to the molecular nature of the two mutations. R304 
in p63 corresponds to R273 in p53, a residue that makes direct contact with DNA. R273H 
mutant p53 retains wild type conformation to a large extent 357. R204 in p63 corresponds 
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to p53 R175 that is important for the structural integrity of the DNA-binding domain. The 
p53 R175H mutant shows severe structural defects. The structural consequences of the 
R204W mutation in p63 are presumably similar to those of p53R175H mutation, and 
extensive unfolding may make APR-246-mediated rescue less efficient. However, we 
cannot exclude that the observed differences are due to inter-individual variation in the 
response to APR-246 that is unrelated to p63. Intriguingly, we also observed restoration 
of gene expression and DNA binding mediated by APR-246 for a p63 mutation that is 
localized in the C-terminal SAM domain and associated with the AEC syndrome (Figure 
S6.3E, S6.3G and S6.4D). This domain is not conserved in the p53 protein, and therefore 
the effect of APR-246 on this type of mutations has not been investigated so far. Previous 
studies suggest that the AEC mutations may affect the conformation of the p63 protein 
or protein-protein interactions of p63 with other co-factors to affect transactivation 180. 
Therefore, the rescue effect of APR-246 on these mutants may be due to stabilization 
of the overall protein conformation of p63 or by modulating critical protein-protein 
interactions.
Based on our expression analysis, we identified a cluster of potential target genes whose 
expression was de-regulated in p63 mutant keratinocytes. One of them is ADH7, a class 
IV alcohol hydrogenase that may be involved in the biosynthesis of retinoic acid that is 
important for cellular differentiation. The expression of ADH7 during early differentiation 
was almost completely lost in p63 mutant keratinocytes (Dataset S6.3), indicating that p63 
normally activates ADH7 and that mutations in the p63 DNA-binding domain disrupt this 
regulation. Consistent with this notion, we found that wild type p63 normally binds to 
specific sites near the ADH7 promoter (Figure 6.1C) and activates transcription (Figure 6.1D), 
whereas mutations in the DNA-binding domain of p63 abolished the transactivation (Figure 
6.1D and 6.3C). Interestingly, another enzyme in the retinoic acid biosynthesis pathway, 
Retinal short-chain Dehydrogenase (retSDR1, also known as dehydrogenase/ reductase 
member 3, DHRS3) has recently been reported as a p63 target gene and its expression was 
shown to be affected by EEC syndrome p63 mutations 518. These data suggest that p63 
plays a role in the retinoic acid biosynthesis pathway and that EEC syndrome mutations 
disrupt cellular differentiation mediated by retinoic acid during embryonic development. 
ADH7 and Claudin-1 are probably two among a number of p63 target genes that are up-
regulated in APR-246-treated mutant p63 keratinocytes. Their up-regulation suggests that 
reactivation of p63-dependent transcription is the underlying mechanism of APR-246-
mediated rescue. Thus, we demonstrate that APR-246 partially restores wild type function 
to endogenous mutant p63 in a physiological context where p63 is normally expressed 
at high levels and essential for epidermal differentiation. It will be of interest to identify 
other p63 target genes that are up-regulated upon APR-246 treatment in p63 mutant 
keratinocytes in a genome-wide scale.
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Our findings may open new opportunities for drug screening and development of therapy 
for patients with developmental disorders associated with p63 mutations. This is relevant not 
only to EEC but also to Ectodermal Dysplasia, as APR-246 can target mutations associated 
with AEC, even though these mutations are not localized within the DNA-binding domain. 
AEC syndrome patients often suffer from severe skin phenotypes 194. Further in vivo studies 
of APR-246-mediated rescue of mutant p63 at various embryonic stages will be of great 
interest for exploring such therapy options. Since the retinoic acid biosynthesis pathway 
is affected by p63 EEC syndrome mutations, retinoic acid and related compounds should 
also be further investigated for their effect on epithelial differentiation affected by p63 
mutations. In conclusion, we have shown that the mutant p53-targeting compound APR-
246 partially restores epidermal differentiation of primary adult keratinocytes derived from 
patients with p63 mutations, probably through restoration of p63 target gene expression. 
Our study provides a novel concept for development of treatment for the p63-related 
diseases. The notion of applying targeted therapy for phenotypically distinct diseases 
caused by similar molecular mechanisms could also be relevant to treatment of other 
diseases.
Materials and Methods
Patient information. EEC patient 1 is a 29-year old woman who has a dry albino-like skin and white hair. 
She has dystrophic nails and absence of enamel in her teeth. She is anhydrotic and has dacrocystitis 
in her eyes that is probably caused by the nasolacrimal obstruction. She also has syndactyly in her 
hand and cleft lip and palate. She has a small dysplastic ears and hearing impairment, double sided 
hydronephrosis and narrowed urethra. She has frequent urinary tract infections. Mammary or nipple 
abnormalities have not been observed. It is reported that she carries a heterozygous R204W mutation 
in the p63 gene 178. EEC patient 2 is a 51-year old man, who has a very dry and scaling skin in the 
nose, back of the hands and back. He has a history of a malignant spinocellular epithelioma in his left 
hand that has been exposed to the sun because of his daily work outside. He has prosthesis, his nails 
are hypoplastic and he has no hair. He has corrected dacryostenosis and cleft lip and palate. He has 
syndactyly and ectrodactyly in his hands and feet. He also has several genito-urinary abnormalities: 
double pyelum and ureter on the right side, narrowed bladder neck, prostate hypertrophie and 
hypospadia. He has normal sweating and normal nipples. This patient has been reported to carry a 
heterozygous R279H mutation in the p63 gene 3. EEC patient 3 is a 59-year old man who has a dry, 
but normal sweating skin. His hair is coarse and he carries prosthesis because of teeth problems. 
He has a corrected dycryostenosis on the left side and absence of Meibomian glands in the eye. He 
has ectrodactyly and syndactyly in one hand and foot. And he also has left sided cleft lip and palate. 
He suffers from hearing impairment because of narrowed ear canal and has a history of chronic 
otitis media and a cholesteatoma cyst. He also has several genito-urinary abnormalities: hypospadia, 
prostate hypotrophy, chronical interstitial nephritis and a broaden urethra. This patient has been 
reported to carry a heterozygous R304W mutation in the p63 gene 5. All these three mutations are 
localized in the p63 DNA-binding domain. The AEC patient has been reported to carry a heterozygous 
T533P mutation in the SAM domain of p63 180.
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Ethical approval. All procedures for establishing and maintaining human primary keratinocytes were 
approved by the ethical committee of the Radboud University Nijmegen Medical Centre (“Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen”) with the approval code CMO-PR2004/132. 
Informed consent was obtained from all donors of a skin biopsy. 
Submerged human primary keratinocytes cultures. Skin biopsies were taken from the trunk of healthy 
volunteers or EEC syndrome patients with p63 R204W, R279H, R304W or T533P mutations to establish 
the primary keratinocyte culture 519. APR-246 was applied to keratinocytes during the proliferation stage 
(Fig. S6.3A), and differentiation was initiated by depleting growth factors. KGM consists of Keratinocyte 
Basal Medium, 0.15 mM Ca2+ (Lonza), supplemented with 0.1 mM ethanolamine (Sigma), 0.1 mM 
phosphoethanolamine (Sigma), bovine pituitary extract (0.4%) (Bio Whittaker), 10 ng/ml EGF (Sigma), 5 
μg/ml insulin (Sigma), 0.5 μg/ml hydrocortisone (Calbiochem), 100U/ml penicillin (Gibco) and 100 μg/
ml streptomycin (Gibco). For all experiments cells were grown in 6-well plates in KGM for 6 days and 
then treated with APR-246 every two days for three times (Fig. S6.3A). Differentiation was induced by 
depletion of growth factors and cells were maintained for another 7 days. The differentiation medium 
consists of KGM, 0.15 mM Ca2+ (Lonza), supplemented with 0.1 mM ethanolamine (Sigma), 0.1 mM 
phosphoethanolamine (Sigma), 100U/ml penicillin (Gibco) and 100 μg/ml streptomycin (Gibco). Cells 
were collected at differentiation day 0, 2, 4 and 7 (Fig. S6.3A), and analyzed for gene and protein 
expression, using RT-qPCR, immunostaining, Western blotting and flow cytometry analysis.
RNA extraction and quantitative Real-time RT–PCR. Cells were collected on day 0, and on days 
2, 4 and 7 after induction of differentiation. RNA extraction and cDNA synthesis were carried out 
using the NucleoSpin RNA II kit (740955.50; MACHEREY-NAGEL, Düren, Germany) and iScript cDNA 
synthesis kit (Bio-Rad; 170-8891, CA, Hercules, USA). PCR primers (Dataset S6.4) were designed using 
Primer3 (http://frodo.wi.mit.edu), and PCR reactions were performed in the 7500 Fast Real Time 
PCR System apparatus (Applied Biosystems) by using iQ SYBR Green Supermix (Biorad) according 
to the manufacturer’s protocol. Human acidic ribosomal protein (hARP) and GUSB were used as 
a housekeeping gene to normalize the amount of cDNA. Differences in expression of each gene 
between wild type and mutant samples (relative expression) were calculated by 2ΔΔCt method 427. 
Western blotting. Cells were harvested, washed in phosphate-buffered saline (PBS) and lysed by 1X 
SDS buffer. Cell extracts were incubated for 5 min at 100oC followed by determination of protein 
concentration using the BSA assay (Pierce, CA, USA). Equal amounts of protein from each sample 
were subjected to SDS–polyacrylamide gel electrophoresis at 130V followed by electroblotting to 
nitrocellulose membranes. Membranes were blocked for 1 h with 5% non-fat milk in PBS at room 
temperature and probed with primary antibodies. All antibodies were diluted in PBS containing 5% 
non-fat milk, and 0.05% Tween-20. Blots were visualized by ECL (Amersham Biosciences, Sweden). 
The following antibodies were used for Western blotting: rabbit polyclonal anti-Claudin 1 (717800, 
Invitrogen, USA), mouse monoclonal anti-β-actin (clone AC-15, Sigma, Sweden), and rabbit polyclonal 
anti-p63α (H129) (sc-8344, Santa Cruz Biotechnology, Inc).
Antibodies and immunofluorescence staining of submerged keratinocyte cultures. The following 
antibodies were used for immunofluorescence staining: goat polyclonal anti-K1 (N-20; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), mouse monoclonal anti-K10 (RKSE 60; Progen Biotechnology, 
Heidelberg, Germany), mouse monoclonal anti-involucrin (I9018; Sigma, Missouri, MO, USA), rabbit 
anti-human/mouse transglutaminase-1 (Santa Cruz), mouse monoclonal anti-keratin 14 (LL002, 
Novocastra, Newcastle-upon-Tyne, UK), mouse monoclonal anti-filaggrin (BT-576, Biomedical 
Technologies Inc, Stoughton, MA), rabbit polyclonal anti-LCE2 520 goat anti- mouse secondary 
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antibody conjugated with Alexa 488 (A11001; Invitrogen, California, CA, USA) and chicken anti-
goat secondary antibody conjugated with Alexa 488 (A21467; Invitrogen, California, CA, USA). All 
cells were fixed in 4% paraformaldehyde, washed in PBS, and permeabilized with 0.1% Triton X-100. 
Primary (1:100) and secondary antibodies (1:2000) were diluted in PBS containing 3% BSA and 
incubated with samples at room temperature for 60min. Between all steps, cells were washed in PBS 
3 × 10min. Stained sections were mounted using Vectashield H-1000 containing DAPI stain (Vector 
Laboratories, CA, USA), and examined under a Zeiss Axioplan 2 fluorescence microscope equipped 
with an AxioCam HRm Camera (Carl Zeiss, Germany). The software used for analysis was Axio Vision 
4.2.
Affymetrix exon expression array and data analyses. Keratinocytes established from five different 
normal individuals were used as controls, and keratinocytes from R204W, R279H and R304W 
patients were cultured twice and used as replicas for each mutation. RNA was extracted from 
keratinocytes at differentiation day 2, and used to perform expression analyes using Human Exon 
1.0 ST Array (Affymetrix) according to the manufacturer’s protocol. Quality of total RNA was assessed 
using the Agilent 2100 Bioanalyzer (Agilent Technologies). Two microgram of total RNA was used for 
hybridization on the Gene Chip Human Exon 1.0 ST Array (Affymetrix) according to the manufacturer’s 
protocol (Gene Chip® Whole Transcript (WT) Sense Target Labeling Assay Manual). The Affymetrix 
fileswere first imported into Affymetrix Expression Console version 1.1 where control probes were 
extracted using the default RMA algorithm in order to perform quality analysis checks. The Area 
Under the Curve (AUC) of the Receiver Operator Characteristic was calculated using the positive and 
negative control probes. All arrays had AUC score above the empirically defined threshold of 0.85, 
indicating a good separation of positive controls from negative controls. Subsequently the cell-files 
were imported into Partek® (Partek® Genomic Suite software, version 6.4 Copyright © 2008 Partek 
Inc., St. Louis, MO, USA) for clustering analysis where only core exons were extracted and normalized 
using the RMA algorithm with GC background correction. Core transcript summaries were calculated 
using the mean intensities of the corresponding probe sets. The Anova model was applied on the log2 
intensities and p-values for expression differences for the three pair wise comparisons of each of the 
individual patients versus the controls were generated. In each comparison only genes with p-values 
≤ 0.05 were selected. Heatmap of differentially regulated genes was generated using MultiExperiment 
Viewer (MeV, http://www.tm4.org/mev/) 521.
Data analysis of mRNA synthesis/accumulation. The RT-qPCR data were first plotted in a coordinate 
system displaying mRNA expression related to the corresponding mRNA levels in wile type p63 
keratinocytes at day 0 versus time. Data points were then connected by the Cubic spline interpolation 
method (3rd order polynomial interpolation). The area under curve (AUC) was integrated, providing 
an estimation of the synthesis/accumulation of the corresponding mRNA transcript over time. The 
interpolation and integration procedures were performed by Microcal Origin 8.5 software (Origin Lab, 
Northhampton, MA, USA). Levels of the corresponding mRNA transcripts in the differentiating wild 
type p63 keratinocytes were set as 100%. Statistical analysis was performed by Statistica 10 software 
(Stat Soft. Inc. OK, USA).
Gene Ontology Annotations. Gene Ontology analysis on differentially expressed genes and genes 
mapped by the nearby binding sites was performed using DAVID Bioinformatics Resources (NIH) 
(http://david.abcc.ncifcrf.gov). P value was obtained using default setting in DAVID without multiple 
testing.
Light microscopy. Cell morphology was examined using a Leica light microscope (DM IRB, 
magnification: 20X, Germany) and images were recorded at magnification: 3X (Canon camera, Japan).
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Tet-on inducible p63 cells. The Tet-on inducible expression system established in SAOS2 cells 
described previously 127, was used to generate myc-tagged mouse ΔNp63α wild type and R304W 
mutant stable SAOS2 cell lines. After 18 hours of doxycyclin (Sigma-Aldrich) treatment at 0.2 μg/ml 
to induce expression of myc-ΔNp63α wild type and myc-ΔNp63α R304W mutant p63, APR-246 was 
supplemented in the culture medium at final concentrations of 25 μM and 50 μM for 24 hours. 
Constructs and transactivation assays. The genomic region of the p63 binding site ADH7-BS1 was 
amplified by PCR using Gateway cloning primers (Dataset S6.4) and cloned into a modified ccdB-
containing pGL3-Basic vector which contains a firefly luciferase reporter gene. To mutate the p63 
binding motif, the most conserved cytosine and guanine bases were changed to adenosine. The 
ΔNp63α expression plasmid was described previously 111, and mutagenesis was carried out to 
introduce the R204W, R279H, R304W, L514F and T533P mutations. Transfection and luciferase assays 
in SAOS2 cells were performed as described 134. APR-246 was added in the culture medium at final 
concentrations of 25 μM and 50 μM 24 hours after transfection. All cloning and mutagenesis primers 
are shown in Dataset S6.4. For transient EGFP reporter assays, SAOS2 cells were transfected with a 
reporter construct containing a p53/p63 consensus binding site in front of an EGFP reporter, along 
with the ΔNp63α mutant or wild type p63 plasmids described above. After 24 hours cells were treated 
with APR-246 at several concentrations. Cells were harvested by trypsinization after 20h incubation 
and analyzed by flow cytometry. GFP reporter expression was quantified as geometric mean of the 
fluorescence and normalized to p63 expression levels as assessed by Western blotting.  
Chromatin immunoprecipitation (ChIP). SAOS2 cells carrying inducible p63 were cross-linked with 1% 
formaldehyde for 10 minutes, and chromatin was collected as described 127. Chromatin was sonicated 
using the Bioruptor sonicator (Diagenode) for 16 minutes at high power, 30 seconds on, 30 seconds 
off. Antibodies H129 against p63 (Santa Cruz), and 8WG16 against RNAPII (Santa Cruz) were used in 
ChIP-qPCR experiments. For qPCR of ChIP analysis, one primer set was used for each tested binding 
region (Table S6.4), and ChIP efficiency of certain binding sites was calculated using percentage of 
ChIPped DNA against input of chromatin. Occupancy used in ChIP experiment with SAOS2 cells was 
calculated using ChIP efficiency of the ADH7 BS1 region standardized by that of the chromosome 11 
region (Dataset S6.4).
TransAM DNA binding assays. SAOS2 cells were transfected with the ΔNp63 mutant or wild 
type p63 constructs described above. After 24 hours cells were treated with APR-246 at different 
concentrations of. After 20h incubation cells were harvested by trypsinization and analyzed by flow 
cytometry. Total protein extracts were prepared using RIPA-like lysis buffer and then incubated in a 96-
well plate coated with immobilized oligonucleotides that contains a p53/p63 consensus binding site 
(50-GGACATGCCCGGGCA TGTCC-30; TransAM kit, Active Motif, 41196, Rixensart, Belgium). Bound 
p63 protein was detected by a mouse monoclonal anti-p63antibody (4A4; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) followed by incubation with a secondary horseradish peroxidase-conjugated 
antibody. The signal was developed by TMB substrate followed by termination of the reaction by 
sulfuric acid and quantified by spectrophotometry (450 nm). All data were normalized to p63 
expression levels according to Western blotting.
Flow cytometry. Keratinocytes were washed in PBS, re-suspended in 3ml ice-cold PBS and fixed 
with 4 ml ice-cold ethanol which was added to the cells dropwise while vortexing. Cells were kept 
in the fixative for several days. Then cells were washed with ice-cold TgT buffer (0.01% Triton X-100; 
20mM Tris, pH 7.4; 150mM NaCL; 20% serum) and stained with anti-claudin-1 conjugated with Alexa 
Fluor 488 primary mouse monoclonal antibodies (Invitrogen, California, CA, USA), anti-involucrin 
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Alexa Fluor 647 conjugated rabbit polyclonal antibodies (Bioss, Woburn, MA), anti-transglutaminase-1 
PE-conjugated rabbit polyclonal antibodies (Antibodies online.com), anti-Cytokeratin -1 mouse 
monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) labelled with EasyLink APC/
Cy7 conjugation kit (Abcam, Cambridge, UK), anti-Cytokeratin -10 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) mouse monoclonal antibodies labelled with Zenon Alexa Fluor 700 mouse IgG1 
labelling kit (Invitrogen, California, CA, USA). After 1hs staining and subsequent washings samples 
were analysed on LSR II BD flow cytometer (BD Biosciences, San Jose, CA). Samples were analysed 
by FCS Express 3.0 software (De Novo Software, Los Angeles, CA). 
Generation of human skin equivalents. De-epidermized dermis was generated as reported previously 
522. Human skin equivalents were cultured submerged for three days in medium containing 5% serum, 
consisting of two parts Dulbecco’s modified Eagle’s medium and one part Ham’s F12 medium (both 
from Life Technologies, Inc.) supplemented with 5% calf serum (Hyclone), 4 mmol/l l-glutamine and 50 
IU/ml penicillin or streptomycin (both from Life Technologies, Inc.), 24.3 μg/ml adenine (Calbiochem), 
1 μmol/l hydrocortisone (Merck KGaA), and 50 μg/ml ascorbic acid, 0.2 μmol/l insulin, 1.36 ng/ml 
triiodothyronine, and 10−10 mol/l cholera toxin (all from Sigma). Thereafter, the skin equivalents were 
cultured at the air-liquid interface for ten days in medium without serum, consisting of two parts 
Dulbecco’s modified Eagle’s medium and one part Ham’s F12 medium (both from Life Technologies, 
Inc.) supplemented with 4 mmol/l l-glutamine and 50 IU/ml penicillin/streptomycin (both from Life 
Technologies, Inc.), 24.3 μg/ml adenine (Calbiochem), 1 mg/ml l-serine and 2 μg/ml l-carnitine (both 
from Sigma), bovine serum albumin lipid mix (25 μmol/l palmitic acid, 7 μmol/l arachidonic acid, 15 
μmol/l linoleic acid, and 0.4 μg/ml vitamin E; all from Sigma), 1 μmol/l hydrocortisone (Merck KGaA), 
and 50 μg/ml ascorbic acid, 0.1 μmol/l insulin, 1.36 ng/ml triiodothyronine, 10−10 mol/l cholera toxin, 
5 ng/ml keratinocyte growth factor, and 2 ng/ml epidermal growth factor (all from Sigma). APR-246 
was added in the culture medium during the entire culture period at the air-liquid interface at a final 
concentration of 10 μM.
Morphological and immunolabeling of human skin equivalents. Skin equivalents were fixed in buffered 
4% formalin for 4 hours, and processed for routine histology. Skin equivalents were embedded in 
paraffin, and 6-μm sections were stained with heamatoxylin and eosin (H&E) (Sigma) or processed for 
immunofluorescence or immunohistochemical staining. Primary antibodies against Keratin 10 (1:100; 
Sanbio, Uden, The Netherlands), Involucrin (1:50; Mon150; Sanbio), CysME (1:200; R&D), Keratin 14 
(1:50, Novocastra, Clone LL002), LCE-2 (1:1000 520) and Filaggrin (1:6000, Biomedical Technologies, 
clone BT-576) were fluorescently labeled with ALEXA 488 and ALEXA 594, respectively. Primary 
antibody against ADH7 (Abcam) was used at a 1:200 dilution and the indirect immunoperoxidase 
technique with avidin–biotin complex enhancement (Vectastain) was used according to manufactures 
recommendations. Primary and secondary antibodies (1:200) were diluted in PBS containing 1% BSA 
and incubated at room temperature for 60min. Between all steps, cells were washed in PBS 3 × 5min. 
For immunofluorescence staining, nuclei were stained with DAPI and sections were mounted in 
Fluoromount-G (Southern Biotech). Heamatoxylin (Sigma) was used to counterstain nuclei in ADH7 
immunohistochemically stained sections, and sections were mounted with glycerol gelatin (Sigma).
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Figure S6.1. Exon expression array analysis of p63 in primary keratinocytes. A| Screenshot of UCSC 
genome browser showing genomic structure of the p63 gene, TA and ΔNp63 exons and p63 expression 
revealed by RNA-seq data in Normal Human Epithelial Keratinocytes (NHEK) from the ENCODE 
consortium 96. B| Screenshot of UCSC genome browser showing the C-terminal exons of the p63 gene 
and expression of p63 α, β, g, δ and e isoforms revealed by RNA-seq data in Normal Human Epithelial 
Keratinocytes (NHEK) from the ENCODE consortium. C| Exon array analysis using Affymetrix Exon Array 
of wild type p63, p63 R204W, R304W and R279H shows the expression of individual exons. Expression 
(log2) ratio at 6 is normally considered as the expression detection threshold (dotted line). The expression 
of p63 in patient keratinocytes is slightly higher than that in normal control cells. D| RNAPII ChIP-seq 
was performed in wild type keratinocytes during differentiation (left panel) and wild type and R304W 
keratinocytes with and without treatment of APR-246 (right panel). Specific primers designed at the 
p63 TA or ΔN promoter were used to detect whether any transcript was initiated at specific promoters. 
β-actin promoter was used as a positive control and primers designed at myoglobin exon 2 and at a no 
gene region on chromosome 11 were used as negative controls. E| Hierarchical clustering analysis of 
expression pattern of five normal control samples and three EEC patient keratinocytes.
Figure S6.2. Morphology of EEC patient keratinocytes upon APR-246 treatment. A| Scheme for APR-246 
treatment. Cells were plated and cultured in proliferation medium for six days, followed by APR-246 
treatment in the same medium every second day for three times. When cells were confluent, differentiation 
was initiated by using differentiation-promoting medium without growth factors. Cells were harvested 
at undifferentiation condition (day 0 of differentiation) and on day 2, 4 and 7 at the differentiation 
conditions. B| The cell morphology of keratinocytes with or without APR-246 treatment was photographed 
on different stages of differentiation (day 0, 4, 7), with the same magnification. The border between the 
top and bottom cell layers is indicated by the red dashed line.
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Figure S6.3. Gene expression analysis by RT-qPCR in p63 mutant keratinocytes upon APR-246 treatment. 
A| Expression of CysME and K10 in keratinocytes with wild type or R304W mutant p63 treated with 
APR-246 was analyzed by quantitative real-time RT-PCR (RT-qPCR). The human acidic ribosomal protein 
(hARP) gene and GUSB were used as internal controls. All analyses of gene expression were performed 
in duplicates and repeated three times; B, C, D| Expression of CysME and K10 in wild type, R304W, 
R204W and T533P keratinocytes was assessed by RT-qPCR. E| Expression of GPX2 in wild type, R204W 
and R304W keratinocytes were analyzed by RT-qPCR. F| Combined mRNA expression data for K1, K10, 
Involucrin, CysMe, ADH7 and GPX2 in R304W, R204W and T533P keratinocytes at all analyzed time 
points. Data are related to the expression levels of the corresponding mRNA in the normal keratinocytes 
(set to 100%) over the studied time period. G| Left panel shows relative induction of the corresponding 
proteins detected by flow cytometry in R304W cells. Total protein induction in treated R304W cells over 
7-day differentiation is depicted as a percentage of the protein level in differentiating wild type p63 
keratinocytes. Middle and right panels show induction of mRNA expression of the corresponding genes in 
R304W and R204W. Total mRNA induction over 7-day differentiation is depicted as a percentage of the 
mRNA level in differentiating wild type p63 keratinocytes. Dark blue color, untreated cells; green, change 
in the expression as a result of the treatment with 30µM of APR-246; dark blue plus green, expression in 
treated mutant cells; cyan, the difference between protein levels in treated R304W cells and that in the 
wild type p63 keratinocytes. H| Western blotting analysis of Claudin1 expression during differentiation in 
wild type cells and in R204W cells with and without treatment of APR-246.
Figure S6.4. p63 binding sites at the promoter region of ADH7, and partial restoration of transactivation 
and DNA-binding to mutant p63 by APR-246. A| ChIP-seq analysis in human primary keratinocytes 437 
was performed with two antibodies in three independent cell lines. A screenshot at the genomic locus 
of ADH7 shows two binding sites (BS1 and BS2) near the ADH7 promoter. The p63 binding motif in 
ADH7 BS1 was detected using p63scan 437 and is indicated. B| Left panel, ADH7 BS1-dependent gene 
expression was tested in a transfection assay in the presence of wild type p63 or p63 mutants. Right 
panel, APR-246 treatment enhanced transactivation of p63 mutants in a dose-dependent manner at the 
ADH7 BS1 site. The activation by p63 without APR-246 treatment was set as 1. The enhancement on p63 
mutants was statistically significant (P value = 0.03).
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Figure S6.4. p63 binding sites at the promoter region of ADH7, and partial restoration of transactivation 
and DNA-binding to mutant p63 by APR-246. C| ChIP-qPCR analysis in two independent inducible p63 
R304W SAOS2 stable cell lines that are treated with 25mM and 50 mM of APR-246. Binding of R304W 
p63 to the ADH7 BS1 binding site was moderately induced by at high concentrations of APR-246; D| In 
vitro DNA binding was assessed using an oligonucleotide with a p53/p63 consensus binding motif and a 
panel of EEC and AEC p63 mutants. E| A panel of p63 EEC and AEC mutants were tested in a transient 
transfection assay using an EGFP reporter carrying a p53/p63 consensus binding site. Transfected cells 
were treated with increasing amounts of APR-246.
Figure S6.5. Differentiation marker expression in APR-246-treated 3D human skin equivalents. Skin 
equivalents generated from wild type keratinocytes and R204W and R304W keratinocytes which were 
treated with APR-246 were examined by single immunofluorescence staining for protein expression of 
K14, LCE2 and Filaggrin or by double immunofluorescence staining of Filaggrin/CysME, INV/CysME and 
Ki67/CysME.  The white dotted lines represent the dermis. Nuclei were stained with DAPI (blue). 
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Table S6.1. Validation by qPCR differentially regulated genes from expression array.
Array data Validation by qPCR
Genes Mutations Fold-change Fold-change SD
GPX2* R279H 28.0 37.7 ±6.1
R204W 25.5 35.3 ±8.3
R304W 12.9 8.2 ±0.4
ADH7* R279H 16.4 21.2 ±2.8
R204W 15.7 30.7 ±6.7
R304W 13.9 33.4 ±9.2
GBP6 R279H 15.1 9.6 ±1.8
R204W 9.1 7.6 ±3.0
R304W 8.2 2.6 ±0.6
CTSK* R279H 10.0 9.5 ±3.3
R204W 9.9 9.3 ±0.1
R304W 5.4 5.0 ±0.7
ETV4* R279H 3.4 2.2 ±1.2
R204W 3.0 2.1 ±0.1
R304W 3.4 2.9 ±0.8
FZD7 R279H 3.3 9.8 ±2.9
R204W 2.0 3.0 ±0.1
R304W 1.6 3.3 ±0.0
PORC R279H 2.8 3.2 ±0.9
R204W 2.2 2.7 ±0.0
R304W 2.5 5.4 0.2
CLDN7* R279H 1.9 3.3 ±1.0
R204W 1.7 1.2 ±0.0
R304W 1.7 1.7 ±0.0
IRF6* R279H 2.3 2.5 ±0.4
R204W 1.6 1.1 ±0.2
R304W 1.7 1.1 ±0.3
CTNNB R279H 1.9 1.7 ±0.4
R204W 1.6 2.5 ±0.6
R304W 1.4 3.5 ±0.0
*with a binding site nearby
Dataset S6.1. Differentially regulated genes (with or without a p63 binding site nearby) in keratinocytes 
established from R204W, R279H and R304W patients. (Excel file, not included).
Dataset S6.2. Gene Ontology analysis of differentially regulated genes. (Excel file, not included).
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Dataset S6.3. Primers used in quantitative RT-PCR analysis. 
Dataset S6.3A
Primers for expression analysis
GXP2_exp1_F gcaaccaatttggacatcag
GXP2_exp1_R ccaggacggacatacttgag
GXP2_exp3_F ttcaggagacactgctggac
GXP2_exp3_R gaaaaggaaacaggcagagg
ADH7_exp1_F gagcagaagcaacccttctc
ADH7_exp1_R agattcctgtggccaaaatc
ADH7_exp2_F agatggcaacctttgcattag
ADH7_exp2_R tgccatcagccagtactcc
ADH7_exp3_F tgctcaattcaggacaaagc
ADH7_exp3_R ctcctgccactttggatctc
hARP_qPCR_F CACCATTGAAATCCTGAGTGATGT
hARP_qPCR_R TGACAAGCCCAAAGGAGAAG
GUSB_QPCR_F agagtggtgctgaggattgg
GUSB_QPCR_R ccctcatgctctagcgtgtc
KRT1_exp_fw gatgaaatcaacaagcggacaa
KRT1_exp_rv tggtagagtgctgtaaggaaatcaatt
KRT10_exp_Fw tggttcaatgaaaagagcaagga
KRT10_exp_Rev gggattgtttcaaggccagtt
cystatin M/E_exp_Fw tccgagacacgcacatcatc
cystatin M/E_exp_Rev ccatctccatcgtcaggaagtac
QPCR_Involucrin_F acttatttcgggtccgctaggt
QPCR_Involucrin_R gagacatgtagagggacagagtcaag
P63_TA_specific_F1_QPCR TTCTGGAACAGCCTATATGTTCAGTT
P63_TA_specific_R1_QPCR TCTTCTGATGGTTCATCCACAAA
Dataset S6.3B
Primers for cloning
ADH7_BS1_Cloning_F1 ggggacaagtttgtacaaaaaagcaggcttcTTCATTCTTGCCATTGTCTC
ADH7_BS1_Cloning_R1 ggggaccactttgtacaagaaagctgggtgCAAAAGCGTGACAAATCTGG
ADH7_BS1_SDM_FW ggctagatgAaaActgaaaAtcAtcctttcatacc
ADH7_BS1_SDM_RV ggtatgaaaggaTgaTtttcagTttTcatctagcc
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Dataset S6.3C
Primers for ChIP analysis
IRF6_ BS2 _P58_F TTTCTCACATTCCCACATGC
IRF6_ BS2 _P58_R CCAACCTGACAGACTCCTACC
ADH7_ChIP_qPCR_F1 TCCAACACTGCAAACTCAGG
ADH7_ChIP_qPCR_R1 TTGGCAGAGCTGATGGTATG
ADH7_ChIP_qPCR_F2 ATTCAGAGGCAAGAGCACTG
ADH7_ChIP_qPCR_R2 AGACAAGGCAGAAACCAAGG
myoglobin ex2_FW     aagtttgacaagttcaagcacctg
myoglobin ex2_RV     tggcaccatgcttctttaagtc
ChIP_ctr_chr11_F TTGCATATAAAGGAAACTGAAATGCT
ChIP_ctr_chr11_R TTACTGCCATGGGTCCGTATC
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General discussion 
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Gene regulatory mechanisms orchestrated by p63 in 
epithelial development and related disorders
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Since the discovery of the transcription factor TP63 gene in 1998, it has been 
demonstrated that p63 has a key role in the development of ectoderm derived epithelial-
structures and tissues including limbs, skin, palate, and hair. This is based on studies on 
Tp63 knockout models, ΔNp63-specific knockout models, and knock-in mouse models 
carrying TP63 human disease mutations 6, 116-118, 450, 486, 523. In humans, heterozygous 
mutations in TP63 give rise to several epithelial related disorders with defects in skin, 
limb and orofacial structures 4, 5. Furthermore, there are strong genotype-phenotype 
correlations for p63-associated disorders. However, the exact pathogenic mechanisms 
that cause the phenotypic variability of the p63-associated disorders are still unknown. 
The last seventeen years, efforts have been made to identify p63 target genes in order 
to understand p63 function in normal epithelial development and related diseases. Initial 
studies were restricted to single genes and regulatory mechanisms controlled by p63. 
Subsequent technological advances allowed the use of genome-wide approaches such 
as microarray analysis of p63 knockdown studies using RNAi, which identified several 
hundreds of potential p63-regulated genes 170, 171. 
With the fast developing sequencing technology, some of the array-based genome-
wide analyses have gradually been replaced by sequencing analyses. Although the 
initial ChIP-on-chip experiments provided information on p63 binding, this method has 
several shortcomings and technical limitations as compared to ChIP followed by high-
throughput sequencing (ChIP-seq) such as noise due to hybridization artifacts, less 
coverage and a lower resolution 524. The use of ChIP-seq, a state-of-the-art technique, 
has increased dramatically in recent years and is used to address various questions on 
biological processes by genome-wide discovery of protein-DNA interaction profiles from 
transcription factors and histone modifications. This technique played a central role in 
this thesis, to elucidate the p63 gene regulatory network and provide insight on p63-
dependent regulating mechanisms during epithelial tissue development.
In this thesis, I describe the first p63 ChIP-seq analysis performed using human adult 
skin primary keratinocytes that identified genome-wide p63 binding sites (Chapter 2). 
This very first ChIP-seq analysis (Chapter 2) together with our newest p63 ChIP-seq data 
from differentiating human keratinocytes (Chapter 5) and palatal tissue (Chapter 4), and 
other recent genome-wide studies 438 have identified tens of thousands of p63-bound 
regulatory elements and many new potential p63-target genes. These data have reshaped 
the concept of gene regulation orchestrated by p63 and provided evidence that p63 
governs specific programs involved in epithelial differentiation. Based on the p63 ChIP-
seq results, I also discovered novel disease mechanisms for limb malformation (SHFM1) 
(Chapter 2) and orofacial clefting (CL/P) 490. Next, I discovered that treatment of 2D and 
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3D models generated from EEC and AEC patient keratinocytes using the compound APR-
246/PRIMA-1MET showed consistent rescue of epidermal stratification and p63 target gene 
expression (Chapter 6). These findings open new avenues for novel therapy of patients 
with mutant p63-associated developmental abnormalities.
Here I will discuss the regulatory role of p63 in normal and diseased epithelial development 
in more detail. Furthermore, future perspectives for dissecting the molecular mechanism 
of p63-mediated epithelial development and related disorders as well as for potential 
therapeutic strategies are proposed.
7.1 Advantages of the used model systems to study p63 gene regulation.
The first genome-wide ChIP-on-chip approaches to study the p63 gene network were 
performed using a cervical carcinoma cell line 131 and HaCaT cells 140. However, these 
immortal cell lines do not reflect the physiological balance in pathway activities 525. Here, 
I reported p63 ChIP-seq studies using human adult skin primary keratinocytes (Chapter 
2 and 5). There are several advantages of using the primary keratinocyte model. First, 
skin is one of the affected structures in p63-associated ED syndromes, and p63 is highly 
expressed in the stem cells that reside in the basal layer of the epidermis that mainly consists 
of keratinocytes 154, 159. Second, primary keratinocytes from donors with differences 
in gender, age, and anatomic site show a high proteomic consistency as compared 
to immortal cell lines 525, making primary keratinocytes a preferred choice of model 
system in skin research. This is especially relevant since it is not always possible to obtain 
samples from patients with comparable gender and age. Third, isolation of keratinocytes 
from patients with mutations in TP63 enables the generation of patient disease models 
to study the effect of mutant p63 on gene regulation (Chapter 6). Fourth, keratinocytes 
can be used to generate organotypic cultures. Not only 2D skin models but also 3D skin 
models can be generated to study epidermal differentiation, in which the stratification 
of the epidermis can be analyzed in more detail (Chapter 6). Fifth, primary keratinocytes 
provide a versatile model for direct investigation of the effect of drugs on cell morphology 
and gene expression as shown by our study in Chapter 6. These aspects make primary 
keratinocytes a good physiological model to study gene regulation during epidermal 
differentiation and to elucidate the role of p63 and its regulated gene network (Chapter 2 
and 5). Furthermore, gene regulatory elements were shown to be active in a tissue- and 
species-specific manner 9, 11, 41, 71, 526-528, thus our gained knowledge on regulatory elements 
in human keratinocytes (Chapter 2 and 5) can be directly extrapolated to other human 
epidermis-related studies, demonstrating its importance to a broad field of research. The 
strength of the in vitro keratinocyte studies was evidenced by subsequent in vivo studies 
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in relevant tissues, including mouse palate and limb tissue from various developmental 
stages (Chapter 2, 3 and 4).
7.2 Expression analysis of p63 in keratinocytes using genome-wide approaches2
These studies and that of others showed high expression of ΔNp63 in the epidermis by 
exon expression array analysis of human adult skin keratinocytes (Chapter 6), and RNA-seq 
analysis of human skin keratinocytes (Chapter 5) 93, 94 and mouse developing skin 146. The 
expression of ΔNp63 in our in vitro adult human keratinocyte model was confirmed by 
western blotting experiments (Chapter 5 and 6). Contrary to previous reports that found 
TAp63 expression levels in the basal layer of the epidermis 149, 154 and in the outer layers 
of the epidermis 150, these studies showed no detectable expression of TAp63 isoforms 
at any stage of epidermal differentiation and skin development. However, we cannot 
exclude this is due to difficulties of detecting very low gene expression of the approaches 
used. Nevertheless, the clear contrast of high expression of ΔNp63 and the extremely low 
expression of TAp63, if existent at all, does emphasize the biological importance of ΔNp63 
in the epidermis. This is consistent with recent reports of several ΔNp63-specific knockout 
models that confirm that the ΔNp63 isoform is indispensable for proper development of 
epithelial structures 450, 486, 523. Expression of the C-terminal isoforms α, β, and g isoforms 
was confirmed by RNA-seq analysis of the mouse developing skin 146. Expression of the 
C-terminal δ and e isoforms was confirmed at the transcript and protein levels 135, but not 
evident in exon array and RNA-seq analyses in human epithelial cells (Chapter 5 and 6) and 
mouse developing skin 146.
7.3 Gene regulation controlled by p63 in epidermal keratinocytes
In 2010, we reported the first p63 ChIP-seq analysis using human adult skin primary 
keratinocytes (Chapter 2). With a stringent analysis threshold, 11,368 p63-bound genomic 
regions were identified, and in a more recent study using deeper sequencing 38,980 p63 
binding sites were reported (Chapter 5) with 98% and 91% containing a p63 consensus-
binding motif, respectively. Out of the 11,368 p63 bound regions from the first study, 
11,333 (99.7%) were also present in all 38,980 p63 bound regions found in this new study 
(Chapter 2 and 5). Analysis of the p63 ChIP-seq data demonstrated that genomic regions 
bound by p63 are localized at gene promoters, in genes and also in intergenic regions that 
are far away from genes (Chapter 2 and Chapter 5). Many of these p63-bound regions are 
also confirmed by another ChIP-seq analysis using primary human foreskin keratinocytes 
2 Some of the next paragraphs are published in: Evelyn N. Kouwenhoven, Hans van Bokhoven, Huiqing Zhou. 
Gene regulatory mechanisms orchestrated by p63 in epithelial development and related disorders. BBA. 2015
188
Chapter 7
438. Out of 7574 p63 bound-regions reported in neonatal foreskin ChIP-seq, 5840 (77%) 
were present in the 11,368 p63BS and 7443 (98.3%) were present in all 38,980 p63-bound 
regions in the human adult skin primary keratinocytes. The significant overlap of p63-
bound genomic regions in these three studies shows the reproducibility of the ChIP-seq 
method. Using these ChIP-seq strategies, genes identified in the vicinity of p63-bound 
regions have been shown to be involved in epidermal and ectodermal development. The 
enriched function of p63-regulated genes in epidermal and ectodermal development was 
to be expected but was not shown significant in previous p63 ChIP-on-chip studies 131, 
140. Furthermore, there are p63-target genes reported that are involved in cell adhesion, 
proliferation, differentiation and cell death (Chapter 2, 3, 4 and 5), which confirms previous 
expression and ChIP-on-chip experiments 131, 140, 170, 275, 308, 438.
7.3.1 Newly identified p63 target genes and molecular mechanisms in epidermal 
keratinocytes
Recently, several RNA-seq analyses of human epidermal cells or mouse epidermis 
have been reported (Chapter 5) 93, 94, 146. These studies were performed during normal 
differentiation of epidermal keratinocytes and they revealed a large number of differentially 
regulated genes during epidermal differentiation and development. 
In this thesis, I report the identification of many novel p63 target genes, including ADH7 
that encodes subclass IV alcohol hydrogenase 7 subunits and possibly plays a role in 
retinol oxidation in the retinoic acid biosynthesis pathway (Chapter 6). Another enzyme 
in the retinoic acid biosynthesis pathway, Retinal short-chain Dehydrogenase (retSDR1, 
also known as dehydrogenase/ reductase member 3, DHRS3) has also been reported 
as a p63 target gene and its expression was shown to be affected by EEC syndrome 
TP63 mutations 518. These data indicate a role for p63 in the retinoic acid biosynthesis 
pathway. Other new p63 target genes include different marker genes of skin differentiation 
(e.g. KRT1) and a group of non-coding RNAs, including approximately 100 pri-miRNAs 
(such as pri-miR-203 and pri-miR-205) that are expressed in the epidermis (Chapter 5). 
Furthermore, I identified at least 68 potential p63 target genes that are expressed at various 
stages of keratinocyte differentiation and associated with different types of skin diseases 
(e.g. KRT10, DSG1, LAMB3, COL17A1 and FLG), including several known p63 target genes 
(Chapter 5). Multiple known p63 target genes were confirmed in keratinocytes, such as 
GPX2, KRT14 and Claudin1 (Chapter 6). 
Recently, p63 was also shown to regulate expression of genes such as SATB1 that 
control higher-order chromatin remodeling, covalent histone modifications, and nuclear 
assembly 529, 530. SATB1 is known to establish region-specific epigenomic modifications by 
targeting chromatin-remodeling enzymes and transcription factors to the genomic locus 
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that includes genes encoding the major components of the cornified cell envelope such 
as Involucrin, Loricrin, Filaggrin, small-proline-rich and late cornified envelope proteins. 
In a mouse study, Satb1 expression could partially restore epidermal phenotypes in p63-
deficient skin explants, suggesting that SATB1 is a downstream target of p63 529. This 
shows a novel molecular mechanism of p63 regulating gene expression in epidermal 
development.
These findings demonstrate and confirm the essential role of p63 in epidermal 
development and provide novel insights into p63-orchestrated gene regulation during 
skin keratinocyte differentiation.
7.3.2 Complex gene expression mechanism orchestrated by p63
Comparison of ChIP-seq analyses in epidermal keratinocytes (see Table 7.1) (Chapter 2 
and 5) 438 with previous expression array analyses (see Table 7.2) 131, 140, 170, 308 showed that 
the number of p63-bound genomic regions was several orders of magnitude larger than 
p63-dependent genes. This is consistent with the study of ChIP-on-chip and expression 
analysis by RNAi knockdown of p63 in ME180 cells 131. The majority of the p63-bound 
regions located in intergenic non-coding regions overlap with the enhancer mark 
H3K4me1, and a smaller percentage also overlap with H3K4me3 and H3K27ac based on 
the ENCODE consortium data from Normal Human Epithelial Keratinocyte (NHEK) cells 
and our data on H3K27ac occupancy in differentiating adult human keratinocytes (Chapter 
5) 438, 531. These data suggest that the identified p63-bound regions are indeed enhancer 
regions but not all of them are active. However, H3K27me3 and H3K9me3, repressive 
histone modification marks associated with poised enhancers in embryonic stem cells and 
heterochromatin 96, 470, 532, respectively, were not detected at any of the active or inactive 
p63 binding sites, even though these marks were present at promoters of inactive genes 
(Chapter 5) 531. Detailed analysis of the ChIP-seq of RNAPII, p63 and H3K27ac occupancy 
during keratinocyte differentiation showed that H3K27ac signals correlate with gene 
expression. This is consistent with previous reports that showed that H3K27ac occupancy 
levels at enhancers reflect global cell-type-specific gene expression 533. P63 binding itself 
was not shown to correlate with gene expression. These results indicate that H3K27ac 
signal at p63 binding sites rather than p63 binding signal alone is informative for prediction 
of the transcriptional program regulated by p63, and that assessing H3K27ac occupancy 
at p63 binding sites could facilitate the identification of p63 target genes in keratinocytes 
(Chapter 5). 
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Table 7.2. Methods to determine p63 DNA-binding
Approach Cells/ Tissues Type of array Antibody References
p63 ChIP-on-
chip
Human ME180 cells
Affymetrix 14 
array set of high-
density, tiled 
whole human 
genome
4A4 131
p63 ChIP-on-
chip
Primary Human 
Keratinocytes from thigh 
skin
12K CpG 
islands and 12K 
promoters
anti-p63 140
p63 ChIP-
cloning
Human HaCaT 
keratinocytes
H129 (Santa 
Cruz) and 
RR-14
307
p63 ChIP-on-
chip
Primary Mouse 
Keratinocytes
Agilent 244K-array 
60-mer Oligo
H137 (Santa 
Cruz)
170
p63 ChIP-on-
chip
Human HaCaT 
keratinocytes
12K CpG islands 
and the 12K 
promoters
4A4 (Santa 
Cruz) and 
anti-p63
308
p63 ChIP-on-
chip
Normal primary 
human basal epithelial 
keratinocytes (NHEKs)
Affymetrix array H129 448
p63 ChIP-seq
Primary Human 
Keratinocytes
4A4 (Abcam) 
and H129 
(Santa Cruz)
437
p63 ChIP-seq
Primary Human Neonatal 
Foreskin Keratinocytes, 
RNAi depleted 
endogenous TP63 and 
WT or AEC TP63 mutants 
were introduced at near-
endogenous levels
4A4 (Santa 
Cruz)
534
p63 ChIP-seq
Primary Neonatal Human 
Foreskin Keratinocytes 
(HFKs)
4A4 (Santa 
Cruz)
438
p63 ChIP-seq
Human HaCaT 
keratinocytes
anti-p63 
(Genespin)
482
p63 ChIP-seq
Human Prostate Cells 
(EP156T)
4A4 (Abcam) 439
p63 ChIP-seq
Primary Neonatal Human 
Foreskin Keratinocytes 
(HFKs)
4A4 (Santa 
Cruz)
129
p63 ChIP-seq
Human Squamous Cell 
Carcinomas (SCC cells)
anti-p63 535
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Master transcription factors control cell-specific genes and define cellular identities 536. 
Recent publications show that high levels of lineage-specific master transcription factors 
and co-activators bind to clustered enhancers, also referred as super-enhancers through 
which they drive gene expression to define cell lineage identity 42, 43. Characterization of 
our p63 binding profiles identified both single p63 binding sites (p63BS) as well as clusters 
of p63 binding sites (cl-p63BS) reminiscent of super-enhancers (Chapter 5). These findings 
in part explain the difference between the number of p63 binding sites and the number 
of differentially regulated genes. Involvement of p63 has been shown in both activation 
and repression of gene expression of p63 target genes 307, 448. It should be noted that in 
our analysis we did not discriminate whether p63 acts as an activator or a repressor factor; 
especially for genes with “inactive” p63 binding sites (without H3K27ac signal) nearby, 
p63 may function as a repressor. But it is unlikely that p63 recruits repression complexes 
such as polycomb proteins or induces heterochromatin formation, as p63 binding sites 
are co-localized with open chromatin regions marked by DHS and with enhancer marks 
such as H3K4me1 but are not co-localized with H3K27me3 and H3K9me3 marks (Chapter 
5). Furthermore, analysis of the H3K27ac occupancy during keratinocyte differentiation 
identified single and clustered epidermal enhancers (cl-epidermal enhancers) (Chapter 5). 
We demonstrated that cl-p63BS overlapping the cl-epidermal enhancers (active cl-p63BS) 
in differentiating keratinocytes (30% of the identified cl-p63BS) are associated with genes 
involved in epidermis development and also with known skin disease genes. While, the cl-
p63BSs that are inactive are associated with genes essential in the development of other 
epithelial structures, such as limbs (Chapter 5). These observations suggest that the binding 
of p63 may mark epithelial lineage related regulatory elements as a placeholder during 
epithelial commitment, and the recruitment of different sets of co-regulators is required 
for gene regulation in an epithelial-related tissue- and stage-specific manner (Figure 7.1). 
This paradigm of transcription factor-mediated regulation has also been shown for some 
transcription factors such as FoxA and GATA proteins that serve as placeholders in lineage 
progenitor cells 491. The p63-bound genomic regions seem to be preferentially located in 
the nucleosome-enriched regions based on computational analysis on the co-occurrence 
of specific histone modifications and the accessibility of the chromatin at p63 motifs 531, 
suggesting that p63-DNA interaction is likely to shape the chromatin accessibility. 
We also found changes in activity of single and cl-epidermal enhancers, and active 
cl-p63BS as measured by H3K27ac occupancy at different stages of keratinocyte 
differentiation, whereas no H3K27me3, H3K9me1 or H3K9me2 occupancy was detected 
at these sites throughout keratinocyte differentiation (Chapter 5). These findings indicate 
that (p63 bound) clustered enhancers can also play a role in fine-tuning gene expression 
to control cell specification rather than only function in cell-fate decision 71, 537.
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Although 24% of all p63-bound regions are located at transcription start sites, many of 
the regions are located in gene bodies as well as in intergenic regions (Chapter 5). This 
suggests that p63-bound regions may regulate gene expression over long distance. 
Indeed, p63-bound regulatory elements are found at 250 kb and 10 kb distance from 
their cognate target gene limb and palatal development, respectively (Chapter 2 and 
3). This data and those obtained in other genome-wide studies on transcription factor 
p63 binding, chromatin status and RNA expression start to change the view of how p63 
regulates transcriptional regulation during epithelial development. 
7.4 Co-factors of p63
The notion that p63 binding alone does not explain epidermal gene expression (Chapter 
5) 438, 531 raises the possibility that p63 orchestrates the activation of gene transcription 
in a spatial and temporal specific manner through recruitment of co-activators (Figure 
7.1). Several studies proposed that specific master transcription factors control lineage-
specification of stem cells by a core transcriptional regulatory circuit consisting of 
transcription factors that are driven by super-enhancers and co-occupy their own super-
enhancers 42, 43. Furthermore, a recent study showed that SOX9 acts as a pioneer factor to 
drive hair-follicle lineage specification by activation of other super-enhancer controlled 
hair follicle specific transcription factor genes 537. This indicates that a core transcriptional 
regulatory circuit that includes the direct regulation of co-transcription factors (through 
super-enhancers) is a common mechanism of master regulators in controlling cell-
lineage specification. It was previously shown that p63 functions as a master regulator 
during the development of ectoderm-derived epithelial tissues and structures 6, 116-118, 450, 
486, 523. Another study once more emphasized the important role of p63 in protecting the 
commitment to epidermal cell fate 168. Therefore, it is of interest to determine whether p63, 
like the other master regulators functions similarly in driving tissue specification by directly 
regulating its co-factors in epidermal specification. Several studies predicted p63 co-
factors by scanning all p63-bound genomic regions identified in ChIP-on-chip and ChIP-
seq analyses to search for over-represented transcription factor binding motifs (Chapter 2) 
131, 531. This strategy resulted in the identification of several groups of transcription factors 
such as TFAP1, TFAP2, and bZIP family proteins that potentially cooperate with p63. One 
of the p63 ChIP-seq studies showed that the motif of TFAP-2 factors are enriched and 
localized in 37.8% of p63-bound regions 438, which predicts the cooperation of TFAP-2 
factors with p63. This cooperation was subsequently validated by transient transfection 
experiments. The fact that not all p63 binding sites coincide with TFAP-2 binding suggests 
that other co-regulators might be required to drive p63-dependent gene regulation at 
other p63-bound regions. 
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In our latest study, we used a slightly different method to predict p63 co-factors by scanning 
different groups of p63 bound genomic regions depending on specific characteristics 
to search for over-represented transcription factor binding motifs (Chapter 5). First, we 
scanned the active and inactive groups of p63 binding sites to search for p63 co-factors 
with specific functions. An enrichment from specific transcription factor families such as 
ZFX, RUNX, and EBF1 families was found in the active p63 binding sites, the NR2 family 
receptor motif was enriched in the inactive p63 binding sites. Consistent with the previous 
findings the TFAP2α binding motif was enriched in both active and inactive p63 binding 
sites. Co-operative binding of both RUNX1 as well as TFAP2α at p63 binding sites was 
confirmed using ChIP-QPCR (Chapter 5).
Subsequently, we scanned the seven clusters of p63 binding sites that show differential 
H3K27ac occupancy patterns during keratinocyte differentiation to search for potential 
p63 co-regulators that act during specific stages of epidermal stratification. Several 
transcription factor family motifs were enriched in the specific clusters of p63 binding sites 
with differential H3K27ac occupancy patterns, including FOXQ1, MAFB, SP100, E2F, and 
VDR (Chapter 5). Although the precise function of these transcription factors in epidermal 
stratification is not yet clear, it is likely that they cooperate with p63 in keratinocyte 
differentiation as they have been shown to regulate cell proliferation and differentiation 
473-477. Interestingly, many of these identified co-regulators of p63 including RUNX1 480, VDR 
481, RXRA 482 and FOXQ1 in epidermal keratinocytes are either known p63 target genes or 
were identified as potential p63 targets (Chapter 5). Furthermore, we specifically identified 
active cl-p63BS near several p63 co-regulators, including RUNX1, RXRA, MAFB, ASCL2, 
and VDR (Chapter 5). These findings suggest that p63 controls the expression of its co-
regulators to co-regulate p63 target genes, which is consistent with the master regulator 
role of p63 in epithelial cells. These results prompt further studies to refine the core p63-
transcriptional regulatory circuitry that is essential to drive the specification of specific 
epithelial cell lineages, and confirm the co-regulators of p63 in the epidermal lineage. 
7.5 Gene regulation controlled by p63 in the development of other epithelial 
tissues including limb and palate and related diseases
In addition to epidermal development, p63 has an important role in epithelial structures 
during embryonic limb and palate development. 
7.5.1 A role for p63 in limb development
Syndromic disorders caused by TP63 mutations with the SHFM phenotype include EEC, 
LMS and ADULT. Many of these TP63 mutations are located in the DNA-binding domain 
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of TP63 3-5, 176-179. Presumably these mutations affect DNA binding of p63 and expression 
of its target genes involved in limb development. DLX5 and DLX6 genes are important for 
limb development. One study showed that deleting both of these genes led to the SHFM 
phenotype in mouse 199. Interestingly the same study also showed that these genes are 
p63 target genes, and EEC mutations of TP63 disrupt gene regulation of DLX5 and DLX6. 
Isolated SHFM has been mapped to six different genomic loci (SHFM1-6) 195. Before the 
initiation of my PhD research project only two of these SHFM loci were associated with 
mutations in coding genes, namely mutations in TP63 (SHFM4) and WNT10B (SHFM6). 
Missense mutations in the TP63 gene associated with SHFM4 are widely distributed in 
different p63 domains, the TA, DBD, or TI domains. Recently, also the SHFM1 locus was 
shown to associate with mutations in a coding gene, namely the DLX5 gene 200, 201. 
Disruption of long-range gene regulation has been implicated in disrupted limb 
development. Examples include regulation of Sonic Hedgehog (SHH) 216 and Hox genes 72 
by long-range enhancers. Therefore it was hypothesized that SHFM conditions could also 
result from disruption of enhancer elements. We applied a p63 ChIP-seq profile obtained in 
skin keratinocytes to search for enhancer elements in the SHFM1 locus on Chromosome 7, 
and identified a p63-dependent enhancer that is located within CTCF binding sites, more 
than 250kb away from DLX5 and DLX6 genes and controls expression of these genes 
(Chapter 2). This p63-dependent enhancer is within a genomic deletion of a SHFM patient, 
and the deletion of this element might cause SHFM in this patient. This study showed that 
disruption of p63-dependent gene regulation could be one of the disease mechanisms 
of SHFM. Recently, other enhancers in the same locus have been associated with SHFM1 
538-540. Exons 15 and 17 of the DYNC1I1 gene were shown to have regulatory activity (also 
called exonic enhancers, eExons) in embryonic limb that drive gene expression of DLX5/6 
in mouse and zebrafish 538, 541. A small microdeletion within the SHFM1 locus was identified 
that deleted these eExons at the DYNC1I1 gene locus that showed an association of these 
eExons with limb malformation (SHFM1) 539. It will be of interest to investigate whether 
any of these newly identified enhancers are also regulated by p63. Collectively, these 
findings reveal a complex regulatory landscape of p63 bound enhancers and potentially 
other transcription factor binding sites and epigenetic modifications that are essential for 
gene regulation in limb development. Because of the important role of long-range gene 
regulation in limb development it will be of interest to study the regulatory landscape 
within and surrounding other SHFM loci to investigate the function of the enhancers and 
the bound regulators (e.g. transcription factors and co-factors). This can help to determine 
whether p63-mediated gene regulation is also involved in these loci and/or to identify 
novel disease mechanisms. Preliminary investigation of the loci that are associated with 
SHFM1 to SHFM6 shows that one or more p63 binding sites lie within these loci (data not 
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shown). Closer examination of these loci is required to discover all regulatory elements 
and molecular processes that are involved in limb development to assess a link between 
variations in these regions with limb malformations.
7.5.2 p63 in palatal development
Mutations in TP63 also give rise to cleft palate with or without cleft lip (CL/P) in syndromic 
and non-syndromic forms. Syndromic CL/P is present in EEC, LMS and AEC/RHS 
syndromes associated with TP63 mutations. Approximately only 0.1% of NSCL/P is caused 
by TP63 mutations 542. Isolated non-syndromic CL/P is generally considered as a complex 
disorder, caused by the combination of a number of genetic variants and environmental 
factors. Due to this genetic complexity, it is difficult to establish the cause of individual cases 
of CL/P. It is plausible that many of the genetic contributors will act in common molecular 
networks. Indeed, in Chapter 3 we showed that the expression of transcription factor IRF6 
which underlies syndromic forms of CL/P 429, is controlled by p63. Another study showed 
that IRF6 can also regulate p63 protein levels through proteasome-mediated degradation 
316. These findings demonstrate a cooperative mechanism of these two key transcription 
factors in orofacial development. Interestingly, independent studies confirmed that the 
same p63-dependent enhancer that regulates IRF6 expression is involved in orofacial 
clefting 260, 490. A SNP located in this enhancer that affects TFAP-2α binding is associated 
with an increased risk of cleft lip (CL) 260. In a recent study, a heterozygous duplication of 
an A nucleotide (350dupA) in the p63 binding consensus motif within this enhancer was 
identified in a family with VWS without IRF6 mutations 490. Two p63 motifs were previously 
identified within this enhancer. In vitro transient transfection studies showed that the 
disruption of each p63 motif individually by altering the highly conserved nucleotides that 
are relevant for p63 binding did not affect transactivation activity whereas disruption of 
both motifs simultaneously resulted in a loss of transactivation (Chapter 3). This suggests 
that either of the two motifs in this enhancer element is sufficient for p63 binding. However, 
the 350dupA mutation disrupted the spacing in one of the p63 motifs through a nucleotide 
duplication, and resulted in a complete loss of p63 binding and loss of p63-dependent 
transactivation 490. Furthermore, it is proposed that this 350dupA mutation also creates a 
de novo repressor binding site that interferes with the p63 binding to the second p63 motif 
through a yet uncharacterized mechanism. A possible reasoning might be that binding of 
p63 marks this genomic locus as an enhancer and thereby preventing repressor proteins 
to bind, thus showing the importance of p63-binding in this region. Therefore, the CL/P in 
this VWS family is caused by disruption of IRF6 transcription via a loss-of-p63 activity and 
gain-of-repressive function mechanism 490. These findings provided an incentive to search 
for other p63 target genes with a role in palatogenesis that might be causative genes of 
CL/P. Given the critical role that p63 plays in palatal development, we determined the 
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regulatory gene network of p63 in palatal epithelia by p63 ChIP-seq profiling and gene 
expression analysis using palatal shelves dissected from mouse embryos (Chapter 4). 
Data analysis identified a large number of p63 binding sites near genes that are involved 
in skin development and cell adhesion. Significant enrichment of genes associated with 
he epidermolysis bullosa disease, a genetic skin disorder that is caused by altered cell 
adhesion, was found near p63 binding sites identified in the palatal tissue. These findings 
are consistent with the p63 profiling analysis in keratinocytes (Chapter 2 and 5), suggesting 
that p63 binding occurs near genes involved in adhesion in both keratinocytes as well as 
palatal epithelia (Chapter 4). In Chapter 4, downregulation of p63 by siRNAs in palatal tissue 
demonstrated gene expression changes of genes involved in cell adhesion, including 
CDH3, Lef1, Pkp1, Col7a1, Col17A1, and Lamb3, which all have p63 binding sites located 
nearby. Genes involved in cell adhesion programmes were also identified and confirmed 
as p63 target genes in keratinocytes, including Lamb3, Col7a1, and Pkp1 448 (Chapter 4). 
These results indicate the important role of p63 in cell adhesion for proper development 
of both epidermis and palate, and confirm the importance of p63 in regulating gene 
expression in multiple epithelial tissues (Chapter 2, 3, 4 and 5). 
A group of genes that were previously identified in keratinocytes as p63-target genes 
were reported to carry mutations in patients with cleft palate 438. Direct regulation of these 
genes by p63 in the palate had not been demonstrated yet. By characterizing p63 binding 
during palatal development, we identified a large number of p63 binding sites near these 
causative genes of CL/P and showed that p63 can regulate these genes, including Fgfr2, 
Pdgfa and Pvrl1 and transcription factor genes, such as Grhl3 and TFAP2α (Chapter 4). 
These genes were also identified as potential p63 target genes by our studies on primary 
human keratinocytes (Chapter 2 and 5). Mutations in Grhl3 and TFAP2α cause Van der 
Woude syndrome (VWS) 442 and branchio-oculo-facial syndrome 415, respectively.
The p63 binding sites in the Tfap2α locus were identified in both human keratinocytes 
and mouse palatal tissue (Chapter 4 and 5) suggesting that the transcription factor TFAP2α 
is transcriptionally regulated by p63 in both tissues. Although TFAP2α was not affected in 
basal keratinocytes of the dorsal skin of ΔNp63-null mice 450, the expression of TFAP2α 
was significantly down-regulated in the palatal epithelia of Tp63-null mice, suggesting 
that p63 positively regulates Tfap2α in palatal epithelia (Chapter 4). Interestingly, p63 
expression in keratinocytes is induced and maintained by cooperative interaction between 
p63 and TFAP2α via a positive auto-regulatory feedback mechanism 293. In addition, p63 
and TFAP2α transcriptionally co-regulate several target genes including the PVRL1 gene 438 
which is associated with human cleft lip/palate- ectodermal dysplasia syndrome (CLPED1, 
MIM 225060). Patients with CLPED1 syndrome display cleft lip and/or cleft palate, limb 
malformations, hidrotic ectodermal dysplasia that include nail dystrophy, alopecia, and 
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palmoplantar hyperkeratosis, and in some cases mental retardation. These findings 
indicate a close cooperative role for p63 and TFAP2α during the development of palatal 
tissues as well as during keratinocyte differentiation.
Identification of a role for p63 in regulating tissue-specific regulatory elements and genes 
during palatal development would require detailed epigenomic profiling of the active 
regulatory elements during palatal formation as well as determining the tissue-specific 
co-factors that are essential to drive p63 controlled gene-regulation in palatogenesis. 
Defining all p63-dependent regulatory elements and those active ones in palatal tissue 
might help to elucidate the regulation of genes important for orofacial development and 
novel disease mechanisms of isolated CL/P.
Another approach to identify new molecular mechanisms that underlie isolated CL/P 
would be to study previously identified SNPs associated with CL/P that occur in haplotype 
blocks in combination with our p63 binding profiles 224 together with epigenomic profiles 
from different stages of palatal development. Haplotype blocks contain a set of closely 
linked alleles on a chromosome that tend to inherit together consisting of SNPs that exhibit 
high linkage disequilibrium (LD) with each other. These haplotype blocks have proven 
useful for genetic studies of complex diseases to identify segregating genomic regions 
with specific traits to identify disease causes 245. Studying haplotype blocks containing 
common SNPs that significantly associate with isolated CL/P in more detail enables the 
discovery of candidate (p63-bound) regulatory elements that lie in LD with these SNPs. 
Sequence analyses of these candidate (p63-bound) regulatory elements can contribute to 
the identification of new disease causing mechanisms.
Taken together, genetic data in SHFM and CL/P studies showed that p63-bound regions 
identified in p63 ChIP-seq analysis of skin keratinocytes can function as enhancers to 
regulate gene expression for proper embryonic limb and palate development (Chapter 
2, 3, 4 and 5). These data are consistent with the proposed model that p63 serves as a 
placeholder to bookmark regulatory elements and regulate gene expression at different 
stages and in different tissues during development, as not all p63-bound regions identified 
in skin keratinocytes are active in these cells (Chapter 5, see Section 7.3.2). These finding are 
consistent with the observation that p63 binding sites identified in epidermal keratinocytes 
were found to associate with Split Hand/Foot Malformation (Chapter 2) and with van der 
Woude Syndrome that has cleft lip/palate as a major feature (Chapter 3) 490. This p63-
dependent spatial and temporal regulation may be mediated by co-regulators of p63 (see 
section 7.4). Based on the observations described in this thesis I propose a model of p63-
dependent gene regulation (Figure 7.1). 
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7.6 The p63 gene network and Ectodermal dysplasia
Ectodermal dysplasia is not a single disorder, but a group of conditions that are defined by 
abnormalities of ectoderm derived tissues. The p63 controlled regulation of genes in the 
epidermis has been discussed extensively in earlier sections. Therefore, this paragraph on 
the relation of p63 regulation and the affected tissues in ectodermal dysplasia will be brief.
In Chapter 4 and 5, we identified an association of p63 binding sites near skin disease 
genes and genes associated with CL/P and/or SHFM. Some of these genes also give rise 
to EDs, for example the CDH3 gene that is a known p63 target gene. Various ED causing 
genes fall within the same or a related gene network of p63. Examples of disease genes 
that are associated with ED, include PKP1, PVRL1, GTF2IRD1, and FOXN1. These genes 
were found to be occupied by multiple p63 binding sites (cl-p63BS) with high activity 
during keratinocyte differentiation (Chapter 5) and both PKP1 and PVRL1 were identified as 
p63 target genes (Chapter 4) 448. Research on other complex diseases, such as ciliopathies 
indicate that phenotypically related diseases are often caused by functionally related genes 
543. These findings suggest that the identification of the full p63 gene regulatory network 
that is active in different tissues and its co-regulators could help to provide a new strategy 
to study the underlying pathogenic mechanism of EDs. 
Figure 7.1. Model of p63-dependent gene regulation. A| cl-p63 binding sites (grey) near genes (white). 
B| active genes in epidermal differentiation associate with the activity of cl-p63BS (in pink) as defined 
by H3K27ac and can be regulated by these sites while other sites are inactive (grey). C| Inactive cl-
p63BS during epidermal differentiation can potentially be active and drive gene expression during the 
development of other epithelial cells such as in the AER during limb development (in blue) 148.
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7.7 Future prospects
7.7.1 p63-orchestrated gene regulation during embryonic development
Although our study on the function of p63 during epidermal differentiation indicates that 
p63 serves as a placeholder by bookmarking regulatory elements in adult keratinocytes, 
the mechanisms that initiate the epidermal commitment and the role of p63 in this process 
still remain a mystery. The key role of p63 in controlling the early embryonic epidermal 
switch became evident by studying Tp63 knockout mice 157 and the embryonic stem cell 
model 167, 299. It is known that p63 is expressed at the switch from ectodermal precursors to 
epithelial cell state during early embryonic development, and p63 was shown to play an 
important role in protecting the commitment to epidermal cell fate 168. Nonetheless, there 
are limited data on the function of p63 in gene regulation during this switch.
It would be interesting to test the hypothesis whether p63 can shape chromatin 
accessibility and by binding to the genome can bookmark regulatory regions during 
epithelial commitment. This can be investigated by performing a complete epigenomics 
analysis during epithelial commitment, for example during epithelial differentiation of 
pluripotent stem cells such as iPSCs and epithelial development during embryogenesis 
in animal models. Open chromatin regions and different histone marks that define 
chromatin states can be analyzed together with p63 expression and DNA-binding during 
epithelial commitment. This will determine whether p63 functions as I) an active pioneer 
factor that controls the shaping of the chromatin or whether it acts as II) a passive pioneer 
factor that exploits a pre-formed enhancer landscape, is the first to engage to its target 
site and recruits tissue-specific co-regulators to drive specific genes in different tissues to 
establish cell lineage, such as super-enhancer regulated transcription factor genes. To this 
end, a recently developed technique, ATAC-seq that can identify open chromatin regions 
in a small number of cells (500 to 50,000 cells), can be used to identify enhancers that are 
opening up in differentiating iPSCs 544, 545. Furthermore, correlation of these datasets with 
gene transcription and/or gene expression data is required to determine whether the initial 
binding of p63 causes expression changes of genes with specific functions, such as other 
tissue specific transcription factor genes. This will provide a better understanding of the 
role of p63 in defining epithelial structures and cell fate.
In addition, it is important to identify the interactions between p63-bound enhancers with 
their target genes by chromatin interaction techniques such as 4C, 5C, Hi-C or Capture-C 
104-106, 546. This can also help to study the differences in interactions between single p63 
binding sites and cl-p63BS to their respective target genes. 
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Identification of co-regulators of p63 during epithelial development
To identify co-regulators that cooperate with p63 during epithelial development is another 
interesting question. This can be addressed by performing protein pull-down assays using 
label free nuclear extracts 547 or nuclear extracts that are labelled using stable isotope 
labeling by amino acids in cell culture (SILAC) 548 followed by mass spectrometry (MS) 
analysis. SILAC is a simple, powerful and accurate method to compare protein expression. 
In SILAC experiments, different stable isotopes are used to label proteins and make them 
distinguishable in the mass spectrometer. This allows the comparison of protein expression 
in cultured cells between two or three different experimental conditions. However, to 
perform SILAC experiments SILAC kits are required or the generation of SILAC media 
from custom media depleted of lysine, arginine and methionine. In contrast, label free 
quantitation can be applied to any unlabeled protein sample and enables comparisons 
between many different samples (highly multiplex versus two- or three-plex of SILAC). 
Alternatively, pull-down with oligonucleotides containing p63 binding consensus motifs 
followed by MS analysis can be performed to get a first indication of co-regulators or as a 
confirmation of the other approaches 549-551.
Previous studies performed protein pull-down experiments from p63-tag transfected 
H1299 cells that do not express endogenous p63 followed by mass spectrometry analysis 
to identify interacting partners of p63 552, 553 providing a proof-of-principle for this type 
of approach. However, the limitation of these studies is that p63 is not endogenously 
expressed in physiologically irrelevant H1299 cells and important expression of p63 co-
factors in these cells might also be absent.
Ideally, keratinocytes and other adult epithelial cells lines such as cornea cells could be 
used to identify tissue-specific interacting partners of p63. Since p63 was shown to play a 
role in multiple tissues of ectodermal origin, it would be more interesting to use iPS cells 
that can form different epithelial cells types, such as keratinocytes and cornea cells, and 
to discern whether co-factors expressed in specific tissues play a role in regulating tissue-
dependent subsets of p63-regulated genes. 
7.7.2 Pathogenic mechanisms of p63-associated disorders
How different mutations in TP63 cause affect regulation of different target genes that lead 
to variations in phenotypes is still not fully understood at the molecular level.
To answer this question, patient-derived cellular models such as primary keratinocytes 
or human induced pluripotent stem cells (iPSCs) are useful. The patient-derived primary 
keratinocytes can provide information about the different regulation of genes caused 
by different TP63 mutations in keratinocytes. From iPSCs multiple different cell lineages 
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can be generated to study the affect of different TP63 mutations on gene regulation in 
different epithelial tissues and structures, such as keratinocytes or cornea cells. 
In stead of using patient-derived iPSCs, control-derived iPSCs with different TP63 
mutations introduced using for example CRISPR-Cas is even more beneficial because 
then the genetic background is more homogeneous as compared to the patient-derived 
iPSCs and primary keratinocytes. Knock-in animal models with different TP63 mutations 
using CRISPR-Cas can also be generated. These knockin models can complement the 
studies in human cells to determine the affect of TP63 mutations in a homogenous 
genetic background.
All three major ED characteristics observed in patients with mutations in TP63 are present 
in EEC syndrome patients. Elucidating p63 function in EEC syndrome can be the first step 
to take and can provide valuable information for all p63-related disorders. In Chapter 6, 
the differences in morphology and gene expression between keratinocytes derived from 
three EEC-patients and control individuals were described. Many genes were shown to be 
differentially regulated in EEC patient derived keratinocytes, suggesting that the mutation 
in TP63 causes alterations in p63-dependent gene regulation. Preliminary data showed 
that p63 binding in EEC-patient derived keratinocytes with heterozygous mutations in 
the DNA binding domain of TP63, was not completely abolished (data not published). 
However, these data require more detailed analysis to determine specific differences in 
p63 binding between these datasets. 
These findings indicate that it would be fruitful to perform a quantitative analysis of 
p63 binding in p63 ChIP-seq datasets generated from control and EEC-patient derived 
keratinocytes in combination with detailed epigenomic profiling of different histone marks 
that define chromatin states and gene-expression analysis to determine which genes 
and regulatory elements are misregulated in patient cells. Additionally, it is worthwhile 
to identify the p63-interacting proteins in normal and patient HKCs using pull-down 
experiments from nuclear extracts of normal or patient HKCs followed by MS (see section 
7.7.1). As a follow-up, protein pull-down followed by MS can be performed using different 
epithelial cell lines generated from iPSCs with different TP63 mutations to identify whether 
p63 protein complexes are affected, potentially by loss of p63 protein complex formation 
with tissue-specific co-regulators. This will provide more insight in the pathogenic 
mechanisms that cause misregulation of p63-dependent gene regulation in patients due 
to different mutations in TP63 and might explain the variation in phenotypes between 
different mutations in patients with similar syndromes.
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7.7.3 Genetic studies of other epithelial-related disorders
The studies described in this thesis have contributed in the identification of a large 
number of p63-dependent genes and enhancers by genome-wide analyses. Since these 
approaches are becoming easier, many more genome-wide studies will be performed 
to understand p63 function in different aspects during development. In addition, these 
genome-wide datasets provide a good basis for validation studies to test individual target 
genes or enhancers. Therefore it can be predicted that this list of p63-regulated target 
genes and enhancers will be modified and improved. Since proof-of-principle studies have 
shown that the p63-regulated target gene and enhancer elements can be used to study 
the genetic basis of epithelial-related diseases (Chapter 2 and 3) 490, this list provides a rich 
resource to identify the genetic basis of these epithelial related diseases. For example, p63-
regulated target genes obtained in epidermal keratinocytes can be used to prioritize genes 
identified in exome sequencing of skin diseases. Moreover, enhancer elements that are 
bound by p63 can be used to identify the causative elements leading to SHFM and CL/P.
7.7.4 The relevance of our studies in an era of whole-genome sequencing
The ultimate goal in human genetics is to identify the cause of the whole spectrum of 
diseases and to explain the variation in phenotypic traits that are caused by genetic factors. 
Initially, candidate gene approaches were used to study genetic defects in inherited 
diseases. The introduction of exome sequencing has enabled sequencing of all known 
coding sequences, which achieved major advances in the field of human genetics to 
identify disease links with mutations in coding genes. With the arrival of whole-genome 
sequencing the necessity of gaining knowledge and understanding the role of non-coding 
DNA has become of high importance. By contrast, a limited number of changes in gene 
regulatory sequences have so far been linked to human diseases. The interpretation of non-
coding variants in relation to disease phenotypes might not be feasible without functional 
information of the active regulatory regions in specific cell types. The establishment of 
new techniques (e.g. ChIP, 5C, DNase1 hypersensitivity assays, etc.) in combination 
with high-throughput sequencing is currently improving the identification of regulatory 
elements and their function. It is remarkable that the number of regulatory elements that 
are identified so far exceed the number of protein coding genes identified 513. We also 
demonstrated that the determination of topological domains using CTCF binding sites can 
help to identify a regulatory element that can drive gene expression of genes that lie far 
away (250kb distance) and can help to identify novel disease mechanisms (Chapter 2). Our 
studies and others show the presence of many regulatory elements that have temporal 
activity correlating with tissue specific transcriptome activity (Chapter 5) 9, 41, 71, 526. 
These findings demonstrate the challenging tasks that lie ahead: to identify all regulatory 
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elements that drive gene regulation in all tissues during development, and to assess the 
relationship between variations in these regions and human disease. 
It was recently suggested that super-enhancer regions that are only identified in specific 
tissues and are regulated by master-regulators have a higher probability to contain disease 
causing mutations 43. This demonstrates the importance of information on tissue-specific 
activation of regulatory regions to assess a link between variations in these regions with 
altered gene regulation and specific human disease phenotypes.
Mutations in coding-regions can cause translation into altered proteins, including proteins 
with structural changes, complete loss of function, or alterations of protein activity 1, 5, 190-
193, 267, 554. Mutations in regulatory elements disturb gene regulation that affect the amount 
of produced protein but these mutations leave the DNA sequence of the coding region of 
the corresponding gene intact. If it is somehow possible to repair the gene regulation that is 
altered by mutations in regulatory elements, normal protein production could be restored. 
This highlights the importance to identify regulatory elements and gaining knowledge on 
their function. Here, I have put the emphasis on regulatory elements such as enhancers 
and silencing elements but there are other categories of functional elements in the non-
coding genome including promoters, insulators, and non-coding RNAs. These functional 
elements are also crucial components that control gene regulation that need identification 
and detailed characterization to study their role in human biology and disease. These 
studies can aid the development of novel treatments to restore gene regulation in patients 
with changes in regulatory regions or other functional elements. 
7.7.5 Therapeutic strategies for p63-associated disorders
To date, besides reconstruction of the teeth, orofacial region, and limbs by surgery, no 
specific therapies have been developed to treat patients with mutations in TP63. The 
hotspot mutations in p63-associated disorders correspond to the sites of p53 hotspot 
mutations in cancer. In two recent studies, APR-246/PRIMA-1MET, a small compound 
that restores the functionality of mutant p53 and that is under clinical trials for cancer 
treatment 511, reinstated normal function to mutant p63 and reverted epidermal and 
corneal differentiation of patient cells with TP63 mutations (Chapter 6) 168. These studies 
have opened new possibilities to develop therapeutic strategies for patients with p63-
associated disorders. Many compounds have been developed targeting p53 mutations 
296, 297, 555-557. These compounds can also be tested for their ability to rescue phenotypes 
caused by TP63 mutations. 
To treat skin and cornea, one approach would be to generate iPS cells from patient with 
mutations in TP63 and correct the mutations with TP63 by genome-editing to restore 
the WT allele. For example, using homologues recombination to restore the WT allele or 
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by performing a targeted deletion of the mutant TP63 allele, based on the disease model 
that the mutant TP63 allele has dominant-negative or gain-of-function properties. This 
genome-editing could be done by conventional targeting methods or by engineered 
proteins with nuclease activity such as zinc finger nucleases (ZNFs), transcriptional 
activator-like effector nucleases (TALENs), or CRISPR/Cas9. Although these methods are 
rapidly advancing, there are still several safety concerns around engineered proteins with 
nuclease activity, such as off-targeting effects. These concerns make these genome-
editing methods less attractive to use for correction during therapeutic iPSC manufacturing. 
However, adeno-associated viral (AAV) variant (AAV-DJ)-mediated genome editing could 
be a potential alternative for genome-editing in iPSCs. It was shown that AAV-DJ-mediated 
homologous recombination (HR) rates are comparable to those of CRISPR/Cas9 and AAVs 
have been previously used in human gene therapy trials, showing low off-target rates, and 
are easily detectable 558.
After the establishment of corrected iPSCs, this can be followed-up by generation of 
epithelial keratinocyte sheets for autologous grafting, such as epidermal sheets or cornea. 
With this it would be possible to patch wounds or to generate a cornea that can be 
transplanted. A similar approach was successfully used in a very recent study in which they 
repaired mutations in the COL7A1 gene and generated epidermal sheets 558.
To this end, understanding the regulatory mechanism controlled by p63 and p63-
dependent target genes in related disorders (see Section 7.3) is essential. This could 
assist to assess the quality and specificity of drug treatment and genome-editing towards 
rescuing phenotypes caused by TP63 mutations.
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Transcription factor p63 is a key regulator during the development of epithelial structures 
derived from ectodermal origin such as the epidermis, limbs, and the palate. In humans, 
heterozygous mutations in the TP63 gene are associated with at least seven dominantly 
inherited clinical conditions with three major characteristics ectrodactyly (split hand/foot 
malformations, SHFM), orofacial clefting (CL/P) and ectodermal dysplasia (ED) including 
defects in skin, teeth, nails, hair, and diverse exocrine glands. The disorders associated 
with TP63 mutations range from isolated disorders, only affecting one organ or tissue, to 
severe syndromes in which multiple tissues are affected, such as Ectrodactyly, ectodermal 
dysplasia, and cleft lip/palate syndrome (EEC). Multiple p63 target genes have been 
identified that are essential in the development of ectoderm-derived epithelial tissues. 
However, the complete p63-controlled gene regulatory network remains to be elucidated. 
Creating a comprehensive catalogue of p63-controlled gene networks will improve our 
understanding on the molecular processes underlying p63-associated diseases and other 
related disorders.
The aim of my thesis was to elucidate the complete gene regulatory network that is 
controlled by p63 in various epithelial tissues to identify:
1. P63- dependent regulatory regions in different epithelial tissues.
2. The role of p63 in epidermal differentiation.
3. Novel disease mechanisms.
Additionally, I set out to study new opportunities for therapeutics to treat patients with 
p63-associated diseases.
Within my thesis I, I) unraveled the p63-dependent repertoire of target genes and regulatory 
elements including several novel p63 target genes in diverse epithelial tissues (Chapter 2, 3, 
4 and 5), II) discovered a role of p63 in transcriptional regulation of epidermal differentiation 
(Chapter 5), III) described novel disease mechanisms causing SHFM1 (Chapter 2) and CL/P 
(Chapter 3), and IV) provided novel directions for therapeutic development (Chapter 6).
Chapter 1 of my thesis covers a general introduction on various mechanisms of gene 
regulation, the transcription factor p63, p63-associated disorders and the role of 
p63 in gene regulation during development. I also provided an overview of diseases 
phenotypically related to p63-associated disorders, and an argument of the importance 
of therapeutic development for this group of patients.
Chapter 2 describes the first p63 ChIP-seq, followed by next-generation sequencing in 
proliferative keratinocytes. In this study, I identified genome-wide p63-bound regulatory 
elements and p63 target genes that were enriched for genes involved in epidermal and 
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ectoderm development. In Chapter 5, I studied the role of p63 in epidermal differentiation 
in-depth, using a 2D-differentiation skin model. Here, I performed a systematic analysis 
of I) p63 binding by p63 ChIP-seq, II) enhancer activity by analyzing H3K27ac occupancy, 
and III) transcriptome analysis using RNA-seq and RNAPII ChIP-seq. The results indicate 
that p63 serves as a placeholder and bookmarks genomic loci during the commitment of 
the epithelial lineage and regulates genes through temporal- and spatial-specific active 
enhancers. My findings suggest the involvement of co-regulators in p63 gene regulation 
during differentiation. Indeed, analyses of transcription factor motif enrichment and 
ChIP-qPCR experiments indicate that co-regulators play a role in cooperating with p63 
to regulate gene expression in keratinocytes. Interestingly, some of the identified p63 co-
regulators are known or candidate p63 target genes, suggesting that p63 regulates the 
expression of these co-regulators. These findings are consistent with the role of p63 as a 
master regulator in epithelial cells.
Besides having a key role in epidermis development, p63 also plays an important role in 
limb and palatal development. By studying p63 controlled gene regulation in these tissues, 
novel disease mechanisms were discovered for limb malformation (SHFM1) (Chapter 2) 
and orofacial clefting (CL/P) (Chapter 3) 490.
In Chapter 2, I identified a p63-dependent cis-regulatory element in keratinocytes that 
regulates the distal DLX5 and DLX6 genes, important for limb development. In this study, I 
demonstrated that disruption of this p63-dependent cis-regulatory element is causative of 
split hand/foot malformation (SHFM1). These findings provide a novel disease mechanism 
for SHFM1 and demonstrate the importance of p63 in gene regulation during limb 
development. 
In Chapter 3, I described an important role for p63 in palatogenesis by regulating IRF6 
via a p63-dependent regulatory element identified in keratinocytes. Furthermore, genetic 
studies using mice models demonstrated a cooperative role of p63 and IRF6 in palatal 
development. In a follow-up study described in Chapter 4, mouse palatal tissue was 
used to generate genome-wide expression and p63 binding profiles at different stages of 
development. This study showed that p63 plays a direct role in the regulation of adhesion 
molecules in both the developing palate as well as in keratinocytes. Additionally, it was 
shown that p63 regulation is essential to maintain adhesion homeostasis in the developing 
palate and that p63 is required for periderm formation.
My thesis includes a comprehensive catalogue of genes and regulatory elements that are 
dependent and independent of p63 regulation in epidermis development (Chapter 5) and 
palate development (Chapter 4). This provides a rich resource to study the cause of skin 
diseases or potentially other epithelial related disorders. These datasets contain information 
on coding and many non-coding regions and will be of importance as it can help to 
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identify pathogenic mechanisms of ectodermal disorders caused by variants outside the 
coding regions. With the introduction of whole-genome-sequencing knowledge on non-
coding regions has become increasingly important because thus far information was 
mainly limited to coding regions.
Chapter 6 describes both 2D and 3D models generated from mutant TP63-patient derived 
keratinocytes treated with APR-246/PRIMA-1MET. This study showed that this compound can 
partially but consistently rescue the morphological defects and it restored the expression 
of p63 target genes (including ADH7, GPX2 and CLDN1) and terminal differentiation 
genes that are required for the epidermal barrier formation. These findings provide new 
directions for drug-screening and therapeutic development to alleviate symptoms of 
patients with p63-associated disorders. Furthermore, patients with phenotypically related 
diseases caused by similar molecular mechanisms could also benefit from the discovery 
and development of new therapies.
In Chapter 7 the main findings, conclusions and implications of my work are discussed 
and future experiments are proposed. 
To conclude, my thesis provides novel findings of p63 controlled gene regulatory 
mechanisms during epithelial development. It has led to the discovery of novel disease 
mechanisms and thereby improve diagnosis and clinical practice of patients with 
phenotypes that resemble the p63-associated disorders. Furthermore, these insights 
could provide the foundation of new therapeutic strategies to treat patients with p63-
associated disorders and diseases that display similar phenotypes. 
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Transcriptiefactor p63 speelt een belangrijke rol tijdens de ontwikkeling van verscheidene 
epitheliale weefsels die afkomstig zijn van het ectoderm, waaronder de epidermis (de 
bovenste huidlaag), het gehemelte en de ledematen. Heterozygote mutaties in het 
TP63 gen zijn geassocieerd met minimaal zeven aandoeningen met een dominant 
overervingspatroon. Deze aandoeningen zijn herkenbaar aan drie karakteristieke 
afwijkingen, namelijk afwijkingen van de ledematen (het ontbreken of vergroeiing van 
vingers of tenen), schisis (een spleet of groef in bovenlip, kaak of gehemelte) en ectodermale 
dysplasie, waarbij een afwijkende ontwikkeling optreedt van onder andere de huid, haar, 
nagels, tanden en exocriene klieren. P63-geassocieerde ziekten kunnen variëren van 
geïsoleerde aandoeningen, die slechts een enkel orgaan of weefsel aantasten, tot ziekten 
waarbij meerdere weefsels aangedaan zijn, zoals het Ectrodactyly ectodermal dysplasia 
clefting syndroom (EEC). Er zijn verschillende p63 target genen geïdentificeerd met een 
rol in de ontwikkeling van het ectoderm en gerelateerde epitheliale weefsels, maar het 
complete p63-gereguleerde gennetwerk was tot op heden nog onbekend. De identificatie 
van het p63-gecontroleerde gennetwerk is noodzakelijk om moleculaire mechanismes te 
begrijpen die ten grondslag liggen aan p63-geassocieerde aandoeningen en vergelijkbare 
ziektenbeelden. 
Het doel van mijn promotieproject was het ontrafelen van het complete p63-gereguleerde 
gennetwerk in verscheidene epitheliale weefsels. Dit maakt het mogelijk om: 
1. P63-afhankelijke genregulatie in verschillende epitheliale weefsels te onderzoeken.
2. De functie van p63 tijdens epidermale differentiatie te achterhalen.
3. Nieuwe pathogene mechanismes te ontdekken.
Daarnaast was het ook mijn ambitie om nieuwe mogelijkheden te toetsen waarmee 
therapieën ontwikkeld kunnen worden om symptomen van p63-geassocieerde 
aandoeningen te behandelen.
De volgende bevindingen zijn voortgekomen uit mijn onderzoeksproject: I) een catalogus 
van het complete door p63 gereguleerde repertoire aan genen en regulerende elementen 
in verschillende epitheliale weefsels (Hoofdstuk 2, 3, 4 en 5), II) het belang van p63 in 
epidermale differentiatie (Hoofdstuk 5), III) identificatie van nieuwe, verstoorde genregulatie 
mechanismes die splijthand/-voet (Hoofdstuk 2) en schisis (Hoofdstuk 3) veroorzaken 
en IV) strategieën voor het ontwikkelen van nieuwe behandelingen voor patiënten met 
specifieke TP63 mutaties (Hoofdstuk 6). 
Hoofdstuk 1 van mijn proefschrift introduceert verschillende mechanismes die belangrijk 
zijn voor genregulatie. Daarnaast wordt transcriptiefactor p63 besproken, evenals p63-
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geassocieerde aandoeningen en wat er bekend is over de rol van p63 in genregulatie 
tijdens de ontwikkeling. Vervolgens presenteer ik een overzicht van enkele aandoeningen 
en de hiervan eerder beschreven oorzakelijke genen. Deze vertonen fenotypes die 
overeenkomen met fenotypes bij patiënten met een TP63 mutatie. Tot slot beschrijf 
ik de noodzaak van de ontwikkeling van nieuwe therapieën voor patiënten met p63-
geassocieerd aandoeningen.
Hoofdstuk 2 beschrijft het eerste p63-ChIP experiment gevolgd door ‘next-generation 
sequencing’ in prolifererende keratinocyten. In deze studie heb ik alle p63-gebonden 
elementen en p63-gereguleerde genen voor het gehele genoom geïdentificeerd. Veel 
van deze genen spelen een rol in de ontwikkeling van de epidermis en het ectoderm. 
In Hoofdstuk 5, heb ik de regulerende rol van p63 in differentiërende keratinocyten 
vastgesteld, door gebruik te maken van een in vitro 2D model voor huiddifferentiatie. 
Door middel van een systematische analyse heb ik I. p63 binding bepaald met p63 ChIP-
sequensen, II. enhancer activiteit aangetoond door het analyseren van H3K27ac signaal 
en III. transcriptoom analyses uitgevoerd middels RNA-sequensen en RNAPII ChIP-
sequensen. Deze resultaten suggereren dat p63 een rol speelt als marker van regulerende 
elementen, waarmee het genexpressie tijdens de ontwikkeling van epitheliale weefsels 
kan reguleren. Daarnaast lijken co-regulatoren betrokken te zijn bij genregulatie door 
p63 tijdens de differentiatie van keratinocyten. Dit wordt inderdaad bevestigd door de 
analyse van p63 bindingsplaatsen op aanwezige transcriptiefactor motieven en ChIP-
qPCR experimenten. Intrigerend hierbij is dat sommige van de geïdentificeerde p63 co-
regulatoren al bekend zijn als p63 targetgenen of kandidaat targetgenen zijn. Dit toont aan 
dat p63 de expressie van zijn eigen co-regulatoren kan reguleren en bevestigd de rol van 
p63 als master regulator in epitheliale cellen. 
Buiten het feit dat p63 een belangrijke rol speelt in de ontwikkeling van de epidermis, heeft 
het ook een belangrijke rol gedurende de ontwikkeling van ledematen en gehemelte. 
Door de p63 gecontroleerde genregulatie in deze weefsels te bestuderen, werden er ook 
nieuwe pathogene mechanismes gevonden die oorzakelijk zijn voor splijthand/-voet type 
1 (SHFM1; Hoofdstuk 2) en schisis (Hoofdstuk 3) 490.
In Hoofdstuk 2 beschrijf ik een p63-afhankelijk regulerend element dat de DLX5 en DLX6 
genen reguleert over grote afstand. DLX5 en DLX6 zijn essentieel voor de ontwikkeling 
van ledematen. Deze studie toont aan dat verlies van dit p63-afhankelijk regulerend 
element de oorzaak is van splijt-hand/voet malformaties bij sommige patiënten. Dit is een 
nieuw mechanisme voor deze aandoening wat tevens het belang laat zien van p63 in 
genregulatie gedurende de ontwikkeling van ledematen. In Hoofdstuk 3 beschrijf ik de 
rol van p63 gedurende de ontwikkeling van het gehemelte. P63 reguleert IRF6 via een 
specifiek cis-regulerend element dat ik geïdentificeerd had in keratinocyten. Daarnaast 
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hebben genetische studies in muizen een belangrijke samenwerkende rol van p63 en 
IRF6 tijdens orofaciale ontwikkeling aangetoond. In een vervolg studie hebben we de 
p63 bindingsprofielen van het volledige genoom van de muis in kaart gebracht voor 
verschillende ontwikkelingsstadia van het gehemelte/lip weefsel. Hoofdstuk 4 laat zien dat 
p63 verscheidene genen reguleert die belangrijk zijn bij cel-cel verbindingen in zowel de 
ontwikkeling van gehemelte/lip weefsel en de epidermis. Deze studie toonde aan dat p63-
afhankelijke genregulatie essentieel is voor een goede balans van cellulaire verbindingen 
en dat p63 belangrijk is tijdens de ontwikkeling van het periderm.
Dit manuscript bevat een complete catalogus van actieve genen en regulerende 
elementen, die zowel afhankelijk als onafhankelijk van p63 kunnen zijn tijdens de 
ontwikkeling van de epidermis (Hoofdstuk 5) en gehemelte (Hoofdstuk 4). Dit is een bron 
van informatie die van grote waarde kan zijn voor het bestuderen van huidafwijkingen 
en andere epitheel-gerelateerde aandoeningen. Daarnaast kan deze dataset als startpunt 
dienen bij het identificeren van pathogene variaties in niet-coderende regio’s. Met de 
introductie van ‘whole-genome-sequencing’ wordt de kennis over niet-coderende 
regio’s nog waardevoller, omdat er voorheen voornamelijk informatie over gecodeerde 
regio’s bekend was.
Hoofdstuk 6 beschrijft de behandeling met APR-246/PRIMA-1MET van 2D en 3D 
huidmodellen, gegenereerd van keratinocyten afkomstig van patiënten die drager zijn 
van TP63 mutaties. De behandeling met deze drug herstelde deels de morfologische 
defecten, de expressie van p63-gereguleerde genen (waaronder ADH7, GPX2 en CLDN1) 
en de terminale differentiatie van de keratinocyten. Terminale differentiatie is belangrijk 
voor de vorming van de epidermale barrière. Deze bevindingen bieden nieuwe inzichten 
voor drug-screening en het ontwikkelen van nieuwe therapeutische methodes om de 
symptomen van patiënten met TP63 mutaties te verminderen. Daarnaast kunnen ook 
patiënten met andere aandoeningen die veroorzaakt worden door de verstoring van 
soortgelijke mechanismen baat hebben bij het ontdekken en ontwikkelen van deze 
nieuwe therapieën.
In Hoofdstuk 7 worden de belangrijkste bevindingen, conclusies en implicaties van dit 
werk bediscussieerd en vervolg experimenten voorgesteld. 
Samengevat hebben de bevindingen die beschreven staan in mijn thesis een bijdrage 
geleverd aan een beter inzicht in p63-gereguleerde processen gedurende epitheliale 
ontwikkeling. Daarnaast heeft het geresulteerd in de ontdekking van nieuwe p63 target 
genen en de etiologie van bepaalde gevallen van SHFM1 en schisis. Dit verbetert de 
diagnostiek en biedt nieuwe mogelijkheden voor het ontwikkelen van behandelingen 
voor patiënten met TP63 mutaties en vergelijkbare aandoeningen.
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2D  two-dimensional
3D  three-dimensional
ADULT  Acro-dermato-ungual-lacrimal-tooth syndrome
AEC  Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome
BS  Binding site
CL  Cleft lip
CL/P  Cleft lip and cleft palate, orofacial clefting
CP  Cleft palate
CpG Regions of DNA in which a cytosine nucleotide occurs next to a 
guanine nucleotide in a linear sequence of bases
DBD  DNA-binding domain
DNA  Deoxyribonucleic acid
EEC  Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome
eGFP  Enhanced green fluorescent protein
GO  Gene ontology
GTF  General transcription factor
GWAS  Genome-wide association study
Kb  Kilobase
LMS  Limb mammary syndrome
lncRNAs  Long non-coding RNAs
mESCs  Mouse embryonic stem cells
miRNA  MicroRNA
mRNA  Messenger RNA
MS  Mass spectrometry
ncRNA  Non-coding RNA
NSCL/P  Non syndromic cleft lip and cleft palate
PIC  Pre-initiation transcription complex
PPS  Popliteal pterygium syndrome
PRC  Polycomb repression complex
RACK1   Receptor for protein kinase C
RHS  Rapp-Hodgkin syndrome
RNA  Ribonucleic acid
RNAi  RNA interference
RNA-seq RNA sequencing
RNAPII  RNA polymerase II
SAM  Sterile-alpha-motif domain
SHFM  Split hand/foot malformation, limb malformation
shRNA  short hairpin RNA
siRNA  Small interfering RNA
SNHL  Sensorineural hearing loss
snRNA  Small nuclear RNA
STF  Sequence-specific (DNA-binding) transcription factor
TAF  TBP associated factor
TF  Transcription factor
TI  Transactivation inhibitory domain
TSS  Transcription start site
VWS  Van der Woude syndrome
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het opzetten van mijn experimenten. Wieteke, wat leuk dat we aan het eind van mijn AIO 
periode tegelijkertijd zwanger waren! Bedankt voor de fijne gesprekken en gezellige thee 
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ieder geval naar uit. Ook wil ik graag Siebe, Willem en alle andere analisten bedanken voor 
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was a pleasure to meet you guys and good luck with your PhDs! I hope you’ll have as 
much fun during your PhD as I had. Martin, an extra special thanks to you, as the analysis I 
tried to do became more and more complex, you were always there to count upon. This 
way you have really helped me find my way through the massive amount of data. Thank 
you so much for your help with finalizing our big paper. Also many thanks for commenting 
on other manuscripts, and for the nice talks we had. You are an excellent bioinformatician 
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the fun we had at parties, so all in all for making my PhD a great experience. Therefore I’d 
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to you guys!
Roberta, Federica and Kim, le ragazze si sono favolosi (meiden jullie zijn fantastisch). Thank 
you girls for being there for me. Roberta, we shared great times going to the gym, having 
coffee/tea or lunch breaks, discussing about work (or many other things), having nice 
diners, going to conferences or other events, and so much more. I will treasure this for a 
lifetime. Federica, you recently joined Jo’s group, but we have already talked, laughed and 
spend so much time together. Thank you for the great times and all your help. I do not 
know how you always get tangled up in the strangest situations possible, but I do know 
that often it is funny as hell (afterwards). Good luck with your PhD and keep me up-dated.
Furthermore, I would like to thank all the many people with whom I collaborated. Thank 
you for involving and trusting me with your projects. Professor Jill Dixon, it was a great 
pleasure to meet you and to work together on several papers. Professor Klas and Jinfeng 
(Jin), thanks to the p63 consortium we were able to start up a successful collaboration. 
Jin, at the last p63 meeting we briefly talked about how nice it would be to test the 
PRIMA1 compound in keratinocytes and soon afterwards, we were walking together in the 
corridors of the Human Genetics department in Nijmegen. With the help of Ellen van den 
Boogaard and Professor Joost Schalkwijk, this project resulted in a really nice paper. Jin, 
you are a very nice person, and I have really enjoyed our talks and diners together. I wish 
you all the best. Sandra Tjabrinka en Ellen jullie waren een super hulp voor mijn primaire 
keratinocyten werk. Sandra, Ellen en Joost, bedankt voor al het voorkweek werk en de 
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Jou kennende zal dat wel goed komen. Elisabeth (Elli), it was really nice to work with you 
and we’ve really spend a great time together. I will never forget all the fun moments and 
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to read the oocyte paper someday. Furthermore, I would very much like to thank Jose-
Luis for giving me the opportunity to spend one month in your lab and for the great time 
I spent at the conference in Barga. It’s a great pleasure to welcome you in my corona. I 
would like to thank all the fantastic people from your group and the neighboring group 
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for the friendly atmosphere and all the help I received from all of you. A special thanks to 
Juan, Silvia, Ana, Jose, Özren, and Miriam for the nice diners (I still love the Spanish food), 
our nice talks, beach visits, Feria d’Abril (as an outsider, it was really awesome to experience 
the Feria so up-close). Muchos gracias!
Er zullen ongetwijfeld nog mensen zijn die ik hier niet heb benoemd, maar die mij in de 
afgelopen jaren hebben geholpen of beïnvloed en ook jullie wil ik hierbij heel hartelijk 
bedanken.
Lieve vrienden en familie, in dit boekje kunnen jullie precies lezen wat ik de afgelopen 
jaren nou eigenlijk allemaal heb uitgespookt. Ik ben nu echt klaar met ‘studeren’. Bedankt 
voor alle steun en belangstelling voor mijn onderzoek. Vooral ook bedankt voor alle 
leuke dingen die we altijd samen doen, waarbij ik lekker mezelf kan zijn en heerlijk kan 
ontspannen, zoals: stapavonden, bruiloften, verjaardagen, vakanties, weekendjes weg, 
meidendagjes, kraamvisites, knutselprojecten en carnavallen. Lieve tante Brigitte, jou 
plezier en passie voor je werk en de korte snuffel stage bij jou op het werk heeft destijds 
mijn studierichting bepaald. Hier ben ik tot op de dag van vandaag nog steeds heel erg blij 
en dankbaar voor! Het is een bewogen tijd geweest. Je weet niet hoe blij ik ben dat ik 23 
Maart jouw gezicht in de zaal zal zien.
Lieve Lotte, Jasper, Marco, Evelyn en Ilona, we hebben het (soms wilde) studenten leven 
van: intro’s, feesten, carnavallen, soos en bank hangen, uitjes, onvergetelijke weekendjes 
weg, (buitenlandse) stages en (soms toch ook hard) studeren ingeruild voor: heerlijke 
zeven gangen diners, bbq’s, verjaardagen, housewarmings, bruiloften, promoties en 
kraamvisites. Het is altijd onwijs gezellig en ik hoop dat we nog vaak bij elkaar over de vloer 
zullen komen. Bedankt voor al deze jaren vriendschap en jullie steun en interesse voor mijn 
onderzoek tijdens mijn AIO. Dear Tess and Sarah, we met at La Mancha were I had some 
of the best time of my life. Girls I will never forget your friendliness and pretty smiles. It’s 
great that we are still able to keep in touch with each other and I hope we will have another 
reunion soon. Lieve Kristy en Metamia, mede-CGDB’ers en mede-bakkertjes, bij jullie kon 
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Al het beste meiden en hopelijk tot snel weer. Lieve Kirsten, een hele tijd liep ik stage bij de 
bakkertjes en hadden we plezier op feesten, maar eigenlijk leerde we elkaar pas echt goed 
kennen toen ik bezig was met mijn scriptie. Je bent een hele lieve meid, zo heerlijk down-
to-earth en samen (met de kleintjes) hebben we de gezelligste lunchmomenten. Bedankt 
voor je steun en vriendschap. Lieve Hinta, mede-paranimf, we hebben elkaar in een korte 
tijd heel goed leren kennen en samen bedachten we de meest gave dingen en hadden 
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Grinsven). Monique en Kim, hoewel ik soms afhaakte omdat ik druk bezig was met een 
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jou heb ik echt alles eruit gehaald wat erin zat. Bedankt voor alle steun, onze geweldige 
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alle momenten die we de afgelopen jaren samen hebben gedeeld. Met jullie naast mij kan 
ik op 23 maart gerust ademhalen.
Lieve schoonfamilie, bedankt voor alle steun, interesse en gezelligheid. Lieve 
schoonouders, eten zonder dat er gekletst wordt is er al lang niet meer bij. Ik voel me bij 
jullie altijd welkom, gesteund en helemaal thuis, bedankt hiervoor. Ook is het heel leuk om 
te zien hoe lief jullie zijn met Silvie. Lieve Siebe en Laura, Siebe bedankt dat je me geholpen 
hebt om wat zinnen in stukjes te hakken en wat leuk dat er een nichtje of neefje komt! Heel 
veel succes en plezier de komende tijd.
Lieve opa en oma, ik heb mijn ‘studie’ eindelijk afgerond. Het is toch wat hè, een 
kleindochter met een doctorstitel. Bedankt voor alle interesse en gezelligheid.
Lieve Ralph, mijn grote broer en plaaggeest, ik kan me geen betere broer indenken dan 
jij. Bedankt dat je zo lekker jezelf bent. Al vele jaren ben je samen met Amy, mijn lieve 
schoonzusje met wie ik heerlijk kan stappen, knutselen, carnavallen en een geweldig 
weekend in Sevilla heb beleefd (8 uur slapen in een weekend was plenty!). Lieve Amy, jij 
bent nu nog aan het ‘knokken’ om je studie af te ronden. Ik weet dat je het kan, zet hem 
op, de aanhouder wint!
Lieve pa en ma, dankzij jullie ben ik uitgegroeid tot een zelfstandige en zelfverzekerde 
vrouw die precies weet wat ze belangrijk vind en met vol overgave van het leven geniet. 
Bedankt! Ook als iets net effe anders uitpakt dan ik hoopte, staan jullie altijd voor me klaar. 
Stiekem vind ik het heel leuk dat jullie alle interessante krantenknipsels voor me bewaren 
of even naar me toe sturen. Bedankt dat jullie me altijd aangemoedigd hebben om kansen 
te pakken en voor jullie oneindige steun en begrip. Het is heel leuk om te zien hoe onwijs 
enthousiast jullie zijn met Silvie.
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Chapter 10
Lieve Tijl, je bent de liefde van mijn leven en al vele jaren zijn wij heel gelukkig samen. 
Ik kan me geen leven indenken zonder jou. In de afgelopen jaren heb je mij lekker mijn 
gang laten gaan. Wat ik me ook op de hals haalde en waar ik ook weer naartoe ging, 
jij was er altijd: om me bij te staan, om naar me te luisteren, om me te helpen en was 
er altijd als ik weer thuis kwam. Bedankt voor al je steun in de afgelopen jaren! Je bent 
mijn allerbeste maatje, mijn rustpunt en rots in de branding. Samen hebben we de leukste 
dingen meegemaakt: onze eerste date met zweethandjes, geweldige vakanties, gezellige 
etentjes, carnavallen, trouwen, de vierdaagse lopen maar bovenal ouders worden van een 
klein wondertje. We hebben een geweldig leven opgebouwd. Ik hield mijn hart vast toen 
je afgelopen jaar in het ziekenhuis belandde. Gelukkig is alles goed gekomen, maar je mag 
me nooit meer zo laten schrikken! Het is heerlijk om jou te zien stralen terwijl je met een 
giechelende Silvie door het huis zoeft. Ik hou van je en ben benieuwd naar alles wat we 
nog gaan meemaken samen.
Lieve Silvie, je bent nu al een super lief, schattig, mooi, vrolijk klein giechelkontje van 5 
maanden met een stralende lach en ik houd echt onwijs veel van je! Je bent een droom 
die uit is gekomen. Ik vind het heerlijk om je te zien groeien en iedere dag nieuwe dingen te 
zien leren. Ik kijk echt uit naar alles wat we nog samen gaan meemaken en ben benieuwd 
hoe jij opgroeit tot een jonge vrouw met je eigen karakter. Ik wil en zal er in ieder geval bij 
zijn, om dit te allen tijde vast te leggen. Onthoud goed, het belangrijkste in het leven is: dat 
je gelukkig bent!
Evelyn *
